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Abstract 
This thesis describes a comprehensive study investigating the roles of the MaxiK 
potassium channel (KCNMA1), L-Type calcium channel (CACNA1C) and T-Type 
calcium channel (CACNA1G) in the maintenance of quiescence (relaxed myometrium), 
the preparation for parturition (non-contracting myometrium) and the regulation of the 
co-ordinated contractions characteristic of parturition itself (contracting myometrium). 
The role of these channels was investigated using primary human myometrial cell cultures 
under relaxed, non-contracting and contracting conditions. Protein studies revealed 
changes in both the amount and channel isoforms expressed between the different 
conditions. Protein-protein interaction studies revealed that the KCNMA1 and 
CACNA1C associated with Caveolin-1, Gαs and β2-Adrenergic Receptor. RNA studies 
revealed that the different incubation conditions modified expression of total channel 
mRNA and that of various splice variants. Previous research has demonstrated that the 
CACNA1C channel C-terminus can function as a transcription factor termed CCAT. 
Within this thesis inmmunohistochemistry staining and protein localisation studies 
revealed nuclear localisation of both the CACNA1C and KCNMA1 C-terminii. 
Therefore, genomic studies were undertaken utilising the ChIP assay, coupled with ChIP 
sequencing, to study the role of the KCNMA1 channel as a transcription factor. Chip-
sequencing data files were then analysed using Galaxy, an open access web-based 
platform. Peak calling generated 47 peaks, 21 were successfully mapped to known genes, 
including RB1, JPH2 and MAP3K7. Motif discovery was then undertaken for both the 
KCNMA1 protein utilising GYM and the successfully mapped peaks using the Panoptic 
Motif Search Tool. A helix-turn-helix motif was discovered in the C-terminal region of 
the KCNMA1 protein and ten putative transcription factor binding motifs were 
discovered within the peak regions. The significance of these findings is discussed. 
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Chapter 1 Introduction
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1.1 Reproduction 
Reproduction is a fundamental process which occurs in all living organisms.  It is 
arguably the most important, as successful reproduction ensures the survival of the 
species. In mammals, successful reproduction includes the distinct processes of: 
fertilisation, implantation, maturation (pregnancy) and birth (parturition). Despite the 
critical importance of these processes our understanding of them is still limited, especially 
in terms of describing the regulation of the switch between the pregnant state and 
parturition.  
 
1.1.1 Parturition as a Controlled Inflammatory Event 
Traditionally, parturition was thought to be a hormonal event driven predominantly by 
changes in progesterone or cortisol synthesis. This thesis was based on strong evidence 
from animal models; however, human parturition does not reflect such models (Golightly, 
Jabbour et al. 2011). This has lead to a number of theories regarding the regulation of 
human parturition. Firstly, it has been suggested that multiple paracrine/autocrine events, 
fetal hormonal changes and overlapping maternal/fetal control mechanisms are 
responsible for triggering parturition. Alternatively, there is growing evidence to suggest 
that the process of human parturition is a controlled inflammatory event coupled with a 
functional progesterone withdrawal (see Section 1.2.5 Progesterone Withdrawal).  At the 
onset of physiological parturition there is an influx of pro-inflammatory cytokines which 
coincides with an influx of inflammatory cells, neutrophils and macrophages, in both the 
upper and lower myometrium (Thomson, Telfer et al. 1999, Osman, Young et al. 2003, 
Golightly, Jabbour et al. 2011). These inflammatory cytokines and cells are significantly 
reduced in women undergoing elective Caesarean section in comparison to women 
undergoing term parturition. This demonstrates the role these factors have in term 
parturition. This inflammation is not caused, in the majority of cases, by infection, but 
instead is a form of sterile inflammation (Gomez-Lopez, Guilbert et al. 2010, Kobayashi 
2012). However, a study examining the presence of inflammation in uterine and 
gestational tissues found that inflammation was rare in these tissues prior to the onset of 
parturition (Keski-Nisula, Aalto et al. 2000). This would seem to suggest that 
inflammation is a consequence of parturition as opposed to the cause of parturition.  
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1.1.2 Sterile Inflammation 
Whereas non-sterile inflammation is a response to pathogens, sterile inflammation occurs 
as a response to physical, chemical or metabolic noxious stimuli. Each stimulus produces 
a tightly regulated stress response. These stress responses induce the recruitment of 
inflammatory cells such as neutrophils, macrophages and leukocytes and result in 
inflammation (Rubartelli, Lotze et al. 2013).   
 
Preceding parturition there are a number of events which could initiate or enhance this 
sterile inflammation pathway. Firstly, towards the end of pregnancy the myometrium is 
stretched by the growing fetus, this mechanical stretch induces an increase in the secretion 
of pro-inflammatory cytokines which could initialise or promote sterile inflammation 
(Kobayashi 2012). Secondly, the process of cervical ripening which involves the 
degradation of extracellular matrix proteins also leads to the release of molecules that 
activate inflammatory signalling pathways and could enhance the sterile inflammation 
process (Christiaens, Zaragoza et al. 2008, Challis, Lockwood et al. 2009).  Finally, the 
concentration of pro-inflammatory cytokines found in amniotic fluid increases towards 
parturition. These pro-inflammatory cytokines have been shown to induce chemotaxis of 
neutrophils, macrophages and leukocytes into the uterus. Once in the uterus, these 
inflammatory cells then release cytokines, matrix metalloproteinases (MMPs), 
prostaglandins and more chemokines (Gomez-Lopez, Guilbert et al. 2010). This then 
amplifies inflammatory signalling and could again enhance the sterile inflammation 
process. 
 
1.2 Regulation of These Parturition Events 
The contractions seen at parturition is the culmination of a process involving fetal  
maturation, membrane rupture, placental separation, cervical ripening and dilation which 
then ultimately lead to co-ordinated uterine contractions (Lindstrom and Bennett 2005). 
Over the last few years a significant body of research has been undertaken to define these 
events leading up to, and including, parturition. 
 
The process of parturition is characterised by an increase in pro-inflammatory cytokines 
such as Interleukin 1 beta (IL-1β), Interleukin 6 (IL-6) and Tumour Necrosis Factor 
(TNF) (Romero, Mazor et al. 1992, Opsjln, Wathen et al. 1993, Keelan, Marvin et al. 
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1999, Osman, Young et al. 2003). These cytokines are thought to enhance the production 
of Interleukin 8 (IL-8) and prostaglandins, which then work in concert to promote cervical 
ripening and ultimately, uterine contractions. However, the induction of this 
inflammatory signalling cascade is still to be fully elucidated.  
 
There are also signalling cascades generated from both the fetal and the endocrine 
systems. Briefly, the fetus has been shown to co-ordinate parturition associated changes 
in the myometrium via its influence on placental steroid hormone production. Alongside 
this there is a shift from progesterone to estrogen predominance, increased myometrial 
oxytocin receptor and prostaglandin expression and GAP junction formation. These 
changes are followed by activation of the fetal hypothalamic-pituatry-adrenal (HPA) axis 
and ultimately parturition (Kota, Gayatri et al. 2013; Figure 1.1). 
 
There have been a number of suggestions as to the key events which regulate the initiation 
of these signalling cascades including: secretion of surfactant protein A (SP-A) as a signal 
of fetal lung maturity, initiation of membrane rupture and cervical ripening through 
increased MMP expression, prostaglandin synthesis promoting myometrial contractions, 
transcriptional regulation by Nuclear Factor kappa B (NFκB) promoting the expression 
of pro-contractile genes, functional progesterone withdrawal resulting in the removal of 
the support for quiescence, and regulation of ion channel expression to increase the 
contractility of the myometrium (Figure 1.1). These are discussed below. 
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Figure 1.1 Regulation of Parturition 
A summary of the current understanding regarding the regulation of the processes of cervical ripening, 
membrane rupture and myometrial contractility. The sterile inflammation process is within the grey shaded 
box. Briefly, leukocyte infiltration from the fetus leads to an influx of proinflammatory cytokines. The 
increase in pro-inflammatory cytokines alongside an increase in SP-A leads to the activation of MMPs, 
Protaglandins, collagenases and NFκB. These, alongside an increase in CACNA1C and a decrease in 
KCNMA1 expression, subsequently lead to softening and dilation of the cervix, rupture of the fetal 
membranes and increased myometrial contractility (black arrows). The endocrine process is within the blue 
shaded box. Briefly, there is a switch to estrogen predominance leading to increased prostaglandins 
synthesis alongside increased oxytocin responsiveness again leading to softening and dilation of the cervix 
and increased myometrial contractility (blue arrows). Fetal factors are within the green shaded box. Briefly, 
activation of the fetal Hypothalmic-pituitary-adrenal (HPA) axis leads to activation of the placental 
endocrine axis which promotes the switch to estrogen predominance and the increased expression of 
prostaglandins and oxytocin responsiveness. Alongside this fetal growth produces uterine stretch and SP-
A production which can then activate the sterile inflammation pathway. Both again lead to softening and 
dilation of the cervix, rupture of the fetal membranes and increased myometrial contractility (green arrows). 
 
1.2.1 The Role of Surfactant Protein A (SP-A) 
SP-A is secreted by the fetal lungs and is used as a marker of fetal lung maturity (King, 
Ruch et al. 1975, Hallman, Arjomaa et al. 1988, Miyamura, Malhotra et al. 1994). Levels 
of SP-A peak at term and it is thought they may provide a fetal signal for the 
commencement of parturition (Mendelson and Condon 2005, Mendelson 2009). 
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Increased SP-A induces the activation of NFκB and production of IL-1β from fetal  
macrophages, which in turn migrate to the uterus and cause an inflammatory response 
and an increase in uterine NFκB (Condon, Jeyasuria et al. 2004; Figure 1.1). Injection of 
the amniotic sacs of mice 15 days post coitum with 6μg SP-A was seen to induce nuclear 
localisation of the NFκB RelA subunit and preterm parturition (Condon, Jeyasuria et al. 
2004, Lindstrom and Bennett 2005, Garcia-Verdugo, Tanfin et al. 2008). These findings 
suggest that the signal for the initiation of parturition is the secretion of SP-A, which then 
causes the migration of macrophages into the uterus, followed by the secretion of pro-
inflammatory cytokines. These pro-inflammatory cytokines then activate NFκB which in 
turn promotes the transcription of pro-contractile genes such as Cyclo-oxygenase 2 (Cox-
2) leading to contractions. It is important to note however, that NFκB can also be activated 
by cellular stress (Hoesel and Schmid 2013). Therefore, the increase in nuclear 
localisation observed in the above studies may be as a response to stress rather than SP-
A 
 
In addition to its role in regulating fetal macrophage migration into the uterus, SP-A is 
also a ligand for Toll-like receptor 2 (TLR2; (Sato, Sano et al. 2003, Yamada, Sano et al. 
2006, Henning, Azad et al. 2008) and Toll-like receptor 4 (TLR4; (Henning, Azad et al. 
2008). Toll-like receptors (TLRs) are a family of membrane bound proteins that recognise 
pathogens and as such binding of TLRs constitutes the initial event in the activation of 
the immune response. Binding of TLRs also results in the activation of NFκB and the 
initiation of an inflammatory cascade. A recent study into the interaction between SP-A 
and both TLR2 and TLR4 made the surprising discovery that when SP-A is administered 
into the uterine cavity it supressed both inflammation and parturition (Agrawal, Smart et 
al. 2013). This would appear to refute its role in the initiation of parturition as this 
research has shown SP-A can supress parturition.  
 
A further mechanism by which surfactant proteins may regulate the timing of parturition 
is through their role in the synthesis of prostaglandins. Surfactant protein is secreted from 
the fetal lung into the amniotic fluid, this surfactant protein is then responsible for the 
release of arachidonic acid which is the precursor for prostaglandin synthesis (Newman, 
Phizackerley et al. 1993, Bernal and Phizackerley 2000, Nayak, Dodagatta-Marri et al. 
2012). Briefly, arachidonic acid is cleaved from a phospholipid by phospholipase. Within 
the amninon, acrachidonic acid is synthesised by the cleavage of amniocyte diacyl 
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phosphatidylethanolamine by phospholipase A2 or phosphatidylinositol by 
phospholipase C and diacylglycerol lipase. Following this, arachidonic acid is converted 
to prostaglandin G2 by cyclooxygenase enzymes. Prostaglandin G2 is then converted to 
prostaglandin H2 by the peroxidase activity of the cyclooxygenase enzymes. Finally, 
prostaglandin H2 is converted by different prostanoid synthases to various prostanoids 
including prostaglandin E2 and prostaglandin F2α  (Gualde and Harizi 2004).  
 
Clearly, the study by Agrawal et al. (Agrawal, Smart et al. 2013) contradicts the earlier 
findings by Condon et al. that SP-A is involved in pro-inflammatory signalling and can 
induce preterm parturition (Condon, Jeyasuria et al. 2004). This may be due to the fact 
that in the study by Condon et al. SP-A was injected into the amniotic sac whereas in the 
study by Agrawal et al. SP-A was injected into the uterine cavity. It is possible therefore 
that SP-A has different roles depending on its location. A second possible explanation for 
these differences is that the study by Agrawal et al. specifically examined the role of SP-
A in infection induced parturition. In the presence of infection the anti-inflammatory role 
of uterine SP-A may be important in delaying parturition until the fetus is fully matured 
at which stage the pro-inflammatory action of SP-A from the amniotic sac initiates 
parturition. In addition to this the role of surfactant protein in the synthesis of 
prostaglandins could either lead to a support for contraction or relaxation depending on 
which prostaglandin receptors are expressed (The role of prostaglandins is more fully 
discussed in Section 1.2.3 Prostaglandin Synthesis).  Further work is needed to 
understand these conflicting roles for SP-A. 
 
1.2.2 Matrix Metalloproteinase (MMP) Expression 
The processes of fetal membrane rupture and cervical ripening both involve extensive 
remodelling of the extracellular matrix (ECM; (Bryant-Greenwood and Yamamoto 1995, 
Kelly 2002). The ECM of the fetal membranes and decidua is composed primarily of 
collagen types I, III, IV and V (Aplin, Campbell et al. 1985, Leushner and Clarson 1986). 
Within the cervix the ECM contains collagen types I and III (Minamoto, Arai et al. 1987, 
House, Kaplan et al. 2009). Remodelling of the ECM is achieved through a course of 
programmed collagenolysis which is mediated by MMP enzymes. Collagen degradation 
is vital in the process of cervical ripening as it causes the cervix to soften and become 
distensible, which in turn facilitates the passage of the fetus.   
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It has been shown that during parturition there is a decrease in collagen concentration, an 
increase in collagen solubility and activation of MMPs (Hampson, Liu et al. 1997, 
Goldman, Weiss et al. 2003).  At parturition there has been reported to be a significant 
increase in MMP3 mRNA (41-fold) and protein within the myometrium. MMP3 degrades 
collagen types I, II and IV as well as fibronectin, laminin and elastin all of which are 
components of the cervical ECM (Bryant-Greenwood and Yamamoto 1995, O'Brien, 
O'Shaughnessy et al. 2007). This suggests that MMP3 has a significant role in 
remodelling the cervical ECM in preparation for birth. MMP3 is also able to activate 
MMP9 (Van den Steen, Dubois et al. 2002, O'Brien, O'Shaughnessy et al. 2007). MMP9 
expression in the fetal membranes has been reported to be significantly increased both at 
term and preterm parturition (Xu, Alfaidy et al. 2002). MMP9 degrades collagen types 
IV and V which are components of the ECM of both the fetal membranes and decidua 
(Aplin, Campbell et al. 1985, Leushner and Clarson 1986, Delclaux, Delacourt et al. 
1996). This suggests that MMP9 has a significant role in the ECM degradation cascade 
leading to membrane rupture. MMP9 has also been implicated as a regulatory factor in 
neutrophil migration across basement membranes (Delclaux, Delacourt et al. 1996). The 
increase in MMP3 leads to cervical ripening and remodelling of the ECM (Figure 1.1). 
MMP3 could then activate MMP9 leading to fetal membrane rupture. These events would 
also enhance the sterile inflammatory state of the myometrium via the release of 
inflammatory molecules due to the degradation of the ECM and the facilitation of 
neutrophil migration by MMP9.  
 
1.2.3 Prostaglandin Synthesis  
Prostaglandins play a central role in the process of cervical ripening, dilation and 
stimulation of myometrial contractions. Prostaglandin synthesis has been shown to be a 
dynamic process which is dependent on both gestational stage and stimulus (Pollard and 
Mitchell 1996). Spontaneous active labour is associated with a surge of prostaglandin E2 
(PGE2) and prostaglandin F2α (PGF2α) which leads to a biochemical cascade similar to 
a localised acute inflammatory response (Romero, Munoz et al. 1996, Brown, Alvi et al. 
1998). Inhibition of prostaglandins has been utilised to halt the progression of parturition 
(Besinger, Niebyl et al. 1991), while administration of prostaglandins has been shown to 
induce parturition (Ray and Garite 1992).  
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PGE2 has been shown to have a diverse set of physiological actions which are dependent 
on the distribution and subtype of receptors (EP) available. There are four PGE2 receptors 
(EP1, EP2, EP3, EP4), all of which are expressed in the myometrium during pregnancy. 
Both EP1 and EP3 can couple to either G protein alpha subunit, group Q (Gαq) or G protein 
alpha subunit, group I (Gαi; Rundhaug, Simper et al. 2011). When PGE2 binds to its EP1 
receptor it initialises a signalling cascade that activates phospholipase C (PLC), resulting 
in the production of both 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). 
DAG results in the activation of protein kinase C (PKC) whilst IP3 results in the 
mobilisation of calcium (Figure 1.2; Rundhaug, Simper et al. 2011).  When PGE2 binds 
to its EP3 receptor it initialises a separate signalling cascade which blocks the activation 
of adenylate cyclase (AC), with the effect of reducing adenosine-3’,5’-cyclic 
monophosphate (cAMP) levels.  This then reduces the levels of active protein kinase A 
(PKA), leading to an increase in myosin light chain phosphorylation (Rundhaug, Simper 
et al. 2011) and ultimately an increase in contractility (Figure 1.2).  The binding of PGE2 
to either of these receptors would promote both contraction and the potentiation of the 
inflammatory signal. Conversely, EP2 and EP4 couple to G protein alpha subunit, group 
S (Gαs) and stimulate AC activity and cAMP, while suppressing inflammatory cytokines 
(Rundhaug, Simper et al. 2011). The binding of PGE2 to either of these receptors would 
therefore lead to relaxation and suppression of inflammation (Slater, Astle et al. 2006) 
Figure 1.2). As such PGE2 may also have a role in maintaining quiescence (Figure 1.2).  
 
Similar to PGE2 its receptors EP1-4 are also regulated in a dynamic fashion during 
gestation and parturition (Olson 2003). The pro-contractile EP3 receptor is down-
regulated by 40% between non-pregnant and pregnant human myometrium (Matsumoto, 
Sagawa et al. 1997). In a primate model parturition was associated with a decrease in the 
pro-relaxatory EP2 receptor (Olson 2003), and in a sheep model parturition was associated 
with an increase in the pro-contractile EP3 receptor (Wu, Ma et al. 1999). Potentially 
therefore, tightly regulated temporal expression of specific prostaglandins and their 
associated receptors could regulate the contractility of the myometrium and hence the 
timing of labour. 
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Figure 1.2 Signalling Pathways Activated by the EP Receptors for PGE2  
EP1 activates phospholipase C (PLC), resulting in the production of both 1,2-diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3). DAG activates protein kinase C (PKC) whilst IP3 results in the 
mobilisation of calcium.  EP3 blocks the conversion of adenylate cyclase (AC), reducing adenosine-3’,5’-
cyclic monophosphate (cAMP) levels leading to a reduction in protein kinase A (PKA). EP2 and EP4 couple 
to Gαs and stimulate AC activity and cAMP (Adapted with permission from (Rundhaug, Simper et al. 2011). 
 
1.2.4 Transcriptional Regulation by NFκB 
NFκB is involved in a variety of cellular processes including immune regulation, 
inflammation, cell cycle and apoptosis. NFκB is a rapid-acting transcription factor, a 
transcription factor that is present in the cell in an inactive state and so does not need new 
protein synthesis to be activated, meaning that it can be rapidly induced and acts as a first 
responder to cell stimuli (Perkins 2012).  
 
NFκB has long been associated with inflammation, and is known to be activated by many 
of the cytokines which are prevalent during parturition such as TNF and IL-1β (Perkins 
2007, Perkins 2012). In addition to this, many parturition associated genes are regulated 
by NFκB. A recent array study highlighted that NFκB influenced a wide variety of gene 
networks within the myometrium  and many of these NFκB regulated genes have been 
shown to be differentially regulated during parturition (Chan, van den Berg et al. 2014).  
 
NFκB is comprised of five subunits: p50; p52; p65 (RelA); cRel and RelB. Active NFκB 
consists of homo or heterodimers formed from the various subunits, the most prevalent 
of these being the p50/RelA heterodimer. Chapman et al. (Chapman, Europe-Finner et al. 
2004) showed that there was a specific pattern of expression of each of the NFκB subunits 
in myometrium throughout human pregnancy and parturition. RelA, c-Rel, p100, p105 
and p50 were all detected at high levels in the non-pregnant myometrium, however, there 
was a significant reduction of all of these, with the exception of RelA, in both pregnant 
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non-labouring and labouring myometrium. RelA was significantly reduced between 
pregnant and labouring myometrium, however the level of p50/RelA DNA binding was 
shown to increase. This increase in DNA binding was demonstrated using Electrophoretic 
Mobility Shift Assay (EMSA) and so the caveat to this is that it does not demonstrate 
binding in the context of the native promoter state (Saccani, Pantano et al. 2003), it also 
cannot provide any information on whether this regulation is stimulatory or inhibitory. 
 
As stated previously, parturition is characterised by an increase in pro-inflammatory 
cytokines such as IL-1β, IL-6 and TNF (Romero, Mazor et al. 1992, Opsjln, Wathen et 
al. 1993, Keelan, Marvin et al. 1999, Osman, Young et al. 2003). This influx leads to the 
activation of NFκB, which in turn promotes the expression of pro-contractile genes such 
as PGF2α, Cox -2, oxytocin receptor (OR) and GAP junction protein Connexin 43 
(Mendelson 2009; Figure 1.1). Studies in the mouse have shown that nuclear localisation 
of the p50 and RelA subunits increased closer to term and that administration of SN50, 
an NFκB inhibitor, delayed the onset of labour (Condon, Jeyasuria et al. 2004, Lindstrom 
and Bennett 2005).  Unfortunately this study did not specifically determine that this 
increase in nuclear localisation was associated with an increase in DNA binding. Also 
SN50 is not a NFκB specific inhibitor it is in fact a more general inhibitor of nuclear 
importation (Boothby 2001). Therefore the delay in labour onset seen could be attributed 
to a general inhibition of the nuclear importation of transcription factors or co-factors. 
 
A more recent study utilised ChIP-on-chip combined with expression array analysis to 
reveal the role of RelA-containing NFκB dimers in the regulation of parturition. The 
immortalised PHM1-31 human mymoterial cell line was utilised in this study with TNF 
stimulation used to represent the labouring state. The ChIP-on-chip analysis revealed that 
13,300 genomic regions were bound by RelA-containing dimers in the presence of TNF 
and 11,110 genomic regions were bound in the un-stimulated cells. A portion of these 
bound regions were localised to genes known to be involved in parturition such as Cox-
2 and Potassium Large Conductance Calcium Activated channel subfamily M Beta 
member 3 (KCNMB3). When this ChIP-on-chip data was combined with matched 
expression array analysis it revealed that 14 regions bound by RelA-containing dimers in 
the presence of TNF were up-regulated and a further five were repressed (Cookson, Waite 
et al. 2015). These genes with enriched RelA binding and up-regulated expression levels 
are also documented by Chan et al. (Chan, van den Berg et al. 2014) in their RNA-seq 
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study identifying differentially expressed genes in human myometrium from pregnant, 
non-labouring and actively labouring myometrium. Although this demonstrates that 
NFκB does have role in regulating gene expression during parturition the specifics of this 
role still need to be fully explored. 
 
1.2.5 Progesterone Withdrawal  
Evidence demonstrates that throughout pregnancy, progesterone acting via its nuclear 
receptor, regulates target genes to maintain uterine quiescence. At the end of pregnancy, 
in the majority of mammalian species, the levels of progesterone drops significantly and 
the uterus moves from a state of quiescence into a contractile state (Hardy, Janowski et 
al. 2006). In contrast to this, in humans, there is no reduction in circulating progesterone. 
Instead both progesterone levels and progesterone receptor levels remain elevated 
throughout pregnancy and into labour (Challis JRG, Matthews et al. 2000, Hardy, 
Janowski et al. 2006). It has been suggested, therefore, that a functional withdrawal of 
progesterone occurs through action on the progesterone receptors. There are three 
progesterone receptor isoforms: PR-A, PR-B and PR-C. PR-A and PR-B once stimulated, 
bind to progesterone receptor elements in the genome and regulate transcription. PR-C 
lacks the DNA binding domain and once bound sequesters progesterone away from the 
other receptors (Condon, Hardy et al. 2006). Studies utilising transfection techniques on 
various cell lines (MCF-10, HeLa, CV-1, MCF7) have demonstrated that these three 
isoforms have different effects on the genes they regulate. These effects were found to be 
strongly influenced by the cell and promoter context within which the receptor was acting 
and also which co-factors were recruited (Vegeto, Shahbaz et al. 1993, Chalbos and 
Galtier 1994, Wen, Xu et al. 1994). In most cell contexts PR-B enhances transcription 
while PR-A represses transcription and PR-C binds progesterone sequestering it away 
from PR-B (Vegeto, Shahbaz et al. 1993, Giangrande, Kimbrel et al. 2000, Condon, 
Hardy et al. 2006).  
 
Studies in the PHM1-31 human myometrial cell line have shown that PGF2α increases 
the expression of PR-A mRNA but not PR-B mRNA. PGF2α has been shown to increase 
at the onset of parturition (Romero, Munoz et al. 1996, Brown, Alvi et al. 1998) which 
has led to the hypothesis that functional progesterone withdrawal occurs via the action of 
PGF2α promoting the increased expression of PR-A which in turn represses the 
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transcription of the pro-quiescent genes (Madsen, Zakar et al. 2004). This research, 
however, did not examine the effect of increased expression of PR-A on either gene 
expression or cell contractility. As regulation by PR-A and PR-B has been shown to be 
cell type and promoter context specific it would be necessary to look at the effect on gene 
expression within the PHM1-31 cells in order to prove or disprove this hypothesis. 
 
When comparing PR expression between non-labouring and labouring human and mouse 
myometrium, Condon et al. noted there was a significant up-regulation of both the PR-B 
and PR-C isoforms in labouring tissue. Within the mouse, PR-B mRNA significantly 
increased with parturition in both the upper and lower myometrium, however, PR-B 
protein levels were only seen to increase in upper myometrium. There was also a 200-
fold increase in the expression of the PR-C isoform, which they hypothesised could then 
act as an inhibitor of PR-B function and so may contribute to the functional withdrawal 
of progesterone (Condon, Hardy et al. 2006). However, PR are rapidly downregulated 
when cells are removed from the body and so this may affect the levels measured above. 
 
1.2.6 Ion Channel Expression 
Once the processes of fetal maturation, membrane rupture and cervical ripening and 
dilation are underway, the next step in the process is co–ordinated uterine contractions. 
The myometrial quiescent state is characterised by slow wave potentials where the 
membrane potential cycles between depolarisations and repolarisations without reaching 
the threshold level.  However, within term pregnant myometrium, these slow wave 
potentials become frequent and synchronised action potentials during which the 
membrane potential rapidly rises and falls, causing the muscle to contract (Wilde and 
Marshall 1988).  
 
Both the quiescent state and these co-ordinated contractions are thought to be mediated 
by ion channels, in particular the balance between the large conductance calcium 
activated potassium channel (KCNMA1, MaxiK, BK or slo-1) and the L-type calcium 
channel (CACNA1C). 
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1.2.6.1 The MaxiK Channel (KCNMA1) 
It has been demonstrated that KCNMA1 plays a crucial role in regulating the contractility 
of the myometrium. Studies within the rat myometrium have revealed that KCNMA1 is 
differentially expressed throughout pregnancy. Non-pregnant and early pregnant rat 
myometrium express high levels of KCNMA1 protein and these levels are significantly 
reduced at the end of pregnancy and post-partum (Song, Zhu et al. 1999). KCNMA1 
provides a strong repolarising current which would support myometrial quiescence. 
Therefore, the high levels of KCNMA1 protein seen early in pregnancy would help 
maintain the quiescent phenotype then, as the levels of KCNMA1 reduce towards 
parturition, the myometrium would switch to a more contractile state. This theory would 
need to be studied in human tissue in order to determine if it is relevant to human 
parturition.  
 
1.2.6.2 L-Type Calcium Channel (CACNA1C) 
The CACNA1C is thought to be a critical component of excitation-contraction coupling 
in smooth muscle and as such could contribute to the regulation of labour contractions. 
Studies within the rat myometrium revealed an increase in the number of CACNA1Cs 
within the membrane in late gestation. However, this work utilised the binding capacity 
of the CACNA1C inhibitor Dihydropyridine (DHP) as a measure of the number of 
channels and so this will not necessarily be a representative measure of active or 
functional channels. Although the number of CACNA1Cs was seen to increase there was 
no sharp increase immediately before or during parturition which seems to refute a role 
for these channels in triggering the onset of parturition (Mershon, Mikala et al. 1994). It 
is possible however, that changes in CACNA1C conductance rather than protein number 
may provide the trigger for parturition. 
 
In these final stages of parturition there are clear indications of ion channel involvement. 
More research needs to be done to fully define the channels within the myometrium and 
how they work co-ordinately with each other to change the contractility of the tissue. 
 
1.2.7 Summary of Current Theories 
Although a considerable amount of research has been done to try and understand the 
processes which trigger the onset of parturition there is still no consensus on which 
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process or combination or processes are ultimately responsible for the switch to the 
labouring state. As such there is still a lack of understanding of the key steps involved in 
the switch from quiescence to contractility and further research into this is still needed. 
 
1.3 Preterm Birth 
Why is this research necessary? The human species is clearly surviving and expanding. 
The problem is that the process of parturition can and does go wrong, and when this 
happens it can result in preterm birth. 
 
Each year preterm birth is the biggest cause of death in new born babies. In England and 
Wales nearly 8% (1 in 13) of live births are born prematurely (prior to 37 completed 
weeks of gestation). Evidence suggests that women who have had a previous preterm 
birth are two-and-a-half times more likely to have a further preterm birth than a woman 
who has not (Mercer, Goldenberg et al. 1999). Historically, research has focused 
primarily on improving the survival and health of preterm babies. Such efforts, however, 
have done nothing to decrease the incidence of preterm birth and in fact the incidence of 
severely preterm birth, which is prior to 26 completed weeks of gestation, is increasing 
(Goldenberg, Culhane et al. 2008, Chang, Larson et al. 2013). 
 
Preterm birth can occur as a result of preterm premature rupture of membranes, labour 
induction or Caesarean delivery for maternal or fetal indication or following spontaneous 
labour.  Current research suggests that iatrogenic causes of preterm labour include, 
infection, pre-eclampsia and intrauterine growth restriction. However, spontaneous 
labour accounts for 40-45% of preterm births and the cause of this is still poorly 
understood (Goldenberg, Culhane et al. 2008). 
 
1.3.1 Current Tocolytic Therapies 
Tocolysis, (Greek: tokos – childbirth; lysis – loosening, dissolving, dissolution) the 
inhibition of myometrial contractions, is currently the primary treatment for preterm birth, 
with the goal being to delay birth by a minimum of 18 hours. There are a number of 
tocolytics (anti-contraction medications) currently used which have been designed around 
our current understanding of the events leading up to parturition, which have been 
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described above. These include beta-adrenergic receptor agonists, calcium channel 
antagonists, oxytocin receptor antagonists and progesterone. These current tocolytics, 
however, are associated with contraindications for both mother and child (Gyetvai, 
Hannah et al. 1999).  
 
1.3.1.1 β2 Agonists 
The β2 Adrenergic Receptor (β2AR) is associated with both Gαs and CACNA1C. Once 
activated Gαs activates AC by catalysing the formation of cAMP, which in turn activates 
PKA. PKA in turn acts on a number of smooth muscle structures such as; the sarcolemma, 
resulting in a decrease in calcium influx; the sarcoplasmic reticulum (SR), enhancing 
calcium uptake and the actin-myosin filaments, decreasing their interaction (1992) which 
ultimately leads to smooth muscle relaxation.  
 
β2 agonists activate this pathway and promote an increase in intra-cellular cAMP, a 
decrease in intracellular calcium, via increased SR uptake and decreased calcium influx 
(Figure 1.3; Anotayanonth, Subhedar et al. 2004). Within airway smooth muscle cells, 
treatment with β2 agonists has been shown to cause KCNMA1 channels to open, leading 
to hyperpolarisation of the cells. The combination of decreased intracellular calcium, 
increased potassium efflux and decreased interaction of actin and myosin filaments leads 
to muscle relaxation. 
 
There are three β2 agonists currently used: Terbutaline (currently used Off-Label as the 
FDA have not approved it for tocolysis), Ritrodrine and Salbutamol. These three are 
effective at delaying delivery by 24 to 48 hours with no significant differences seen 
between the effectiveness of each one. Treatment with these tocolytics beyond 48 hours 
has no effect on the reduction of preterm birth nor does it improve perinatal morbidity or 
mortality (Haram, Mortensen et al. 2003). Prolonged use of these drugs is associated with 
the phenomenon of receptor internalisation which results in desensitization of the target 
tissue to their relaxant effects. (van Geijn, Lenglet et al. 2005) 
 
These β2 agonists are not uterine specific and so all three are associated with side effects 
ranging from tremor, anxiety, palpitations, nausea and headache, and the more rare but 
serious side effects of pulmonary oedema (fluid accumulation in the lungs), myocardial 
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ischemia (restricted blood flow causing lack of oxygen to the heart) and cardiac arrest. 
They can also cause metabolic side effects such as hyperglycaemia, due to the non-
specific activation of adrenergic receptors in the liver, leading to hyperinsulinemia 
(excessive circulating insulin) and finally to hypokalemia (excessive potassium in the 
blood) due to a shift in potassium caused by insulin. They can also pass through the 
placenta and may result in fetal tachycardia and fetal hypo- or hyperglycemia at birth 
(Chan, Cabrol et al. 2006, Wisanskoonwong, Fahy et al. 2011).  
 
1.3.1.2 Calcium Channel Antagonists 
Calcium Channel antagonists act by preventing calcium influx through membrane-
spanning calcium channels. This leads to a reduction in intracellular calcium which, in 
turn, leads to a reduction in the creation of calcium:calmodulin complexes, a decrease in 
myosin light chain kinase (MLCK) phosphorylation and subsequently a decrease in 
myosin light chain phosphorylation. This then results in decreased myosin and actin 
interaction promoting smooth muscle relaxation (Figure 1.3). 
 
There are two calcium channel anatgonists currently used: Nifedipine, which is  used Off-
Label, is not recommended for use with patients with hypertension as it can cause an 
increased risk of adverse cardiovascular events (Jaju and Dhabadi 2011), and Nicardipine 
(Laas, Deis et al. 2012). These have been shown to be capable of delaying birth up to 7 
days, however, this has only been demonstrated with a total of 242 patients in 2 studies 
(van Geijn, Lenglet et al. 2005). 
 
There are again side effects with the use of calcium channel antagonists but these are less 
severe than those seen with the β2 agonists (Economy and Abuhamad 2001, King, 
Flenady et al. 2002, Haram, Mortensen et al. 2003). Nifedipine was also responsible for 
less severe side effects in comparison to Nicardipine (Laas, Deis et al. 2012). These side 
effects include dizziness, nausea, headache, weakness and oedema (fluid retention) and 
more rarely transient hypotension (abnormally low blood pressure; Dustan 1989, van 
Geijn, Lenglet et al. 2005). Like β2 agonists, calcium channel antagonists can cross the 
placenta but data of the effect on the fetus is scarce.  
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A 2011 study demonstrated there was an increased risk of seizures among infants whose 
mothers were treated with calcium channel blockers, possibly due to the effect of 
decreased intracellular calcium in these infants. Neonatal seizures can be serious and can 
be associated with poor neurodevelopment (Davis, Eastman et al. 2011). 
 
Unlike the β2 agonists there is no reduction in efficiency with prolonged use of calcium 
channel antagonists (Economy and Abuhamad 2001, van Geijn, Lenglet et al. 2005). 
 
 
Figure 1.3 Mechanisms of Action for Tocolytics  
Nifedipine, a calcium channel antagonist, promotes relaxation by blocking calcium influx through 
membrane-bound calcium channels and in doing so blocks this contractile pathway (black arrows). 
Atosiban, an oxytocin receptor antagonist, inhibits activation of the oxytocin receptor and the associated 
contractile pathway (blue arrows). Ritrodrine, a β2 agonist, activates the β2 adrenergic receptor and the 
associated pathway (green arrows) promoting relaxation. 
 
1.3.1.3 Oxytocin Receptor Antagonist 
The Oxytocin receptor is associated with Gαq. Once activated, Gαq stimulates PLC which 
then generates both DAG and IP3 through the cleavage of phosphatidylinositol 4,5-
bisphosphate (PIP2). IP3 is then released and binds to calcium channels located on the 
endoplasmic reticulum (ER); in turn this causes an increase in intracellular calcium and 
ultimately smooth muscle contraction (Gimpl and Fahrenholz 2001; Figure 1.3). 
Oxytocin receptor antagonists block activation of the oxytocin receptor and so block this 
signalling pathway thereby promoting smooth muscle relaxation. 
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There are currently two oxytocin receptor antagonist used for tocolysis: Atosiban and 
Barusiban (Reinheimer, Bee et al. 2005). Atosiban has been shown to be effective at 
delaying birth for up to seven days but had no significant effect in reducing the number 
of births prior to 37 weeks (Saez, Germain et al. 2003, Papatsonis, Flenady et al. 2005) 
 
Again, oxytocin receptor antagonists can cause side effects including: headache, vomiting 
and nausea and, more rarely, tachycardia, hypotension and hyperglycaemia although less 
so than Ritodrine (Wex, Abou-Setta et al. 2011). Once again Atosiban crosses the 
placenta and, although it does not appear to accumulate in the foetus (de Heus, Mulder et 
al. 2010), it can cause fetal  tachycardia (Wex, Abou-Setta et al. 2011).  
 
1.3.1.4 Progesterone 
The drawback of employing progesterone as a tocolytic is the fact that the mechanism of 
progesterone action is unclear. Progesterone is thought to modify the cellular structure of 
the myometrium through the inhibition of gap junction formation preventing co-ordinated 
muscular contraction (Garfield, Puri et al. 1982). It also blocks the action of oxytocin 
(Borna and Sahabi 2008). 
 
Progesterone was shown to be effective in reducing pre-term birth prior to 37 weeks (Su, 
Samuel et al. 2010). Noted side effects of this drug, however, include headaches, nausea, 
breast tenderness and coughing. The long term potential for harm from the treatment is 
not known and research is needed in this (Wisanskoonwong, Fahy et al. 2011). 
 
1.3.1.5 Summary 
Tocolytics are only able to delay delivery temporarily and are rarely successful beyond 
48 hours. This is sufficient time to allow the woman to be transferred to a specialist unit 
and for corticosteroids to be administered to reduce neonatal organ immaturity, but it is 
insufficient time for the baby to grow and fully mature (Gyetvai, Hannah et al. 1999, 
Chatterjee, Gullam et al. 2007).  
 
An American study in 2003 demonstrated the cost burden of preterm birth. Briefly, the 
neonatal cost for a newborn weighing between 500-700g was $224,000 compared to 
$1,000 for a newborn weighing over 3000g. These costs increased exponentially as 
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gestational age and weight decreased (Gilbert, Nesbitt et al. 2003). This study did not 
take into consideration any longer term care. 
 
Preterm birth, however, does not only affect the infants in the weeks and months 
following birth but in fact one-in-ten babies born severely preterm will develop a 
permanent disability such as lung disease, cerebral palsy, blindness or deafness (Marlow, 
Wolke et al. 2005). Taking into account these additional long-term costs a British study 
calculated that delaying birth by as little as a week would save the UK economy up to 
£260m a year (Mangham, Petrou et al. 2009).  
 
Evidently it is vitally important to develop better strategies for preventing preterm birth 
both in terms of the health of the babies involved and the health care costs (2008), and 
this can only be done by understanding the processes which move the myometrium from 
its relaxed quiescent state to the contractile state seen at parturition.  The development of 
such strategies must begin with understanding the fundamental nature of myometrial 
smooth muscle and its contractile mechanisms. 
 
1.4 Smooth Muscle Structure 
There are three varieties of muscle: smooth, cardiac and skeletal. These all contract by 
sliding thin actin filaments past stationary thick myosin filaments in response to an 
increase in calcium and they all use adenosine triphosphate (ATP) as the energy source 
for this process. This, however, is where the similarities end as each muscle type has a 
different; structure, organisation, mechanism of excitation, excitation-contraction 
coupling, and response to contraction. 
 
Smooth muscle is mostly located within hollow organs and vessels including the vascular 
system, or the digestive tract where contraction acts to move the contents of the tube 
forward. In hollow organs, such as the bladder or uterus, contraction acts to expel the 
contents of the organ.   
 
Smooth muscle cells are spindle shaped, with a single nucleus and are much smaller than 
the multi-nucleated skeletal muscle cells. Smooth muscle itself is further sub-categorised 
as either single unit or multi-unit smooth muscle. Multi-unit smooth muscle is rare and 
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can be found in the eye muscles (related to distance vision), the base of hair follicles and 
the iris. Within this type of muscle tissue the smooth muscle cells are organised into 
functional units which are then separately stimulated by the autonomic nervous system. 
Each of these units is functionally independent from the other units. Single-unit smooth 
muscle is more common; it can be found in the stomach walls and the uterus. Within this 
type of muscle tissue the smooth muscle cells are organised into sheets, with the cells 
lying roughly parallel to each other. Each of the cells is connected to its neighbour via 
gap junctions and they contract together as a single unit. Gap junctions act as low 
resistance pathways which enable electrical signals to rapidly spread throughout the 
tissue. This tissue is stimulated both through the autonomic nervous system and myogenic 
activity. 
 
1.4.1 Molecular Basis of Smooth Muscle Contraction 
When calcium channels on the smooth muscle membrane open and calcium diffuses into 
the cell, this increase in intracellular calcium causes the SR to release small quantities of 
calcium. Four calcium ions then bind to each calmodulin, a messenger protein which 
binds calcium ions and modifies their interactions with various proteins.  In this instance 
activated calmodulin activates MLCK, which in turn phosphorylates myosin through the 
conversion of ATP to adenosine diphosphate (ADP).  Finally, phosphorylated myosin 
binds with actin and cross bridge cycling begins (Figure 1.4).  
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Figure 1.4 Molecular Mechanism of Contraction  
Schematic of the molecular basis of smooth muscle contraction. Calcium enters the cell via calcium 
channels and causes the release of calcium from the sarcoplasmic reticulum (SR). This calcium then binds 
to calmodulin forming a complex which then activates myosin light chain kinase (MLCK). Once activated 
MLCK then phosphorylates the myosin light chain (MLC) which then binds to actin causing contraction. 
Myosin Light Chain Phosphatase (MLCP) removes the phosphate group from MLC and leads to relaxation. 
 
The cross bridge cycle is the process by which the chemical energy stored in the terminal 
phosphate group of ATP is converted into movement.  It begins with the binding of 
phosphorylated myosin to actin, followed by the release of the phosphate group which 
causes a conformational change in myosin, which leads to the power stroke, causing the 
filaments to slide and ADP to be released. A new ATP binds to myosin, allowing it to be 
released from actin.  The ATP is converted to ADP and myosin returns to its original 
conformation.  The cycle then begins again (Figure 1.5). 
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Figure 1.5 Cross Bridge Cycling  
Schematic representation of the Cross Bridge cycling process. 1) ATP binds to the myosin head in its low 
energy configuration; 2) ATP is split into ADP and Pi and the myosin head cocks; 3) The myosin cross 
bridge attaches to the actin filament with the myosin head in the high energy configuration; 4) During the 
power stroke ADP and Pi are released from the myosin head and the head pivots and bends as it pulls the 
actin filament. 
 
Relaxation occurs when calcium is removed from the smooth muscle cell via the use of 
the sodium calcium exchanger or the plasma membrane calcium ATPase transporter 
protein (PMCA) or the Sarco/Endoplasmic reticulum calcium ATPase transporter protein 
(SERCA) or a combination of these. The phosphate group is then removed from myosin 
by myosin light chain phosphatase (MLCP), meaning that myosin can no longer bind to 
actin to form the cross bridges. 
 
1.4.2. Stimulation of Smooth Muscle Contraction 
Smooth muscle can be stimulated electrically. Single-unit smooth muscles, such as lymph 
vessels, have pacemaker regions. In these regions contractions are spontaneously and 
rhythmically generated because of automatic changes in cell permeability.  Once an action 
potential is fired in a pacemaker cell, it will then spread to the rest of the smooth muscle 
cells via gap junctions.  In the intestine the membrane potential gradual alternates between 
hyperpolarizing and depolarizing potentials.  This is termed slow wave potential and is 
caused by cyclical changes in the active transport of sodium.  Although this does not 
always result in an action potential, when it does it again spreads across the whole tissue.  
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A second excitation mechanism in smooth muscle is based on receptor activity; this form 
of stimulation is independent of changes in membrane potential. Increases in IP3, through 
activation of Gαq and PLC, causes a release of calcium from intracellular stores and then, 
via PKC, cause an influx of calcium through the CACNA1C.  The activity of MLCP can 
also be inhibited through antagonists acting through a G protein.  This reduction in MLCP 
activity results in increased myosin phosphorylation and hence increased contraction 
(Christopher 1996). 
 
Finally, smooth muscle can be stimulated by mechanical activity i.e. stretching. 
Stretching either arterial or uterine muscles induces light chain phosphorylation to the 
same extent as muscles contracted by either potassium or norepinephrine. Once the stretch 
is released the contraction which follows is spontaneous.  However, if either a chelating 
agent such as ethylene glycol tetraacetic acid (EGTA), or a calmodulin inhibitor such as 
chlorpromazine, is added, both the light chain phosphorylation and upon release of the 
stretch the spontaneous contraction is abolished. This indicates that mobilisation of 
calcium is needed for both these activities.  It is possible that these effects are the result 
of mechanosensitive receptors in the smooth muscle interacting with calcium release 
channels. 
 
1.4.3 Myometrial Contractility 
The myometrium is composed of smooth muscle cells embedded in an extracellular 
matrix of collagen fibres and functions as single-unit smooth muscle.  In the same way as 
single-unit smooth muscle, the myometrial muscle cells communicate with each other via 
gap junctions.  The contractile state of the myometrium is predominantly controlled by 
intracellular calcium ion concentration.  
 
1.4.3.1 Resting Membrane Potential 
The resting membrane potential of myometrial myocytes has been estimated to be 
between -35 and -80V (Kao 1989, Parkington and Coleman 1990, Sanborn 2000). Similar 
to the intestine this resting potential gradually alternates between hyperpolarizing and 
depolarizing potentials, i.e. slow wave potential.  The oscillations in membrane potential 
correlate with the distribution of calcium, sodium, potassium and chloride ions and the 
permeability of the cell membrane.  Within the myometrium, the cellular excitability is 
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dependent on the movement of sodium, chloride and calcium ions into the cells and 
potassium ions out of the cells. Calcium is the key ion for increasing cellular excitability. 
This arises as calcium ions have the largest electrochemical gradient so there is a rapid 
and significant rise in calcium ion concentration upon the opening of calcium channels in 
the membrane, whereas resting potential is maintained by potassium channels.  Potassium 
channels conduct an outward current while the muscle is inactive to maintain the resting 
potential. Also, after stimulus this outward current conducted by the potassium channels 
repolarises the membrane and hence decreases the excitability of the cell (Figure 1.6).  
The KCNMA1 channel is thought to be the key potassium channel to conduct these 
currents within the myometrium as it is able to respond to changes in calcium as well as 
membrane potential (Aguilar and Mitchell 2010).  
 
 
 
Figure 1.6 Schematic Representation of the Generation of an Action Potential  
Briefly, the membrane potential gradually rises and falls due to ion flux across the membrane but these 
fluctuations do not cross the threshold level. Then, once the calcium channels open, calcium floods into the 
cell and the cell membrane rises (depolarisation) and an action potential is generated. Subsequently, when 
potassium channels open, potassium leaves the cell, the cell membrane potential falls (repolarisation), the 
calcium channels close and the action potential is terminated. Calcium is also removed from the cytoplasma 
by the combined action of the plasma membrane calcium ATPase (PMCA), sarco/endoplasmic menmbrane 
calcium ATPase (SERCA) and the sodium calcium exchanger, the cell then returns to its resting state.  
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1.4.3.2 Generation of Action Potentials 
Contractile activity within the myometrium, like other smooth muscles, is mediated by 
changes in intracellular calcium ion concentration.  The CACNA1C is the predominant 
channel within the myometrium (Tezuka, Ali et al. 1995, Parkington, Tonta et al. 1999, 
Collins, Moore et al. 2000).  When the membrane depolarises to ~ -40mV, the 
CACNA1Cs open and calcium ions flood in causing a significant increase in intracellular 
calcium concentration.  This increase in intracellular calcium activates the contractile 
pathway described above. 
 
T-type calcium channels (CACNA1G) have also been found in the myometrium (Fry, Sui 
et al. 2006, Blanks, Zhao et al. 2007, Lee, Ahn et al. 2009).  It is thought that these 
channels use their faster gating kinetics to propagate the action potential, or possibly by 
opening at more negative voltages they are able to elevate the membrane potential to the 
voltage necessary for the CACNA1C to open. 
 
Once an action potential has been generated this is then transmitted to the rest of the tissue 
via gap junctions.  Garfield et al. demonstrated that the number of gap junctions within 
the myometrium increased in the final stages of pregnancy up until the start of parturition 
(Garfield, Puri et al. 1982).  This increase in gap junctions forms an electrical syncytium 
which is necessary for the generation of co-ordinated myometrial contractions.  
 
1.4.3.3 Return to Resting Membrane Potential 
Once the contraction has taken place it is necessary for the calcium to be removed, in 
order to promote relaxation of the muscle and to allow the SR to replenish its calcium 
stores in preparation for the next contraction. 
 
Calcium can be removed from the cell in a number of ways.  One such way is the use of 
the sodium calcium exchanger.  In simple terms this exchanger utilises the energy from 
the electrochemical gradient of sodium, allowing sodium to flow down the gradient into 
the cell in exchange for the removal of calcium ions (Blaustein and Lederer 1999, Noble 
and Herchuelz 2007). Another method utilises the PMCA.  This transporter protein 
functions by hydrolysing ATP to ADP, with one calcium ion being removed for each 
molecule of ATP hydrolysed (Noble and Herchuelz 2007). The SERCA functions in the 
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same way as the PMCA, with the exception that it transports the calcium from the cytosol 
into the lumen of the SR.  In this way the SR can replenish its stores of calcium (Franklin, 
Winz et al. 2001, Borge, Moibi et al. 2002). 
 
It has been demonstrated that the expression of PMCA and SERCA protein is increased 
in human myometrium during parturition. This would allow for a more rapid recovery 
after a contraction and so these may have a functional role in the regular contractions seen 
during parturition (Tribe, Moriarty et al. 2000).  
 
1.4.4 Regulation of Uterine Contractility 
The non-pregnant myometrium contracts as a reflex response to stretch.  During 
pregnancy this reflex response is suppressed and the myometrium enters a state of 
relaxation termed quiescence. Prior to parturition the myometrium again becomes 
contractile initially, experiencing weak irregular contractions which culminate with a 
relatively short burst of strong rhythmic contractions at parturition.  
 
Although the molecular basis of contraction is understood, the triggers which move the 
myometrium from the quiescent state seen during gestation to the contractile state seen at 
parturition are poorly understood. 
 
It has been suggested that calcium sensitisation may play a role in this switch. Calcium 
sensitisation is the phenomenon by which a given concentration of intracellular calcium 
results in a larger than expected force of contraction (Ratz, Berg et al. 2005, Arthur, 
Taggart et al. 2007, Wray 2007).  Inhibition of myosin light chain phosphatase has been 
suggested to be the mechanism through which calcium sensitization occurs (Uehata, 
Ishizaki et al. 1997). Another putative mechanism for calcium sensitization is via the loss 
or reduction in calcium sensitivity of calcium-activated potassium channels. A reduction 
in, for example, KCNMA1 channel calcium sensitivity would result in a reduction in the 
repolarising current supplied by these channels and hence an increase in contractility. 
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1.5 Calcium Activated Potassium Channels and Voltage-Dependant 
Calcium Channels Within the Myometrium 
Calcium-activated potassium channels, such as the KCNMA1 channel, have an important 
role regulating action potentials in some smooth muscles.  By responding to calcium 
influx they are able to maintain relaxation.  Calcium channels such as the CACNA1C and 
CACNA1G, voltage-dependant calcium channels, regulate the flow of calcium into the 
cell and hence control the contractility of the muscle.  It has been shown that calcium 
release from the SR causes the CACNA1Cs to open, which in turn causes myometrial 
contractions.  The increased intra-cellular calcium level, however, then activates the 
KCNMA1 channel which in turn leads to relaxation (Figure 1.7; Chanrachakul 2006).  In 
theory, the balance between these calcium and potassium channels could result in either 
quiescence or contractility within the myometrium. 
 
 
Figure 1.7 Contraction/relaxation Mechanisms  
A simplified scheme of the contraction/relaxation mechanisms of pregnant human myometrial cell 
(Adapted with permission from Chanrachakul 2006).  
 
1.5.1 The KCNMA1 (BK or slo-1) Channel 
KCNMA1 channels are integral membrane proteins that contain seven membrane-
spanning domains, a pore-forming domain and a cytoplasmic tail region containing four 
hydrophobic domains, and a calcium bowl. KCNMA1 channels can be formed by two 
subunits, the pore-forming α-subunit and the modulatory β-subunit (Figure 1.8).  
 
Activation of the KCNMA1 channels results from changes in membrane electrical 
potential and/or increasing concentrations of intracellular calcium ions (Ca2+; Miller 
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2000, Yuan, Leonetti et al. 2010), making it a unique member of the potassium channel 
family.  The effect of this dual sensitivity is that the KCNMA1 channel can open at 
increasingly negative membrane potentials.  Once open, potassium ions passively flow 
through the channel, down the cells electrochemical gradient.  This leads to a reduction 
in intracellular potassium levels and hence membrane hyperpolarisation, resulting in 
decreased cell excitability.  Intracellular calcium also regulates the physical association 
between the α- and β- subunits. 
 
The link that the KCNMA1 channel provides between free calcium in the cytosol and 
membrane potential is thought to have an important role in membrane excitability (Cui, 
Cox et al. 1997, Schreiber and Salkoff 1997, Schreiber, Yuan et al. 1999).  There is, 
however, a high degree of functional variability observed in the KCNMA1 channel and a 
large proportion of this is related to its calcium and voltage sensitivity (Lagrutta, Shen et 
al. 1994).   
 
 
Figure 1.8 The KCNMA1 Channel  
A schematic representation of the Maxi K channel. The α-subunit is comprised of an extracellular N-
terminus followed by seven transmembrane-spanning domains (S0-S6), with the pore (p) located between 
S5 and S6, and a cytoplasmic ‘tail’ containing four hydrophobic domains and a calcium bowl and ends with 
an intracellular C-terminus. The β-subunit consists of and intracellular N-terminus followed by two trans-
membrane spanning domains and then an intracellular C-terminus (Adapted with permission from Orio, 
Rojas et al. 2002) 
 
1.5.1.1 Calcium Sensitivity in the KCNMA1 Channel 
Calcium sensitivity is thought to be derived from an EF motif in the tail region of the 
KCNMA1 Channel (Korovkina and England 2002).  An EF motif is comprised of two 
alpha-helices (E and F) joined by a loop; calcium is bound by that loop region. Braun and 
Sy used mutational analysis combined with transfection and electrophysiology to locate 
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putative EF motifs in the mouse brain mSlo α-subunit.  Their findings indicate that there 
are two imperfect EF structures – one located in the N terminal region and one 
overlapping the calcium bowl in the C terminal region (Braun and Sy 2001).  
 
The calcium bowl is a highly conserved segment of the KCNMA1 protein which is 
located between S9 and S10 (Schreiber and Salkoff 1997) and the remarkable level of 
conservation between species would indicate that this region is a functionally important 
part of the channel.  The calcium bowl contains a number of aspartic acid residues which 
cause the region to carry an extremely negative charge.  Aspartate is known to co-ordinate 
the calcium ions within calcium binding proteins.  Mutations abolishing the calcium 
sensitivity of the calcium bowl results in a channel which opens more easily at 
physiological voltages with the effect of reducing membrane excitability (Schreiber, 
Yuan et al. 1999).  This research indicates that the calcium sensing region of the 
KCNMA1 channel is predominately located in the C-terminal tail region. 
 
1.5.1.2 Voltage Sensitivity in the KCNMA1 Channel 
Cui et al. showed that the voltage sensitivity of the channel is intrinsic to the channel 
itself and independent of calcium binding (Cui, Cox et al. 1997).  Voltage sensitivity of 
the KCNMA1 channel is thought to be found in the S1 – S4 domain.  Within this, the S3 
/ S4 regions contain some conserved charged residues and a series of three regularly 
spaced arginine residues essential in voltage dependent gating (Meera, Wallner et al. 
1997, Ma, Lou et al. 2006).  Mutational analysis of the charged residues in regions S1 - 
S4, showed that although S4 contains five charged residues, only one of these actually 
contributes to the channel’s gating charge.  This is in sharp contrast to the Shaker channel 
in which five of the seven charged residues in S4 contribute to its gating charge (Ma, Lou 
et al. 2006).  This would account for the lower voltage dependence of the KCNMA1 
channel compared to the Shaker channel despite similarities in structure.  Mutation of the 
charged residues in S2 and S3 showed that these residues accounted for ~50% of the 
voltage sensitivity of the KCNMA1 channel. For a review of the different potassium 
channels see Sansom et al. (Sansom, Shrivastava et al. 2002).   
 
Koval et al. extended this mutagenesis-based study to include the S0 region, which is 
unique to the KCNMA1 channel.  This region is highly conserved between different 
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species and so is thought to be functionally important either as a link between the α- and 
β-subunits or as part of the voltage sensing mechanism (Koval, Fan et al. 2007). Mutation 
of a number of conserved residues within the S0 region was shown to greatly alter the 
gating of the channel (Koval, Fan et al. 2007).  The mechanism of this alteration would 
suggest a multifaceted role of the S0 region including the modulation of active and resting 
state equilibrium, the transduction of β-subunit actions and the stabilisation of the resting 
state channel (Liu, Li et al. 2000). The voltage sensitivity is therefore a property of the 
N-terminal trans-membrane segments of the KCNMA1 Channel.  
 
1.5.1.3 Splice Variants in the KCNMA1 Channel 
Splicing of the KCNMA1 channel transcript has been shown in species as diverse as 
Drosophila (Adelman, Shen et al. 1992, Lagrutta, Shen et al. 1994, Wei, Solaro et al. 
1994); Mouse (Pallanck and Ganetzky 1994, Wei, Solaro et al. 1994, Benkusky, Fergus 
et al. 2000, Holdiman, Fergus et al. 2002); Chicken (Navaratnam, Bell et al. 1997); 
Bovine (Knaus, Eberhart et al. 1995) and Human (Dworetzky, Trojnacki et al. 1994, 
Pallanck and Ganetzky 1994, Tseng-Crank, Foster et al. 1994, Korovkina, Brainard et al. 
2006, Davies, Zhao et al. 2007, Korovkina, Stamnes et al. 2009) this is not surprising 
considering the sequence homology found between these species (~92%). Alternate 
splicing of the KCNMA1 channel can alter its calcium sensitivity, voltage sensitivity, 
sensitivity to protein phosphorylation and cellular localisation. This provides a 
mechanism for fine tuning the channels response to a diverse range of regulatory and 
conductance requirements.  
 
Splice variants can be generated by various means such as the alternative use of cassette 
exons or mutually exclusive exons, alternative splice donor sites, alternative splice 
acceptors sites and intron retention. A cassette exon is the name given to an optional exon 
which can be retained by optional splicing within an intron.  When one of two exons is 
retained, but not both these are termed mutually exclusive exons. Splice donor sites cause 
either elongation or shortening of the preceding exon by splicing at an alternative intron 
sequence near the 5' end.  Splice acceptor sites cause either elongation or shortening of 
the following exon by splicing at an alternative intron sequence near the 3' end (Figure 
1.9; Jurkat-Rott and Lehmann-Horn 2004). There are a number of splice variants found 
in the human KCNMA1 channel, which are summarised in Table 1.1. 
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Korovkina et al. demonstrated the presence of a 132 base pair (bp) exon (M1 / Mk44; 
accession number AF349445) which, if inserted, would result in a 44 amino acid (aa) 
segment being inserted into the S0 – S1 linker region.  This forms a functional channel 
with diminished sensitivity to intracellular calcium and also voltage.  The amino acid 
sequence of the insert contains two consensus sites for protein phosphorylation and also 
a myristylation site (Korovkina, Fergus et al. 2001, Korovkina, Brainard et al. 2006).  
 
 
Figure 1.9 Splicing Events  
Diagrammatic representation of the basic types of alternate splicing events (Gathman 2009) 
 
Phosphorylation alters channel function (Lieberman and Mody 1999). Yan et al. 
demonstrated that phosphorylation of affinity purified KCNMA1 channels from rat brain 
membranes altered the channels dependence on voltage and calcium for activation (Yan, 
Olsen et al. 2008). Phosphorylation can also have a role in protein-protein interactions, 
cell membrane localisation and subcellular targeting.  
 
Myristylation has an important function in membrane localisation of proteins and 
interaction between different subunit proteins (Raju, Kakkar et al. 1997). Given that 
membrane localisation of the KCNMA1 channel is essential for its activity and that 
association with its accessory β-subunit can affect calcium sensitivity, the presence of a 
myristylation site within this splice variant is worthy of further investigation. 
 
Korovkina et al. went on to show that the Mk44 variant undergoes proteolytic digest. The 
N-terminus was localised to the cell membrane using co-localisation experiments.  
However, Korovkina demonstrated that the Mk44 C-terminus was not expressed on the 
cell membrane but instead was intracellular and localised specifically with the 
endoplasmic reticulum (Korovkina, Brainard et al. 2006).  After calcium release from the 
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sarcoplasmic reticulum-based stores, however, the C-terminus was found to translocate 
to the membrane and reconstitute with the N-terminus, forming a functional channel. 
 
Table 1.1 KCNMA1 Splice Variants 
Splice variants found in the human KCNMA1 Channel, their location, exon profile and the effects they 
have on channel function. 
Locus Channel 
Region 
Splice Variation 
Profile 
Putative Effects References 
M1 
Mk44 
 
S0-S1 linker 132bp insert 
between exons 1 
and 2 
Decreased voltage 
and Ca2+ 
sensitivity 
 (Korovkina, 
Fergus et al. 2001, 
Curley, Morrison 
et al. 2004) 
M2 S6-S7 linker Mutually 
exclusive use of 
exons 10 and 11 
or 11 and 12 
Truncation of the 
protein 
(Curley, Morrison 
et al. 2004) 
M3 
SRKR 
S8-S9 linker 3 variants of exon 
19 – a 3’ 
truncation, 
skipping of exon 
19 or the use of 
the entire exon 
unknown (Tseng-Crank, 
Foster et al. 1994, 
Curley, Morrison 
et al. 2004, 
Davies, Zhao et 
al. 2007)   
M4 
STRE
X 
S8-S9 linker Differential 
utilization of 
exons 22 and 23 
(deletion of both – 
insertless, 
inclusion of 22 – 
STREX-1 and 
inclusion of both – 
STREX-2) 
Mechano-
sensitivity 
Hypoxia 
inhibition 
Altered response 
to PKA 
(Curley, Morrison 
et al. 2004, 
Davies, Zhao et al. 
2007, Lu, Alioua 
et al. 2006, 
Pietrzykowski, 
Friesen et al. 
2008) 
M4 
IYF 
S8-S9 linker Inclusion of exon 
22 
Hypoxia 
insensitivity 
 (Zarei, Zhu et al. 
2001, Davies, 
Zhao et al. 2007) 
M5 
Ca27 
S9-S10 linker Insertion or 
deletion of exon 
29 
Increased 
activation rate 
 (Tseng-Crank, 
Foster et al. 1994, 
Yan, Olsen et al. 
2008) 
 
Davies et al. investigated a splice variant in the S8 – S9 linker region. The identified two 
variants; SVcyt which contained an additional 255bp and SV0 which lacked the 255bp 
insert. They found that SVcyt was retained within the cytoplasm, while SV0 was 
expressed on the membrane (Davies, Zhao et al. 2007).  SVcyt was found to be an inactive 
form of the KCNMA1 channel while SV0 was active.  
 
The SVcyt splice variant is actually a collection of three distinct but adjacent splice sites 
which have been reported in the S8-S9 linker region.  There is some difficultly correlating 
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the research of these different splice sites as there is no common nomenclature used for 
the different sites.  
 
There is a 12bp insert known as SRKR (M3), within the S8-S9 region.  However, the 
effect of this insert on human channel function has not been fully explored (Tseng-Crank, 
Foster et al. 1994). 
 
The STress Regulated EXon (M4 / STREX), also located between S8 and S9, has been 
shown to increase the mechano-sensitivity of the channel (Lu, Alioua et al. 2006, Wang, 
Huang et al. 2010) and to confer hypoxia inhibition (McCartney, McClafferty et al. 2005).  
The STREX insert also contains a cAMP dependant PKA consensus motif.  
Phosphorylation of the KCNMA1 channel with the STREX insert by PKA facilitates 
membrane depolarisation.  However, PKA phosphorylation of the KCNMA1 channel 
without the STREX insert facilitates membrane repolarisation. In simple terms 
phosphorylation by PKA in the presence of STREX facilitates contraction and 
phosphorylation in the absence of STREX facilitates quiescence (Tian, Coghill et al. 
2004).  
 
An alternative sequence to the STREX insert is the amino acid triplet IYF (M4; Appendix 
1 Amino acid code), which confers insensitivity to hypoxia (McCartney, McClafferty et 
al. 2005).  Also reported in this region is the Ca27 (M5) insert (Tseng-Crank, Foster et 
al. 1994, Yan, Olsen et al. 2008) which is found proximal to the calcium bowl and 
contains a phosphorylation site.  Channels containing the Ca27 insert have increased 
activation rates and their co-operativity with calcium is modified (Ha, Jeong et al. 2000, 
Yan, Olsen et al. 2008), possibly due to its proximity to the putative EF hand motif and 
calcium bowl. 
 
The differential expression of KCNMA1 isoforms in different tissues and species, and 
the fact that multiple isoforms can be present in a single cell, combined with different 
research techniques – whether RNA transcription or protein expression was studied or if 
whole cell protein or membrane protein was extracted and the tissue type used - means 
that it is difficult to combine this extensive research into one complete picture.  
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1.5.1.4 KCNMA1 Channel Expression During Gestation 
The expression of different KCNMA1 channel isoforms is both tissue- and stimulus-
specific. During gestation, the myometrial cell is increasingly permeable to calcium and 
membrane potential increases to more depolarised potentials at term (Benkusky, Fergus 
et al. 2000). Therefore, alternative splicing of the KCNMA1 channel may be a mechanism 
by which uterine contractility can be modulated during gestation. 
 
The non-pregnant myometrium naturally contracts when subjected to stretch but the 
pregnant myometrium must stretch to accommodate the growing foetus. This reflex 
contraction must be inhibited until the initiation of labour, when the myometrium must 
rhythmically contract to expel the fetus.  Calcium channels are responsible for the 
contractility of smooth muscle, and the calcium-activated potassium channels counteract 
the influx of calcium and maintain smooth muscle relaxation.  A fine balance of these 
two channels would appear to be essential in the maintenance of quiescence during 
gestation and then the progression into labour. 
 
There is general agreement that the predominant potassium channels in myometrial cells 
are KCNMA1 channels (Khan, Smith et al. 1993, Song, Zhu et al. 1999, Curley, Morrison 
et al. 2004) and that the calcium sensitivity of these channels decreases at the onset of 
labour (Khan, Smith et al. 1993, Khan, Smith et al. 1997, Song, Zhu et al. 1999, Curley, 
Morrison et al. 2004). There is much less agreement, however, on whether this reduction 
in calcium sensitivity is due to reduced expression of the channel (Chanrachakul, 
Matharoo-Ball et al. 2003, Gao, Cong et al. 2009) or if it is due to a change in splice 
variant expression (Khan, Smith et al. 1997).  
 
Gao et al. demonstrated that the expression of the α- and β-subunits is significantly 
decreased between pregnant and labouring samples in both the upper and lower segment 
myometrium, but the portion of the various splice variants present were not examined 
(Gao, Cong et al. 2009).  Other research has reported a switch in the splice variant 
expression between non-labouring and labouring myometrium, but these studies tend not 
to put this in the context of overall expression of the KCNMA1 channel (Curley, Morrison 
et al. 2004). 
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The Mk44 splice variant has been shown to be present in the human myometrium (Curley, 
Morrison et al. 2004) and has been shown to be up-regulated in labouring myometrium 
(Curley, Morrison et al. 2004). This particular splice variant has decreased calcium and 
voltage sensitivity and so could explain the decreased calcium sensitivity of KCNMA1 
channels found in labouring myometrium.  
 
The expression of a second splice variant, Ca27, was found to be unchanged in labouring 
myometrium. Indeed, this particular variant is responsible for increased activation of the 
KCNMA1 channel. Faster activation of the KCNMA1 channel would result in a faster 
response to membrane depolarisation. This variant may then contribute to the 
maintenance of quiescence.   
 
Finally, although STREX variant expression in the myometrium has not been directly 
studied, Zhu et al. have looked at the effect of PKA in pregnant and non-pregnant 
myometrium (Zhu, Eghbali et al. 2005). cAMP and cyclic guanidine monophosphate 
(cGMP) can activate potassium channels and specifically the KCNMA1 channel and in 
this way may contribute to the maintenance of quiescence.  KCNMA1 channels 
phosphorylated by PKA via cAMP, and by endogenous membrane bound Protein Kinase 
G (PKG) via cGMP generate increased activity in the pregnant myometrium (Zhou, Wang 
et al. 2000). This increased activity would inhibit the natural contractile response to 
stretch.  Conversely in non-pregnant myometrium, PKG has been shown to inhibit 
KCNMA1 channels.  The switch between enhancing and inhibitory effects of PKA / PKG 
between pregnant and non-pregnant myometrium would indicate that there are different 
splice variants present whose response to PKA / PKG differs. This switch effect correlates 
well with the known properties of the STREX variant, specifically the facilitation of 
membrane depolarisation following PKA phosphorylation when STREX is present, and 
facilitation of membrane repolarisation following PKA phosphorylation when STREX is 
absent. 
 
The activation of PKA is dependent on the presence of cAMP. Essentially, cAMP being 
formed as a result of AC-mediated catalytic cyclization of ATP.  This process is 
dependent on the Gαs subunit of a stimulated G-protein complex.  Europe-Finner et al. 
demonstrated that Gαs levels in the myometrium were increased during pregnancy and 
decreased during labour (Europe-Finner, Phaneuf et al. 1994, Europe-Finner, Phaneuf et 
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al. 1997).  This would result in increased PKA during pregnancy and a decrease during 
labour.  The effect of these changes on the KCNMA1 channel would be dependent on the 
splice variant expressed at the different time points, and so a study specifically looking at 
STREX variant expression in the pregnant and labouring myometrium would be the next 
logical step in this research.  
 
1.5.1.5 Regulation of KCNMA1 Expression 
The KCNMA1 channel promoter has been cloned and characterised and this research has 
revealed two regions of the promoter which are necessary for positive promoter 
regulation. These regions are located -567bp to -220bp, and +80bp to +355bp from the 
Transcription Start Site (TSS). SP1 binding is thought to be responsible for the promoter 
activity in the -567bp to -220bp region as this region contains 3 SP1 binding sites 
(consensus sequence 5’-(G/T)GGGCGG(G/A)(G/A)(C/T)-3’; -331bp, -226bp, and -
222bp) and deletion of this region decreased promoter activity. Whilst the +80bp to 
+355bp region is thought to contain positive regulatory elements as deletion of this region 
decreased promoter activity by 50% (Dhulipala and Kotlikoff 1999). The KCNMA1 
promoter was also shown to contain a CCTCCC sequence which is located 27bp upstream 
of a TATA like sequence, this positioning is identical to that found in the SM1/2 gene 
and in this gene it results in increased transcriptional activity of the gene within smooth 
muscle (Dhulipala and Kotlikoff 1999). Two CArG boxes (consensus sequence 5’-
CC(A/T)6GG-3’) were also identified at positions -361bp and -1449bp. A CArG box is a 
conserved sequence motif located in genes which comprise the MADS-box gene family 
of transcription factors, such as serum response factor (Schwarz-Sommer, Huijser et al. 
1990). MADS-box genes are involved in a variety of functions such as muscle 
development and cell proliferation (Shore and Sharrocks 1995). Binding of serum 
response factor to CArG box chromatin has been shown to have a pivotal role in 
controlling the transcription of smooth muscle specific genes (McDonald, Wamhoff et al. 
2006).  This research, however, did not demonstrate specific transcription factor binding 
but rather inferred the importance of transcription factor binding due to the location of 
their binding sites in relation to the regions found to be required for positive promoter 
regulation. In addition to this hypermethylation of the KCNMA1 promoter has been 
shown to result in down regulation of transcription in pancreatic duct cells (Vincent, 
Omura et al. 2011). 
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1.5.1.6 Regulation of Splice Variant Expression 
It is clear that the different splice variants allow the KCNMA1 channel to fine-tune its 
response to changing physiological conditions, but what triggers the expression of the 
different variants at the correct times is poorly understood.  Estrogen and progesterone 
have been shown to affect the expression of the STREX exon.  Estrogen elicits a reduction 
in STREX expression while progesterone causes an increase in expression (Holdiman, 
Fergus et al. 2002, Zhu, Eghbali et al. 2005).  
 
A wide range of adrenal androgens and glucocorticoids have also been shown to affect 
STREX expression in chromaffin cells. Androgens seem to promote STREX expression 
while glucocorticoids inhibit its expression (Xie and McCobb 1998, Lai and McCobb 
2002). 
 
SVcyt is down regulated in diabetic mice, with an observed increase of up to 80 fold in 
the insert-less SV0 variant compared to the SVcyt variant.  Treatment with insulin 
increased the expression of SVcyt (Davies, Zhao et al. 2007). The difficulty with this 
observation is that, as stated before, the SVcyt insert is comprised of three different 
inserts. Therefore it is necessary to clarify which of the variant sequences is key before 
conclusions can be drawn from this observation. 
 
1.5.2 Voltage-Dependant Calcium Channels 
These are a group of voltage-gated ion channels found in excitable cells that are 
permeable to calcium. They are voltage-dependant as they are activated at depolarized 
membrane potentials. Activation allows calcium to enter the cell which, depending on the 
cell type, results in muscular contraction, excitation of neurons, up-regulation of gene 
expression, or release of hormones or neurotransmitters. Voltage-dependent calcium 
channels are formed as a complex of several different subunits: α1, α2δ, β1-4, and γ.  
 
The α1-subunit forms the ion-conducting pore and is comprised of four repeats (I – IV) 
with each repeat containing six membrane-spanning domains (S1 – S6 Figure 1.10).  
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Figure 1.10 Voltage-depenant Calcium Channel  
Subunit structures of a voltage-dependant Calcium Channel (Adapted from Sigma Aldrich) 
 
There are several different kinds of voltage-dependant calcium channels: the neural N-
type channel, the R-type channel involved in poorly defined processes in the brain, the 
closely-related P/Q-type channels, the CACNA1G involved in pacemaker activity and 
the CACNA1C responsible for excitation-contraction coupling of skeletal, smooth and 
cardiac muscle and for hormone secretion in endocrine cells. 
 
1.5.2.1 Calcium Selectivity in the Voltage-Dependant Calcium Channel 
The channel pore is comprised of a narrow external pore lined by the pore loop (Catterall 
2000). The S5 and S6 membrane spanning domains and the membrane-associated linker 
region between them are responsible for the formation of the pore lining. Within the pore 
there are four glutamate residues, one in each repeat. Mutational analysis has shown that 
these glutamate residues are responsible for the high affinity the channel has for calcium 
(Ellinor, Yang et al. 1995). 
 
1.5.2.2 Voltage Sensitivity in the Voltage-Dependant Calcium Channels 
The S4 membrane spanning domains in each repeat serve as the voltage sensor for the 
channel (Yamakage and Namiki 2002). This region is comprised of repeating positively 
charged amino acids such as arginine or lysine in every third or fourth position. These 
positive residues function as gating charges. Mutational analysis of the positively charged 
residues found in the S4 segment of both potassium and sodium channels have shown 
that each positively charged residue does not contribute equally to the gating charge 
(Catterall 1995).  When the membrane becomes depolarised, the S4 segment moves 
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outwards as a result of these positively charged residues and the pore opens (Reuter 1996, 
Catterall 2000) 
 
1.5.3 The L-Type Calcium Channel (CACNA1C) 
The L-type calcium channel is a type of voltage-dependent calcium channel. "L" stands 
for long-lasting referring to the length of activation. Five subunits (α1, α2, β, γ, and δ) 
make up the CACNA1C.  Like the others of this class, the α1-subunit is the one that 
determines most of the channel's properties. They are responsible for normal myocardial 
and vascular smooth muscle contractility. 
 
1.5.3.1. Splice Variants in the CACNA1C Calcium Channel 
As with the KCNMA1 channel, the CACNA1C is also subject to splicing.  Eleven sites 
of variation have been identified which span the whole length of the channel these are 
summarised in Table 1.2. Splice variants of the CACNA1C can affect functions as diverse 
as membrane expression, voltage dependence, calcium sensitivity, calcium dependent 
inactivation, excitation contraction coupling, β-subunit binding and sensitivity to DHP 
block (Perez-Reyes, Wei et al. 1990, Snutch, Tomlinson et al. 1991, Diebold, Koch et al. 
1992, Soldatov 1992, Soldatov 1994, Yang, Chen et al. 2000, Yang, Obinata et al. 2000, 
Abernethy and Soldatov 2002, Tang, Liang et al. 2004, Bannister, Thomas-Gatewood et 
al. 2011).  
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Table 1.2 CACNA1C Calcium Channel Splice Variants 
Splice variants founds in the human CACNA1C calcium channel, their location, exon profile and the effects they have on channel function 
Locus Channel 
Region 
Splice Variation Profile Putative Effects References 
L1 N-terminus Mutually exclusive insertion of exon 1, 
1b or 1c 
Membrane expression  (Snutch, Tomlinson et al. 1991, 
Soldatov 1992, Bannister, Thomas-
Gatewood et al. 2011) 
L2 N-terminus / I 
S1 
4 nucleotide insertion between exons 2 
and 3 
Unknown (Snutch, Tomlinson et al. 1991, 
Soldatov 1992) 
L3 I S4 – S5 12 nucleotide deletion between exons 6 
and 7 
Modification of calcium sensitivity (Soldatov 1992, Abernethy and Soldatov 
2002) 
L4 I S6 - II Inclusion of one of two mutually 
exclusive exons: 8 or 8a or the deletion 
of both, alongside the insertion or 
deletion of exon 9 
Modification of dihydropyridine block 
sensitivity 
(Soldatov 1992) 
L5 Linking loop 
between I - II 
inclusion or deletion of an exon: 9* Production of non functional channel (Tang, Liang et al. 2004) 
L6 Linking loop 
between I - II 
inclusion or deletion of an exon: 10* Production of non functional channel (Tang, Liang et al. 2004) 
L7 II S4 –S5 73 nucleotide deletion Modification of β subunit binding (Soldatov 1992, Soldatov 1994, 
Abernethy and Soldatov 2002) 
L8 Linking loop 
between II - III 
12 nucleotide deletion Modification of excitation / contraction 
coupling 
(Snutch, Tomlinson et al. 1991) 
L9 III S2 Inclusion of one of two mutually 
exclusive exons: 21 or 22 or the deletion 
of both 
Modification of voltage dependence (Soldatov 1992, Soldatov 1994) 
L10 IV S2 – S4 There are twelve combinations of the 5 
exons (30, 31, 32, 33, and 34) in this 
region. 
Modification of voltage dependence, in 
relation to the length of the linking loop 
(Perez-Reyes, Wei et al. 1990, Yang, 
Chen et al. 2000) 
L11 C-terminus 52nt insertion Modification of Calmodulin binding and 
calcium dependant inactivation. 
(Perez-Reyes, Wei et al. 1990, Snutch, 
Tomlinson et al. 1991, Diebold, Koch et 
al. 1992, Soldatov 1992, Soldatov 1994, 
Tang, Liang et al. 2004). 
L12 C-Terminus Mutually exclusive insertion of exons: 45 
or 45* with or without a 57 nucleotide 
deletion. 
Removal of cAMP dependant protein 
Kinase A site 
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It has also been shown that use of different splice variants, or combinations of splice 
variants, have a marked effect on current density, activation/inactivation kinetics and cell 
excitability (Snutch, Tomlinson et al. 1991, Soldatov 1992, Kepplinger, Kahr et al. 2000, 
Koschak, Reimer et al. 2001, Tang, Liang et al. 2004, Cheng, Pachuau et al. 2009, 
Bannister, Thomas-Gatewood et al. 2011). Temporal expression of specific variants 
could therefore be utilised to promote either relaxation or contraction depending on the 
needs of the cell. This ability to alter the physiological properties of the channel makes it 
an attractive target to study when examining the switch between myometrial quiescence 
and contractility. There is, however, a paucity of information regarding the control of 
expression of the different splice variants. 
 
The ability of DHP to block CACNA1Cs is commonly utilised to quantify the number of 
channels in a particular cell or tissue sample. This could be responsible for giving 
researchers false information regarding the levels of CACNA1C expression, as there are 
variants with modified sensitivity to DHP block (Soldatov 1992). This highlights the 
importance of directly quantifying the level of channel expression and not relying solely 
on indirect methods. 
 
Most studies have focused on a single splice variant and from this have inferred the 
specific variant’s effect on the channels properties.  However, this can give a distorted 
picture. It is unlikely that there is only one splice variant present and the expression of a 
combination of splice variants could have the effect of either amplifying the effects of 
individual splice variants or conversely they could reduce the effects of individual 
variants. This was demonstrated in a study by Cheng et al. where it was shown that the 
use of exon 33 with exon 9* leads to a negative shift in activation and inactivation 
potential, and inclusion of 33 without 9* leads to a positive shift in both the activation 
and inactivation potentials (Cheng, Pachuau et al. 2009).  
 
Further studies by Soldatov et al. and Kepplinger et al. also demonstrate the cumulative 
effect of multiple splice variants. They both examined the region covering exons 39 – 43, 
which may modulate tethering of calmodulin to the C-terminal and therefore have an 
effect on calcium dependant inactivation of the channel (Soldatov, Zuhlke et al. 1997, 
Kepplinger, Kahr et al. 2000).  
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Three variants have been studied in this region 1C86, 1C72 and 1C77. These three 
variants contain different complements of exons: 1C86 contains exon 40 with a 17bp 
deletion, exon 40B and exon 43 with a 132bp extension; 1C72 contains exon 40, exon 
41, an additional 57bp, exon 42 and exon 43, 1C77 contains exons 40, 41, 42, and 43.  
 
It was found that 1C86 had the fastest inactivation kinetics and recovery of the three 
variants. Both 1C86 and 1C72 were inactivated at more negative potentials than 1C77 
with 1C86 inactivating at the most negative potential. Calcium-dependant inactivation 
was eliminated in 1C86 and was highest in 1C77 (Soldatov, Zuhlke et al. 1997). Also, 
1C77 was more efficiently targeted to the cell membrane and had higher conductance 
and open probability than 1C86 (Kepplinger, Kahr et al. 2000).  
 
It is possible that the poor targeting, low conductance and fast inactivation of the 1C86 
channel are protective measures due to the lack of calcium-dependant inactivation found 
in this channel. These would limit the amount of calcium the channel could allow into the 
cell. 
 
Another point which is frequently overlooked when studying the CACNA1C is the fact 
that the channel is only active when it is inserted into the membrane. Clearly, however, 
there are splice variants which result in the channel being held in the cytoplasm in an 
inactive state. Hence, it is important to separate active membrane-bound channels from 
inactive cytosolic channels when measuring expression levels, especially if inferences are 
then made about the effect of channel expression on cell excitability. It would be 
interesting to examine if cytosolic retention of the CACNA1C is a reversible process as 
has been demonstrated with the Mk44 variant of the KCNMA1 channel, as this would 
open up the possibility of the cell being able to house a cytoplasmic store of CACNA1Cs 
which could be rapidly translocated to the cell membrane when required. 
 
The different splice variants have been shown to affect smooth muscle contractility and 
so manipulation of the expression of these variants could hypothetically lead to repression 
of contractility, and may be of therapeutic use in the treatment of preterm birth. Hence, it 
is important to now focus on the physiological triggers for specific splice variant 
expression. 
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1.5.3.2 C-Terminal Proteolytic Cleavage of the CACNA1C Calcium Channel 
The CACNA1C has been shown to exist in two forms: a long ~220kDa protein and a 
shorter ~190kDa protein. The shorter protein is formed by proteolytic cleavage of the C- 
terminal tail region. Calpain has been shown to be responsible for this cleavage (Hell, 
Westenbroek et al. 1996) which occurs in exon 42 between splice variants 11 and 12. 
Interestingly, it has been shown that calmodulin binds calpain substrates and in doing so 
can regulate calpain-mediated proteolysis causing inhibition of this process (Wang, 
Villalobo et al. 1989, Iwamoto, Lu et al. 2010). The 52 bp insertion at splice site 11 has 
been shown to modulate calmodulin binding and therefore this splice site could have an 
effect on the cleavage of the channel.  
 
Once cleaved, the C-terminal fragment can either co-localise with the rest of the channel 
or can move into the nucleus (Hell, Westenbroek et al. 1996, Gerhardstein, Gao et al. 
2000, Hulme, Konoki et al. 2005, Gomez-Ospina, Tsuruta et al. 2006, Hulme, Yarov-
Yarovoy et al. 2006, Schroder, Byse et al. 2009, Satin, Schroder et al. 2011). 
 
Cleavage of the C-terminus results in a calcium channel with four to six fold higher ion 
conductance in comparison with the full-length channel (Hell, Westenbroek et al. 1996), 
which would suggest that the C-terminal region exerts some form of inhibitory control. 
After proteolytic processing the C-terminal fragment associates non-covalently with the 
body of the channel and this interaction reduces the coupling of gating charge movement 
to channel opening, and the voltage dependence of the channel is moved to more positive 
membrane potentials (Hulme, Yarov-Yarovoy et al. 2006). This inhibition, however, is 
relieved by cAMP-dependant phosphorylation (Hulme, Konoki et al. 2005), due to the 
fact that phosphorylation of a putative PKA consensus sequence at serine 1,700 modifies 
the interaction of the C-terminal fragment with the body of the channel (Hulme, Yarov-
Yarovoy et al. 2006). Again, there is a splice site in this location, site 12, where a 57 bp 
insertion removes a cAMP-dependant PKA serine site in exon 48. This gives another 
layer of control over channel activity. 
 
Within the nucleus, the C-terminal fragment of the CACNA1C has been shown to bind 
to its own promoter and down-regulate transcription (Schroder, Byse et al. 2009, Satin, 
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Schroder et al. 2011). It has also been shown to regulate the expression of a number of 
genes including connexin 3.1 in neurons, the Na/Ca exchanger which works co-ordinately 
with the calcium channel to maintain cellular calcium (Schroder, Byse et al. 2009) and 
the potassium channel KCNN3 (Figure 1.11).  
 
 
Figure 1.11 Changes in mRNA Expression due to CACNA1C C-terminal Fragment Expression  
A subset of mRNAs identified in microarray experiments that were up regulated (red bars) or down 
regulated (green bars) by expression of the CACNA1C C-terminal proteolytically cleaved fragment 
(Reprinted with permission from Gomez-Ospina, Tsuruta et al. 2006).  
 
C-terminal fragment nuclear localisation has been shown to be mediated by intracellular 
calcium, with decreasing calcium levels promoting nuclear localisation. Nuclear 
localisation has also been shown to be increased by serum-mediated cellular hypertrophy 
in cardiac myocytes (Gomez-Ospina, Tsuruta et al. 2006). 
 
1.5.3.3 CACNA1C Calcium Channel Expression During Gestation 
Information regarding expression levels of the CACNA1C protein or mRNA in the 
human myometrium during gestation is sparse. Parkington showed that there is an 
increase in myometrial cell excitability in the third trimester, which coincides with 
decreasingly negative membrane potentials. This has the effect of increasing the open 
probability of voltage-dependant calcium channels, which in turn provides the calcium 
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influx that is a critical component for both excitation-contraction coupling and for the 
phosphorylation of myosin light chains, which is necessary for their contraction 
(Parkington, Tonta et al. 1999). 
 
Channel-blocking experiments have provided evidence that the majority of calcium 
currents are due to CACNA1Cs (Tezuka, Ali et al. 1995, Parkington, Tonta et al. 1999, 
Collins, Moore et al. 2000). The CACNA1C senses membrane depolarisation, opens and 
increases both intracellular calcium concentration and cell contraction.  
 
Studies of rat myometrium have shown that the mRNA for the α-subunit of the 
CACNA1C channel increases gradually during gestation, peaking at around a 6.9 fold 
increase prior to labour then decreases sharply during labour and post-partum. This 
increase in the α-subunit is comprised of at least two splice variants, termed SIV3A and 
SIV3B.  These two variants correlate well with some of the variants found within splice 
site 10. Splice site 10 occurs between IV S2 and S4 and involves the differential utilisation 
of exons thirty to thirty four.  SIV3A correlates with the usage of exons 30, 31, 33 and 34 
or 30, 31, 34 and SIV3B correlates with the usage of exons 30, 32, 33 and 34 or 30, 32, 
34 (Mershon, Mikala et al. 1994). Prior to parturition the SIV3B splice variant is 
expressed in an approximately 2.5:1 ratio with the SVI3A variant. Then at parturition this 
ratio changes to a 10:1 ratio and post-partum the ratio reverts back to 2.5:1 (Mershon, 
Mikala et al. 1994). Huang et al. showed that in rabbit ventricular myocytes the SVI3B 
variant was associated with greatly increased excitation-contraction coupling (Huang, Xu 
et al. 2006). In the myometrium the increase in expression of this variant at parturition 
would support myometrial contractions. 
 
Tribe et al. isolated two different sized α-subunit RNAs from myometrial tissue and 
showed that there was a greater increase in the longer α-subunit RNA compared to the 
shorter one (Tribe, Moriarty et al. 2000). Combining this information with the research 
by Mershon et al. related to the expression of the specific splice variants would indicate 
that the larger α-subunit RNA could correlate with the SIV3B variant, and the shorter α-
subunit RNA could correlate with the SVI3A variant. These splice variants are in a region 
known to be involved in voltage dependence.  
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Voltage dependence has been shown to be linked to the length of the linking loop between 
repeat IV S3 and S4 (Perez-Reyes, Wei et al. 1990, Yang, Chen et al. 2000). The fact that 
Tribe et al. isolated two different sized α-subunit RNAs from the myometrial tissue would 
suggest that the splice variants would result in different sized proteins, and combining 
this information with the splice variants described by Mershon et al. would point to the 
fact that this difference in size could be specifically related to the IV S3-S4 linker region. 
These changes in α-subunit levels were found to be associated with both term and preterm 
induced labour.  
 
Tezuka et al. demonstrated that if progesterone is used to prevent the α-subunit from 
reaching its peak levels then labour does not occur (Tezuka, Ali et al. 1995). In this 
research Onapristone, a progesterone receptor antagonist, is used to induce labour. As 
there is little understanding of the mechanisms by which a reduction in progesterone leads 
to the induction of parturition, it is difficult to ascertain just how accurate a picture of 
labouring myometrium this use of onapristone provides. 
 
Both the regulation of expression of the CACNA1C and its functions would indicate that 
it could potentially play a significant role in the preparation of the myometrium for the 
switch from quiescence to contractility at labour. 
 
1.5.3.4 Regulation of CACNA1C Calcium Channel Expression 
The CACNA1C promoter is less well characterised, early research into the transcriptional 
regulation of the CACNA1C was carried out on the rat CACNA1C gene, in cardiac 
myocytes and vascular smooth muscle and this research identified a possible eight TSS 
and determined that the promoter did not contain a TATA box. This early research did, 
however, identify an initiator sequence spanning one of the TSS and so this was termed 
the major TSS. The region between -726bp and -234bp of the major TSS provided the 
majority of basal promoter activity (Liu, Fan et al. 2000). Later research revealed a >69% 
homology between the rat and human CACNA1C promoters (Dai, Saada et al. 2002). 
The CACNA1C, however, can utilise three different N-terminal sequences depending on 
the usage of either exon 1a, exon 1b or neither exon. Within smooth muscle it has been 
demonstrated that the majority of transcripts utilise exon 1b (Pang, Koren et al. 2003). 
Transcripts containing exon 1b have been shown to possess a unique 5’ untranslated 
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region, and the region immediately upstream of exon 1b was shown to have promoter 
activity suggesting that these exon 1b containing transcripts are regulated by a separate 
promoter (Saada, Dai et al. 2003).  This putative exon 1b promoter (Promoter B) was also 
shown to be a TATA-less promoter. The absence of TATA or CAAT boxes alongside the 
presence of several GC-rich SP1 consensus elements mean that Promoter B is 
characteristic of a housekeeping-type promoter (Pang, Koren et al. 2003). Promoter B has 
been shown to contain a putative cAMP response element and binding of CREB and CBP 
have been shown to induce gene expression (Fan, Chen et al. 2000). Further interrogation 
of the Promoter B sequence revealed a putative CArG box sequence located +288bp from 
the TSS (Sun, Chen et al. 2006) and a CCTCCC sequence -597bp from the TSS, both of 
these elements are important for the regulation transcription of smooth muscle genes. 
Using the YAPP Eukaryotic Core Promoter Predictor tool a putative initiator sequence 
was located close to the TSS (Cartharius, Frech et al. 2005, Gershenzon and Ioshikhes 
2005, Jin, Singer et al. 2006) and using the PROMO transcription factor binding motif 
search tool a TFII-I binding sequence was located +48bp from the TSS (Messeguer, 
Escudero et al. 2002, Farré, Roset et al. 2003), TFII-I has been shown to be important in 
initiating transcription from TATA-less promoters (Manzano-Winkler, Novina et al. 
1996). Within TATA-less promoters the initiator sequence performs a similar function to 
the TATA box in that it co-ordinates the formation of a stable initiation complex which 
is necessary to facilitate the binding of RNA Polymerase II and the initiation of 
transcription (O'Shea-Greenfield and Smale 1992, Manzano-Winkler, Novina et al. 
1996). As the CACNA1C promoter is CG-rich it is possible that methylation has a role 
in the regulation of transcription and within the heart hypomethylation of the CACNA1C 
promoter has been shown to increase gene expression (Koczor, Torres et al. 2015). Within 
colonic smooth muscle, however, although inflammation led to a suppression of the 
CACNA1C channel transcription, no changes in the methylation status of the promoter 
were observed (Choi, Chen et al. 2011). This would indicate that the effect of methylation 
on the CACNA1C promoter is tissue and / or stimulus specific. 
 
1.5.4 The T-type Calcium Channel (CACNA1G) 
The T-type calcium channel is another member of the voltage-gated calcium channel 
family. "T" stands for transient referring to the length of activation. As with other sub-
types of voltage-gated calcium channel, the α1 subunit is the one that determines most of 
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the channel's properties. CACNA1G calcium channels may contain one of three α1 
subunits, α1G (Cav3.1), α1H (Cav3.2) or α1I (Cav3.3; Nilius, Talavera et al. 2006, 
Talavera and Nilius 2006). 
 
The CACNA1G calcium channel produces the pacemaker potential in the sino-atrial (SA) 
node of the heart (Mangoni, Couette et al. 2006). Similarly, in the central nervous system 
(CNS), CACNA1G calcium channels contribute to tonic bursting activity in the thalamus 
(Huguenard 1996). Both of these properties are potentially important in the generation of 
the rhythmic spontaneous contractions seen in the labouring myometrium. 
 
1.5.4.1 Splice Variants in the CACNA1G Calcium Channel 
Variants of the CACNA1G calcium channel are formed by the alternative use of six 
cassette exons (8, 14, 16, 26, 34 and 35), two alternative splice donor sites (25C and 30B), 
four alternative splice acceptors sites (25A, 25A', 25A'' and 31A) and one protein-coding 
intron (38B; Mittman, Guo et al. 1999, Chemin, Monteil et al. 2001, Bertolesi, Walia Da 
Silva et al. 2006, Emerick, Stein et al. 2006, Shcheglovitov, Vitko et al. 2008). These are 
summarised in Table 1.3.  
 
Splicing of the CACNA1G has been shown to affect ion conductance, membrane 
expression, PKA phosphorylation sites and interaction with effector proteins (Chemin, 
Monteil et al. 2001, Bertolesi, Walia Da Silva et al. 2006, Emerick, Stein et al. 2006, 
Shcheglovitov, Vitko et al. 2008). Expression of these different variants results in 
channels with different activation/inactivation kinetics and firing patterns (Bertolesi, 
Walia Da Silva et al. 2006, Emerick, Stein et al. 2006). Splicing of this channel is mainly 
located in the cytoplasmic loop regions (Emerick, Stein et al. 2006, David, Garcia et al. 
2010). 
 
Splice variants have been described which are incapable of conducting ions due to the 
removal of differing amounts of the repeat II S6 helix (Chemin, Monteil et al. 2001, 
Bertolesi, Walia Da Silva et al. 2006, Emerick, Stein et al. 2006). If these variants are 
still inserted in the membrane as inactive channels, this then opens up the possibility that 
they could compete for accessory subunit or effector protein binding and hence have a 
negative effect on overall channel activity i.e. a dominant-negative inhibitor.   
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Table 1.3 CACNA1G Calcium Channel Splice Variants 
Splice variants founds in the human CACNA1G calcium channel, their location, and their exon profile 
Locus Channel 
Region 
Splice Variation 
Profile 
Putative Effects References 
T1 Linking loop 
between I - II 
Insertion or deletion 
of exon 8 
Modification of 
protein trafficking 
(Shcheglovitov, 
Vitko et al. 2008) 
T2 Linking loop 
between II - III 
Insertion or deletion 
of exon 14 
Addition of a PKC 
Phosphorylation 
site 
(Bertolesi, Walia 
Da Silva et al. 
2006) 
T3 Linking loop 
between II - III 
Insertion or deletion 
of exon 16 
Modification of 
interaction with 
effecter proteins 
(Chemin, Monteil et 
al. 2001) 
T4 Linking loop 
between III - 
IV 
Three splice 
acceptors sites in 
exon 25 (25A, 
25A’, 25A’’) 
Non ion conducting 
channels 
(Chemin, Monteil et 
al. 2001, Bertolesi, 
Walia Da Silva et 
al. 2006, Emerick, 
Stein et al. 2006) 
T5 Linking loop 
between III - 
IV 
Splice donor site in 
exon 25 (25C) 
Modification of ion 
permeation and 
gating 
T6 Linking loop 
between III - 
IV 
Insertion and/or 
deletion of exons 
25C and 26 
Modification of ion 
permeation and 
gating 
T7 Linking loop 
between IV S4 
– S5 
Splice donor site in 
exon 30 (30B) 
Modification of 
voltage dependent 
activation 
(Emerick, Stein et 
al. 2006) 
T8 IV S5 Splice acceptor site 
in exon 31 (31A) 
Prematurely 
truncated protein 
(Emerick, Stein et 
al. 2006) 
T9 C-terminus Insertion or deletion 
of exon 34, 35 and 
protein coding 
intron 38 
Modification of 
length and binding 
site complement of 
C-terminal Tail 
(Bertolesi, Walia 
Da Silva et al. 
2006). 
 
As with the KCNMA1 and CACNA1C, the CACNA1G also has a variant which affects 
membrane expression. The fact that all three channels have variants which affect 
membrane expression would indicate that control of the channel in this way is 
evolutionarily important. It would be interesting to examine if the cytosolic retention of 
the CACNA1G is a reversible process as has been demonstrated with the Mk44 variant 
of the KCNMA1 channel, as this would open up the possibility of the cell being able to 
house a cytoplasmic store of CACNA1G which could be rapidly translocated to the cell 
membrane when required. 
 
A number of studies have demonstrated that, as with the CACNA1C, expression of a 
combination of variants can have a cumulative effect on channels properties.  
 
Studies of the effect of exons 14, 25C, 26, and 38B on channel properties have illustrated 
that inclusion of exon 25C generates a channel which is activated at the most negative 
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potentials and has the most negative steady state midpoint.  Channels lacking both exons 
25C and 26 are activated at more positive potentials and have the most positive steady 
state midpoints, and those expressing exon 26 activate at midpoint potentials and a mid-
range steady state midpoint.  
 
The expression of exon 14 with either exon 25C or 26 increases the rate of inactivation 
of these channels. The most rapid inactivation is seen with the combination of exons 14 
and 25C. The expression of exon 14 without either exons 25C or 26 slows the inactivation 
of the channels.  
 
In combination with either exons 25C or 26 with or without exon 14, the expression of 
exon 38B has no effect on inactivation.  However, in the absence of all of these, exon 
38B slows inactivation. Channels expressing exon 26 and with exon 38 absent have 
substantially increased steady state magnitude.  However, the absence of exon 38 in the 
presence of exon 25C decreases steady state magnitude, and the absence of both exons 
25C and 26 combined with the absence of exon 38 has no effect on steady state magnitude 
(Chemin, Monteil et al. 2001, Jagannathan, Punt et al. 2002, Bertolesi, Walia Da Silva et 
al. 2006, Emerick, Stein et al. 2006). 
 
One set of variants worthy of further research are exons 34, 35 and 38. These are found 
in the C-terminal region which contains binding sites for calcium, calmodulin and Gβγ 
proteins. Although functional studies are lacking for these variants, analogous variants in 
other CACNA1G have resulted in premature truncation, slowed activation, accelerated 
inactivation and slowed recovery from inactivation. These final three culminate in 
sustained firing patterns (Jurkat-Rott and Lehmann-Horn 2004), which are important in 
the generation of rhythmic contractions like those seen during labour. 
 
Some of these variants have been shown to be developmentally regulated.  For example, 
there is an almost global switch from exon 26 expression in the fetus to exon 25C 
expression in the adult (Emerick, Stein et al. 2006). 
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1.5.4.2 CACNA1G Calcium Channel Expression During Gestation 
There is little direct information regarding CACNA1G protein or mRNA levels during 
gestation, although it has been reported that the expression levels of the CACNA1G vary 
in relation to gestational age, with a general increase throughout gestation (Fry, Sui et al. 
2006, Blanks, Zhao et al. 2007, Lee, Ahn et al. 2009).  
 
There is, however, electrophysiological evidence demonstrating the presence of these 
channels in the myometrium (Knock and Aaronson 1999, Fry, Sui et al. 2006, Blanks, 
Zhao et al. 2007, Shmygol, Blanks et al. 2007, Lee, Ahn et al. 2009, Aguilar and Mitchell 
2010) and a large amount of information on the potential role of these channels in relation 
to myometrial contractility. Known CACNA1G functions could contribute to processes 
which are vital for myometrial smooth muscle contraction, control of resting membrane 
potential and increased intracellular calcium.  
 
The myometrium is capable of generating spontaneous phasic contractions in response to 
rising intracellular levels of calcium independent of external stimuli (Tribe, Moriarty et 
al. 2000, Shmygol, Blanks et al. 2007, Lee, Ahn et al. 2009). The generation of these 
spontaneous phasic contractions is due to the ability of the cell to fire regenerative action 
potentials (Lee, Ahn et al. 2009). Regenerative action potentials are created when a 
channel opening at a low threshold is able to initiate the opening of enough channels to 
initiate an action potential.  
 
One of the properties of the CACNA1G is that it opens upon small membrane 
depolarisations and allows calcium to enter the cell.  This has the effect of further 
depolarising the cell membrane, which in turn allows the opening of other voltage 
dependent ion channels and initiates action potential bursts. Once the membrane has 
repolarised the CACNA1G deactivate slowly, which results in a significant calcium 
influx following an action potential.  
 
This influx of calcium following the action potential is a potentially significant feature of 
the CACNA1G function as calcium is an important secondary messenger which, via 
myosin light chain kinase, is responsible for generating the force of contraction (Blanks, 
Zhao et al. 2007).  
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Transient hyperpolarisation of the cell membrane as a result of action potential bursts can 
also activate tonically inactivated CACNA1G. This results in more channels becoming 
available to open when the membrane next depolarises and increases their ability to 
generate further action potential bursts (Blanks, Zhao et al. 2007, Aguilar and Mitchell 
2010). The net effect of this is an increase in intracellular calcium levels, which in turn 
could potentially have a significant role in the generation of the spontaneous phasic 
contractions seen in the myometrium (Lee, Ahn et al. 2009). Specific inhibition of the 
CACNA1G results in decreased force, frequency and amplitude of contractions, as well 
as a reduction in the magnitude of the initiation spike (Fry, Sui et al. 2006, Lee, Ahn et 
al. 2009, Aguilar and Mitchell 2010).  
 
This evidence points to a role for calcium entry via CACNA1G in the initiation, frequency 
and force of myometrial contractions.  
 
1.5.4.3 Regulation of CACNA1G Calcium Channel Expression  
Two core promoters have been identified in the promoter region of the CACNA1G the 
first located between -43bp and +7bp (PA) and the second located between +154bp and 
+204bp (PB) from the TSS (Bertolesi, Jollimore et al. 2003). Sequential 5’ deletions of 
the promoter region revealed a putative enhancer region located between -383bp and -
231bp from the TSS as there was a decrease in promoter activity when this sequence was 
deleted. This enhancer region increased activity from the PA promoter (Bertolesi, 
Jollimore et al. 2003). A second research group identified the region -105bp to the start 
ATG (+267bp to +372bp from the TSS) as important for strong activation of gene 
transcription, whilst they demonstrated that the region from -312bp to -280bp from the 
start ATG (-474bp to -442bp from the TSS) was responsible for negative regulation of 
gene transcription (van Loo, Schaub et al. 2012). It is possible, therefore, that the region 
between +267bp to +372bp may act as an enhancer for the PB promoter. The region 
between the two promoters (+7bp to +154bp) and promoter PB were shown to reduce the 
activity of the PA promoter (Bertolesi, Jollimore et al. 2003). The activity of the two 
promoters was shown to be cell type specific (Bertolesi, Jollimore et al. 2003). Both 
CACNA1G promoters have the characteristics of a TATA-less core promoter and share 
sequence similarity to other initiator sequences. Within the promoters there are numerous 
binding sites for both SP1 and NFκB. As both promoters are TATA-less, SP1 may be 
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responsible for the recruitment of TATA-binding protein associated factors and may also 
facilitate the interaction between the basal transcription machinery and the core promoter 
(Bertolesi, Jollimore et al. 2003). Egr1 was shown to strongly activate CACNA1G 
transcription, the binding of Egr1 was shown to occur in the region between -1588bp and 
-1350bp from the TSS (van Loo, Schaub et al. 2012). Conversely, the first intron of the 
CACNA1G gene contains a highly conserved REST binding site, REST is a repressor 
element, binding of REST to the CACNA1G was shown to strongly counteract Egr1 
activation of the CACNA1G (van Loo, Schaub et al. 2012). Methylation of the region 
between -300bp to -800bp from the start ATG in the CACNA1G was show to closely 
correlate with gene inactivation in colon cancer (Toyota, Ho et al. 1999), and so 
methylation may have a role to play in the regulation of transcription of the CACNA1G. 
 
1.5.5 Accessory Proteins of the Voltage Dependant Calcium Channels 
As stated previously, voltage-dependent calcium channels are formed as a complex of 
several different subunits: α1, α2δ (CACNA2D1-4), β1-4 (CACNB1-4), and γ (CACNG1-
8). The binding of these accessory subunits to the core α-subunit can have a marked effect 
on channel kinetics, amplitude and trafficking. 
 
1.5.5.1 Role of the Beta (β) Subunit (CACNB1-4) 
The β-subunit binds with high affinity to the linker loop between repeats I and II in the 
α1-subunit (Bichet, Cornet et al. 2000, Dolphin 2003, Opatowsky, Chen et al. 2004, Van 
Petegem, Clark et al. 2004), and binding of this β-subunit has been shown to modify 
channel trafficking (Birnbaumer, Qin et al. 1998, Bichet, Cornet et al. 2000, Meir, Bell 
et al. 2000, Dolphin 2003, Opatowsky, Chen et al. 2004), voltage dependant activation 
and inactivation rates (Birnbaumer, Qin et al. 1998, Bichet, Cornet et al. 2000, Meir, Bell 
et al. 2000, Dolphin 2003, Van Petegem, Clark et al. 2004), current amplitude (Meir, Bell 
et al. 2000, Dolphin 2003), channel open probability (Opatowsky, Chen et al. 2004), G 
protein and kinase regulation (Bichet, Cornet et al. 2000, Meir, Bell et al. 2000), and both 
the number of drug binding sites and the affinity of drug binding (Bichet, Cornet et al. 
2000, Hering 2002, Van Petegem, Clark et al. 2004). 
 
The β-subunit binding site on the α1-subunit of the CACNA1C, the α-interaction domain 
(AID), is flanked by two endoplasmic reticulum retention signals, the first occurring 16aa 
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before the AID and the second 74aa after the AID (Bichet, Cornet et al. 2000). In the 
absence of the β-subunit these ER retention signals severely restrict surface expression of 
the channel. In the presence of the β-subunit, however, surface expression is increased, 
suggesting that binding of the β-subunit either masks the ER retention signal or facilitates 
the release of the channel from the ER (Bichet, Cornet et al. 2000). As the channel is only 
active once it is expressed on the cell surface this possibility of ER retention highlights 
the importance of separating active channel from inactive channel when examining the 
expression of the channel and inferring what effects these changes in channel expression 
may be having. Interestingly, the CACNA1G does not require the β-subunit for surface 
expression (Dolphin 2003).  
 
Binding of the β-subunit causes a shift in the voltage dependence of activation and steady 
state inactivation in the hyperpolarising direction (Dolphin 2003).  This results in 
channels which open at more negative membrane potentials and an increased number of 
channels opening. Overall, β-subunit binding creates channels with increased mean open 
time and decreased mean closed time (Dolphin 2003), which will increase intracellular 
calcium. This increased intracellular calcium is vital for myometrial contraction. 
 
1.5.5.2 Role of the Alpha 2 Delta (α2δ) Subunit (CACA2D1-4) 
The α2δ-subunit is composed of an extracellular α2 segment linked by disulphide bonds 
to a trans-membrane δ segment, which anchors the α2 segment (Gurnett, De Waard et al. 
1996, Felix, Gurnett et al. 1997, Klugbauer, Marais et al. 2003).  
 
Putative binding sites for the trans-membrane segment have been shown in both repeats 
III and IV in the link between S5 and S6 (Felix, Gurnett et al. 1997).  However, a binding 
site has not been found in the α1-subunit of the CACNA1G (Klugbauer, Marais et al. 
2003). Binding of the α2δ-subunit to the α1-subunit has been shown to modify channel 
kinetics (Klugbauer, Marais et al. 2003), voltage dependence of both activation and 
inactivation (Bichet, Cornet et al. 2000, Klugbauer, Marais et al. 2003), channel 
trafficking (Klugbauer, Marais et al. 2003), current amplitude (Gurnett, De Waard et al. 
1996, Felix, Gurnett et al. 1997) and both the of number drug binding sites and the affinity 
of drug binding (Felix, Gurnett et al. 1997, Bichet, Cornet et al. 2000) 
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Co-expression of this subunit with the α1 / β-subunits form channels with accelerated 
activation and inactivation kinetics; this has been shown to be a function primarily of the 
δ segment. Co-expression also increased surface expression of the channel with a 
resulting 2-fold increase in current density in COS7 cells and this has been shown to be a 
function of the α2-subunit specifically (Klugbauer, Marais et al. 2003). COS7 cell are a 
fibroblast cell line and so care must be taken when extrapolating from this data into 
smooth muscle cells. An increase in current amplitude of around 10-fold has also been 
reported after binding of the α2δ-subunit (Gurnett, De Waard et al. 1996). It is unclear if 
these changes are a result of either improved targeting or stabilisation, or if the α2δ-
subunit is having a direct modulatory effect. Overall, the binding of the α2δ-subunit will 
result in increased intracellular calcium and so again will promote myometrial 
contractility. 
 
1.5.6 KCNMA1, CACNA1C and CACNA1G Channel Associations. 
Caveola, specialist lipid rafts, are small invaginations of the plasma membrane (Anderson 
1998). The presence of caveolae changes the local morphology of the plasma membrane 
and may play a role in excitation-contraction coupling (Calaghan and White 2006). They 
are formed and maintained primarily by caveolin proteins, namely caveolin-1, -2 and -3 
 
(Daniel, El-Yazbi et al. 2006). Caveolin-1 and -3 can form discrete subcellular signalling 
compartments while caveolin-2 is thought to stabilise caveolae formed by caveolin-1 
(Balijepalli, Foell et al. 2006). Caveolin-1 and -2 are ubiquitously expressed while 
caveolin-3 is smooth muscle specific (Capozza, Cohen et al. 2005, Kozera, White et al. 
2009). 
 
1.5.6.1 Caveola and Caveolins in the Myometrium 
Caveolin-1 and -2 have been identified within the myometrium (Taggart, Leavis et al. 
2000, Turi, Kiss et al. 2001, Smith, Babiychuk et al. 2005). Caveolin-3, however, appears 
to be difficult to detect.  It has been reported as absent in mouse uterine biopsies (Li, Liu 
et al. 2001, Turi, Kiss et al. 2001) but reported as present both in rat uterine longitudinal 
smooth muscle and myocytic cells (Taggart, Leavis et al. 2000, Capozza, Cohen et al. 
2005, Smith, Babiychuk et al. 2005). This confusion may arise through species specific 
differences in expression or in tissue specific differences in expression (i.e. between 
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longitudinal versus circular muscle in the uterus) this would mean that studies in different 
species or tissues could show different levels of expression.  
 
The active KCNMA1 channel is located on the plasma membrane and can be found within 
caveolae (Grunnet and Kaufmann 2004, Brainard, Miller et al. 2005, Daniel, El-Yazbi et 
al. 2006). In the myometrium, KCNMA1 channels have been found to associate with 
caveolin-1 and -2 (Brainard, Miller et al. 2005, Lu, Alioua et al. 2006). The CACNA1C 
has also been co-localised to caveolae in canine airway smooth muscle (Darby, Kwan et 
al. 2000) and has been specifically co-localised with caveolin-3 in cardiac and skeletal 
muscle. The CACNA1G has also be co-localised with caveolin-3. 
 
1.5.6.2 The Role Caveolae in Calcium Handling 
Caveolae have been implicated in calcium handling (Darby, Kwan et al. 2000, Taggart, 
Leavis et al. 2000, Brainard, Miller et al. 2005). Within the myometrium it is thought that 
caveolae facilitate the localisation of key calcium handling components. Interestingly the 
SR is also closely associated with caveolae (Darby, Kwan et al. 2000) and the caveolae 
may have a role controlling the formation of local SR calcium release (Löhn, Fürstenau 
et al. 2000) 
 
The structure of the calveolae creates a micro-domain which can ‘house’ a transient 
increase in calcium due to a caveola localised calcium channel, which in turn causes a 
local calcium release event (a calcium ‘spark’) from the closely associated SR (Löhn, 
Fürstenau et al. 2000; Figure 1.12). It is possible then for these calcium ‘sparks’ to occur 
without appreciable cytosolic calcium elevation. 
 
1.5.6.3 The Hormonal Control of Caveolae and Caveolins 
Recent work has revealed that caveolae may be under hormonal control, estrogen and 
progesterone have been shown to regulate both the number of caveolae and the levels of 
caveolins. Stimulus with estrogen reduced the number of caveolae by ~90% and, although 
progesterone had no effect on its own, when it was used in conjunction with estrogen it 
prevented this down regulation. A membrane bound form of estrogen receptor has been 
found localised within caveolae.   
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Figure 1.12 Schematic Representation of the Generation and Effect of Calcium Sparks  
Calcium influx through calcium channels housed within caveolae can result in a localised calcium release 
event (calcium spark) from ryanodine receptors on closely associated sarcoplasmic reticulum this is termed 
calcium induced calcium release. 
 
1.5.6.4 Role of Caveolae and Caveolins During Gestation 
In rats it has been shown that during the first half of gestation caveolin-1 and -2 expression 
is suppressed to levels below that seen in non-pregnant controls.  In the second half of 
pregnancy levels of caveolin-1 gradually increase until the day before parturition when 
they reach levels close to that seen in non-pregnant controls, while levels of caveolin-2 
remain at around 25-30% of control levels throughout gestation (Turi, Kiss et al. 2001).  
 
Cholesterol has also been shown to affect the formation of caveolae. During pregnancy 
there is a significant increase in cholesterol which increases the number of caveolae and 
inhibits uterine activity. This could indicate that caveolae are involved in uterine 
signalling cascades and possibly contractility. When cholesterol is reduced there is an 
increase in the force of contraction and calcium levels, which would indicate that caveolae 
use ion channels as mediators. This leads to the hypothesis that reduced cholesterol levels 
in pregnancy would result in an increased risk of preterm birth and conversely that high 
cholesterol levels would result in an increased risk of a prolonged labour due to the 
decreased force of the contractions (Smith, Babiychuk et al. 2005). 
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The β2AR has been directly linked to both the CACNA1C in neurons (Davare, Avdonin 
et al. 2001, Liu, Shi et al. 2004), the KCNMA1 channel (Liu, Shi et al. 2004) and both 
channels together (Liu, Shi et al. 2004). This macromolecular complex (Figure 1.13) may 
also contain a G protein, an adenylyl cyclase, an A-kinase anchor protein and PKA 
(Chanrachakul, 2006). This complex would enable specific local regulation of both 
channels. Whether this complex exists within the caveolae, or whether this is a separate 
process by which the two channels can be brought into close proximity, is yet to be 
determined.  
 
 
Figure 1.13 Proposed Macromolecular Complex  
A molecular model of the proposed KCNMA1, CACNA1C, β2 adrenergic receptor macromolecular 
complex (Adapted with permission from Liu, Shi et al. 2004) 
 
Interestingly, some of the components of this complex are required for the maintenance 
of quiescence and are utilised as targets for current tocolytics For example, Ritodrine, a 
β2AR agonist, targets the β2AR on the outer membrane of myometrial cell, and activates 
AC which increases the level of cAMP, which in turn decreases intracellular calcium (Li, 
Zhang et al. 2005). Nifedipine, a calcium channel antagonists, targets calcium channels 
leading to a reduction in intracellular calcium. Both these lead to a decrease in uterine 
contractions. This may indicate that the formation of this complex is involved in the 
regulation of the timing of labour contractions. 
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1.6 Work Described in this Thesis 
This project focuses primarily on the changes in the excitability of the myometrium as it 
progresses from quiescence to co-ordinated uterine contractions, and specifically the roles 
KCNMA1, CACNA1C and CACNA1G channels play in these changes.  
 
The myometrium undergoes a number of changes during gestation and at the initiation of 
parturition. The most obvious of these is suppression of contraction during gestation and 
the generation of strong rhythmic contractions during labour. As well as these changes, 
there are a number of less obvious modifications including an increasingly depolarised 
plasma membrane, an increase in intracellular calcium, increased myometrial cell 
excitability and increased levels of cholesterol, estrogen and progesterone. In mice there 
is also a decrease in progesterone around the onset of parturition. This decrease in 
progesterone is not seen in humans and so a different mechanism may be in place. 
 
To date it has been shown that all three channels (KCNMA1, CACNA1C and 
CACNA1G) can be modulated through the expression of splice variants with differing 
calcium and voltage sensitivities and gating kinetics. This would suggest that these ion 
channels play a central role in both the maintenance of quiescence and in the generation 
of contractions at parturition.  
 
Quiescence could be initiated and maintained through the co-ordinated expression of 
KCNMA1 variants, with increased activation kinetics and increased calcium sensitivity 
such as the Ca27 and / or the STREX negative variant and high β-subunit expression. 
Alongside the expression of CACNA1C variants with slower activation kinetics, 
increased calcium dependant inactivation and reduced membrane expression such as 
variants containing exons 1c, 8, 19 or 17 and 18 and / or exon 33 and reduced β-subunit 
expression.   
 
Towards the end of gestation, contraction could be initiated through a shift in the splice 
variant expression. At this time KCNMA1 channels with low calcium sensitivity such as 
the Mk44 and STREX insert channels could be expressed which would promote 
contraction. At the same time expression of CACNA1Cs with faster activation kinetics, 
improved membrane targeting and decreased calcium dependant activation such as 
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variants containing exon 1, 8*, 9* and possibly variant α1C86 would also promote 
contraction. Increased expression of the CACNA1G channel variants which promote 
sustained firing would help maintain contractions.  
 
Temporal control of expression of different ratios of channel splice variants could have a 
significant role in both the maintenance of quiescence and in the initiation and 
maintenance of contractility. Splicing requires the formation of the spliceosome complex. 
The spliceosome is formed in the following way: U1 binds to the GU site in the pre-
mRNA, SF1 binds to the ‘A’ branch site and U2AF binds to the pyrimidine rich sequence. 
Then, following ATP hydrolysis SF1 leaves the complex and U2 binds to the ‘A’ branch 
site. Following this the U4/U6.U5 tri snRNA is incorporated into the complex and links 
U1 and U2. Finally the complex undergoes rearrangement, where U6 replaces U1 at the 
GU site, to form a catalytically active complex in which U2 and U6 interact. The 
formation of this complex is regulated by splicing factors which bind to splicing 
regulatory elements and either enhance or silence splicing. Serine-Arginine rich proteins 
are splicing factors which recruit the splicing machinery to splice sites while 
heterogeneous nuclear ribonucleoproteins are splice factors which repress splicesome 
assembly.Within the myometrium it has been demonstrated that splice factors Splice 
factor 2 (SF2) and hnRNPA1 are controlled in a spacio-temporal fashion (Pollard, Sparey 
et al. 2000, Shin and Manley 2004). SF2 is a transacting splicing factor which is necessary 
for all splicing to occur, as it promotes the recruitment of U1 to the splicesome while 
hnRNPA1 is a splicing suppressor, which represses spliceosome assembly by 
multimerization, blocking the binding of the splicing machinery.  
 
Pollard et al. demonstrated that during gestation there was a substantial increase in 
SF2/ASF levels concomitant with a decrease in the levels of hnRNPA1/A1B in the lower 
uterine region. This pattern of expression was shown to be reversed in the upper uterine 
region (Pollard, Sparey et al. 2000). During labour there was a further increase in 
hnRNPA1/A1B in the upper uterine region and a significant decrease in the levels of 
SF2/ASF in the lower uterine region. Pollard et al. hypothesised that this polariation of 
expression could regulate the spacial expression of specific protein isoforms (Pollard, 
Sparey et al. 2000). This specific spacial protein isoform expression may be important in 
defining the functions of the different uterine regions e.g. the upper region governs 
contraction whilst the lower region governs dilation.  
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Tyson-Capper et al. also studied the role of splicing in the regulation of uterine activity, 
specifically the regulation of the splicing of Cyclic AMP-response Element Modulator 
(CREM) protein (Tyson-Capper, Bailey et al. 2005). CREM has a major role in the 
regulation of cAMP-responsive genes which are involved in uterine activity during 
gestation. CREM can exist as two isoforms: CREMτ2α, a potent transcriptional activator 
and CREMα, a transcriptional repressor. The expression of these isoforms is regulated by 
SRp40. Tyson-Capper et al. showed that SRp40 was down-regulated during pregnancy 
which lead to the expression of the CREMα isoform and hence a repression of cAMP-
responsive genes (Tyson-Capper, Bailey et al. 2005). This previous research 
demonstrates the potentially important role splicing has in the regulation of uterine 
function. 
 
Functional analysis has revealed potential Exonic Splicing Enhancer (ESE) motifs for 
SF2 within the CACNA1C (Beitelshees, Navare et al. 2009).  Given the similarities 
between the channels, it is possible that the KCNMA1 and CACNA1G may also contain 
ESE motifs for SF2. Further investigation of the role of channel splice variant expression 
and its role in the regulation of the myometrium during gestation and parturition is 
necessary. 
 
The hypothesis is therefore: 
 
Expression of the KCNMA1, CACNA1C and CACNA1G channels and / or specific 
splice variants, alongside their sub-cellular localisation regulates the switch between 
quiescence and contractility at the end of pregnancy 
 
The aims of this project are to: 
 
1 To establish myometrial cell cultures as a model system to examine the role 
of ion channels in the switch between relaxation and contractility. 
2 To measure the expression levels of the KCNMA1, CACNA1C and 
CACNA1G channels and to identify which splice variants are expressed 
within the model system. 
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3  To define the sub-cellular localisation of the KCNMA1, CACNA1C and 
CACNA1G channels within the model system. 
4  To identify which transcription factors are utilised in the expression of the 
KCNMA1, CACNA1C and CACNA1G channels. 
5  To identify protein interactions between the KCNMA1 and CACNA1C 
channels and the components of the proposed macromolecular complex 
discussed in Section 1.5.6.4, namely the β2Adrenergic receptor, Gαs and 
Caveolin-1. 
6 To determine if the results from aims 2-5 are affected by altering the 
contractility of the myometrial cell cultures. TNF will be used to induce 
contraction and Trichostatin A (TSA) will be used to induce relaxation. TNF 
has previously been shown to induce contraction in myometrial smooth 
muscle strips, however the mechanism by which it achieved this is still unclear 
(Webster, Waite et al. 2013). TSA, a pan class I/II histone deacetylase 
(HDAC) inhibitor, has previously been shown to affect the expression the 
myometrial Gαs gene with subsequent effects on contractility but can also 
affect this activity independent of chromatin remodelling via regulating non-
nuclear acetylation of contractile proteins as observed by Moynihan et al. 
(Moynihan, Hehir et al. 2008) and Karolczak-Bayatti et al. (Karolczak-
Bayatti, Sweeney et al. 2011).  
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Chapter 2: Materials and Methods
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2.1 Materials 
2.1.1 General Materials Reagents and Enzymes 
The reagents used for the following procedures were obtained from Fisher 
(Loughborough. Leics., U.K.), Sigma (Poole, Dorset, U.K.) and VWR International Ltd. 
(Lutterworth, Leics., U.K.). iScript cDNA synthesis kits were purchased from Bio-Rad 
Laboratories (Hercules, CA, USA).  PCR Master Mix and DNA loading dye was 
purchased from Promega and primers from Eurofins MWG Biotech (London, U.K.). 
Herculase II Fusion polymerase and dNTPs were purchased from Agilent (Stockport, 
Cheshire, U.K.). All cell culture plastic-ware was supplied by Sarstedt (Leicester, U.K.). 
Fetal Calf Serum (FCS) was purchased from Lonza (Wokingham, U.K.) and DMEM D-
valine medium was purchased from PAA (Yeovil, Somerset, U.K.). Channel antibodies 
for the KCNMA1 (APC-021), CACNA1C (ACC-003) and CACNA1G (ACC-021) 
channels were purchased from Alomone Labs (Jerusalem, Israel). Antibodies for NFκB 
RelA (sc-372), CBP (sc-25748), MZF (sc-66991), SP1 (sc-14027), KCNMA1 Channel 
N-terminus (sc-14746) and CACNA1C channel C-terminus (sc-16230) were purchased 
from Santa Cruz Biotechnology Inc. (CA, USA), KCNMA1 channel N-terminus 
(ab104624) and CACNA1C channel C-terminus (ab140766) for use in western blotting 
were purchased from Abcam (Cambridge, U.K.), NFκB p50 (ab1602) from Millipore 
(Watford, U.K.) goat anti-rabbit and rabbit anti-goat HRP-conjugated secondary 
antibodies were purchased from Dako (Ely, Cambs, U.K.). All staining reagents were 
purchased from Vector Laboratories (CA, USA) excluding the antibody diluent which 
was purchased from Dako (Ely, Cambs, U.K.). ChIP reagents were purchased from 
Millipore (Watford, U.K.). Subcellular protein fractionation kit was purchased from 
Pierce Biotechnology (Rockford, USA). MeDIP reagents were purchased from Epigentek 
(Farmingdale, NY, USA). 
 
2.1.2 Apparatus 
All capital laboratory equipment marked (*) was purchased with funding from the MRC 
(Grant No. 84891 to Dr N. R. Chapman) 
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Equipment Model and Supplier 
Freezers -80º  New Brunswick Scientific Innova U535, Wolflabs* 
-20º Freezer GG5210, Fisher* 
Fridges 4º Fridge Liebherr sparkfree, Wolflabs* 
Chromatography Cabinet, Wolflabs* 
Centrifuges Eppendorf Centrifuge 5415R 
Sigma 1-14 
Sigma 1-16 Rotor 
DNA Electrophoresis Geneflow Multisub Midi, Geneflow Multisub mini 
Gel Documentation Syngene G:Box iChemi, Syngene Genetools version 4 
quantification software 
Dell Vostro 1510 
Homogeniser IKA Ultra Turrax T25 
Incubators Thermo Scientific Hera Cell 240 
Sanyo CO2 Incubator MCO-18AIC 
PCR Machine SensoQuest Gradient Thermalcycler 
pH Meter Jenway 3020 pH Meter 
Power Pack Geneflow MP-250N 
Protein Blotting Bio-Rad Trans-Blot™ SD Semi-Dry Transfer cell 
Geneflow OmniPage Blot Mini 
Protein Electrophoresis Bio-Rad Mini-protean® Tetra Cell 
Rocking Platform Stuart 
Shaking incubator Stuart Orbital Incubator S1500 
Sonication Sonics Vibra Cell 
Spectrophotometer Nanophotomer (Implen) 
UV Transilluminator TFX-20M, Vilber Lourmat 
Water Purification Ultra Clear TWF UV Plus, SG Wasseraufbereitung und 
Regenerierstation GmbH Germany. 
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2.1.3 General Buffers used 
Buffer Composition 
SDS-PAGE 4X Lower Buffer 1.5M Tris pH 8.8 and 0.4% (w/v) SDS 
SDS-PAGE 4X Upper Buffer 0.5M Tris pH 6.8 and 0.4% (w/v) SDS 
SDS Loading Buffer Prepared to a final volume of 24ml: 
3.0ml 500mM Tris pH 6.8, 2.4ml glycerol, 
4.8ml 10% (w/v) SDS, 1.2ml β-
mercaptoethanol, 600µl 0.05% (w/v) 
bromophenol blue and 12.0ml MilliQ water 
(18 M 
Towbin Transfer Buffer (TTB) 25mM Tris pH 7.4, 192mM Glycine and 20% 
(v/v) Methanol 
Tris Glycine Buffer  (TGB) 25mM Tris, 192mM Glycine, 0.1% (w/v) SDS 
and 10% (v/v) Methanol 
10X Electrophoresis Buffer Prepared to a final volume of 1L: 
250mM Tris, 520mM Glycine, 10% (w/v) 
SDS. 
Phosphate buffered Saline pH 7.3 (PBS) 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4 
Phophate buffered Saline (Tween 20) pH 
7.4 (PBS-T) 
As PBS but including 0.05% (v/v) Tween-20 
Tris buffered Saline (TBS) 50mM Tris-Cl, pH 7.6, 150mM NaCl 
Tris buffered Saline (Tween 20) (TBS-T) As TBS but including 0.1% (v/v) Tween-20 
Membrane Blocking Buffer Milk (TBS-
TM) 
As TBS-T but including 10% (w/v) low fat 
dried milk powder (Marvel, Premier Foods) 
Tris Acetate EDTA (TAE) Prepared as a 50X stock concentrate: 242g 
Tris, 57.1ml glacial acetic acid and 100ml 
500mM EDTA pH 8.0 
Whole Cell Lysis Buffer 150mM Sodium Chloride, 0.5% (v/v) Sodium 
Deoxycholate, 0.1% (v/v) SDS, 50mM Tris 
pH 8.0 and 0.1% (v/v) Igepal 
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2.2 Cell Culture Methods 
2.2.1 Myometrial Biopsy Collection 
The myometrial cell cultures utilised in this Thesis had been previously derived from 
myometrial biopsies obtained under ethical approval by the Rotherham Local Research 
Ethics Committee (Ref No. 05/Q2306/22). This favourable review was renewed by the 
Leeds Bradford Research Ethics Committee in 2012 (Appendix 2; Ref No. 12/YH/0229).  
Use of these previously derived cultures ensured women were not subjected to any 
unnecessary surgical procedures. 
 
For these previously derived cultures, all women were recruited at the Department of 
Obstetrics and Gynaecology at the Jessop Wing Hospital for Women, Sheffield.   
 
Lower segment myometrial biopsies were taken from women undergoing elective 
Caesarean sections at term. The lower segment biopsies were taken from the upper lip of 
the incision using tooth biopsy forceps and curved scissors and placed immediately into 
D-valine-DMEM pre-chilled to 4ºC.  
 
2.2.2 Cell Culture Techniques 
2.2.2.1 Generation of Myometrial Cells 
Biopsies were collected in D-valine medium and washed in PBS to remove excess blood. 
A collagenase mix containing 10mg collagenase, 0.2mg DNase, 2mg elastase, 2mg 
trypsin inhibitor and 2mg Bovine Serum Albumin (BSA) was prepared in a sterile tube, 
and was diluted with 10ml PBS immediately prior to use. This was then sterilised using 
a 0.22µm syringe filter. The biopsy was minced into 3mm3 pieces and added to the 
collagenase mix and incubated in a shaking incubator (80rpm) at 37ºC for three to four 
hours. The debris was then allowed to settle under gravity. The supernatant was 
transferred to a fresh sterile tube and centrifuged at 500g for ten minutes. The pellet was 
then resuspended in D-valine medium supplemented with 10% (v/v) FCS, 2mM L-
glutamine, 100U/ml penicillin and 0.1mg/ml streptomycin and placed into a 25cm2 tissue 
culture flask. After one hour the cell supernatant, containing the myocytes, was removed 
and placed into a fresh 25cm2 tissue culture flask and maintained in a humidified 
atmosphere at 37ºC and 5% CO2. The replacement of L-valine with D-valine in the culture 
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medium selectively inhibits fibroblast proliferation as fibroblasts are unable to metabolise 
D-valine (Gilbert and Migeon 1975). After 24 hours the medium was replaced with fresh 
supplemented D-valine medium. A single biopsy was used to generate each individual 
cell culture. 
 
2.2.2.2 Myometrial Cell Passaging 
The cells were passaged on reaching 90% confluence and expanded from a 25cm2 flask 
to a 75cm2 flask. When confluent the 75cm2 flask was expanded one to three etc. Cells 
were passaged by discarding the medium, washing the cells briefly with sterile PBS 
containing 1mM EDTA in order to remove any traces of serum prior to the addition of 
trypsin (6U/ml), 3ml of trypsin was added and the flask incubated at 37ºC for five 
minutes. The detached cells were then gently dispersed by pipetting and then redistributed 
into flasks containing fresh medium. 
 
2.2.2.3 PHM1-31 Cell Passaging 
PHM1-31 cells were a kind gift from Prof. Barbara Sanborn, Colorado State University, 
USA (Monga, Ku et al. 1996). Cells were maintained in DMEM medium supplemented 
with 10% (v/v) FCS, 2mM L-glutamine, 100U/ml penicillin, 0.1mg/ml streptomycin and 
0.1mg/ml geneticin (Invitrogen). Passaging was performed as described above. PHM1-
31 cells were used as a myocyte positive control during molecular characterisation of 
primary myocyte cultures. 
 
2.2.2.4 Oral Fibroblast Cell Passaging 
Primary oral fibroblast cells were a kind gift from Vannessa Hearnden, Dental School, 
University of Sheffield. Cells were maintained in DMEM medium supplemented with 5% 
(v/v) FCS, 2mM L-glutamine, 100U/ml penicillin and 0.1mg/ml streptomycin. Passaging 
was performed as described above. Fibroblasts were used as a fibroblast positive control 
during molecular characterisation of primary myocyte cultures. 
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2.3 Immunocytochemistry Techniques 
2.3.1 Immunocytochemical Staining for the KCNMA1, CACNA1C and CACNA1G 
Channels. 
Myometrial cells were cultured in a six-well plate. Upon reaching 80% confluence the 
cells were stimulated with 10ng/ml TNF for one hour, or 2μg/ml TSA for 24 hours with 
non-stimulated wells serving as a control. The cells were then fixed in 1% (v/v) 
formaldehyde overnight at 4ºC. Prior to staining the cells were washed three times for 
five minutes in PBS and permeabilised with PBS containing 1% (w/v) BSA and 0.1% 
(v/v) Triton X-100 with three, five minute washes. After rinsing again in PBS, 
endogenous peroxidase was quenched with 3% (v/v) hydrogen peroxide for 10 minutes. 
The Vectastain® Elite ABC Kit was used for the following reactions. Non-specific 
background was blocked with PBS containing goat serum and avidin for one hour at room 
temperature. The block was removed and the primary antibody was diluted in antibody 
diluent and biotin and incubated overnight at 4ºC. The cells were washed in PBS and the 
secondary anti-mouse IgG added to each well for 30 minutes at room temperature. After 
washing, the ABC reagent was added for 30 minutes at room temperature. Excess was 
removed by washing with PBS and the AEC chromagen substrate added for 10 minutes 
at room temperature. Cells were stored in PBS and photographed. 
 
Antibody dilutions were as follows: 
 
 Antibody Dilution for: Antibody used for 
Immunoprecipitation Antibody Immuno-
cytochemistry 
Western 
Blot 
Anti-BKCa  1:200 1:2,000 - 
Anti-Cav1.2  1:300 1:4,000 2.5µg 
Anti-Cav3.1  1:200 1:4,000 - 
L-Type Ca++CP α1C  1:50 1:3,000 - 
Anti-MaxiK K+ channel α - 1:5,000 2.5µg 
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2.4 Collagen Gel Contraction Assay 
2.4.1 Preparation of Collagen for use in Collagen Gels 
A 0.2% (v/v) acetic acid solution was prepared and filter sterilised using a 0.2μm filter. 
This was then added to the collagen to prepare a 6mg/ml collagen solution; this solution 
was gently agitated for five days at 4ºC to ensure the collagen was completely in solution. 
Once the collagen was completely dissolved the solution was diluted with an equal 
volume of filter sterilised water to produce a 3mg/ml collagen solution. This was gently 
agitated for a further day at 4ºC to equilibrate the solution. 
 
2.4.2 NaOH Titration of Collagen  
In order to optimise the solidification of each batch of collagen it was necessary to carry 
out a titration in order to identify the optimal amount of NaOH to add to the collagen 
medium mixture. Briefly, 0.4ml DMEM medium was added to each of eight 
microcentrifuge tubes. Then to each tube in turn 0.2ml 3mg/ml collagen was added, 
followed immediately by 1.0μl 1M NaOH. This mixture was pipetted up and down three 
times then left to solidify for 20 minutes. This process was repeated across all eight tubes 
using increasing amounts of 1M NaOH (1-8μl). 
 
The rigidity and colour of the resulting gels were then compared, to determine the lowest 
volume of NaOH required to produce the most rigid of gels, whilst turning the phenol red 
indicator a pale pink colour. 
 
2.4.3 Pouring Populated Collagen Gels 
Trypsin (3mls) was added to a confluent 75 cm2 flask of myometrial cells and the flask 
incubated at 37ºC for five minutes. The detached cells were then gently dispersed by 
pipetting and then 270μl of suspended cells were transferred to a 15ml centrifuge tube 
and 3.33mls of fresh media added. This cell suspension was then split into 400μl aliquots. 
Then to each of these aliquots in turn 200μl of 3mg/ml collagen was added along with the 
previously optimised quantity of NaOH. This mixture was pipetted up and down three 
times then 500μl transferred to each well of a 24 well plate and left to solidify for 20min. 
Finally a further 500μl of cell culture medium was added to each well.    
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2.4.4 Collagen Gel Contraction Assay 
Upon reaching 80% confluence the collagen gel was dissociated from the sides of the 
well by running the tip of a 200μl pipette tip around the edges of the gel. Then the plate 
was gently swirled to ensure the gel was free floating. The myometrial cells were then 
stimulated with 10ng/ml TNF, or 2μg/ml TSA, or 10mg/ml Oxytocin or left un-
stimulated. PHM1-31 cells were used as contraction positive controls while HEK293 cells 
were used as contraction negative controls. At pre-determined time points the plate was 
removed from the incubator for image acquisition. Images were captured using the 
Syngene G:BOX Chemi-16 gel documentation system. The Syngene Genetools Version 
4 quantification software (SynGene, Cambridge UK) was used to trace the outline of the 
gel at each time point and to calculate the mean pixel area. The surface area at each time 
point is reported as a percentage of the initial gel surface area in that well, a decrease in 
surface area indicates contraction whilst an increase indicates relaxation. 
 
2.5 Protein Methods 
2.5.1 Whole Cell Lysis (WCL) of Cultured Myocytes 
Confluent 75 cm2 flasks of cultured myocytes were stimulated with 10ng/ml TNF or, 
2μg/ml TSA or, 10ng/ml TNF followed by 2μg/ml TSA or, 2μg/ml TSA followed by 
10ng/ml TNF with a non-stimulated 75 cm2 flask serving as a control. The medium was 
removed and the cells washed with ice cold PBS. Then 500 µl of ice cold whole cell lysis 
buffer containing protease inhibitors (Complete Mini, Roche) was added to each flask. 
Cells were scraped off the flask and transferred to a fresh pre-cooled microcentrifuge tube 
and then incubated for 30 minutes at 4ºC on a roller. Following this incubation the lysate 
was centrifuged in a pre-cooled microcentrifuge tube for 20 minutes at 11,400g at 4ºC. 
Protein was quantified using the nanophotometer (Implen, Germany) by measuring UV 
absorbtion at 280nm, amino acids with aromatic rings primarily absorb at 280nm. Using 
the Beer Lambert Law where an absorbtion of one equates to a concentration of 90μg/ml 
protein. The ratio of UV absorbtion at A260 and A280nm was used to assess the purity 
of the sample. The A260/280 for protein is between 0.5 and 1.5. 
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2.5.2 Sequential Extraction of Protein from Cultured Myocytes 
Confluent 75cm2 flasks of cultured myocytes were stimulated 10ng/ml TNF or, 2μg/ml 
TSA or, 10ng/ml TNF followed by 2μg/ml TSA or, 2μg/ml TSA followed by 10ng/ml 
TNF with a non-stimulated 75 cm2 flask serving as a control. Sequential extraction was 
performed using Pierce Subcellular Protein Fractionation Kit according to the 
manufacturers’ guidelines. Briefly, the medium was removed and the cells washed with 
ice cold PBS. Then 500µl of ice cold PBS with protease inhibitors was added to each 
flask. Cells were scraped off the flask and transferred to a fresh pre-cooled 
microcentrifuge tube and then centrifuged at 500g for five minutes. The supernatant was 
removed and 200µl cytoplasmic extraction buffer was added to the cell pellet and 
incubated on a roller for ten minutes at 4ºC. The lysate was then centrifuged at 500g for 
five minutes and the supernatant transferred to a fresh pre-cooled microcentrifuge tube, 
this is the cytoplasmic fraction. The cell pellet was then resuspended in 200µl membrane 
extraction buffer, vortexed vigorously for five seconds then incubated on a roller for ten 
minutes at 4ºC. The lysate was then centrifuged at 3,000g for five minutes and the 
supernatant transferred to a fresh pre-cooled microcentrifuge tube, this is the membrane 
fraction. The cell pellet was then resuspended in 100µl nuclear extraction buffer, vortexed 
vigorously for 15 seconds then incubated on a roller for 30 minutes at 4 ºC. The lysate 
was then centrifuged at 5,000g for five minutes and the supernatant transferred to a fresh 
pre-cooled microcentrifuge tube, this is the soluble nuclear fraction. The cell pellet was 
then resuspended in 100µl nuclear extraction buffer containing 5mM CaCl2 and 300 units 
Micrococcal Nuclease, vortexed vigorously for 15 seconds then incubated at room 
temperature for 15 minutes. The lysate was then vortexed vigorously for 15 seconds and 
centrifuged at 16,000g for five minutes and the supernatant transferred to a fresh pre-
cooled microcentrifuge tube, this is the chromatin bound nuclear fraction. The cell pellet 
was then resuspended in 100µl pellet extraction buffer, vortexed vigorously for 15 
seconds then incubated at room temperature for ten minutes. The lysate was then 
centrifuged at 16,000g for five minutes and the supernatant transferred to a fresh pre-
cooled microcentrifuge tube, this is the cytoskeletal fraction. Protein was quantified using 
the nanophotometer (Implen, Germany) by measuring UV absorbtion at 280nm, amino 
acids with aromatic rings primarily absorb at 280nm. Using the Beer Lambert Law an 
absorbtion of one equates to a concentration of 90μg/ml protein. The ratio of UV 
absorbtion at A260 and A280nm was used to assess the purity of the sample. The A260/280 
for protein is between 0.5 and 1.5. 
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2.5.3 Co-Immunoprecipitation of Proteins 
2.5.3.1 Lysis of cell Monolayer 
Confluent 75cm2 flasks of cultured myocytes were stimulated with 10ng/ml TNF or 
2μg/ml or TSA for 24 hours with a non-stimulated 75 cm2 flask serving as a control. Cell 
lysis was performed using Pierce Crosslink Magnetic IP/Co-IP Kit according to the 
manufacturers’ guidelines. Briefly, the media was removed from the flasks and the cells 
washed with PBS. Seven hundred and fifty microliters of ice cold IP lysis/wash buffer 
was added to each flask. The flasks were then incubated on ice for five minutes with 
periodic mixing. The lysate was then transferred to a microcentrifuge tube and centrifuged 
at 13,000g for ten minutes to pellet the cell debris. Finally the supernatant was transferred 
to a new microcentrifuge tube and the protein quantified quantified using the 
nanophotometer (Implen, Germany) by measuring UV absorbtion at 280nm, amino acids 
with aromatic rings primarily absorb at 280nm. Using the Beer Lambert Law where an 
absorbtion of one equates to a concentration of 90μg/ml protein. The ratio of UV 
absorbtion at A260 and A280nm was used to assess the purity of the sample. The A260/280 
for protein is between 0.5 and 1.5. 
 
2.5.3.2 Binding of Antibody to Protein A/G Beads 
Briefly, 2ml of 1X coupling buffer (10mM sodium phosphate, 150mM NaCl; pH 7.2) was 
prepared for each reaction by diluting 0.1ml 20X coupling buffer and 0.1ml IP lysis/wash 
buffer in 1.8ml ultrapure water. The protein A/G beads were vortexed and 25μl added to 
a microcentrifuge tube per sample. Using a magnetic stand the beads were collected and 
the storage buffer removed. The beads were then washed twice with 500μl 1X coupling 
buffer. The antibody was then diluted 1:20 with 20X coupling buffer and IP lysis/wash 
buffer to a final concentration of 5μg in 100μl. This was then added to the beads and 
incubated with rotation for 15 minutes at room temperature. The beads were then 
collected and the antibody solution removed. The beads were then washed three times 
once with 100μl 1X coupling buffer and then twice with 300μl 1X coupling buffer. 
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2.5.3.3 Crosslinking the Bound Antibody 
Briefly, crosslinking reagent was prepared combining 2.5μl 20X coupling buffer, 4μl 
0.25mM Disuccinimidyl suberate (DSS, a protein cross-linking agent, which forms stable 
amide bonds with the amine side chains of the antibody) and 43.5μl ultrapure water. This 
was then added to the beads and incubated with rotation for 30 minutes at room 
temperature. The beads were then collected using a magnetic stand and the crosslinking 
reagent removed. The beads were then washed three times with 100μl elution buffer for 
five minutes, then twice with 200μl ice cold IP lysis/wash buffer.  
 
2.5.3.4 Immunoprecipitation of the Protein 
The protein was diluted to a concentration of 300μg per 500μl and this was added to the 
crosslinked magnetic beads and incubated overnight at 4°C with rotation. The beads were 
then collected and the supernatant removed. The beads were then washed twice with 
500μl of IP lysis/wash buffer and once with 500μl ultrapure water. Finally the protein 
was eluted off the beads with 50μl elution buffer. Then 5μl neutralization buffer was 
added to the eluate in order to neutralize the low pH. The resulting samples were then 
diluted 1:5 with reducing loading buffer and then boiled for 5 minutes at 100°C. A fifth 
of this was loaded per lane of the Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS PAGE) gels. 
 
2.5.4 Optimisation of Block 
Two of the antibodies used are raised in goat (KCNMA1 channel N-terminus, sc-14746; 
CACNA1C channel C-terminus, sc-16230) and require an anti-goat secondary antibody 
to be used. However anti-goat secondary antibodies can bind to bovine IgG as well as 
goat IgG (Buchwalow, Samoilova et al. 2011). If this were to happen and the membrane 
had been blocked with a block containing bovine IgG it could result in the secondary 
antibody binding to the block and giving very high background. Routinely either dried 
milk or BSA is used as a block, BSA contains bovine IgG and commercial milk often 
contains some bovine IgG contamination. To test if there is any interaction between the 
block and the secondary antibody, nitrocellulose membrane was blocked for two hours at 
room temperature. The membrane was then washed using TBS-T as follows: 
 
2 x quick rinses 
100 
 
1 x Fifteen minute wash 
2 x Five minute washes 
 
After washing the membranes were incubated in a 1:20,000 or 1:40,000 dilution of HRP 
conjugated secondary antibody for one hour at room temperature. The membranes were 
the washed a final time and then developed using ECL reagents according to the 
manufacturers guidelines using the Syngene G:BOX Chemi-16 gel documentation system 
followed by visualisation with Syngenes Ingenius Bioimaging software GeneSnap and 
GeneTools Version 4 quantification software (SynGene, Cambridge UK) 
 
2.5.5 Dot Blot 
Dot blots are a quick and effective method of determining the optimum, protein 
concentration and primary antibody dilution to use during SDS-PAGE and Western 
Blotting. 
 
A range of protein concentrations (5, 10 and 50µg) was spotted onto nitrocellulose 
membrane and allowed to dry. The membrane was then blocked using either TBS-TM, 
or Non-protein block (Pierce) for one hour at room temperature. The membrane was then 
washed using TBS-T as follows: 
 
2 x quick rinses 
1 x Fifteen minute wash 
2 x Five minute washes 
 
Then each blot was incubated with primary antibody, overnight at 4ºC with gentle 
agitation. The following day the membranes were washed as detailed previously and then 
incubated in a 1:10,000 dilution of HRP conjugated secondary antibody for one hour at 
room temperature. The membranes were the washed a final time and then developed using 
ECL reagents according to the manufacturers guidelines using the Syngene G:BOX 
Chemi-16 gel documentation system followed by visualisation with Syngenes Ingenius 
Bioimaging software GeneSnap and GeneTools Version 4 quantification software 
(SynGene, Cambridge UK) 
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2.5.6 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples were analysed by SDS-PAGE. Samples were diluted either 1:1 with 
SDS-loading buffer (prepared to a final volume of 25.0ml: 3.0ml 500mM Tris pH 6.8, 
2.4 ml glycerol, 4.8 ml 10% (w/v) SDS, 1.2 ml β-mercaptoethanol, 600 µl 0.05% (w/v) 
bromophenol blue and 12.0 ml MQ water) or 1:4 with Lane Marker Reducing Sample 
Buffer (Thermo Scientific) depending on the concentration of the protein sample. 
Samples were then boiled at 95ºC for ten minutes before briefly centrifuging for 30 
seconds at 1,200g in a Sigma 1-14 microcentrifuge.  
 
For the large L- and CACNA1G calcium channel proteins (~170kDa and ~262kDa 
respectively) a gradient system was employed using 4 – 20% precast gels (Bio-Rad). The 
gel was subject to electrophoresis at 150V until the dye had migrated to the end of the gel 
cassette. A discontinuous 8% gel was used for the smaller KCNMA1 channel (~100kDa) 
and C-Terminal of the CACNA1C Channel again the gel was subject to electrophoresis 
at 150V until the dye had migrated to the end of the gel cassette. 
 
2.5.7 Wet Transfer 
The larger proteins from the 4-20% precast gel underwent a wet transfer. Briefly, a 
nitrocellulose membrane and six pieces of 3mm Whatman paper were cut to the size of 
the gel and soaked in Tris Glycine buffer (TGB: 25mM Tris, 192mM Glycine, 0.1% (w/v) 
SDS and 10% (v/v) Methanol) Three pre-soaked pieces of Whatman paper and the 
nitrocellulose membrane were stacked onto the foam on the black side of the cassette the 
gel was rinsed in TGB and layered on top of the nitrocellulose membrane followed by 
three Whatman papers, foam and the red side of the cassette. The cassette was closed and 
place into the Geneflow omniPAGE electroblotting tank and the tank filled with TGB. 
The proteins were transferred for 2.5 hours at 4ºC and 40V. The membrane was stained 
using PonceauS solution to determine if the transfer was successful. 
 
2.5.8 Semi-Dry Transfer 
The smaller proteins from the 8% gel underwent a semi-dry transfer. Briefly, a 
nitrocellulose membrane and six pieces of 3mm Whatman paper were cut to the size of 
the gel and soaked in Towbin’s Transfer buffer (TTB: 25mM Tris pH 7.4, 192mM 
Glycine and 20% (v/v) Methanol) Three pre-soaked pieces of Whatman paper were 
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stacked onto the platinum anode of the Trans-Blot® SD Semi-Dry Electrophoretic 
Transfer Cell (Bio-Rad) and rolled with a glass rod to remove any air bubbles. The 
nitrocellulose membrane was then placed onto the Whatman paper and rolled again to 
remove air bubbles. The gel was rinsed in TTB and layered on top followed by three 
Whatman papers and rolled for a final time to remove any air bubbles. The cathode was 
placed onto the stack and the latches engaged. The safety cover was then placed on the 
unit and the proteins were transferred for 20 minutes at 20V. The membrane was stained 
using Ponceau-S solution to determine if the transfer was successful. 
 
2.5.9 Western Blot 
The membrane was rinsed in TBS and blocked in TBS-TM at room temperature for two 
hours. The blot was washed in TBS-T for two quick rinses, one 15 minute wash and two 
five minute washes. The primary antibody was incubated either overnight at 4ºC (APC-
021) or overnight at room temperature (ACC-003, ACC-021, ab104624 and sc-16230). 
The blot was washed in TBS-T for two quick rinses, one 15 minute wash and two five 
minute washes. An HRP-conjugated secondary antibody was incubated with the blot for 
one hour at room temperature, before washing in TBS-T for two quick rinses, one 15 
minute wash and two five minute washes. The blot was developed using ECL reagents 
according to the manufacturers guidelines using the Syngene G:BOX Chemi-16 gel 
documentation system followed by visualisation with Syngenes Ingenius Bioimaging 
software GeneSnap and GeneTools Version 4 quantification software (SynGene, 
Cambridge UK). After development of the blot, manual band quantification was 
performed using the Gene Tools software from Syngene (Geneflow, Staffs).  All 
experiments were performed a minimum of three times and results are expressed as the 
mean ± SEM. All data analyses were conducted on GraphPad Prism Version 6 (GraphPad 
Software, San Diego, California) where a one way ANOVA with Dunett’s post-test was 
performed to compare the individual stimulations against the un-stimulated control; 
p<0.05 was considered statistically significant. 
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2.6 RNA Methods 
2.6.1 Total RNA Extraction 
Cells were cultured in 25cm2 flasks. On reaching 90% confluence the cells were 
stimulated 10ng/ml TNF or, 2μg/ml TSA or, 10ng/ml TNF followed by 2μg/ml TSA or, 
2μg/ml TSA followed by 10ng/ml TNF with a non-stimulated 25cm2 flask serving as a 
control. The cells were then processed by discarding the medium, washing the cells 
briefly with sterile PBS containing 1mM EDTA in order to remove any traces of serum 
prior to the addition of trypsin (6U/ml), 3mls of trypsin was added and the flask incubated 
at 37ºC for five minutes. The detached cells were then transferred to a 15ml centrifuge 
tube and centrifuged at 250g for five minutes. Total RNA was extracted from the cell 
pellet using the EZRNA extraction Kit (Geneflow Lichfield, Staffs. U.K.), Briefly, the 
medium was removed and the cells lysed directly in the flask by addition of 0.5ml 
denaturing solution, the lysed cells were scraped off the flask and transferred to a clean 
microcentrifuge tube, and incubated at room temperature for five minutes. An equal 
volume (0.5 ml) of extraction solution was then added, the samples mixed vigorously, 
then incubated at room temperature for 15 minutes and then centrifuged at 12,000g for 
15 minutes at 4ºC. The aqueous colourless (upper) phase was transferred to a fresh 
microcentrifuge tube and total RNA precipitated by the addition of an equal volume of 
isopropanol (0.5 ml) and subsequent incubation at -20ºC overnight. Following this the 
sample was centrifuged at 16,000g for 15 minutes at 4ºC and the supernatant discarded. 
The pellet was washed by vortexing in 1ml 75% (v/v) ethanol and then centrifuged at 
16,000g for five minutes at 4ºC, the supernatant was discarded. The pellet was allowed 
to air dry for five-to-ten minutes and then dissolved in 25µl Diethylpyrocarbonate 
(DEPC,) water. DEPC water was used as it inactivates RNase enzymes by the covalent 
modification of the active site of histidine, lysine, cysteine and tyrosine residues. The 
extracted total RNA was quantified using the nanophotometer by measuring UV 
absorbtion at 260nm, using the Beer Lambert Law where an absorbtion of one equates to 
a concentration of 50μg/ml RNA. The ratio of UV absorbtion at A260 and A280nm was 
used to assess the purity of the sample. The A260/280 for pure RNA is ~2. 
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2.6.2 cDNA Synthesis of Cultured Myocyte mRNA 
cDNA synthesis was performed using Bio-Rad iScript cDNA synthesis Kit according to 
the manufacturer’s guidelines, briefly 1µg of total RNA was added to 4µl of 5x iScript 
reaction mix and made up to 20µl with nuclease free water. The reaction was then 
incubated as follows: 
 
5 minutes at 25ºC 
30 minutes at 42ºC 
5 minutes at 85ºC 
 
Hold at 4ºC 
 
One microlitre of cDNA was used per PCR. 
 
2.7 The Chromatin Immunoprecipitation (ChIP) Assay  
Two confluent 75cm2 flasks of myocytes were stimulated with 10ng/ml TNF for one hour, 
two confluent 75cm2 flasks of myocytes were stimulated with 2μg/ml TSA for 24hrs, with 
two non-stimulated 75cm2 flasks serving as controls. The ChIP assay was carried out 
using the Millipore EZ magna ChIP Kit according to the manufacturer’s guidelines. 
 
2.7.1 In Vivo Crosslinking and Lysis 
Briefly, the cells were fixed by the addition of 37% formaldehyde to the media to a final 
concentration of 1% for ten minutes. Glycine was added to a final concentration of 
125mM for five minutes to quench any unreacted formaldehyde. The medium was 
removed and the cells washed twice in ice cold PBS.  
 
After the second wash the cells were scraped off the flask into 2ml of ice cold PBS 
containing protease inhibitors. The cells were centrifuged at 800g for five minutes at 4ºC. 
The cell pellet was resuspended in 0.5mls cell lysis buffer containing protease inhibitors 
and incubated on ice for 15 minutes with brief vortexing every five minutes. The cell 
suspension was centrifuged at 800g for five minutes at 4ºC. The cell pellet was 
resuspended in 0.5ml nuclear lysis buffer.  
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2.7.2 Sonication to Shear DNA 
The cell suspension was then sonicated using a vibra cell 150 (sonics) with an exponential 
probe at maximum amplitude for ten seconds three times with ten second intervals and 
then centrifuged at 12,300g for ten minutes at 4ºC to remove any insoluble material. The 
sheared chromatin was the aliquoted into 50µl aliquots with one being retained to analyse 
sheared chromatin size by agarose gel electrophoresis.   
 
2.7.3 Immunoprecipitation of Crosslinked Protein/DNA 
Each aliquot was diluted one in ten with ChIP dilution buffer containing protease 
inhibitors. An input sample representing the starting material was taken. Protein G 
magnetic beads were prepared by pre-absorbing them with salmon sperm DNA to reduce 
background, 20µl of these prepared beads was added to each aliquot along with 5µg of 
either SP1, MZF, CBP, RelA, p50 or KCNMA1 C terminal antibody or a rabbit IgG 
negative control and left to incubate overnight, on a roller at 4ºC. Protein G beads were 
captured with a magnetic separator and the complex washed for five minutes each with a 
low salt buffer, a high salt buffer, a lithium chloride buffer and a TE buffer.  
 
2.7.4 Elution of Protein/DNA complexes and Reversal of Crosslinks of 
Protein/DNA complexes to free DNA 
The chromatin:RelA antibody:magnetic bead complex was resuspended in 100µl ChIP 
elution buffer containing 1µl Proteinase K and incubated at 62ºC for two hours with 
shaking in a  Stuart Orbital Incubator S1500 followed by a ten minute incubation at 95ºC. 
The magnetic beads were then captured using a magnetic separator and the supernatant 
containing the chromatin was removed to a fresh tube.  
 
2.7.5 DNA Purification Using Spin Columns 
The chromatin was then purified using Sigma Genelute PCR Clean-up Kit columns 
(Sigma) according to the manufacturer’s protocol. Briefly, 500µl of column preparation 
solution was added to each column, centrifuged and the flow through discarded. The DNA 
solution was diluted in five volumes of DNA binding solution, mixed, added to the 
column then centrifuged for one minute and the flow through discarded. The filter was 
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washed with 500µl ethanol wash solution, centrifuged and the flow through discarded. 
The column was then re-centrifuged to remove any residual ethanol. DNA was eluted 
from the filter by applying 30µl of ultrapure water and incubating at room temperature 
for one minute before centrifuging. This was then repeated with 20µl ultrapure water to 
maximise DNA yield. All centrifugations were performed at 16,000g. 
 
2.8 The Methylated DNA Immunoprecipitation (MeDIP) Assay  
Two confluent 75cm2 flasks of myocytes were stimulated with 10ng/ml TNF for one hour, 
two confluent 75cm2 flasks of myocytes were stimulated with 2μg/ml TSA for 24hrs, with 
two non-stimulated 75cm2 flasks serving as controls. The MeDIP assay was carried out 
using the EpiQuik Methylated DNA Immunoprecipitation Kit (Epigentek Farmingdale 
NY USA) according to the manufacturer’s guidelines. 
 
2.8.1 Antibody Binding to Assay Plates 
Briefly, each well was washed once with 150μl CP1 wash buffer, then 100μl CP2 
antibody buffer was added to each well followed by 1μl of either Anti-5-methylcytosine, 
or normal mouse IgG. The wells were sealed and incubated at room temperature for one 
hour. 
 
2.8.2 Cell Collection 
The culture medium was removed from the tissue culture flasks and the cells washed once 
with PBS. Then 500μl CP3B lysis buffer was added to each flask and incubated at room 
temperature for five minutes. Finally the cell suspension was pipetted up and down 
several times to break the cells.  
 
2.8.3 DNA Shearing 
The cell solution was then transferred to a microcentrifuge tube and incubated at room 
temperature for five minutes. The cell solution was then vortexed vigorously for ten 
seconds. The cell suspension was then sonicated using a vibra cell 150 (sonics) with an 
exponential probe at maximum amplitude for ten seconds three times with ten second 
intervals. The sonicate was then clarified by centrifugation at 12,300g for ten minutes at 
4ºC to remove any insoluble material. 
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2.8.4 Methylated DNA Immunoprecipitation 
One hundred and sixty microliters of the supernatant from above was then transferred to 
a new microcentrifuge tube and 160μl CP4 ChIP dilution buffer added. To serve as the 
input 7.5μl was removed and placed into a new microcentrifuge tube. The antibody 
solution was then removed from the wells and the wells washed three times with 150μl 
CP2 antibody buffer. Then 150μl of the cell lysate was added to each well. The wells 
were sealed and incubated at room temperature for 90 minutes on a rocking platform at 
50-100rpm. The supernatant was then removed and the wells washed six times with 150μl 
CP1 wash buffer for two minutes each at 100rpm on a rocking platform (Stuart). Followed 
by a wash with 150μl TE for two minutes at 100rpm on a rocking platform. 
 
 2.8.5 Manual DNA Isolation / purification 
One microliter Proteinase K was added to 40μl CP5 DNA release buffer and mixed. This 
was then added to each well including the input wells, a further 40μl CP6 reverse buffer 
was added to the input wells. The wells were then sealed and incubated at 65°C for 15 
minutes, then 40μl CP6 reverse buffer was added to each of the sample wells and the 
wells re-sealed and incubated at 65°C for 30 minutes. For each sample a spin column was 
added to a 2ml collection tube, then 150μl CP7 binding buffer was added to each sample 
and the sample transferred to a spin column. The spin columns were centrifuged at 
10,500g for 20 seconds, then 200μl 70% (v/v) ethanol was added to each column and the 
columns spun at 10,500g for 20 seconds. Next 200μl 90% (v/v) ethanol was added to each 
column and the columns spun again at 10,500g for 20 seconds, then 200μl 70% (v/v) 
ethanol was added to each column and the columns spun at 10,500g for 20 seconds. The 
spin column was then placed in a new collection tube and 20μl CP8 elution buffer was 
added to each column which was then centrifuged at 10,500g for 20 seconds. The DNA 
was then stored at -20°C 
 
108 
 
2.9 Polymerase Chain Reaction (PCR) 
2.9.1 Primer Design 
For characterisation of the primary cultures Actin α2 (NM_001141945.1) was chosen as 
an indicator of the presence myocytes and Thy-1 cell surface antigen (NM_006288.3), as 
an indicator of the presence of fibroblasts. Primers were designed to amplify each of the 
RNAs (Table 2.1), PHM1 RNA was used as a positive control for actin α2 and a negative 
control for Thy-1, fibroblast RNA was used as a positive control for Thy-1. Optimised 
PCR conditions are detailed in Table 2.2. 
 
Table 2.1 Primers 
Region of Interest Primer Sequence 
actin α2 Forward 
Reverse 
5’-TGGCTTGGCTTGTCAGGGCTTG-3’ 
5’-CGGGTGCTCAGAACGCTGGA-3’ 
Thy-1 Forward 
Reverse 
5’-CTGGGTGCAGCAACCGGAGG-3’ 
5’-TGCTCAGGCACCCCCACAGT-3’ 
 
 
Table 2.2 PCR Conditions 
Region of 
Interest 
Annealing 
Temperature 
Duration of 
Denature/Anneal/elongation 
No. of 
Cycles 
Product 
size (bp) 
and 
Actin α2 64.6 25 / 30 / 45 30 239 
Thy-1 65 25 / 30 / 45 25 307 
 
For the detection of channel splice variants within the primary cultures a combination of 
a literature review and Genbank sequence data was used to design primers to cover an 
un-spliced region in each channel and also to cover a number of spliced regions in each 
channel. Details of the primers are listed in Table 2.3. 
 
For the ChIP and MeDIP PCRs the TransFac promoter database (http://www.gene-
regulation.com/pub/databases.html) was used to identify the channel promoters. Then the 
MethPrimer database (http://www.urogene.org/methprimer/) was used to identify CpG 
islands within these promoter regions and also to design primers to cover the promoter 
regions of the three channels. Details of the primers are listed in Table 2.4 also included 
are the IκBα primers which were used as a positive control for the RelA ChIP. 
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Table 2.3 KCNMA1, CACNA1C and CACNA1G channel and splice variant primers 
Channel / Region Primer Sequence (5’-3’) 
KCNMA1 Forward 
Reverse 
5’- CGGAGGCAGCAGTCTTAG-3’ 
5’-AAGAAAGTCACCATGGAGGAG-3’ 
KCNMA1 132 (M1) Forward 
Reverse 
5’-CTCCTCCATGGTGACTTTCTT-3’ 
5’-TTACAAGTGCACCGATGCTG-3’ 
KCNMA1 2 (M2) Forward 
Reverse 
5’-GGAAACCGCAAGAAATAC-3’ 
5’-ACCTCATGGAGAAGAGGTTG-3’ 
KCNMA1 srkr (M3) Forward 
Reverse 
5’-GGTCTGTCCCACNA1GCTACTGT-3’ 
5’-CAAAGATGCAGACCACGACA-3’ 
KCNMA1 strex (M4) Forward 
Reverse 
5’-GTGCCAGCAACTTTCATTAC-3’ 
5’-TCAGGGTCATCATCATCGTC-3’ 
KCNMA1 5 (M5) Forward 
Reverse 
5’-ACAGCATTTGCCGTCAGTG-3’ 
5’-AATATTCAAGGCAGACAAAG-3’ 
CACNA1G Forward 
Reverse 
5’-AAGTGCTACAGCGTGGAGGC-3’ 
5’-CTCTGACCCAGCAGACCTGG-3’ 
T 14 (T2) Forward 
Reverse 
5’-GTTTGCCTCTGAGCGGGATG-3’ 
5’-AGGCTGGGTGAGAAGAAATC-3’ 
T 25a (T4) Forward 
Reverse 
5’-GGGCGAGGATACCAGGAACA-3’ 
5’-GCTGCCGACACTTGTGGAAG-3’ 
T 25C (T6) Forward 
Reverse 
5’-GGAGAAGCGCCTACGAAGAC-3’ 
5’-CCGATGACACCTGTGATGAA-3’ 
T 30 (T8) Forward 
Reverse 
5’-CATGCGGGCGCTGCTGGACA-3’ 
5’-GAGACTCGGAAGAGGGTTAG-3’ 
CACNA1C Forward 
Reverse 
5’-GCCCTATGTGGCCCTCCTGATCGTGAT-3’ 
5’-CTTGTCCAGCTCCTCCTCAGCGGTGAGA-3’ 
L 8 / 8* (L4) Forward 
Reverse 
Reverse 
5’-CAGTGCCAGAACGGCACGGT-3’ 
5’-CGCTCAACACACCGAGAACCA-3’ 
5’-CGCTAAGCACACCGAGAACCA-3’ 
L 31 (L10) Forward 
Reverse 
5’-GGAATACGCCCTCAAGGCCCG-3’ 
5’-GGGAGAGCATTGGGTATGTTCAGC-3’ 
L 41 (L11) Forward 
Reverse 
5’-TGGTCCATCCTTGGTCCCCACC-3’ 
5’-AGCAGCGGACACAGCCTCCT-3’ 
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Table 2.4 KCNMA1, CACNA1C and CACNA1G channel promoter primers and ChIP positive 
control primers 
Channel / 
Region 
Primer Sequence (5’-3’) Product 
Size (bp) 
KCNMA1 5’ 
CpG 
Forward 
Reverse 
5’-GGCGTGGCGACAGGACTAGG-3’ 
5’-CCCGAGCGCCGAGAGCCAG-3’ 
407 
KCNMA1 3’ 
CpG 
Forward 
Reverse 
5’-CCTGGCTCTCGGCGCTCGG -3’ 
5’-TTGGGCTCGTGGACCGAGGA -3’ 
509 
CACNA1C  
CpG 1 
Forward 
Reverse 
5’-GCGCGAGGGGGTGTG-3’ 
5’-TCTCTGCTGTCAAAGGGAGC-3’ 
532 
CACNA1C 
CpG 2 
Forward 
Reverse 
5’-TTGCCGGCTCCCTTTGACAGC-3’ 
5’-GCCGTGGTCTGCAGCGTTTC-3’ 
343 
CACNA1G 
CpG1 
Forward 
Reverse 
5’-CCGCCCCTCCCGGACAGTGA-3’ 
5’-GGGCTCTAGGGCGCAAGCTGA-3’ 
475 
CACNA1G 
CpG2 
Forward 
Reverse 
5’-CGCCCTAGAGCCCACCAGAT-3’ 
5’-CGTGCCCCGAAGGATATGGGTT-3’ 
377 
IκBα Forward 
Reverse 
5’-GACGACCCCAATTCAAATCG-3’ 
5’-TCAGGCTCGGGGAATCACNA1G-3’ 
300 
 
2.9.2 PCR Reactions 
For the cell characterisation and splice variant PCRs a Taq polymerase from Promega 
was used. The 25µl reaction volume was comprised of 12.5µl PCR Master Mix 
(Promega), 50pmol of both forward and reverse primers, 2µl cDNA and 9.5µl ultrapure 
water. The individual PCR reaction conditions are detailed in Table 2.5.  
 
For the ChIP and MeDIP PCRs, Agilent’s Herculase II Fusion Polymerase was used as it 
is optimised for the amplification of GC-rich regions.  The 25μl reaction was  comprised 
of 5μl Herculase buffer, 0-4% (v/v) DMSO, 125μM dNTPs, 0.125μM both forward and 
reverse primers, 0.25μl Herculase II fusion DNA Polymerase (note that the manufacturer, 
Agilent, did not provide a value for the number of enzyme units/μl), 1-2μl DNA and then 
up to 25μl with ultrapure water.  These conditions were optimised for each of the 
individual primer pairs. The optimised conditions are listed in Table 2.6. 
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Table 2.5 PCR Conditions for KCNMA1, CACNA1C and CACNA1G channel and splice variant PCRs 
Channel / Region Annealing 
Temperature 
Duration of 
Denature/Anneal/elongation 
No. of Cycles Product size (bp) and exon complement 
KCNMA1 52 20/45/60 35 242 
KCNMA1 132 (M 1) 54 25/30/45 35 (+ 132) 437/ (Δ132) 305 
KCNMA1 2 (M 2) 50 25/30/45 35 565 
KCNMA1 srkr (M 3) 54 25/30/45 35 547 
KCNMA1 strex (M 4) 52 25/30/45 35 (+ strex) 622/ (Δ strex) 535 
KCNMA1 5 (M 5) 53 25/30/45 35 857 
CACNA1G 63 30/30/60 40 394 
T 14 (T2) 55.4 25/30/45 40 (+14) 360/ (Δ14)291 
T 25a (T4) 57 25/30/45 40 (+25A) 311/ (Δ25A) 209 
T 25C (T6) 55.4 25/30/45 40 (+25C+26) 219 / (Δ25C+26) 198/ (+25CΔ26) 165 / 
(Δ25CΔ26) 144 
T 30 (T8) 58 25/30/45 40 (+30B+31A) 213 / (Δ30B+31A) 192 / (+30BΔ31A) 
164 / (Δ30BΔ31A) 143 
CACNA1C 63 30/60/30 40 940 
L 8 / 8* (L4) 59 25/30/45 40 244 
L 31 (L10) 59 25/30/45 40 (+30+31+32+33+34) 454 / (+30+31+33+34) 370 / 
(+30+32+33+34) 343 / (+30+32+34) 259 
L 41 (L11) 59 25/30/45 40 (+40+41++42+43)  672 / (+40-+40b+43+) 643 / 
(+40+41+42+43) 615 
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Table 2.6 PCR Conditions for KCNMA1, CACNA1C and CACNA1G ChIP PCRs 
Channel / Region Annealing 
Temperature 
Duration of 
Denature/Anneal/elongation 
No. of Cycles 
KCNMA1 5’ CpG 54.6 20/30/20 34 
KCNMA1 3’ CpG 60.3 20/30/20 34 
CACNA1C CpG 1 54.9 20/30/30 38 
CACNA1C CpG 2 54.5 20/30/20 38 
CACNA1G CpG1 61.6 20/30/30 38 
CACNA1G CpG2 58.8 20/30/30 34 
IκBα 60.0 45/60/60 38 
 
2.9.3 Agarose Gel Electrophoresis 
The PCR products were analysed by agarose gel electrophoresis. A 1.5% (w/v) agarose 
gel was used for the analysis of the characterisation PCRs and a 3.0% (w/v) agarose gel 
for the channel splice variant PCRs. The gels were prepared by adding either 1.5g (1.5% 
w/v) or 3.0g (3% w/v) agarose to 100ml Tris Acetate EDTA (TAE; 40mM Tris Acetate 
and 1mM EDTA) buffer. This was heated in a microwave on high power until the agarose 
had completely dissolved. The liquid gel was then cooled to around 55ºC and GelRed 
solution, a DNA intercalating agent which fluoresces under ultra violet light and enables 
the visualisation of double stranded DNA,  added at a 10,000x dilution (Cambridge 
Bioscience). The gel was then poured into a pre-prepared gel cast and left to set at room 
temperature. The gel was placed into a gel tank and covered in one times TAE buffer. 
DNA loading dye (0.03% bromophenol blue, 0.03% xylene cyanol FF, 0.4% orange G, 
15% Ficoll®400, 10mM Tris-HCL [pH 7.5] and 50mM EDTA [pH 8.0] Promega) was 
added to each sample at a six times dilution and loaded into the gel. A current of 80V was 
applied across the gel for around 40 minutes and the separated DNA fragments were 
visualised using UV light at a wavelength of 310nm.  Syngene G:BOX Chemi-16 gel 
documentation system followed by visualisation with Syngenes Ingenius Bioimaging 
software GeneSnap and GeneTools Version 4 quantification software (SynGene, 
Cambridge UK). 
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2.9.4 Analysis of PCR Products 
Bands were quantified using manual band quantification software in GeneTools. Briefly, 
a box was drawn around the band taking care not to include any non-specific banding, 
this box was copied across all visible bands by double clicking the mouse, to ensure the 
box remained the same size.  
 
The percentage of myocytes and fibroblasts in the primary cultures was calculated using 
the following equations: 
 
 
 
 
The analysis of the splice variant PCRs was performed as follows: first each individual 
sample set and PCR reaction were analysed separately. Within each sample set and PCR 
reaction the un-stimulated sample was quantified as 100% the stimulated samples for the 
matching PCR reactions were then quantified as a percentage of the un-stimulated 
reaction. The data for each sample set was then loaded into Prism and a one way ANOVA 
for matched samples with Dunette’s post-test was performed to compare the individual 
stimulations against the un-stimulated control. 
 
2.9.5 Extraction of DNA from an Agarose Gel 
The DNA bands were extracted from the gel for sequence analysis using Geneflow Q-
Spin Extraction Purification Kit. Briefly, the DNA band was excised from the gel and 
transferred to a clean microcentrifuge tube. An equal volume (w/v) binding buffer was 
added to the gel slice and incubated at 65ºC for ten minutes with occasional vortexing. 
The dissolved gel was then added to a spin column incubated at room temperature for two 
minutes and then centrifuged at 6,000g for one minute. The flow through was discarded 
and 500µl wash solution added to the column, and the column centrifuged at 6,000g for 
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15 seconds. The column was then centrifuged for a further minute to remove any residual 
wash solution and then placed into a clean collection tube. Thirty micolitres elution 
solution was added to the column and incubated for two minutes at room temperature and 
then centrifuged at 10,500g for one minute. The eluted DNA was sent for sequencing at 
the Medical School Genomics Core Facility. 
 
2.10 ChIP Sequencing Methods 
2.10.1 Preparation of Samples 
2.10.1.1 ChIP DNA Whole Genome Amplification (WGA) 
Primary myocyte ChIP chromatin from 2.7.1, including both the KCNMA1 and IgG 
fractions were amplified using the Sigma Whole Genome Amplification Kit (WGA) as 
detailed in the manufacturer’s instructions with slight modifications. One microlitre of 
ChIP DNA was diluted with 9µl of ultrapure water. Two microlitres of library preparation 
buffer together with 1µl of library stabilisation solution was added to this and heated at 
95ºC for two minutes before cooling on ice. One microlitre of library preparation enzyme 
was then added and the reaction incubated in the thermal cycler for the following: 
 
20 minutes at 16ºC (pre-cooled to this temperature) 
20 minutes at 20ºC 
20 minutes at 37ºC 
5 minutes at 75ºC 
4ºC hold 
 
During the incubation a master mix containing 7.5µl of 10x amplification master mix, 
47.5µl ultrapure water and 5µl (2 units/µl) of Whole Genome Amplification (WGA) 
DNA polymerase was prepared. This was added to each sample and incubated in the 
thermal cycler for the following: 
 
3 minutes at 95ºC 
Then 20 cycles of: 
15 seconds at 95ºC 
5 minutes at 65ºC 
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4ºC hold 
 
Ten percent of the amplified DNA was run on an agarose gel to ensure a DNA smear of 
the correct size was obtained. The remainder of the DNA was purified using Sigma 
Genelute™ PCR Clean-Up Kit following the manufacturers guidelines, as detailed in 
section 2.7.5. 
 
2.10.1.2 Re-Amplification of Amplified DNA 
One round of amplification did not produce enough DNA for ChIP sequencing 
experiments, therefore, the amplified DNA was re-amplified using the WGA re-
amplification kit to generate the 7.5µg required. The method was as follows: 1µl of 
amplified DNA was added to 9µl of ultrapure water. As master mix containing 47.5µl 
ultrapure water, 7.5µl amplification master mix, 2.5units WGA polymerase and dNTPS 
(10 mM dGTP, 10 mM dCTP, 10 mM dTTP and 10 mM dATP) was prepared. This was 
added to each sample and incubated in the thermal cycler for the following: 
  
3 minutes at 95ºC 
Then 20 cycles of: 
15 seconds at 95ºC 
5 minutes at 65ºC 
4ºC hold 
 
Ten percent of the amplified DNA was run on an agarose gel to ensure a DNA smear of 
the correct size was obtained. The remainder of the DNA was purified using Sigma 
Genelute™ PCR Clean-Up Kit following the manufacturer’s guidelines, as detailed in 
section 2.7.5. The DNA was quantified using the nanophotometer by measuring UV 
absorbtion at 260nm. Using the Beer Lambert Law where an absorbtion of one equates 
to a concentration of 50μg/ml DNA. The ratio of UV absorbtion at A260 and A280nm 
was used to assess the purity of the sample. The A260/280 for pure DNA is ~1.8-2.0. 
 
2.10.1.3 ChIP Sequencing End Repair 
The ChIP sequencing (ChIP-seq) was carried out by Dr Paul Heath in Sheffield Institute 
for Translational Neuroscience (SITrAN). End Repair was carried out using the Kapa 
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Biosystems Library Preparation Kit according to the manufacturer’s instructions. Briefly, 
a reaction mix comprising 8μl water, 7μl 10x Kapa end repair buffer, 5μl Kapa end repair 
enzyme mix and 50μl fragmented DNA was prepared and incubated at 20°C for 30 
minutes. Following this 120μl of Agencourt® AMPure® XP Reagent was added to each 
reaction and incubated at room temperature for 15 minutes. This reaction was then placed 
on a magnet until the supernatant was clear. The supernatant was discarded and the beads 
washed twice with 200μl 80% (v/v) ethanol.  
 
2.10.1.4 Addition of ‘A’ Bases to the 3’ end of the DNA Fragments 
This was again carried out using the Kapa Biosystems Library Preparation Kit according 
to the manufacturer’s instructions. Briefly, a reaction mix comprising the beads (from 
above), 42μl water, 5μl 10x KAPA A tailing buffer, 3μl KAPA A tailing enzyme was 
prepared. This was incubated at 30°C for 30 minutes. This reaction was then placed on a 
magnet until the supernatant was clear. The supernatant was discarded and the beads 
washed twice with 200μl 80% (v/v) ethanol. 
 
2.10.1.5 Ligate Adapters to DNA Fragments 
At this point the protocol was switched to the NEBNext Ultra DNA Library Preparation 
Kit and the manufacturer’s protocols followed. Briefly, a reaction mix comprising the 
beads (from above), 15μl Blunt/TA Ligase Master Mix, 2.5μl NEBNext Adaptor for 
Illumina, 1μl Ligation Enhancer was prepared. This mix was incubated at 20°C for 15 
minutes. At this point 3μl USER enzyme was added to the mix and incubated at 37°C for 
15 minutes. This reaction was then placed on a magnet until the supernatant was clear. 
The supernatant was discarded and the beads washed twice with 200μl 80% (v/v) ethanol. 
The DNA was then eluted from the beads by the addition of 22μl 10mM Tris HCl and 
incubation at room temperature for two minutes. This reaction was then placed on a 
magnet until the supernatant was clear. The supernatant was collected. 
 
2.10.1.6 Enrichment of the Adapter-Modified DNA Fragments by PCR. 
The following PCR reaction mix was prepared: 20μl DNA (from above), 2.5μl Index 
Primer/i7 Primer, 2.5μl Universal primer/i5 primer, 25μl NEBNext High Fidelity 2x PCR 
Master Mix. This was then amplified using the following PCR protocol: 
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30 seconds at 98°C 
Then 18 cycles of: 
10 seconds at 98°C 
30 seconds at 65°C 
30 seconds at 72°C 
Then: 
5 minutes at 72°C 
Hold at 4°C 
 
The DNA was then again purified and eluted in 28μl. The library was then validated using 
the bioanalyser. The bioanalyser utilises chip based electrophoresis to analyse RNA and 
DNA, a dye is intercalated into the sample which then runs past a filter the fragments are 
detected by laser induced fluorescence. Purity, size and concentration of the sample is 
then calculated by calibration against the ladder which is of known size and concentration. 
Briefly, 1μl of both the construct and the negative control are loaded onto the bioanalyser 
and the size purity and concentration of the sample were checked. 
 
2.10.1.7 Cluster Generation by Bridge Amplification 
The flow cell surface is coated with single stranded oligonucleotides corresponding to the 
adaptor sequences which were ligated to the DNA. These single stranded adapter ligated 
fragments were bound to the surface of the flow cell in the presence of reagents for 
polymerase based extension. The flow cell and bound DNA then underwent a series of 
denaturation and extension cycles resulting in localised amplification of single molecules 
in millions of unique locations across the flow cell surface. 
 
2.10.1.8 Sequencing by Synthesis 
The flow cell (from above) which now contains millions of unique clusters was then 
loaded into the sequencer for automated cycles of extension and imaging.  
 
2.10.2 Analysis of ChIP Sequencing Data 
The .fastq files (raw data) were imported into Galaxy (https://usegalaxy.org), an open 
access web based platform for Next Generation Sequencing (NGS) analysis. Galaxy is a 
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framework for integrating computational tools, the majority of NGS analysis tools can be 
run from the Galaxy interface. Initially, for quality control, summary statistics were 
computed for each sample. This was done by running the “NGS: QC and Manipulation > 
FASTQ Summary Statistics” tool. Next the “NGS: QC and Manipulation > FASTQ 
Groomer” tool was used to convert the FASTQ data to Sanger data. The next step was to 
map the reads onto a reference genome, the H19 build of the human genome was loaded 
as the reference genome and the “NGS: Mapping > Map with Bowtie for Illumina” tool 
was used to carry out the mapping. Once the reads were mapped peak calling was 
performed using the “NGS: Peak Calling > SICER” tool. This is a statistical tool for the 
identification of ChIP enriched regions. Once significantly enrich regions were located 
the NCBI Map Viewer (http://www.ncbi.nlm.nih.gov/mapview/) was used to identify 
genes associated with the enriched regions.  
 
2.10.3 ChIP Sequencing Motif Enrichment Analysis 
To perform the motif enrichment analysis the first step was to retrieve the genomic DNA 
sequences for the Peaks located above. This was done using the “NGS: Fetch Sequence 
< extract genomic DNA” tool. This generated a FASTA file containing the genomic DNA 
sequences. To identify overexpressed motifs the Panoptic Motif Search Tool 
(http://www.pms.engr.uconn.edu/index.php?page=motifseq) was used. Panoptic Motif 
Search is a motif discovery algorithm which has been designed to find short, core DNA-
binding motifs for Eukaryotic transcription factors and is optimised to handle large ChIP-
seq datasets. The FASTA data generated in Galaxy was loaded into the Panoptic Motif 
Search tool and the motif discovery algorithm run. 
 
2.10.4 ChIP PCR Validation of ChIP Sequencing  
For validation of ChIP-seq peaks three promoters that where shown to be bound by the 
KCNMA1 protein were selected; MAP3K7, JHP2 and RB1.  Primers were designed to 
amplify a portion of the promoter sequence for each of these genes which was identified 
though ChIP- seq peak calling (Table 2.7).  Optimised PCR conditions are detailed in 
Table 2.8. PCR was carried out as detailed in section 2.9.2 utilising Agilents Herculase II 
Fusion Polymerase. 
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Table 2.7 ChIP Validation Primers 
Gene Primer Sequence (5’-3’) Product 
Size (bp) 
MAP3K7 Forward 
Reverse 
5’-TGATGGCGCTTTGAGACCC-3’ 
5’- ATGCATCTGCCACCATCAGAA -3’ 
127 
JHP2 Forward 
Reverse 
5’- CTGTGCTGGAAGCAAGCATAC -3’ 
5’- AGGGTGCTGAAGAACACCG -3’ 
141 
RB1 Forward 
Reverse 
5’- TGCCAGGTATGAAGGAACTGTG -3’ 
5’- ACTACGTGCAAAGATAAGACCA -3’ 
117 
 
Table 2.8 ChIPseq Validation Optimised PCR Conditions 
Gene Annealing 
Temperature 
Duration of 
Denature/Anneal/elongation 
No. of 
Cycles 
MAP3K7 54.4 20/30/15 30 
JHP2 55.3 20/30/15 30 
RB1 54.4 20/30/15 30 
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Chapter 3: The KCNMA1, CACNA1C and CACNA1G 
Channels Expression in the Cultured Myometrial Cells 
Results and Discussion* 
 
*
This chapter of the thesis has been published in part in - Waite, S. L., S. V. Gandhi, R. N. Khan and N. 
R. Chapman (2014). "The effect of trichostatin-A and tumor necrosis factor on expression of splice 
variants of the KCNMA1 and CACNA1C channels in human myometrium." Front. Physiol. 5: 261. 
(Waite, Gandhi et al. 2014) 
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3.1 Introduction 
As detailed in Chapter One Introduction, in the human myometrium, the cessation of 
uterine quiescence and the onset of both normal and preterm labour are associated with a 
number of pro-inflammatory cytokines, including, but not limited to, IL-1β, TNF and IL-
8. It has been previously demonstrated that external agents such as TNF (potent pro-
inflammatory cytokine) can induce myometrial contractility while other compounds, 
namely trichostatin-A (TSA), can promote myometrial relaxation in isolated human 
smooth muscle strips (Lu, Mazet et al. 1999, Moynihan, Hehir et al. 2008, Webster, Waite 
et al. 2013). The exact means by which this process occurred could not be elucidated. It 
is likely, however, that both agents could influence both ion channel expression and 
subsequent RNA splicing, which, in turn, would modulate myometrial contractility. 
Given the effects previously reported for both TNF and TSA on primary human 
myometrium and myometrial myocytes (Webster, Waite et al. 2013), this chapter aims to 
examine the expression and splicing pattern of the KCNMA1 channel, the CACNA1C 
and the CACNA1G in cultured human myometrial cells and define whether these 
parameters were influenced by TNF and TSA. 
 
TNF is a potent pro-inflammatory cytokine which is secreted in response to inflammatory 
stimuli. TNF stimulates the inflammatory cascade through NFκB, which in turn promotes 
the expression of pro-contractile genes (Mendelson 2009). Within the myometrium 
activation of NFκB by TNF has been shown to promote the expression of a number of 
labour associated genes (Chan, van den Berg et al. 2014, Cookson, Waite et al. 2015). 
Therefore, it is possible that the TNF may increase the contractility of the myometrium 
via an effect on the expression or splicing pattern of the KCNMA1, the CACNA1C and 
the CACNA1G channels. 
 
TSA is a broad spectrum lysine de-acetylase inhibitor, and so prevents the removal of the 
acetyl groups from the histones and other proteins. Prevention of the removal of these 
acetyl groups from histone lysines will have the net effect of maintaining the more open 
accessible state of the DNA, this may be a mechanism by which it affects the expression 
or splicing of the channels. However, it is important to remember that TSA also prevents 
the removal of lysine acetyl groups from other proteins and the relaxatory effect of TSA 
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may also be as a result of this general increase in lysine acetylation. Chen et al. 
demonstrated that TSA could promote the relaxation of arterial tone in vascular smooth 
muscle cells via the increased acetylation of several myofilamentous proteins (Chen, 
Karolczak-Bayatti et al. 2013). 
 
3.2 Characterisation of Myometrial Cell Cultures 
Full details of the methods used in this chapter can be found in Chapter 2 Materials and 
Methods.  
 
3.2.1 Identification of Cells in the Myometrial Cell Cultures 
The aim of this chapter was to determine if TNF and TSA exerted their effect on 
myometrial smooth muscle contractility via the regulation of the expression of either the 
KCNMA1, CACNA1C and CACNA1G or their splice variants. As a first step the 
myometrial cells derived from the biopsies were characterised to verify their suitability 
as samples for this purpose. To this end it was first established that the myometrial cell 
cultures consisted primarily of myocyte cells rather than fibroblasts. This was done by 
measuring the expression of Actin α2, a smooth muscle actin and Thy-1 a cell surface 
antigen expressed specifically from fibroblasts. An immortalised human myometrial cell 
line, PHM1-31 (Monga, Ku et al. 1996) was used as a smooth muscle positive control 
and oral fibroblasts as a fibroblast cell positive control.  PCR using Thy-1, showed only 
faint bands ( Figure 3.1A) in the PHM1-31 cell line and the myometrial cell cultures 
indicting there is only a low level of fibroblast or myofibroblast contamination. In contrast 
to this and as expected, the fibroblast culture showed a much more intense Thy-1 band ( 
Figure 3.1A). All cultures gave an intense band when Actin α2 primers were employed 
in the PCR indicating the presence of smooth muscle cells ( Figure 3.1B). Importantly, 
within the myometrial cell cultures the level of fibroblast contamination was found to 
vary between 1.2 and 11% which is comparable with the immortalised PHM1-31 cell line 
( Figure  3.1C). 
 
3.2.2 Channel Immunocytochemistry 
Culturing of primary cells has been shown to be able to affect certain functional properties 
of the cells such as the loss of steroid receptors (Berns, Brinkmann et al. 1985, Tyagi, 
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Tyagi et al. 2006). The effect of culturing on ion channel expression is unclear. 
Consequently it was important to determine if the myocyte cell cultures expressed the 
KCNMA1, CACNA1C and CACNA1G channels. 
 
 
Figure 3.1 Myometrial Cell Cultures are Composed Primarily of Myocytes and Express the 
KCNMA1, CACNA1C and CACNA1G Channels 
RNA from myometrial cell cultures was extracted and amplified by PCR. (A) Myometrial cell cultures 
express a low level of Thy-1 mRNA indicating a low level of Fibroblasts in the culture. (B) Myometrial 
cell cultures express a high level of Actin-α2 mRNA indicating a high level of myocytes in the culture. 
Manual quantification of the relative band intensities was used to confirm the presence of myocytes and to 
estimate the level of fibroblast contamination. (C) Myometrial cell cultures are comprised of 88 – 98% 
myocytes (grey bar) and between 1.2 and 11% fibroblasts (striped bar) which is comparable to the PHM1 
cultures. (D) Myometrial cells were staining using antibodies specific to KCNMA1 (I) and CACNA1C (II) 
CACNA1G (III) channels. Controls excluded primary (IV) and secondary antibody (V). Dark red/brown 
staining denotes specific staining of the protein of interest (scale bar is 100µm). 
 
125 
 
Immunocytochemistry demonstrated that all three channel types remain present in 
myometrial cell cultures (KCNMA1 - Figure 3.1D, Panel I; CACNA1C – Figure 3.1D, 
Panel II; CACNA1G – Figure 3.1D, Panel III Antiserum controls Figure 3.1D, Panels IV-
V). Interestingly, intense nuclear staining (Figure 3.1D Panels I-II black arrows) was 
observed for both the KCNMA1 and CACNA1C channels although the significance of 
this remains unclear at present. 
 
3.2.3 Myocyte Cell Culture Contractility 
The final step in characterising the myocyte cell cultures was determining if they retained 
the ability to contract. A collagen contraction assay was used for this purpose.  Myocyte 
cells were embedded within collagen gels and either left un-stimulated or stimulated with 
TNF (Webster, Waite et al. 2013) or TSA (Chen, Karolczak-Bayatti et al. 2013, Webster, 
Waite et al. 2013) or Oxytocin, as a contraction-positive control (Mitchell, Fang et al. 
1998, Mukaddam-Daher, Yin et al. 2001, Robinson, Schumann et al. 2003). PHMI-31 
cells and HEK293 cells left un-stimulated or stimulated with TNF or TSA or Oxytocin 
were used as positive and negative controls respectively. The area of the gels was 
recorded to determine what effects the stimulants had on the contractility of the cells. A 
reduction in the surface area of the gel after the gel was released was an indication that 
the cells retained smooth muscle tone, i.e. the resistance to passive stretch during resting 
state. Upon the release of the gels from the sides of the well there was a visible reduction 
in the size of the gels containing both cultured myometrial cells and PHM1-31 cells, there 
was no reduction in gel size seen for the HEK293 cells. This demonstrates that the 
cultured myometrial cells still retain contractile tone. The amount of contraction was 
calculated as the inverse of the gel size after release expressed as a percentage of the 
original gel size (Figure 3.2A). 
 
In the collagen gels containing HEK293 cells, no contraction was observed upon 
treatment with Oxytocin or TNF (Figure 3.2B). In contrast to this, however, treatment 
with Oxytocin caused contraction in both collagen embedded PHM1-31 and primary cells 
demonstrating that both these cells can be induced to contract (Figure 3.2B). Also, when 
collagen embedded PHM1-31 or primary cells where stimulated with TNF, there was a 
significant reduction in gel surface area afterwards suggesting that TNF was inducing cell 
contraction (Figures 3.2B, 3.2C).  
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Figure 3.2 Myometrial Cell Cultures Retain Smooth Muscle Tone and the Ability to Contract and 
Relax.  
(A) The reduction of the surface area of the collagen after release demonstrates the retention of smooth 
muscle tone in the myometrial cell cultures. In the more confluent cultures this reduction in gel size 
becomes significant (p<0.05 *) There is no reduction in gel size in the HEK293 cultures. 10ng/ml TNF, 
100ng/ml TSA, 10ng/ml Oxytocin were added to the cells within the collagen gels with non-stimulated 
cells serving as a control. The cells were then imaged at specific time points between 5 minutes and 8 hours 
post-stimulation.  (B) Depiction of the maximum gel contraction for each culture after stimulation.  (C) 
Depiction of the change in collagen gel surface area of the primary cells over the course of the experiment 
(n=5). 
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Significantly, an increase in gel surface area was observed when cultures were treated 
with TSA indicating that it induced a loss of basal tone in the collagen-embedded 
myocytes cultures although this did not reach statistical significance (Figures 3.2B, 3.2C).  
 
3.3 KCNMA1, CACNA1C and CACNA1G Channel Expression and 
Splice Variant Expression 
Full details of the methods used in this chapter can be found in Chapter 2 Materials and 
Methods.  
 
For the detection of channel splice variants within the primary cultures, primers were 
selected to cover an un-spliced region in each channel and also to cover a number of 
spliced regions in each channel. The individual PCR primer sequences are detailed in 
Chapter 2 Materials and Methods Table 2.3; individual splice variant-specific PCR 
conditions are listed in Chapter 2 Materials and Methods Table 2.5. All channel RT-PCR 
reactions were done simultaneously and with the GAPDH control serving experiments 
for both KCNMA1, CACNA1C and CACNA1G channels. Consequently Figure 3.3D is 
duplicated in Figures. 3.4D-3.8D purely for this reason.  
 
3.3.1 KCNMA1 Splice Variants are Expressed in Myometrial Cell Cultures and are 
Down Regulated by Trichostatin A 
Previous studies, have reported differential effects of both TNF and TSA on signalling 
pathways in myometrial cells (Chapman, Smyrnias et al. 2005, Webster, Waite et al. 
2013). This present research sought to determine if such compounds could also influence 
expression of the KCNMA1 mRNA. Total cellular RNA was amplified using primers 
specific for a region within KCNMA1 that is conserved in all splice variants. As such, 
this would give an indication of overall expression of the mRNA for this channel and how 
TNF and TSA affected this. Figure 3.3A demonstrates that TSA was seen to induce a 
significant reduction in expression of KCNMA1 mRNA (Figure 3.3A white bar). In 
contrast to this, TNF was seen to induce small but statistically significant increase in the 
expression of the KCNMA1 channel mRNA (Figure 3.3A grey bar). Neither treatment 
influenced the expression of GAPDH (Figure 3.3D).  
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The KCNMA1 channel is documented to have a number of splice variants (Curley, 
Morrison et al. 2004). Consequently, it was important to determine if the expression of 
such variants also occurred in human myometrial cell cultures. Moreover, it was also 
salient to determine which of these variants were sensitive to TNF or TSA treatment. 
Total cellular RNA was amplified using primers specific for the different splice sites 
published for the KCNMA1 open reading frame. Myometrial cell cultures were seen to 
express a number of different splice variants M1 (including both the Mk44 variants which 
either express a 132bp insert between exons 1 and 2 or have this insert omitted); M2 
(+exon 11 and 12); M3 (+exon 19); M4 (STREX-2) and M5 (+exon 29) (Figure 3.3B, C). 
 
When cultures were subsequently exposed to either TNF or TSA, TSA significantly 
decreased the expression of the Mk44 splice variants in comparison to un-stimulated 
cultures and the ratio between the Mk44 variant containing the 132bp insert and the 
variant lacking this insert was also significantly reduced with TSA stimulation. TNF had 
no effect on either the expression of the Mk44 variant or on the ratio between the insert 
and insert-less forms of the variant (Figure 3B). We also observed a similar TSA-induced 
repression of both the M3 (+ exon 19 variant) and the M4 (STREX-2 variant) (Figure 
3.3B).  
 
The observed reduction in STREX-2 levels, while statistically significant, was, however, 
small in magnitude and the relevance of this remains unclear at present.  Representative 
gels of each treatment are illustrated in Figure 3.3C. No change in GAPDH was observed 
with either treatment (Figure 3.3D). 
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Figure 3.3 The Expression of the KCNMA1 Channel and Splice Variants in Myometrial Cell Cultures 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour, 100ng/ml TSA for 24 
hours or left un-stimulated. Total RNA was extracted, reverse transcribed and amplified using channel and 
splice variant specific primers. Manual quantification of the relative band intensities were used to quantify 
the level of expression and this was expressed as a percentage of the un-stimulated expression (n = 8). (A) 
TNF significantly increased and TSA significantly reduced the expression of the KCNMA1 channel 
(p<0.05 *). (B) Myometrial cell cultures express a range of KCNMA1 splice variants, TNF had no effect 
on splice variant expression and TSA significantly reduced the expression of the Mk44 splice variant 
(p<0.05 *). (C) Representative gel of the RT-PCR products. (D) Neither TNF nor TSA influenced the 
expression of GAPDH. 
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3.3.2 The Combined Effect of TNF or TSA Stimulus on the Expression of the 
KCNMA1 Channel and its Splice Variants in Myometrial Cell Cultures are 
Dependent on the Order in Which they Occur. 
Next it was determined if these compounds had an enhancing or diminishing effect on 
each other. When the cultures were exposed to TNF prior to exposure to TSA the 
expression of the KCNMA1 channel (Figure 3.4A, C) and the M3 splice variant (Figure 
3.4B, C) were significantly reduced in comparison to un-stimulated cultures. In contrast, 
the STREX-2 and M5 variants were significantly up regulated (Figure 3.4B, C) in 
comparison to un-stimulated cultures. Indicating that when TNF is present prior to TSA 
stimulation the effect of these two compounds varies according to which splice variant is 
examined.  
 
In terms of the KCNMA1 channel and the M3 variant this effect enhanced the effect of 
TSA, whereas, with the STREX-2 and M5 variants the effect was different to that seen 
for either of the individual compounds. The relevance of this remains unclear at present. 
 
When the cultures were exposed to TSA prior to exposure to TNF the Mk44 variant 
containing the 132bp insert, and the M3 variant were significantly down regulated (Figure 
3.4B, C) in comparison to un-stimulated cultures. Although the repression of these two 
variants was also observed with TSA stimulation, the addition of TNF following TSA 
had the effect of reducing the level of repression to a small degree. This indicates that 
when TNF exposure follows TSA exposure it has a small diminishing effect on the action 
of TSA. No change in GAPDH was observed with either treatment (Figure 3.4D). 
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Figure 3.4 The Expression of the KCNMA1 Channel and Splice Variants in Myometrial Cell Cultures 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour followed by 100ng/ml 
TSA for twenty-four hours, 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour or 
left un-stimulated. Total RNA was extracted, reverse transcribed and amplified using channel and splice 
variant specific primers. Manual quantification of the relative band intensities were used to quantify the 
level of expression and this was expressed as a percentage of the un-stimulated expression (n = 5). (A) 
TSA/TNF had no significant effect whilst TNF/TSA significantly reduced the expression of the KCNMA1 
channel (p<0.05 *). (B) Myometrial cell cultures express a range of KCNMA1 splice variants, TNF/TSA 
had no effect on splice variant expression with the exception of M3 which was significantly reduced 
(p<0.05 *) and TSA/TNF significantly reduced the expression of the MK44+132bp and M3 (+19) splice 
variants (p<0.05 *). TSA/TNF also significantly increased the expression of the M4 (STREX-2) and M5 
(+29) splice variants (p<0.05 *) (C) Representative gel of the RT-PCR products. (D) Neither TNF/TSA nor 
TSA/TNF influenced the expression of GAPDH. 
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3.3.3 CACNA1C Splice Variants are Expressed in Myometrial Cell Cultures and are 
Down Regulated by Trichostatin A 
Next, it was determined if these compounds also influence expression of the CACNA1C 
mRNA. Total cellular RNA was amplified using primers specific for a region within 
CACNA1C that is conserved in all splice variants. As such, this would give an indication 
of overall expression of the mRNA for this channel and how TNF and TSA affected this. 
Figure 3.5A demonstrates that TSA was seen to induce a reduction in expression of 
CACNA1C mRNA but this did not reach significance (Figure 3.5A white bar). In contrast 
to this, TNF was seen to induce a significant increase in total CACNA1C mRNA 
expression (Figure 3.5A grey bar). Neither treatment influenced the expression of 
GAPDH (Figure 3.5D). 
 
The CACNA1C channel is documented to have a number of splice variants (Tang, Liang 
et al. 2004). Consequently, it was important to determine if the expression of such variants 
also occurred in myometrial cell cultures. Moreover, it was also salient to determine 
which of these variants were sensitive to TNF treatment. Total cellular RNA was 
amplified using primers specific for the different splice sites published for the CACNA1C 
open reading frame (Tang, Liang et al. 2004). Myometrial cell cultures were seen to 
express a number of different splice variants (Figures 3.5B, 3.5C). Briefly, the myocytes 
express the splice site 4 variant containing exon 8* this variant has lower DHP sensitivity, 
more rapid activation and slower deactivation kinetics than the alternative exon 8-
containing variant (Soldatov 1992).  
 
Two splice site 10 variants were observed one containing exons 30, 31, 32, 33 and 34 and 
a second containing exons 30, 31, 33 and 34 these two variants affect the size and rigidity 
of the S3 to S4 linker segments. It has been suggested that shorter linker segments result 
in channels with slower gating kinetics while longer linking segments result in channels 
with faster gating kinetics (Perez-Reyes, Wei et al. 1990, Yang, Chen et al. 2000). Of the 
two variants found in the myometrial cells the one containing 30, 31, 33 and 34 is the 
shorter variant and was found in approximately 80% of the RNA. Finally the splice site 
11 variant containing exons 40, 41, 42 and 43 was also observed.  
 
 
133 
 
 
Figure 3.5 The Expression of the CACNA1C Channel and Splice Variants in Myometrial Cell 
Cultures 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour, 100ng/ml TSA for 24 
hours or left un-stimulated. Total RNA was extracted, reverse transcribed and amplified using channel and 
splice variant specific primers. Manual quantification of the relative band intensities were used to quantify 
the level of expression and this was expressed as a percentage of the un-stimulated expression (n = 7). (A) 
TNF significantly increased the expression of the CACNA1C channel whilst TSA had no significant effect 
(p<0.05 *). (B) Myometrial cell cultures express a range of CACNA1C splice variants. TSA significantly 
induced expression of the exon-8 variant (Left Panel; p<0.05 *) whilst also reducing expression of a number 
of other splice variants (Right Panel; p<0.05 *). TNF had no effect on splice variant expression. (C) 
Representative gel of the RT-PCR products. (D) Neither TNF nor TSA influenced the expression of 
GAPDH. 
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When cultures were subsequently exposed to either TNF or TSA, TSA resulted in the 
novel expression of CACNA1C splice variants utilising exon 8 (Figure 3.5B; Left Panel). 
Un-stimulated cells and those treated with TNF exclusively utilise exon 8*; after 
treatment with TSA, however, approximately 45% of the mRNA expressed contained the 
exon 8 variant. The utilisation of exon 8 leads to the expression of channels with higher 
DHP sensitivity and slower activation and more rapid deactivation curves (Figures 3.5B, 
3.5C).  
 
TSA also resulted in the down regulation of both forms of the splice site 10 variant while 
TNF had little effect (Figures 3.5B, 3.5C). The effect of TSA is what would be expected 
as the faster gating kinetics of the longer form would mean that it would take less time 
for the channels to fully open and hence would increase the influx of calcium and would 
promote contraction. The effect of a decreased expression of this variant would therefore 
lead to relaxation (Figures 3.5B, 3.5C).  
 
TSA also resulted in a down regulation of the splice site 11 variant. All the treatment 
groups expressed the same variant at splice site 11, this variant contained exons 40, 41, 
42 and 43 with no additions or deletions. After TSA treatment the expression of this 
variant was significantly reduced, there was, however, no alternative variant expressed 
(Figures 3.5B, 3.5C). Neither treatment influenced the expression of GAPDH (Figure 
3.5D). 
 
3.3.4 The Combined Effect of TNF or TSA Stimulus on the Expression of the 
CACNA1C Channel and its Splice Variants in Myometrial Cell Cultures are 
Dependent on the Order in Which they Occur. 
Next, as with the KCNMA1 channel it was determined if these compounds had an 
enhancing or diminishing effect on each other. When the cultures were exposed to TNF 
prior to exposure to TSA the expression of the CACNA1C (Figure 3.6A, C) and the splice 
site 11 variant (Figure 3.6B, C) were both significantly down regulated in comparison to 
un-stimulated cultures. The splice site 4 variant containing exon 8 (Figure 3.6B left panel, 
C) was also expressed. When administered in this order the presence of TNF enhances 
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the effect of TSA on both the CACNA1C and the splice site 11 variant. The presence of 
TNF had no effect on the expression of the splice site 4 variant containing exon 8. 
 
When the cultures were exposed to TSA prior to exposure to TNF the expression of the 
CACNA1C (Figure 3.6A, C), both splice site 10 variants and the splice site 11 variant 
(Figure 3.6B, C) were all significantly down regulated in comparison to un-stimulated 
cultures. The presence of TNF enhanced TSA repression of the CACNA1C to significant 
level. However, the presence of TNF did not alter the effect of TSA alone on either of the 
splice site 10 variants or the splice site 11 variant. The presence of TNF, again, had no 
effect on the expression of the splice site 4 variant containing exon 8 (Figure 3.6B left 
panel, C). No change in GAPDH was observed with either treatment (Figure 3.6D). 
 
3.3.5 CACNA1G Splice Variants are Expressed in Myometrial Cell Cultures and 
are Up Regulated by TNF 
Next, it was determined if these compounds also influence expression of the CACNA1G 
mRNA. Total cellular RNA was amplified using primers specific for a region within 
CACNA1G that is conserved in all splice variants. As such, this would give an indication 
of overall expression of the mRNA for this channel and how TNF and TSA affected this. 
Figure 3.7A demonstrates that TSA was seen to induce an increase in expression of 
CACNA1G mRNA but this did not reach significance (Figure 3.7A white bar). Neither 
treatment influenced the expression of GAPDH (Figure 3.7D). 
 
The CACNA1G is documented to have a number of splice variants (Chemin, Monteil et 
al. 2001, Bertolesi, Walia Da Silva et al. 2006, Emerick, Stein et al. 2006, Shcheglovitov, 
Vitko et al. 2008, David, Garcia et al. 2010). Consequently, it was important to determine 
if the expression of such variants also occurred in human myometrial cells. Moreover, it 
was also salient to determine which of these variants were sensitive to TNF treatment. 
Total cellular RNA was amplified using primers specific for the different splice sites 
published for the CACNA1G open reading frame (Emerick, Stein et al. 2006). 
myometrial cell cultures were seen to express a number of different splice variants 
(Figures 3.7B, 3.7C). 
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Figure 3.6 The Expression of the CACNA1C Channel and Splice Variants in Myometrial Cell 
Cultures 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour followed by 100ng/ml 
TSA for twenty-four hours, 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour or 
left un-stimulated. Total RNAwas extracted, reverse transcribed and amplified using channel and splice 
variant specific primers. Manual quantification of the relative band intensities were used to quantify the 
level of expression and this was expressed as a percentage of the un-stimulated expression (n = 4). (A) Both 
TNF/TSA and TSA/TNF significantly reduced the expression of the CACNA1C channel (p<0.05 *). (B) 
Myometrial cell cultures express a range of CACNA1C splice variants. Both TNF/TSA and TSA/TNF 
significantly induced expression of the exon-8 variant (Left Panel; p<0.05 *). TSA/TNF also reduced 
expression of a number of other splice variants (Right Panel; p<0.05 *). TNF/TSA had no effect on splice 
variant expression with the exception of splice site 11 variant containing exons 40, 41, 42 and 43 which 
was significantly reduced (Right Panel p<0.05 *). (C) Representative gel of the RT-PCR products. (D) 
Neither TNF/TSA nor TSA/TNF influenced the expression of GAPDH. 
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Briefly, within the myocytes a splice site 2 variant excluding exon 14 was observed, this 
variant will lack a PKC phosphorylation site (Bertolesi, Walia Da Silva et al. 2006). At 
splice site 4 the variant observed contained exon 25 without the utilisation of the splice 
acceptor sites and so would form a functional channel (Chemin, Monteil et al. 2001, 
Bertolesi, Walia Da Silva et al. 2006, Emerick, Stein et al. 2006). The splice site 5 variant 
observed excluded exon 25C and contained exon 26, this will modify the channels gating 
properties (Chemin, Monteil et al. 2001, Bertolesi, Walia Da Silva et al. 2006, Emerick, 
Stein et al. 2006). Two variants were observed at splice site 7/8 one containing both exon 
30B and 31A, and one excluding exon 30B and containing exon 31A. Exon 30B modifies 
the voltage dependence of the channel (Emerick, Stein et al. 2006), however, exon 31A 
results in prematurely truncated protein (Emerick, Stein et al. 2006), and so both these 
variants will result in truncated protein. 
 
When cultures were subsequently exposed to either TNF or TSA, TNF resulted in a small 
but significant up regulation of splice site 2 variant excluding exon 14 (Figure 3.7B, C), 
this variant will lack a PKC phosphorylation site (Bertolesi, Walia Da Silva et al. 2006). 
PKC has been demonstrated to stimulate CACNA1G activity and so the loss of a PKC 
site would reduce the stimulatory effect of PKC on the channel (Park, Kang et al. 2006).  
 
TNF also resulted in the significant up-regulation of the splice site 4 variant containing 
exon 25, this forms a functional channel which will activate and inactivate at more 
hyperpolarised potentials (Hawkins and Kearney 2012). This will have the effect of 
allowing these channel to open at more negative membrane potentials and so will support 
contraction.  
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Figure 3.7 The Expression of the CACNA1G Channel and Splice Variants in Myometrial Cell 
Cultures 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour, 100ng/ml TSA for 24 
hours or left un-stimulated. Total RNA was extracted, reverse transcribed and amplified using channel and 
splice variant specific primers. Manual quantification of the relative band intensities were used to quantify 
the level of expression and this was expressed as a percentage of the un-stimulated expression (n = 5). (A) 
Neither TNF nor TSA had a significant effect on the expression of the CACNA1G channel. (B) Myometrial 
cell cultures express a range of CACNA1G splice variants, TNF significantly increased the expression of 
T2 (-exon14) and T4 (+exon 25) while TSA significantly increased the expression of T5 (-exon25c +exon 
26) and T7/8 (+exons 30B & 31A) (p<0.05 *). (C) Representative gel of the RT-PCR products. (D) Neither 
TNF nor TSA influenced the expression of GAPDH. 
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The exclusion of exon 25C has the effect of creating CACNA1G which are less 
inactivated at rest and therefore are more readily available to open in response to 
depolarisation of the membrane (Senatore and Spafford 2012).  
 
TSA had little effect on the expression of any of the splice variants observed in the 
primary myocyte cultures. Neither treatment influenced the expression of GAPDH 
(Figure 3.7D). 
 
3.3.6 The Combination of TNF or TSA Stimulus on the Expression of the CACNA1G 
Channel and its Splice Variants in Myometrial Cell Cultures had Differing Effects 
Dependant on the Splice Variant Observed. 
Next, as with the KCNMA1 channel and CACNA1C it was determined if these 
compounds had an enhancing or diminishing effect on each other. When the cultures were 
exposed to TNF prior to exposure to TSA the effects observed were inconsistent. In the 
majority of experiments there were no bands observed on the gels which may indicate 
that the expression of these splice variants was significantly reduced or it may indicate a 
problem with the PCR reactions. Since it was not possible to confidently determine which 
of these explanations was correct any meaningful interpretation of the analysis was 
therefore impossible. 
 
When the cultures were exposed to TSA prior to exposure to TNF the expression of the 
CACNA1G was increased, although this did not reach significance (Figure 3.8A, C). The 
expression of the splice site 4 variant containing exon 25 and the splice site 5 variant 
containing exon 26 and excluding exon 25C were both significantly up regulated (Figure 
3.8B, C) in comparison to the un-stimulated cultures. The addition of TSA prior to TNF 
was observed to have an enhancing effect on both the expression of the CACNA1G and 
the splice site 5 variant as these were increased to a higher level than that seen after 
exposure to TNF alone. The addition of TSA had little additional effect on the expression 
of the splice site 4 variant in comparison to TNF alone. No change in GAPDH was 
observed with either treatment (Figure 3.8D). 
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Figure 3.8 The Expression of the CACNA1G Channel and Splice Variants in Myometrial Cell 
Cultures 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour followed by 100ng/ml 
TSA for twenty-four hours, 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour or 
left un-stimulated. Total RNA was extracted, reverse transcribed and amplified using channel and splice 
variant specific primers. Further analysis was only performed on the TSA/TNF samples. Manual 
quantification of the relative band intensities were used to quantify the level of expression and this was 
expressed as a percentage of the un-stimulated expression (n = 5). (A) TSA/TNF had no significant effect 
on the expression of the CACNA1G channel. (B) Myometrial cell cultures express a range of CACNA1G 
splice variants, TSA/TNF significantly increased the expression of the T4 (+ exon 25) and T5 (-exon 
25c+exon 26) splice variants (p<0.05 *). (C) Representative gel of the RT-PCR products. (D) Neither 
TNF/TSA nor TSA/TNF influenced the expression of GAPDH. 
 
141 
 
3.4 Discussion 
At the end of pregnancy the myometrium switches from a state of relative quiescence, 
which is seen throughout pregnancy, to the contractile state characteristic of parturition. 
Although the molecular basis of contraction is understood, the triggers which move the 
myometrium from the quiescence to the contractile state seen at parturition remain to be 
defined.  
 
The myometrial quiescent state is characterised by slow wave potentials where the 
membrane potential cycles between depolarisations and repolarisations without reaching 
the threshold level for action potential generation (Parkington, Tonta et al. 1999).  
However in the myometrium at parturition, these slow wave potentials become frequent 
and synchronised action potentials during which the membrane potential rapidly rises and 
falls, causing the muscle to contract (Wilde and Marshall 1988). 
 
Both the quiescent state and the coordinated contractions are thought to be mediated 
through mechanisms that involve ion channels and in particular the KCNMA1 potassium, 
CACNA1C and CACNA1G channels.  
 
3.4.1 Analysis of KCNMA1 Channel Expression in Myocytes 
This research has demonstrated that myometrial cell cultures contain a number of 
different KCNMA1 channel splice variants including Mk44 and STREX-2. 
 
Splice site 1 variant (Mk44) comprises a 132bp insertion, which has previously been 
described by Korovkina et al. Variants containing the insert (Mk44 +132bp) have 
diminished calcium and voltage sensitivity, the inserted sequence itself has been shown 
to contain both a phosphorylation and a myristylation site. This variant can also undergo 
proteolytic cleavage after which the N-terminal is located on the membrane while the C-
terminal is held with the endoplasmic reticulum. The C-terminal is released after release 
of calcium from sarcoplasmic reticulum based stores and re-constitutes with the N-
terminus on the membrane (Korovkina, Fergus et al. 2001). The presence of this variant 
shows that there are KCNMA1 channels with diminished calcium and voltage sensitivity 
within the myometrium. 
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Splice site 2 comprises the mutually exclusive use of exons 10 and 11 or 11 and 12, within 
the myocytes exons 11 and 12 are utilised. This variant can result in premature truncation 
of the protein. The loss of the C-terminal tail of the channel will result in the loss of the 
calcium sensitivity of the channel. 
 
Splice site 3 comprises the insertion of 40aa (the utilisation of the entire of exon 19), the 
insertion of 4aa (the 3’ truncation of exon 19) or no amino acids inserted (the skipping of 
exon 19). Within the myocytes the entire of exon 19 is utilised, there is no information as 
to the effect of the inclusion of the whole exon on channel gating kinetics. 
 
Splice site 4 consists of the differential utilisation of exons 22 and 23. The variant present 
in the myocytes contained both exons 22 and 23 and so is the STREX-2 variant. The 
STREX-2 variant has increased mechano-sensitivity and hypoxia inhibition. Interestingly 
the STREX-2 insert also contains a cAMP-dependant PKA consensus motif which when 
phosphorylated facilitates membrane depolarisation and hence promotes the contractile 
phenotype of the cells. 
 
Splice site 5 comprises the insertion or deletion of exon 29, the variant expressed within 
the myocytes contains exon 29. This insertion results in increased activation rates and 
their co-operativity with calcium is modified. It is thought these effects are due to the 
proximity of the splice site to the calcium bowl. 
 
3.4.2 Analysis of CACNA1C Channel Expression in Myocytes 
This research has also demonstrated that the myometrial cell cultures used as a model  
express pro-contractile splice variants of the CACNA1C including splice site 4 containing 
exon 8*, splice site 10 containing exons 30,31,32,33 and 34 and splice site 11 containing 
exons 40, 41, 42 and 43. 
 
Splice site 4 is comprised of the mutually exclusive use of exons 8 and 8*. The PCR 
results show that it is exon 8* that is expressed in the myocytes. The expression of 8* 
results in a channel with decreased DHP sensitivity, rapid activation and slow 
deactivation kinetics (Goodwin, Leeds et al. 1999). The kinetics of the channel would 
promote contraction. 
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The CACNA1C splice site 10 is a complex site which involves the differential usage of 
exons 30, 31, 32, 33 and 34 which result in different lengths of linking loop between IV 
S2 and S4. The myocytes express two forms of this variant, a longer one containing exons 
30, 31, 32, 33 and 34 and a shorter one containing exons 30, 31, 33 and 34. The longer 
form containing exon 32 correlates well with SVI3B, which has been shown to have 
increased excitation-contraction coupling (Huang, Xu et al. 2006) and so the less 
abundant expression of this form would decrease the excitability of the cell and promote 
relaxation. 
 
Splice site 11 encompasses exons 40, 41, 42 and 43, variants in this region include use of 
exon 40A (exon40 – 19bp), +125bp (exon 40B), exon 41A and exon 43 +132bp or the 
use of exons 40, 41, 42 and 43 (Soldatov 1994). The additional 19bp found in exon 40 in 
comparison to exon 40A are thought to modulate the tethering of calmodulin to the C-
terminal and impact on the calcium dependant inactivation of the channel (Gerhardstein, 
Gao et al. 2000). The splice site 11 variant found to be expressed in the myocytes 
contained exons 40, 41, 42 and 43. This variant is the same as the α1C77 variant described 
by Kepplinger et al. (Kepplinger, Kahr et al. 2000). Calcium-dependant inactivation was 
found to be highest in the α1C77 variant. This variant was also found to be more efficiently 
targeted to the cell membrane and had higher conductance and open probability than the 
other variants at this site (Kepplinger, Kahr et al. 2000). The expression of this variant 
would push the cells towards a more contractile state. 
 
3.4.3 Analysis of CACNA1G Channel Expression in Myocytes 
Finally, the results demonstrated that myometrial cell cultures used as a model express a 
number of different CACNA1G splice variants including omission of exon 14, utilisation 
of exon 25 with no additions and utilisation of exon 26. These variants are again 
predominantly pro-contractile. 
 
The CACNA1G splice site 2 involves the insertion or deletion of exon 14, only the deleted 
exon 14 variant was found to be present in the myocytes. Expression of this variant will 
result in the loss of a PKC phosphorylation site. PKC has been demonstrated to stimulate 
CACNA1G activity and so the loss of a PKC site would reduce the stimulatory effect of 
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PKC on the channel (Park, Kang et al. 2006). The inclusion of exon 14 with either exon 
25C or exon 26 results in channels with increased inactivation rates. As exon 14 is not 
expressed in these cultures these channel will not have this increased inactivation rates 
and so will support contraction. 
 
The CACNA1G splice site 4 involves the possible use of a number of splice acceptor sites 
on exon 25. Exon 25 contains 3 splice acceptor sites termed 25A, 25A’ and 25A’’ 
however none of these have been utilised in the myocyte CACNA1G. Use of these splice 
acceptor sites can result in non-ion conducting channels, so the lack of use of these sites 
is a good indicator that the CACNA1G channels are able to conduct calcium ions through 
their pore. Variants containing exon 25 have been shown to activate and inactivate at 
more hyperpolarised potentials (Hawkins and Kearney 2012). This will have the effect of 
allowing these channel to open at more negative membrane potentials and so will support 
contraction. 
 
The CACNA1G splice site 5 comprises the mutually exclusive use of exon 25C or 26. 
Within the myocytes it was exon 26 which was found to be expressed. Channels 
expressing exon 26 have been shown to activate at midpoint potentials and a mid-range 
steady state midpoint (Chemin, Monteil et al. 2001, Jagannathan, Punt et al. 2002, 
Bertolesi, Walia Da Silva et al. 2006, Emerick, Stein et al. 2006) The exclusion of exon 
25C has the effect of creating CACNA1G which are less inactivated at rest and therefore 
are more readily available to open in response to depolarisation of the membrane 
(Senatore and Spafford 2012).   
 
The CACNA1G splice site 7/8 involves the use of a splice donor site in exon 30 (30B) 
and / or the use of a Splice acceptor site in 31 (31A). Within the myocytes there were 
splice variants expressing both exons 30B and 31A and variants expressing just exon 
31A. Inclusion of exon 30B results in channels with modified voltage dependant 
activation, and inclusion of exon 31A results in prematurely truncated protein.  
 
3.4.4 The Effect of TNF 
The initiation of the contractile state seen at parturition is characterised by an increase in 
pro-inflammatory cytokines such as IL-1β, IL-6 and TNF (Romero, Mazor et al. 1992, 
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Opsjln, Wathen et al. 1993, Keelan, Marvin et al. 1999, Osman, Young et al. 2003). The 
data from the collagen gel contraction studies demonstrating the contractile action of TNF 
and the pro-relaxant function of TSA are in broad agreement with the published data on 
the effects of TNF and TSA on contractility of isolated smooth muscle strips (Sadowsky, 
Adams et al. 2006, Fitzgibbon, Morrison et al. 2009, Europe-Finner, Taggart et al. 2013, 
Webster, Waite et al. 2013). 
 
In terms of calcium flux, using hippocampal neurons, TNF stimulation has been shown 
to increase calcium current density by around 20% and this increase can be attributed to 
an increase in CACNA1C current (Furukawa and Mattson 1998). Furukawa et al. went 
on to show that this increase was dependant on NFκB activation as inhibition of NFκB 
resulted in repression of these calcium current increases.  
 
Calcium sensitization has also been suggested as playing a role in the switch from 
quiescence to contractility. Calcium sensitization is the phenomenon by which a given 
concentration of intracellular calcium results in a larger than expected force of contraction 
(Ratz, Berg et al. 2005, Arthur, Taggart et al. 2007, Wray 2007). TNF has been shown to 
enhance Ca2+ responsiveness ten fold in airway smooth muscle. It has been shown that 
TNF may cause this increased Ca2+ sensitivity through inducing increased IP3 turnover 
and hence increased release of Ca2+ from intracellular stores. Another putative mechanism 
for calcium sensitization is via the loss or reduction in calcium sensitivity of calcium 
activated potassium channels. A reduction in, for example, KCNMA1 channel calcium 
sensitivity would result in a reduction in the repolarising current supplied by these 
channels and hence an increase in contractility. 
 
This data demonstrates that TNF induced a small but statistically significantly increase in 
the transcription of the KCNMA1 channel. This initially appears to be at odds with TNF 
promoting contraction, however, an up regulation in transcription does not always 
correspond to an up regulation of translation. Kim et al. demonstrated this lag between 
KCNMA1 RNA and protein up-regulation in chick cochlear development and determined 
that it was due to delays in protein synthesis and trafficking / scaffolding of the channel 
subunits (Kim, Beyer et al. 2010). A similar delay may be occurring in the myometrium. 
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The expression of the KCNMA1 STREX-2 variant was unchanged with TNF stimulation, 
however, Gαs is known to decrease during parturition (Europe-Finner, Phaneuf et al. 
1994) and as a result of this the level of PKA would decrease. This decrease in PKA 
would result in decreased phosphorylation of the KCNMA1 channel, but any 
phosphorylation in the presence of STREX-2 would facilitate membrane depolarisation 
and support contraction (Tian, Coghill et al. 2004). This support of contraction would 
decrease as the levels of PKA decrease. Hypothetically this could lead to support for 
contraction while PKA levels are high at the start of parturition, then a gradual switch to 
support quiescence as the PKA levels drop leading to termination of parturition. 
 
TNF also resulted in a significant up regulation of the CACNA1C while the overall splice 
variant profile was unchanged.  
 
TNF did not affect overall expression of the CACNA1G. It did, however, induce a small 
but statistically significantly increase in the expression of the splice site 2 variant without 
exon 14. The levels of PKC have been shown to increase towards the onset of parturition 
(Li, Zhang et al. 2012) and PKC phosphorylation has been shown to activate the 
CACNA1G (Park, Kang et al. 2006).  Therefore, the loss of a PKC phosphorylation site 
may act to limit the activation of the CACNA1G at this juncture. 
 
TNF also caused an increase in the expression of the splice site 4 variant containg exon 
25. This variant results in channels which open more easily at more negative membrane 
potentials and as such these variants may be key to the myometriums ability to generate 
spontaneous phasic contractions. The generation of these spontaneous phasic contractions 
is due to the ability of the cell to fire regenerative action potentials (Lee, Ahn et al. 2009). 
Regenerative action potentials are created when a channel opening at a low threshold is 
able to initiate the opening of enough channels to initiate an action potential. CACNA1Gs 
with the ability to open at more negative membrane potentials due to the presence of these 
variants will allow calcium to enter the cell and so will push the membrane potential to 
more positive potentials which will then allow the CACNA1Cs to open and generate an 
action potential. 
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3.4.5 The Effect of TSA 
The transition of the myometrium from the quiescent state to the contractile state seen at 
parturition has been shown to be facilitated by the down regulation of the hCG/LH 
receptors. Phillips et al. demonstrated that TSA promoted the transcriptional activation 
of the hCG/LH receptor gene and hence the maintenance of quiescence (Phillips, Tyson-
Capper Née Pollard et al. 2005, Moynihan, Hehir et al. 2008). It has also been shown that 
the maintenance of myometrial quiescence is facilitated by the expression of Gαs. 
Acetylation of the Gαs promoter by CBP is necessary for its expression within the 
myometrium and therefore TSA may also act by preventing the deacetylation of the Gαs 
promoter and hence promote the expression of Gαs and the maintenance of myometrial 
quiescence (Webster, Waite et al. 2013). 
 
This research suggests a further possible mechanism for the pro-quiescent action of TSA 
via its effect on the expression of the KCNMA1 potassium and CACNA1C channels. 
After TSA stimulation the CACNA1C expressed variant containing exon 8 and exon 8*, 
the presence of variants containing exon 8 would result in a less contractile phenotype. 
TSA resulted in a significant down regulation of both channels. This reduction in channel 
transcription would result in cells much less responsive to calcium and hence less 
contractile. 
 
TSA did not affect the overall expression of the CACNA1G, however the expression of 
splice variants containing exon 26 and those containing both exons 30B and 31A were 
significantly up-regulated. The IIIS6 portion of the CACNA1G calcium channel has a 
role in its inactivation, exon 26 lies within this region and therefore may affect the 
inactivation of the channel. The C-terminal tail region of the CACNA1G channel has 
been shown to be responsible for the fast inactivation of the channel (Staes, Talavera et 
al. 2001), therefore, inclusion of exon 31A which can result in premature truncation of 
the protein may alter the inactivation of the channel.  Although further research is need 
to fully explore the effects of these splice variants on myometrial contractility, the 
documented effects of these splice variants would suggest that they would support a more 
relaxed phenotype. 
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3.4.6 The Combined Effect of TNF and TSA 
If histone deacetylase inhibitors are to be developed as potential tocolytics it is important 
to understand their effect on the KCNMA1 channel, CACNA1C and CACNA1G when it 
is introduced either before and after the cytokine influx characteristic of parturition. 
 
When the primary myocytes were stimulated with TSA following TNF stimulation there 
was a significant down-regulation of both the KCNMA1 and CACNA1C channels which 
was greater than that seen with TSA alone. When the myocytes were stimulated with TNF 
following TSA stimulation TNF seems to be able to partially recover the expression of 
the KCNMA1 channel in comparison to that seen with TSA alone. With the CACNA1C 
when added second TNF is only able to prevent the further down-regulation which is seen 
when the stimulants are added in the reverse order.  
 
The expression of the CACNA1C variant containing exon 8, seems to be dependent on 
TSA stimulation. This variant is expressed whether TSA used before or after TNF 
stimulation indicating that acetylation may have an important role in the expression of 
this variant. HDAC inhibition has been shown to alter splicing of ~700 genes and to 
reduce the interaction between splicing regulator SRp40 and the target fibronectin exon 
(Hnilicova 2010). A similar number of genes were observed to change in the myometrium 
upon TSA administration as shown by Karolczak-Bayatti et al. (Karolczak-Bayatti, 
Sweeney et al. 2011).  As TSA is a general HDAC inhibitor this may explain the switch 
in splice variant expression. 
 
The effect on the expression of both the long and short variants at splice site L10 of the 
CACNA1C seem to be dependent on the order of the two stimulations. When TNF 
stimulation occurs first the expression of these two variants is similar to that seen in TNF 
stimulation alone. However, when TSA stimulation occurs first the expression of these 
two variants is similar to that seen with TSA alone. The converse is the case for the 
KCNMA1 splice variant containing exon 19 (M3) When TNF stimulation follows TSA 
stimulation, it appears that TNF blocks the TSA induced down regulation of this variant, 
however when TSA stimulation follows TNF stimulation, TNF is not able to completely 
block the down-regulation of this variant although it is less down-regulated than is seen 
with TSA alone. 
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There are also splice variants were the combined stimulation results in a greater effect 
than either stimulation on its own. This is the case for the KCNMA1 STREX-2 variant 
and the KCNMA1 variant containing exon 29, where TNF stimulation followed by TSA 
stimulation results in a significant up-regulation of both variants.   
 
Webster et al. demonstrated that TNF could overcome TSA induced myometrial 
relaxation in smooth muscle strips (Webster, Waite et al. 2013). When combined with the 
data included here this would indicate that the effect of TNF on the KCNMA1 channel, 
the KCNMA1 Splice site M1 +132bp, M3 exon 19, the CACNA1C splice site L10/11, 
the CACNA1G splice sites T4 and T6 variants are key to inducing contraction. It would 
be necessary, however, to carry out patch clamp recordings and/or collagen gel 
contractions assays to determine the overall electrical/ contractile effect of these 
combined stimuli on the cells to verify this. 
 
3.5 Conclusion 
This research suggests that increasing TNF levels at parturition could promote the 
increased calcium sensitivity of the myometrium through the expression of KCNMA1 
channel slice variants documented to have decreased calcium and voltage sensitivity 
alongside CACNA1C calcium channels documented to have rapid activation, slow 
deactivation kinetics and increased excitation-contraction coupling.  
 
The combined effect of TNF on the increase in transcription of CACNA1C channels and 
the expression of pro-contractile KCNMA1 channel variants may serve to tip the fine 
balance of the channels allowing action potentials to be generated and propagated across 
the tissue resulting in contraction. 
 
TSA was seen to promote a relaxatory effect on the cells, this is appears to be through the 
significant reduction in transcription of both channels resulting in cells that are less 
excitatory.  
 
As these channels will only affect the contractility of the myocytes once they are localised 
to the cell membrane the next step in this research would be to examine the expression 
and localisation of the channel proteins and the effect of exposure to TNF and TSA on 
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this expression and localisation. A further area worthy of investigation is whether the 
expression of the different splice variants observed in the RNA data resulted in the 
expression of different protein isoforms. These two areas will be the focus of the 
following chapter. 
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Chapter 4: Localisation of the KCNMA1, CACNA1C and 
CACNA1G Proteins in Myometrial Cell Cultures Results and 
Discussion 
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4.1 Introduction 
In Chapter 3, the collagen gel contraction assay demonstrated that TNF caused significant 
contraction in myometrial cell cultures and TSA caused relaxation in these cultures. Next, 
the expression of the KCNMA1, CACNA1C and CACNA1G channels were examined to 
determine if the contractile effect of TNF or the relaxatory effect of TSA was mediated 
via changes in the amount of channels expressed or in the splice variant profile of the 
expressed channels. The results of these studies indicated that non-labouring term 
pregnant myocytes expressed a number of different splice variants. These included the 
KCNMA1 Mk44+132bp, Mk44-132bp, M2 (exon 11+12), M3 (exon 19), M4 (STREX2) 
and M5 (exon 29) variants, the CACNA1C L4 (exon 8* or Exon 8), L10 (exons 30, 31, 
33 and 34 or exons 30, 31, 32 and 34) and L11 (40, 41, 42 and 43) variants and the 
CACNA1G T2 (exon 14 deleted),  T4 (exon 25), T6 (exon 26) and T7/8 (exon 31A or 
exon 30B and 31A) variants. Upon TNF stimulation both the KCNMA1 and CACNA1C 
expression was significantly up-regulated and upon TSA stimulation both channels were 
significantly down regulated and the splice variant profile of the CACNA1C and 
CACNA1G was significantly altered.  
 
The KCNMA1, CACNA1C and CACNA1G are membrane-spanning proteins which 
form pores that pass from one side of the membrane to the other. These pores open and 
close in response to particular signals, when open these pores allow the passage of ions 
either into or out of the cell. Each ion channel has specific gating characteristics meaning 
only the correct ion can pass through the appropriate pore.  The charge of the ion passing 
through the channel and the direction in which the ion is moving (either into or out of the 
cell) will affect the potential of the cell membrane, this then triggers further voltage 
sensitive channels to open or close. Within smooth muscle cells this propagated signal 
will then lead to either contraction or relaxation of the cell. 
 
In very simple terms an increased number of KCNMA1 channels would mean an 
increased number of potassium ions leaving the cell for any given activation and this will 
have the effect of reducing the membrane potential and returning the cell to the resting 
state more quickly. In the same way an increased number of CACNA1C and/or 
CACNA1G would mean an increased number of calcium ions entering the cell for any 
given activation and this will have the effect of increasing the membrane potential and 
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generating an action potential more quickly. The caveat to this would be that the channels 
are housed within the plasma membrane and have the same gating kinetics, however, this 
is unlikely to be the case in vivo.  
 
The KCNMA1 channel has been shown to undergo splicing and expression of these 
different splice variants can have diverse effects on the channel from altering the gating 
of the channel, the introduction of cleavage sites and even truncation of the channel 
protein. One such splice variant, Mk44, which was expressed in the myometrial cell 
cultures and has been described by Korovkina et al. undergoes proteolytic digest and after 
this digest the N-terminus of the protein is expressed on the cell membrane while the C-
terminus is intracellular and localised specifically with the endoplasmic reticulum 
(Korovkina, Brainard et al. 2006).  After calcium release from the sarcoplasmic reticulum 
the C-terminus translocates to the cell membrane and non-covalently associates with the 
N-terminus. When the C-terminus is associated with the N-terminus the channel has 
decreased calcium and voltage sensitivity demonstrating that the C-terminus has an 
inhibitory effect on channel gating. Therefore, it is important to determine the location of 
both termini of the KCNMA1 channel in order to understand the potential effect the 
channel will have on membrane potential.  
 
The C-terminal KCNMA1 antibody utilised had been used for western blotting previously 
by a number of research groups (Alioua, Lu et al. 2008, Shi, Liu et al. 2013) and had been 
shown to be specific. The N-terminal KCNMA1 antibody had been tested in western blot 
against the recombinant peptide used as an immunogen but there was no data on its ability 
to detect endogenous protein, therefore less confidence can placed in the data obtained 
from the use of this antibody.  
 
The CACNA1C channel has been shown to exist in two forms, a 220kDa protein and a 
190kDa protein. The shorter channel is formed as a result of the cleavage of the C-
terminal region. Calpain has been shown to be responsible for this cleavage (Hell, 
Westenbroek et al. 1996) which occurs in exon 42 between splice variants 11 and 12. 
Interestingly, it has been shown that calmodulin binds calpain substrates and in doing so 
can regulate calpain-mediated proteolysis causing inhibition of this process (Wang, 
Villalobo et al. 1989, Iwamoto, Lu et al. 2010). An insertion at splice site 11 has been 
shown to modulate calmodulin binding and therefore this splice site could have an effect 
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on the cleavage of the channel. Once cleaved, the C-terminus can either co-localise with 
the N-terminus of the channel or it can translocate to the nucleus. The loss of the C-
terminus of the channel results in a 4-6 fold increase in ion conductance in comparison to 
the full length channel. So similar to the KCNMA1 channel the C-terminus of the 
CACNA1C channel has an inhibitory effect. The primary myocytes were shown to 
express a splice site 11 variant containing exons 40, 41, 42 and 43, this variant may have 
an effect on the cleavage of the CACNA1C. The proteolytic processing of the C-terminus 
of the CACNA1C has been shown to generate fragments of 56, 48 and 30kDa (Figure 
4.1; Gao, Cuadra et al. 2001), which, when they associate with the main body of the 
channel protein and have a role in inhibiting channel function.  
 
 
Figure 4.1 Diagrammatic Representation of the Generation of the Various CACNA1C C-terminal 
Fragments 
 
Therefore, it is again important to determine the location of both termini of the 
CACNA1C channel in order to understand the potential effect the channel will have on 
membrane potential.    
 
The N-terminal CACNA1C antibody utilised had been used for western blotting 
previously by a number of research groups (Li, Zhang et al. 2013, O'Connell, Musa et al. 
2015) and had been shown to be specific. The C-terminal CACNA1C antibody had not 
been tested in western blot, therefore less confidence can placed in the data obtained from 
the use of this antibody.  
 
Immunocytochemistry staining of the myometrial cells, in Chapter 3, showed evidence 
of nuclear localisation for both the KCNMA1 and CACNA1C channels. Although nuclear 
localisation has been previously described for the CACNA1C channel (Gomez-Ospina, 
Tsuruta et al. 2006, Gomez-Ospina, Panagiotakos et al. 2013), nuclear localisation of the 
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KCNMA1 channel was a novel finding. It is important to determine if this nuclear 
localisation was an artefact from the staining protocol or if the KCNMA1 channel does 
indeed localise to the nucleus. If the KCNMA1 channel is shown to localise to the nucleus 
by western blot analysis it is also important to determine which portion of the channel 
(N- or C-terminus or both) is found within the nucleus. For the above reasons both an 
antibody specific to the N-terminus and one specific to the C-Terminus were used for 
western blotting for both the KCNMA1 and the CACNA1C channels.  
 
Studies of the CACNA1G protein within human male germ cells and human cerebellum 
cDNA has revealed that the CACNA1G protein exists in a number of isoforms, including 
a longer 262kDa protein and a shorter 249kDa protein (Monteil, Chemin et al. 2000, 
Jagannathan, Punt et al. 2002). These isoforms have been shown to be the result of 
alternative splicing, with the 249kDa form resulting from the use of an alternative 5’-
splice donor site on exon 25 combined with the acceptor site on exon 27 (Figure 4.2A; 
Monteil, Chemin et al. 2000). Alternatively, the 262kDa protein results from the use of a 
5’-splice donor site on exon 25 combined with the acceptor site on exon 26 (Figure 4.2B; 
Monteil, Chemin et al. 2000). The 249kDa form has the most positive voltage range for 
steady state inactivation (Monteil, Chemin et al. 2000) meaning that the CACNA1G 
inactivates more slowly allowing more calcium to enter the cell. Within the primary 
myocyte cultures the cells were observed to express splice variants containing exon 25 
and exon 26 and so correlate well with the 262kDa form of the protein, however, it is still 
pertinent to identify which isoforms of the CACNA1G are expressed by the primary 
myocytes. 
 
The C-terminal CACNA1G antibody utilised had been used for western blotting 
previously and had been shown to be specific (Nguyen, Biet et al. 2013). 
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Figure 4.2 Diagrammatic Representation of the Generation of the 262kDa and 249kDa CACNA1G 
Isoforms 
 
The aim of this chapter was, therefore, to measure the expression of the KCNMA1 
channel, CACNA1C and CACNA1G proteins and to identify any alternative isoforms 
expressed within the primary myocytes. Further to this, the localisation of the KCNMA1, 
CACNA1C and CACNA1G proteins and their isoforms within the cell was then 
examined. Finally, the effect of TNF and TSA on the expression and localisation of the 
KCNMA1 channel, CACNA1C and CACNA1G was studied. 
 
4.2.2 Gβ Loading Control. 
In order to be certain that any changes in band intensity visible on the western blots were 
as a result of the different stimulations and not as a result of errors, either when 
quantifying the protein or when loading the gel, a western blot was ran utilising a 
housekeeping protein which is unaffected by the different stimulations.  
 
The housekeeping protein chosen was Gβ. This is routinely used in the research group as 
a control and is not part of either the myometrial relaxation or contraction pathways 
(Phaneuf, Europe-Finner et al. 1993, Europe-Finner, Phaneuf et al. 1994, Salomonis, 
Cotte et al. 2005).  All channel western blots were carried out with the same protein 
samples with the Gβ control serving experiments for KCNMA1, CACNA1C and 
CACNA1G channels. No change in Gβ was observed with any treatment in any of the 
protein fractions (Figure 4.3) 
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Figure 4.3 Gβ Expression  
Myometrial cell cultures were stimulated with 10ng/ml TNF, 100ng/ml TSA, 10ng/ml TNF followed by 
100ng/ml TSA (+TNF/+TSA), 100ng/ml TSA followed by 10ng/ml TNF (+TSA/+TNF) or left un-
stimulated. Protein was extracted, separated by SDS PAGE and western blotted. Manual quantification of 
the relative band intensities were used to quantify the level of expression and this was expressed as arbitrary 
units. None of the treatments had any effect on Gβ expression in any of the fractions. 
 
4.3 The KCNMA1 Channel 
4.3.1 N-Terminal KCNMA1 Protein and Protein Fragments are Expressed in 
Myometrial Cell Cultures and are Unaffected by Either TNF or TSA 
This present research sought to determine if TNF or TSA could influence expression of 
the KCNMA1 protein. Total cellular protein was isolated, separated by SDS PAGE and 
subsequently western blotted with an antibody directed to the N-terminus of the 
KCNMA1 protein.  
 
Blotting with the N-terminal antibody did not detect full length KCNMA1 protein as 
evidenced by the lack of band at 138kDa (Figure 4.4A) this may indicated that the protein 
is N-terminally truncated. The N-terminal antibody did detect two fragments of the 
KCNMA1 protein one at 65kDa and one at 50kDa (Figure 4.4A). This would indicated 
that there are KCNMA1 proteins which have had the C-terminal region cleaved from the 
body of the channel expressed within the primary myocyte cultures. Cleavage of the C-
159 
 
terminal region of the KCNMA1 protein has been shown to increase the channels calcium 
and voltage sensitivity and thus would support relaxation. The 65kDa band corresponds 
to a band reported by Knaus et al. They determined that this band was produced when the 
KCNMA1 channel was cleaved between residues 640 and 690 (Knaus, Eberhart et al. 
1995). 
 
When cultures were subsequently exposed to either TNF or TSA, neither had any 
significant effect on either the KCNMA1 protein level or the fragments expressed in 
comparison to un-stimulated samples (Figure 4.4A).  
 
4.3.2 Membrane Localisation of the 50kDa N-Terminal KCNMA1 Protein Fragment 
Expressed in Myometrial Cell Cultures is Significantly Increased by TNF  
Next it was determined if these compounds had an effect on the localisation of the 
KCNMA1 protein or protein fragments. Protein was isolated by sub cellular fractionation, 
separated by SDS PAGE and subsequently western blotted with an antibody directed to 
the N-terminus of the KCNMA1 protein.   
 
Blotting with the N-terminal antibody revealed the same complement of fragments as was 
detected within the whole cell protein preparations (65kDa and 50kDa; Figure 4.4B, C). 
Full length (138kDa) KCNMA1 channel was also detected in the cytoplasmic fraction 
(Figure 4.4B).  
 
When cultures were subsequently exposed to either TNF or TSA, TNF resulted in a 
significant increase in the membrane bound 50kDa KCNMA1 in comparison to 
unstimulated samples (Figure 4.4C; p<0.05). The increase in this fragment would appear 
to be at odds with action of TNF as this fragment would support relaxation due to the lack 
of the inhibitory C-terminal tail region. TNF did not have any significant effect on the 
localisation of the other fragments and TSA had no significant effect on any of the 
fragments observed in comparison to the un-stimulated samples. 
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Figure 4.4 The Expression of the KCNMA1 Channel Protein in Myometrial Cell Cultures Utilising 
an N-terminal Antibody 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for twenty-four hours, 100ng/ml TSA 
for twenty-four hours, 10ng/ml TNF for 1 hour followed by 100ng/ml TSA for twenty-four hours 
(+TNF/+TSA), 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour (+TSA/+TNF) 
or left un-stimulated. Protein was extracted, separated by SDS PAGE and western blotted. Manual 
quantification of the relative band intensities were used to quantify the level of expression and this was 
expressed as arbitrary units (n = 3). (A) Within total cellular protein myometrial cell cultures express two 
KCNMA1 proteins (right panel), +TNF/+TSA caused a significant down regulation of the 50kDa fragment 
in comparison to TSA (p<0.05*). (B) Cytoplasmic localisation of the KCNMA1 protein (right panel), no 
treatment had any effect KCNMA1 protein expression (left panel). (C) Membrane localisation of the 
KCNMA1 protein (right panel), TNF cause a significant increase in membrane localisation of the 50kDa 
fragment in comparison to un-stimulated (p<0.05*), none of the other treatments had any effect KCNMA1 
protein expression (left panel). 
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4.3.3 Localisation of the KCNMA1 Protein and Protein Fragments Expressed in 
Myometrial Cell Cultures is Unaffected by Combined TSA and TNF Stimulation. 
Next it was determined if these compounds had an enhancing or diminishing effect on 
each other.  
 
When the cultures were exposed to TNF prior to exposure to TSA and then blotted with 
the N-terminal antibody there was no significant effect on the expression of the KCNMA1 
channel protein, protein fragments or their subcellular localisation in comparison to un-
stimulated samples (Figure 4.4A, B, C). However, there was a significant decrease in the 
expression of the 50kDa fragment within the total cellular protein in comparison to 
exposure to TSA alone (Figure 4.4A; p<0.05). This fragment was expressed at a level 
similar to the TNF samples, indicating that TSA does not affect the effect of TNF on this 
fragment.   
 
When the cultures were exposed to TSA prior to TNF and blotted with N-terminal 
antibody there was again no significant effect on the expression of the KCNMA1 channel 
protein, protein fragments or their subcellular localisation in comparison to un-stimulated 
samples (Figure 4.4A, B, C). 
 
4.3.4 C-Terminal KCNMA1 Protein and Protein Fragments are Expressed in 
Myometrial Cell Cultures and are Unaffected by Either TNF or TSA 
This present research sought to determine if TNF or TSA could influence expression of 
the KCNMA1 protein. Total cellular protein was isolated, separated by SDS PAGE and 
subsequently western blotted with an antibody directed to the C-terminus of the 
KCNMA1 protein.   
 
When the C-terminal antibody was utilised, a 138kDa protein was detected (Figure 4.5A), 
which represents full length KCNMA1 protein. This is in apparent disagreement with the 
results from the N-terminal antibody, however, this discrepancy could be explained by 
differences in the efficiency of antibody binding between the N- and C-terminal 
antibodies.  
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Figure 4.5 The Expression of the KCNMA1 Channel Protein in Myometrial Cell Cultures Utilising a 
C-terminal Antibody 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for twenty-four hours, 100ng/ml TSA 
for twenty-four hours, 10ng/ml TNF for 1 hour followed by 100ng/ml TSA for twenty-four hours 
(+TNF/+TSA), 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour (+TSA/+TNF) 
or left un-stimulated. Protein was extracted, separated by SDS PAGE and western blotted. Manual 
quantification of the relative band intensities were used to quantify the level of expression and this was 
expressed as arbitrary units (n = 3). (A) Within total cellular protein myometrial cell cultures express two 
KCNMA1 proteins (right panel), +TNF/+TSA caused a significant down regulation of the 138kDa 
fragment in comparison to TSA (p<0.05*). +TSA/+TNF cause a significant down regulation of the 138kDa 
protein in comparison to un-stimulated (p<0.05*) and TNF (p<0.05*) (B) Cytoplasmic localisation of the 
KCNMA1 protein (right panel), TSA caused a significant up regulation of the 65kDa fragment in 
comparison to un-stimulated (p<0.05*) and +TSA/+TNF caused a significant down regulation of the 
138kDa protein in comparison to TSA (p<0.05*). (C) Membrane localisation of the KCNMA1 protein 
(right panel), no treatment had any effect KCNMA1 protein expression (left panel).  
 
A second possible explanation is that the protein detected by the C-terminal antibody is 
lacking a small portion of the N-terminus, this would mean that it would not be detected 
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by the N-terminal antibody, while at the same time the reduction in overall protein size 
would not be immediately apparent. The C-terminal antibody also detected a 65kDa 
KCNMA1 protein fragment (Figure 4.5A). This fragment is lacking the N-terminal 
region, utilising the binding site of the C-terminal antibody it is possible to predict that 
this fragment of the protein is comprised of just the C-terminal tail region and so lacks 
the membrane spanning domains and importantly will not contain the channel pore and 
so cannot conduct ions. 
 
When cultures were subsequently exposed to either TNF or TSA, neither had any 
significant effect on either the KCNMA1 protein level or the fragments expressed in 
comparison to un-stimulated samples (Figure 4.5A).  
 
4.3.5 Cytoplasmic Localisation of the 65kDa C-Terminal KCNMA1 Protein 
Fragment Expressed in Myometrial Cell Cultures is Significantly Increased by TSA  
Next it was determined if these compounds had an effect on the localisation of the 
KCNMA1 protein or protein fragments. Protein was isolated by sub cellular fractionation, 
separated by SDS PAGE and subsequently western blotted with an antibody directed to 
the C-terminus of the KCNMA1 protein.   
 
When the protein was probed with the C-terminal antibody both full length (138kDa) 
KCNMA1 protein and the 65kDa N-terminally truncated fragment were detected within 
the cytoplasmic and membrane bound fractions (Figure 4.5B, C). 
 
When cultures were subsequently exposed to either TNF or TSA, TNF did not have any 
significant effect on the localisation of any of the fragments. TSA, resulted in a small but 
statistically significant increase in the cytoplasmic localisation of the 65kDa fragment but 
had no significant effect on any of the other fragments observed in comparison to the un-
stimulated samples. 
 
4.3.6 KCNMA1 138kDa Protein Expressed in Myometrial Cell Cultures is 
Significantly Decreased by Stimulation with TSA Followed by TNF. 
Next it was determined if these compounds had an enhancing or diminishing effect on 
each other.  
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When the cultures were exposed to TNF prior to exposure to TSA and then blotted with 
the C-terminal antibody there was no significant effect on the expression of the KCNMA1 
channel protein, protein fragments or their subcellular localisation in comparison to un-
stimulated samples (Figure 4.5A, B, C). However, there was a significant decrease in the 
expression of the 138kDa KCNMA1 protein within the total cellular protein in 
comparison to exposure to TSA alone (Figure 4.5A; p<0.05). This fragment was 
expressed at a level similar to the TNF samples, indicating that TSA does not affect the 
effect of TNF on this fragment.  
 
When the cultures were exposed to TSA prior to TNF and blotted with C-terminal 
antibody the 138kDa KCNMA1 protein was significantly decreased in the total protein 
samples (Figure 4.5A; p<0.05) in comparison to the un-stimulated samples. The 138kDa 
KCNMA1 protein was significantly decreased within the total cellular protein in 
comparison to TNF samples (Figure 4.5A; p<0.05) indicating that in this order TNF and 
TSA have a combined effect which is different to either ones individual affect. Within 
the cytoplasmic fraction the 138kDa KCNMA1 protein was significantly decreased in 
comparison to TSA samples (Figure 4.5B; p<0.05). Indicating that in this order TSA and 
TNF again have a combined effect which is different to and greater than the effect of each 
individual stimulus.  
 
Although it is important to understand the mechanism driving the combined effect of TNF 
and TSA on the KCNMA1 channel it is pertinent to remember that they did not cause any 
significant change in membrane bound KCNMA1 protein and therefore may not 
influence the contractility of the cell. 
 
4.4 The CACNA1C Channel  
4.4.1 CACNA1C Protein Isoforms are Expressed in Myometrial Cell Cultures and 
are Unaffected by Either TNF or TSA 
This present research sought to determine if TNF or TSA could influence expression of 
the CACNA1C protein. Total cellular protein was isolated, separated by SDS PAGE and 
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subsequently western blotted with an antibody directed to the N-terminus of the 
CACNA1C protein.   
 
Blotting with the N-terminal antibody revealed that the primary myocytes express both 
the long (240kDa) and short form (190kDa) of the CACNA1C which have been 
previously documented (Figure 4.6A; Hell, Westenbroek et al. 1996). The 240kDa band 
is representative of the full length CACNA1C protein. The 190kDa band is representative 
of CACNA1C proteins which have a modified C-terminus (De Jongh, Warner et al. 
1991). This shorter protein is formed by post-translational proteolytic processing of the 
C-terminus which occurs in vivo and not as an artefact of the protein purification process 
(De Jongh, Colvin et al. 1994). The 240kDa form was approximately two-fold more 
abundant than the 190kDa form (Figure 4.6A).  
 
When cultures were subsequently exposed to either TNF or TSA, neither had any 
significant effect on either the CACNA1C protein isoforms or the fragments expressed in 
comparison to the un-stimulated samples (Figure 4.6A). 
 
4.4.2 Membrane Localisation of the CACNA1C 190kDa Protein Isoform Expressed 
in Myometrial Cell Cultures is Significantly Increased by TNF 
Next it was determined if these compounds had an effect on the localisation of the 
CACNA1C protein isoforms. Protein was isolated by sub cellular fractionation, separated 
by SDS PAGE and subsequently western blotted with an antibody directed to the N-
terminus of the CACNA1C protein.  Blotting with the N-terminal antibody revealed that 
the long (240kDa) and the short (190kDa) CACNA1C isoforms are located in both the 
cytoplasmic and membrane fractions (Figure 4.6B, C). This illustrates the importance of 
sub cellular localisation of the channel proteins as only a portion of the CACNA1C 
detected in the total cellular protein is localised to the cell membrane and hence will have 
an effect on cell contractility.  
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Figure 4.6 The Expression of the CACNA1C Protein in Myometrial Cell Cultures Utilising an N-
terminal Antibody 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for twenty-four hours, 100ng/ml TSA 
for twenty-four hours, 10ng/ml TNF for 1 hour followed by 100ng/ml TSA for twenty-four hours 
(+TNF/+TSA), 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour (+TSA/+TNF) 
or left un-stimulated.  Protein was extracted, separated by SDS PAGE and western blotted. Manual 
quantification of the relative band intensities were used to quantify the level of expression and this was 
expressed as arbitrary units (n = 3). (A) Within total cellular protein myometrial cell cultures express two 
CACNA1C proteins (right panel), +TNF/+TSA caused a significant up regulation of the 190kDa fragment 
in comparison to TSA (p<0.05*). (B) Cytoplasmic localisation of the CACNA1C protein (right panel), no 
treatment had any effect CACNA1C protein expression (left panel) (C) Membrane localisation of the 
CACNA1C protein (right panel), no treatment had any effect CACNA1C protein expression (left panel). 
 
When cultures were subsequently exposed to either TNF or TSA, TNF resulted in a 
significant increase in the membrane localisation of the short (190kDa) CACNA1C 
protein isoform in comparison to un-stimulated samples (Figure 4.6C; p<0.05). The short 
form of the CACNA1C lacks the C-terminal tail region, loss of the C-terminus of the 
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CACNA1C has been shown to result in a 4-6 fold increase in ion conductance in 
comparison to the full length channel. The presence of this isoform of the CACNA1C 
would support contraction. TNF did not result in a significant change in the expression or 
localisation of the longer (240kDa) CACNA1C isoform in comparison to un-stimulated 
samples (Figure 4.6B, C). TSA had no significant effect on the expression or localisation 
of either of the two CACNA1C protein isoforms in comparison to un-stimulated samples 
(Figure 4.6B, C). 
 
4.4.3 Localisation of the CACNA1C Protein Isoforms Expressed in Myometrial Cell 
Cultures is Unaffected by Combined TSA and TNF Stimulation. 
Next it was determined if these compounds had an enhancing or diminishing effect on 
each other.  
 
When the cultures were exposed to TNF prior to exposure to TSA and then blotted with 
the N-terminal antibody there was no significant effect on the expression of either of the 
CACNA1C protein isoforms, protein fragments or their subcellular localisation in 
comparison to un-stimulated samples (Figure 4.6A, B, C). However, the short (190kDa) 
CACNA1C protein isoform was significantly increased within the total cellular protein 
in comparison to TSA (Figure 4.6A; p<0.05). As with the KCNMA1 channel, in this order 
TNF and TSA have a combined effect which is different to and greater than the effect of 
each individual stimulus. 
 
When the cultures were exposed to TSA prior to TNF and blotted with N-terminal 
antibody there was again no significant effect on the expression of the CACNA1C 
channel protein, protein fragments or their subcellular localisation in comparison to un-
stimulated samples (Figure 4.6A, B, C). 
 
 
4.4.4 CACNA1C C-terminal Protein Fragments are Expressed in Myometrial Cell 
Cultures and are Unaffected by Either TNF or TSA 
This present research sought to determine if TNF or TSA could influence expression of 
the CACNA1C protein. Total cellular protein was isolated, separated by SDS PAGE and 
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subsequently western blotted with an antibody directed to the C-terminus of the 
CACNA1C protein.   
 
When western blotting was carried out using the CACNA1C C-terminal antibody it 
revealed that within the primary myocytes the CACNA1C C-terminal region has been 
proteolytically processed resulting in the generation of a number of CACNA1C protein 
fragments (Figure 4.7A). The 48 and 30kDa fragments correspond to those previously 
documented by Gao et al. (Gao, Cuadra et al. 2001), however a third previously un-
reported 102kDa fragment was also detected (Figure 4.7A). This 102kDa fragment was 
only detected at a very low level within the total cellular protein, and appears to comprise 
the entire C-terminal tail, this may have arisen as a result of the extraction process or it 
may be a novel in vitro proteolytic cleavage product. 
 
When cultures were subsequently exposed to either TNF or TSA, neither had any 
significant effect on either the CACNA1C protein isoforms or the fragments expressed in 
comparison to the un-stimulated samples (Figure 4.7A). 
 
4.4.5 Localisation of the CACNA1C C-terminal Protein Fragments Expressed in 
Myometrial Cell Cultures is Unaffected by Either TNF or TSA 
Next it was determined if these compounds had an effect on the localisation of the 
CACNA1C C-terminal protein fragments. Protein was isolated by sub cellular 
fractionation, separated by SDS PAGE and subsequently western blotted with an antibody 
directed to the C-terminus of the CACNA1C protein.   
 
Following blotting with the C-terminal antibody the small C-terminal fragments were 
found in both the cytoplasm and the membrane fractions (Figure 4.7B, C). 
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Figure 4.7 The Expression of the CACNA1C Protein in Myometrial Cell Cultures Utilising a C-
terminal Antibody 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for twenty-four hours, 100ng/ml TSA 
for twenty-four hours, 10ng/ml TNF for 1 hour followed by 100ng/ml TSA for twenty-four hours 
(+TNF/+TSA), 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour (+TSA/+TNF) 
or left un-stimulated. Protein was extracted, separated by SDS PAGE and western blotted. Manual 
quantification of the relative band intensities were used to quantify the level of expression and this was 
expressed as arbitrary units (n = 3). (A) Within total cellular protein myometrial cell cultures express a 
number of CACNA1C proteins fragments (right panel), no treatment had any effect CACNA1C protein 
expression (left panel). (B) Cytoplasmic localisation of the KCNMA1 protein (right panel), no treatment 
had any effect CACNA1C protein expression (left panel) (C) Membrane localisation of the CACNA1C 
protein (right panel), no treatment had any effect CACNA1C protein expression (left panel).  
 
 
The cytoplasmic fraction contained the 102, 48 and 30kDa fragments previously observed 
in the total cell protein blots whilst the membrane contained a 56kDa fragment in addition 
to the 102, 48 and 30kDa fragments (Figure 4.7C). The significance of this observation 
is still to be fully explored. 
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Neither TNF nor TSA had any significant effect on the expression or localisation of any 
of the small C-terminal fragments in comparison to un-stimulated samples (Figure 4.7B, 
C). However, the C-terminal fragment blots were inconsistent which may have 
contributed to the lack of any statistical significance being found between the different 
groups. 
 
4.4.6 Localisation of the CACNA1C C-terminal Protein Fragments Expressed in 
Myometrial Cell Cultures is Unaffected by Combined TSA and TNF Stimulation. 
Next it was determined if these compounds had an enhancing or diminishing effect on 
each other.  
 
When the cultures were exposed to TNF and TSA in either order and then blotted with 
the C-terminal antibody there was no significant effect on the expression of the 
CACNA1C channel protein, protein fragments or their subcellular localisation in 
comparison to un-stimulated samples (Figure 4.7A, B, C). 
 
4.5 The CACNA1G Channel  
4.5.1 CACNA1G Protein Isoforms are Expressed in Myometrial Cell Cultures and 
are Unaffected by Either TNF or TSA 
This present research sought to determine if TNF or TSA could influence expression of 
the CACNA1G protein. Total cellular protein was isolated, separated by SDS PAGE and 
subsequently western blotted. Blotting with the CACNA1G N-terminal antibody revealed 
that the primary myocytes express both the long (262kDa) and short form (249kDa) of 
the CACNA1G which have been previously documented (Figure 4.8A; Monteil, Chemin 
et al. 2000). The 249kDa form utilises exons 25 and 27 whilst the 262kDa form utilises 
exons 25, 26 and 27.  The 249kDa form has the most positive voltage range for steady 
state inactivation (Monteil, Chemin et al. 2000) and so will inactivate more slowly hence 
it will provide a greater contribution to the influx of calcium into the cell. 
 
When cultures were subsequently exposed to either TNF or TSA, TNF resulted in a small 
increase in the 249kDa form whilst TSA resulted in a small decrease in the 262kDa form 
although neither of these reached significance (Figure 4.8A). 
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4.5.2 Membrane Localisation of the CACNA1G 262kDa Protein Isoform Expressed 
in Myometrial Cell Cultures is Increased by both TNF and TSA 
Next it was determined if these compounds had an effect on the localisation of the 
CACNA1G protein or protein fragments. Protein was isolated by sub cellular 
fractionation, separated by SDS PAGE and subsequently western blotted.  
 
Blotting with the CACNA1G antibody revealed that only the 249kDa isoform was located 
within the cytoplasmic fraction (Figure 4.8B), however, the cytoplasmic protein fraction 
was also seen to contain a band at around 157kDa and one at around 69kDa (Figure 4.8B).  
 
These smaller molecular mass bands (~157 and ~69kDa) do not equate to any previously 
reported isoforms of the CACNA1G calcium channel. The most likely explanation is that 
these bands are as a result of a proteolytic process which occurred during the purification 
procedure and are therefore not physiologically relevant. This hypothesis is supported by 
the fact that these small molecular weight bands are only present in the cytoplasmic 
fraction and the full length protein is completely absent from this fraction. Within the 
membrane fraction there was no evidence of the 249kDa isoform and the 262kDa isoform 
was only expressed at a very low level (Figure 4.8C). 
 
When cultures were subsequently exposed to TNF or TSA, neither had any effect on the 
expression of either the 249kDa isoform of the protein fragments within the cytoplasmic 
fraction (Figure 4.8B). However, both TNF and TSA increased the amount of the 262kDa 
isoform within the membrane fraction in comparison to un-stimulated samples although 
this did not reach significance (Figure 4.8C). 
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Figure 4.8 The Expression of the CACNA1G Protein in Myometrial Cell Cultures Utilising an N-
terminal Antibody 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for twenty-four hours, 100ng/ml TSA 
for twenty-four hours, 10ng/ml TNF for 1 hour followed by 100ng/ml TSA for twenty-four hours 
(+TNF/+TSA), 100ng/ml TSA for twenty-four hours followed by 10ng/ml TNF for 1 hour (+TSA/+TNF) 
or left un-stimulated. Protein was extracted, separated by SDS PAGE and western blotted. Manual 
quantification of the relative band intensities were used to quantify the level of expression and this was 
expressed as arbitrary units (n = 3). (A) Within total cellular protein myometrial cell cultures express a two 
CACNA1G proteins (right panel), no treatment had any effect CACNA1G protein expression (left panel). 
(B) Cytoplasmic localisation of the CACNA1G protein (right panel), within this fraction two addition 
protein fragment were observed (right panel). No treatment had any effect CACNA1G protein expression 
(left panel) (C) Membrane localisation of the CACNA1G protein (right panel), no treatment had any effect 
CACNA1C protein expression (left panel).  
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4.5.3 Localisation of the CACNA1G Protein Isoforms Expressed in Myometrial Cell 
Cultures is Unaffected by Combined TSA and TNF Stimulation. 
It was then determined whether these compounds had an enhancing or diminishing effect 
on each other. When the cultures were exposed to TNF and TSA in either order and then 
blotted with the CACNA1G antibody there was no significant effect on the expression of 
the CACNA1G channel protein isoforms or their subcellular localisation in comparison 
to un-stimulated samples (Figure 4.8A, B, C). 
 
4.6 Nuclear Localisation 
4.6.1 The CACNA1C Protein is Found Localised Within the Nucleus in Myometrial 
Cell Cultures 
Previous research has demonstrated that once cleaved, the CACNA1C C-terminal 
fragment can either co-localise with the rest of the channel (Hell, Westenbroek et al. 1996, 
Gerhardstein, Gao et al. 2000, Hulme, Konoki et al. 2005, Hulme, Yarov-Yarovoy et al. 
2006, Schroder, Byse et al. 2009, Satin, Schroder et al. 2011) or can move into the nucleus 
(Gomez-Ospina, Tsuruta et al. 2006, Schroder, Byse et al. 2009, Satin, Schroder et al. 
2011). Within the nucleus the C-terminal fragment of the CACNA1C has been shown to 
act as a transcription factor. It was shown to bind to its own promoter and down regulate 
transcription (Schroder, Byse et al. 2009, Satin, Schroder et al. 2011). It has also been 
shown to regulate the expression of a number of genes including connexin 3.1 in neurons; 
the Na/Ca exchanger, which works co-ordinately with the calcium channel to maintain 
cellular calcium (Schroder, Byse et al. 2009) and the potassium channel KCNN3. To 
determine if the C-terminus of the CACNA1C enters the nucleus within the primary 
myocyte cultures soluble nuclear and chromatin bound nuclear protein was isolated by 
sub-cellular fractionation, separated by SDS PAGE and subsequently western blotted. 
After blotting with the C-terminal CACNA1C antibody a 30kDa bind was observed 
within the soluble nuclear fraction (Figure 4.10A), however no band was observed in the 
chromatin bound nuclear fraction (Figure 4.10B). 
 
When cultures were subsequently exposed to either TNF or TSA, a 30kDa CACNA1C 
protein band was observed in the soluble nuclear protein fraction (Figure 4.10A), again 
there was no band observed in the chromatin bound nuclear fraction (Figure 4.10B). No 
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statistical analysis was carried out on these results as the gels were loaded with the same 
volume of protein and not the same concentration due to the low concentration of protein 
extracted in these fractions. 
 
Although the C-terminal was not localised in the chromatin nuclear fraction in this study, 
as it was found within the soluble nuclear fraction it is possible that it still has role 
regulating transcription in these cells. Although it is outside the bounds of this thesis the 
role of the CACNA1C C-terminal transcription factor within primary myocytes is worthy 
of further investigation. 
 
 
Figure 4.9 Nuclear Localisation of the CACNA1C Protein in Myometrial Cell Cultures Utilising a C-
terminal Antibody 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour, 100ng/ml TSA for twenty-
four hours, or left un-stimulated. Protein was extracted, separated by SDS PAGE and western blotted. 
Manual quantification of the relative band intensities were used to quantify the level of expression and this 
was expressed as arbitrary units (n = 3). (A) The CACNA1C was detected within the soluble nuclear protein 
fraction (B) The CACNA1C was not detected within the chromatin bound nuclear protein fraction.
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4.6.2 The KCNMA1 Channel Protein is Found Localised Within the Nucleus in 
Myometrial Cell Cultures. 
In Chapter 3, following immunocytochemistry staining of the primary myocytes nuclear 
localisation of the KCNMA1 channel was observed. This was a novel finding, therefore 
it was important to rule out the possibility that this nuclear localisation was a staining 
artefact.  To do this, soluble nuclear and chromatin-bound nuclear protein was isolated 
by sub-cellular fractionation, separated by SDS PAGE and subsequently western blotted. 
After blotting with the KCNMA1 C-terminal antibody in the un-stimulated samples there 
was no KCNMA1 protein found within the soluble nuclear protein fraction (Figure 4.9A), 
however, within the chromatin bound nuclear fraction there was a band for the 138kDa 
KCNMA1 protein (Figure 4.9B).  
 
When cultures were subsequently exposed to either TNF or TSA, both resulted in the 
appearance of a 138kDa and a 65kDa KCNMA1 protein band within the soluble nuclear 
fraction (Figure 4.9A). A faint 138kDa KCNMA1 band was observed in the chromatin 
bound nuclear fraction following exposure to TNF, however no bands were observed in 
this fraction after exposure to TSA (Figure 4.9B). No statistical analysis was carried out 
on these results as the gels were loaded with the same volume of protein and not the same 
concentration due to the low concentration of protein extracted in these fractions. 
 
Although these findings support the immunocytochemistry observations, it is important 
to remember that the bands observed could be a result of protein carry over during the 
sub-cellular fractionation protocol. The putative role of the KCNMA1 channel within the 
nucleus is still to be fully explored. 
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Figure 4.9 Nuclear Localisation of the KCNMA1 Protein in Myometrial Cell Cultures Utilising a C-
terminal Antibody 
Myometrial myocyte cell cultures were stimulated with 10ng/ml TNF for 1 hour, 100ng/ml TSA for twenty-
four hours, or left un-stimulated. Protein was extracted, separated by SDS PAGE and western blotted. 
Manual quantification of the relative band intensities were used to quantify the level of expression and this 
was expressed as arbitrary units (n = 3). (A) The KCNMA1 channel was detected within the soluble nuclear 
protein fraction (B) The KCNMA1 channel was detected within the chromatin bound nuclear protein 
fraction 
 
4.7 Discussion 
4.7.1 The KCNMA1 Channel Protein Antibodies 
Firstly, it is necessary to address the differences seen in the results from the two different 
KCNMA1 antibodies. The KCNMA1 N-terminal antibody was raised against a synthetic 
peptide from the N-terminal of the Human KCNMA1 channel conjugated to an 
immunogenic carrier protein, it was supplied as whole serum, not affinity purified and it 
had only been tested in western blot against the recombinant protein used as an 
immunogen. Although these factors would seem to make it a poor choice of antibody for 
this purpose, it was chosen as the majority of other KCNMA1 N-terminal antibodies were 
raised in goat. The issue with using primary antibodies raised in goat for western blotting 
is finding an appropriate blocking solution because the anti-goat secondary will cross-
react with both BSA and milk-containing blocking buffers giving a very high non-specific 
background signal (Buchwalow, Samoilova et al. 2011). The original KCNMA1 N-
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terminal antibody was raised in goat and despite optimisation it was not possible to 
acquire a suitable signal:noise ratio  using a variety of blocking buffers including BSA, 
Milk, non-protein block or serum block at any of the primary and secondary antibody 
concentration combinations investigated. Therefore, a pragmatic decision was taken: 
although the KCNMA1 N-terminal antibody used was not ideal it was the better choice. 
The antibody itself may therefore have contributed to the differences seen in comparison 
to the C-terminal antibody.  
 
There are also intrinsic differences between the protein structures in the region of the 
binding sites for the N- and C-terminal KCNMA1 channel proteins. The N-terminal 
antibody binds between amino acids 100 and 150 of the protein, this region encompasses 
part of the intracellular loop between the S0 and S1 segments, the transmembrane S1 
segment and also part of the intracellular loop between segments S1 and S2 while the C-
terminal antibody  binds at the very end of the intracellular C-terminal tail region. The N-
terminal antibody binds in a region composed of transmembrane helix structures and 
intracellular linking loops while the C-terminal is 848 amino acids in length and is 
composed of intracellular helix and beta strand structures.  
 
The N-terminal region and the S0 transmembrane spanning domain are responsible for 
coupling of the β-subunit (Wallner, Meera et al. 1996, Morera, Alioua et al. 2012). The 
β-subunit increases the calcium and voltage sensitivity of the KCNMA1 channel and 
hence supports quiescence. Korovkina et al. identified and characterised a KCNMA1 
variant in which a 132bp exon is inserted between exons 1 and 2 resulting in an additional 
44aa being inserted in the linking loop between S0 and S1. The inserted amino acids 
contain two consensus sites for protein phosphorylation and also a myristylation site 
(Korovkina, Fergus et al. 2001, Korovkina, Brainard et al. 2006). KCNMA1 channel with 
this insert have been shown to be proteolytically cleaved, when cleaved the N-terminus 
is located in the membrane and the C-terminus localises to the sarcoplasmic reticulum. 
The binding site for the N-terminal antibody is in the vicinity of this proteolytic cleavage 
and therefore if the channel has been cleaved this may destroy the antibody binding site 
(Figure 4.11). 
 
All of the above are plausible explanations for why the N-Terminal antibody worked less 
well in the western blot but ultimately the most probable explanation is that as the 
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antibody recognised a linear peptide epitope i.e. a synthetic peptide, a harsher denaturing 
lysis buffer such as RIPA buffer would have been more appropriate.  This would have 
ensured that the antibody recognised the peptide more readily and was more able to bind. 
The less harsh lysis buffer which was used would have resulted in a decrease in the 
availability of a suitable epitope for the antibody and hence a reduced signal. This then 
combined with the non-specificity of a whole-serum antibody gave blots with low 
signal:noise ratios which were  difficult to interpret.  
 
4.7.2 The KCNMA1 Channel Protein Fragments 
Due to the low signal:noise ratios achieved in the N-terminal western blots it is necessary 
to treat the data generated from these with caution until it can be validated. Various 
fragments were detected by the N-terminal antibody that were not detected when the C-
terminal antibody was used, indicating that these fragments were lacking the C-terminal 
region. Initially these fragments were dismissed as not physiologically relevant as they 
had been identified previously by Knaus et al. and were determined to be by-products of 
proteolytic cleavage which has occurred as a result of the purification process (Knaus, 
Eberhart et al. 1995).  
 
Utilising the knowledge that it is the C-Terminal region that is absent it is possible to 
approximate the location of the cleavage sites for these fragments and interestingly the 
cleavage sites for all three fragments (50, 65 and 90kDa) occur in regions of known splice 
variants (Figure 4.11).  
 
 
Figure 4.10 Diagrammatic Representation of the KCNMA1 protein  
Details the location of key features including the channel pore, splice sites (M2-Red; M3-Green; M5-Blue). 
The C-terminus is highlighted with a grey box and the N-terminus with a black box. The putative cleavage 
sites for the generation of the protein fragments are highlighted by the white boxes. The antibody binding 
sites are detailed as is the Mk44 insertion. 
 
The 90kDa fragment is cleaved in the region of splice site M5 (Figure 4.11), this site is 
located in the linking loop between S9 and S10 in close proximity to the ‘calcium bowl’. 
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Splice site M5 involves the insertion or deletion of exon 29 and results in KCNMA1 
channels with an increased activation rate (Tseng-Crank, Foster et al. 1994, Yan, Olsen 
et al. 2008). In a separate study to identify where the calcium sensitivity of the KCNMA1 
channel was located Schreiber et al. demonstrated that abolishing the sensitivity of the 
calcium bowl resulted in KCNMA1 channels with increased activation rates (Schreiber, 
Yuan et al. 1999). Taken together with the protein and splice variant data in this study, it 
would indicate that the insertion of exon 29 could result in the introduction of a cleavage 
site which then results in the cleavage of the C-terminal tail region effectively removing 
the calcium bowl from the core of the channel and abolishing the channels calcium 
sensitivity resulting in a channel with increased activation rates.  
 
The 65kDa fragment is cleaved in the region of splice site M3 (Figure 4.11), this site is 
located in the linking loop between S8 and S9, the effects of this splice variant have not 
yet been fully identified. The splice site involves differential utilisation of exon 19, at the 
protein level this results in the insertion of 40aa (the utilisation of the entire of exon 19), 
the insertion of 4aa (the 3’ truncation of exon 19) and no amino acids inserted (the 
skipping of exon 19). Tseng-Crank demonstrated that the insertion of the 4aa resulted in 
a KCNMA1 channel with a 3- to 4-fold decrease in calcium sensitivity (Tseng-Crank, 
Foster et al. 1994). These same 4aa are at the start of the 40aa insert but the effect this 
insert had on calcium sensitivity was not examined. Three of the four inserted amino acids 
are positively charged and Tseng suggested that the decrease in calcium sensitivity was 
either because this positive charge was interacting with the calcium binding site or 
because the inserted amino acids were causing conformational changes in the protein 
structure (Tseng-Crank, Foster et al. 1994). Combining the splice variant data, which 
shows that the complete exon 19 is utilised in these primary myocytes, with the protein 
data reported here suggests a third possibility: the utilisation of the complete exon 19 
introduces a cleavage site and that the calcium sensing C-terminal tail can then be cleaved 
from the channel. This would have the effect of reducing the calcium sensitivity of the 
channel. 
 
The 50kDa fragment is cleaved in the region of splice site M2 (Figure 4.11), this site 
involves the mutually exclusive use of exons 10 and 11 or exons 11 and 12. This can 
result in either truncated non-functional channels or functional channels with strongly 
altered gating kinetics (Soom, Gessner et al. 2008). Interestingly, if the location of the C-
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terminal antibody is utilised to approximate the cleavage site for the 65kDa fragment 
detected by this antibody, the cleavage for this fragment occurs in a similar location to 
the cleavage site of the 50kDa fragment: this may indicate that the two fragments 
complement each other. The splice variant data have shown that the primary myocytes 
express exon 11 and 12, and so the C-terminally truncated 50kDa fragment may be 
generated as a result of proteolytic cleavage of the protein at a cleavage site introduced 
via the utilisation of exons 11 and 12. The loss of the C-terminal tail region would alter 
the gating kinetics of the channel which has been reported as an effect of alternative 
splicing in this region. 
 
To determine if any of these scenarios are physioloigially relevant it would be necessary 
to determine the structure of the channel in vivo. It would also be pertinant to undertake 
channel activity recordings in order to determine the specific effect on channel gating. 
 
4.7.3 Protein Fragments of the CACNA1C Channel  
The N-terminal antibody detected two forms of the CACNA1C channel on the western 
blots, the first at 240kDa is representative of the full length channel and the second at 
190kDa is representative of a CACNA1C channel which has undergone post-translational 
modification were the C-terminus has been proteolytically cleaved. The C-terminal 
antibody detected four different fragments. 
 
The 190kDa fragment detected by the N-terminal antibody, has been reported to lack a 
portion of the C-terminal tail of the channel and this cleavage occurs in a known splicing 
region (Figure 4.12). C-terminal truncation of the CACNA1C has been described in 
cardiac cells (Tseng-Crank, Foster et al. 1994, Satin and Schroder 2009), brain cells (De 
Jongh, Colvin et al. 1994) and skeletal muscle (Hulme, Konoki et al. 2005). This cleavage 
has been shown to occur between amino acids 1685 - 1699 of the CACNA1C (De Jongh, 
Warner et al. 1991) close to a calpain cleavage site. Indirect evidence suggests that a 
calpain-like protease is responsible for the proteolytic processing of the channel. De 
Jongh et al. demonstrated that calpain I is capable of cleaving a 37kDa fragment from the 
C-terminus of the CACNA1C (De Jongh, Colvin et al. 1994). This would correlate well 
with the smallest fragment detected by the C-terminal antibody and as such this small 
fragment and the 190kDa fragment may actually be generated as a result of a single 
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cleavage event. Hell et al. went on to show that this cleavage was induced by an influx of 
calcium and that this cleavage can be blocked by calpain inhibitors (Hell, Westenbroek 
et al. 1996).  
 
 
Figure 4.11 Diagrammatic Representation of the CACNA1C Protein  
Details the location of key features including, splice sites (L11-Red; L12-Green). The C-terminus is 
highlighted with a grey box and the N-terminus with a black box. The putative cleavage sites for the 
generation of the protein fragments are highlighted by the white boxes. The antibody binding sites are 
detailed. 
 
Reports on the role of the C-terminus and hence the effects of cleaving the C-terminus 
initially appear to be conflicting. Firstly, it has been shown that cleavage of the C-
terminus removes the major site of cAMP dependant phosphorylation from the body of 
the channel – ser1928 (Gao, Yatani et al. 1997). Phosphorylation of this ser-1928 residue 
has been shown to result in up-regulation of the channel (Gao, Yatani et al. 1997). This 
evidence would suggest then, that cleavage of the C-terminus should result in down 
regulation of the channel. In fact, however, the proteolytically cleaved CACNA1C 
calcium channel has been shown to have a 4- to 6-fold higher ion conductance than the 
full length channel (Wei, Neely et al. 1994). The C-terminally cleaved fragment has also 
been shown to non-covalently associate with the body of the channel on the membrane 
and exert an inhibitory effect (Gao, Cuadra et al. 2001).  Wei et al. suggested that the C-
terminal tail folded over changing the proteins structure and inhibiting the activity of the 
channel (Wei, Neely et al. 1994). If the phosphorylation of ser-1928 resulted in the C-
terminus being unable to fold round as Wei suggests then this phosphorylation would, in 
effect, have the same effect as removal of the C-terminus. 
 
Splicing may be involved in modulating the role of the C-terminus as there are a number 
of splice sites in the C-terminus which have been shown to modulate the gating properties 
of the CACNA1C. Splice sites L11 and L12 involve in the inclusion of additional 
nucleotides and/or the utilisation of an alternative exon and both are in the vicinity of the 
putative cleavage site (aa1685-1699) and ser-1928 and so it is possible that these splice 
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variants may either remove the phosphorylation site or introduce a cleavage site. Splice 
site 11 involves exon 40 which encompasses the putative cleavage site and splice site 12 
involves exon 44 which encompasses ser-1928 (Figure 4.12). The splice variant analysis 
showed that the myocytes express exon 40 with no addition or deletions and so this may 
contain the cleavage site responsible for the truncation of the CACNA1C. 
 
As with the KCNMA1 channel it would be necessary to determine if these splice sites did 
indeed have the effects suggested and to undertake channel activity recordings in order to 
determine the specific effect on channel gating.. 
 
4.7.4 The CACNA1G Channel Protein 
There were two main protein forms for the CACNA1G channel evident from the western 
blots, the first at ~262kDa and the second at ~249kDa, this range in protein size of the 
CACNA1G has been reported previously (Yunker, Sharp et al. 2003, Bertolesi, Walia Da 
Silva et al. 2006). Two forms of the CACNA1G were defined by Monteil et al., a short 
version termed CACNA1G α1G-b and a longer version termed CACNA1G α1G-a. These two 
forms were shown to contain distinct III-IV loops, α1G-b is formed utilising an alternative 
5’ splice donor site in exon 25 combined with the acceptor site on exon 27 (Monteil, 
Chemin et al. 2000). The splice variant analysis revealed that the primary myocytes 
express exons 25 and 26 this would account for the longer form of the CACNA1G. A 
second splice site which could also account for the detection of a smaller CACNA1G 
protein is splice site 9 with can include the deletion of exons 34 and 35 (Ernst and Noebels 
2009; Figure 4.13), this splice site was not included in the splice variant analysis and so 
it is not possible to determine if these exons are present or not. 
 
There were a further two smaller fragments of the CACNA1G also detected. The smallest 
of these (69kDa) occurs within splice site T1 splicing in this region has been shown to 
result in the modification of protein trafficking (Figure 4.13; Shcheglovitov, Vitko et al. 
2008). The second fragment (157kDa) does not occur in or near a known splice site and 
so this fragment may be caused due to the protein extraction techniques and hence is 
physiologically irrelevant or it may be a novel finding (Figure 4.13). As with the 
KCNMA1 and CACNA1C further work is need to fully characterise these channel 
isoforms and fragments. 
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Figure 4.12 Diagrammatic Representation of the CACNA1G Protein  
Details the location of key features including splice sites (T1-Red; T9-Green). The C-terminus is 
highlighted with a grey box and the N-terminus with a black box.  The putative cleavage sites for the 
generation of the protein fragments are highlighted by the white boxes. The antibody binding site is 
detailed. 
 
4.7.5 The Role of the KCNMA1, CACNA1C and CACNA1G Channels in 
Myometrial Contractility. 
In the un-stimulated samples, which are representative of the end of pregnancy prior to 
the initiation of contractions, the data shows that both full length and truncated KCNMA1 
channel forms are present in both the cytoplasm and inserted into the membrane, full 
length and post translational modified CACNA1Cs are present again in the cytoplasm 
and inserted in the membrane, with the cytoplasmic fraction containing more channel than 
the membrane and full length CACNA1G is present in the whole cell lysis but is not 
detectable localised to the membrane. This demonstrates that, at this juncture, the 
myometrial myocytes express channels which have decreased calcium sensitivity 
(truncated KCNMA1 channel forms), and increased ion conductance (truncated 
CACNA1C) meaning when the CACNA1C is triggered to open the membrane will 
depolarise more rapidly and the KCNMA1 channel will respond less rapidly and so the 
cell will repolarise more slowly tipping the fine balance of the cell in favour of 
contraction.  
 
At the initiation of labour the myometrium is subject to an influx of cytokines including 
TNF. Therefore, TNF stimulated cells may serve as a model of this time point. In the 
primary cells after TNF treatment, full length KCNMA1 channel protein was again seen 
in both the cytoplasmic and membrane fractions but the level was unchanged from the 
un-stimulated cultures. Membrane localisation of the 50kDa fragment which represents 
KCNMA1 channels with decreased calcium sensitivity is increased after TNF treatment. 
Post-translational modified CACNA1C was also present in both fractions and membrane 
localisation of this protein was increased after TNF treatment. Finally full length 
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CACNA1G was detected localised to the membrane after TNF treatment. Demonstrating 
that the influx of cytokines, specifically TNF, causes a mobilisation of the post-
translationally modified CACNA1C and CACNA1G proteins from the cytoplasm to the 
membrane whilst promoting the membrane expression of the less responsive 50kDa 
KCNMA1 channel fragment and hence increases the contractility of the cell. 
 
TSA, is a broad spectrum lysine deactylase inhibitor which has been seen to cause 
relaxation in myometrial strips, therefore, TSA-stimulated cells promote a relaxed 
myometrial phenotype. In the primary cells, after TSA treatment, there was an increase 
in the full length KCNMA1 channel protein although this appears to be restricted to the 
cytoplasmic fraction. A decrease in full length LTCC was also observed but this was not 
significant. Visually this decrease in CACNA1C expression appears to be focused in the 
membrane fraction although again this was not significant. Finally the TTCC was again 
present localised to the membrane. This demonstrates that TSA may act by increasing 
transcription of the KCNMA1 channel and by supporting the removal of the CACNA1C 
from the membrane. Importantly TSA seems to be working with slower kinetics than seen 
with TNF. 
 
If histone deacetylase inhibitors are to be developed as tocolytic agents it is important to 
determine the combined effects of TNF and TSA. This will inform the decision of whether 
the tocolytic is more effective administered prior to the cytokine influx or after it.  
 
As TSA has been shown to cause relaxation of the primary cultures it is perhaps 
unsurprising to see that it also causes an increase in KCNMA1 channel protein. However 
this increase in channel protein appears to be confined to the cytoplasmic fraction and not 
the membrane fraction and so would not be expected to contribute to the excitation of the 
membrane.  
 
It is interesting to note that when TNF is added, either before or after TSA, the TSA-
associated increase in KCNMA1 channel protein is not seen indicating that TNF can 
abrogate the effects of TSA on the expression of this protein. TSA has been shown to 
induce ubiquitin-dependent degredation of proteins via the 26s proteasome pathway 
(Caron, Boyault et al. 2005, Alao, Stavropoulou et al. 2006, Kong, Lin et al. 2006).  
Research by Dennis et al. demonstrated the disruption of proteosome function can inhibit 
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progesterone receptor-dependant transcription in a delayed manner. This inhibition was 
linked to a decrease in promoter histone acetylation, however treatment with TSA was 
unable to restore progesterone mediated transcription (Dennis, Lonard et al. 2005). 
Progesterone has been shown to cause an increase in the expression of the KCNMA1 
STREX exon (Holdiman, Fergus et al. 2002, Zhu, Eghbali et al. 2005) and TNF has been 
shown to to up-regulate progesterone receptor A (Jiang, Guo et al. 2012). Progesterone 
receptor A has been shown to repress transcription (Giangrande, Kimbrel et al. 2000, 
Condon, Hardy et al. 2006) and therefore it is possible that in the case of KCNMA1 TSA 
is unable to reverse the effect of TNF on the progesterone receptor-dependent 
transcription of the channel. 
 
The effect of TSA and TNF together on the KCNMA1 channel can be different than that 
of TNF or TSA on their own. For example within the cytoplasmic fraction the mean 
intensity of the KCNMA1 138kDa band is increased in the TNF and TSA stimulated 
groups compared to the un-stimulated group. The intensity of this band then drops to 
below the intensity of the un-stimulated band in both the +TNF/+TSA and +TSA/+TNF 
groups. This could be because the action of TSA represses the transcription of IκBα (Wu, 
Starzinski-Powitz et al. 2010) and so the usual negative feedback loops of IκBα and A20 
may no longer function and inhibit the cascade caused by TNF. The effect is therefore 
enhanced when the TNF cascade is triggered then the negative feedback is blocked as is 
the case with the +TNF/+TSA group. 
 
4.8 Conclusion 
This data has demonstrated that there are multiple isoforms of the KCNMA1, CACNA1C 
and CACNA1G expressed within the primary myocyte cultures. These isoforms could be 
generated either by splicing of the RNA or proteolytic processing of the protein. The 
presence of various protein fragments for both the KCNMA1 and CACNA1C protein 
indicate that these proteins have been cleaved. This cleavage may have been made 
possible by the utilisation of different splice variants in the generation of the RNA. The 
fragments generated by these cleavage events have been shown to be capable of 
regulating channel function and as such have a role in regulating the contractility of the 
cell. Another way in which channel function can be modulated is via the proteins it 
associates with on the cell membrane. The different isoforms and fragments of the 
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KCNMA1 and LTCC reported in this chapter may have role in the selection and or 
recruitment of other proteins which in turn may enhance or repress the action of the 
channel. The next step therefore is to uncover what proteins these channels associate with 
and whether TNF or TSA have an effect on this association, this will be the focus of the 
following chapter. 
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Chapter 5: Co-Localisation of the KCNMA1 and CACNA1C 
Proteins with Caveolin-1, β2 Adrenergic Receptor and Gαs in 
Cultured Myometrial Cells Results and Discussion
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5.1 Introduction 
In Chapter 4 it was shown that TNF causes mobilisation of both the CACNA1C and 
CACNA1G proteins from the cytoplasm to the membrane whilst promoting the 
membrane localisation of the C-terminally truncated 50kDa KCNMA1 channel fragment 
and in this way may increase the contractility of the cell. Moreover, TSA caused a small 
decrease in the CACNA1C localised to the membrane.  
 
The cell membrane consists of approximately 50% protein. As well as these proteins the 
membrane also contains small invaginations called caveolae. Caveolae are flask shaped 
structures which are rich in proteins and lipids, they have a role in the regulation of 
channels and calcium signalling (Parton and Simons 2007).  
 
Previous research has demonstrated that caveolae can facilitate the localisation of key 
calcium handling proteins, and has directly linked the β2AR to both the CACNA1C 
(Davare, Avdonin et al. 2001, Liu, Shi et al. 2004) the KCNMA1 channel (Liu, Shi et al. 
2004) and both channels together (Liu, Shi et al. 2004). This macromolecular complex is 
thought to also contain a guanosine-5’-triphosphate (GTP)-binding protein complex and 
may also involve actin filaments (Chanrachakul, Broughton Pipkin et al. 2004, Brainard, 
Miller et al. 2005, Chanrachakul 2006). This complex would enable specific local 
regulation of both channels. It has not been elucidated whether this complex exists within 
the caveolae (Figure 5.1) or whether this is a separate process by which the two channels 
can be brought into close proximity. 
 
Therefore, the next step was to understand the membrane microenvironment within which 
the channels are functioning. 
 
Using co-immunoprecipitation and western blotting this chapter seeks to determine what, 
if any protein complexes containing the KCNMA1 and CACNA1C are present in the 
myometrium and if these complexes exist within caveolae. Further to this, the possible 
effect of TNF and TSA on any complexes discovered was investigated 
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Figure 5.1 Diagrammatic Representation of the Putative Caveolae Microdomain Housing Calcium-
handling Proteins  
CACNA1C – CACNA1C calcium channel; GPCR – G protein coupled receptor; Ca2+ - Calcium ions; α 
– G protein α subunit; β – G protein β subunit;  – G protein  subunit. 
 
5.2 Optimisation of Protein and Antibody Concentrations for 
Western Blotting 
As in Chapter 4 a dot blot was utilised to optimise the protein and antibody concentrations 
for use in western blotting. Different quantities of protein (5μg, 10μg and 50μg) were 
applied directly to a nitrocellulose membrane (Geneflow, Staffs) as dots, then incubated 
with different dilutions of primary antibody (1:500, 1:1000 and 1:2000). Secondary 
antibody was then added and the blots developed using Westar Supernova (Geneflow, 
Staffs) detection reagents. At least one combination for each antibody produced clear dots 
on the dots blots (Figure 5.2) 
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Figure 5.2 Dot Blot Optimisation  
The antibody target and antibody dilutions are detailed in the figure. The numbers 1, 2, 3, 4 related to the 
amount of protein added in that dot; 1 - 5μg; 2 - 10μg; 3 - 50μg and 4 – negative control (no protein). The 
lack of dot in the negative control of each blot and the lack of background on the majority of blots show 
the block is effective and that each antibody is working. The dark spots indicate the antibodies are 
detecting protein. Blots were developed with WestStar Supernova ECL reagent. 
 
5.3 Analysis of Data 
After manual band quantification of the western blot images, analysis was performed as 
follows. Within each sample set, the un-stimulated sample was quantified as 100%, the 
stimulated samples for the matching western blots were then quantified as a percentage 
of the un-stimulated sample. For the co-immunoprecipitation experiments the value 
ascribed to non-specific binding of IgG was subtracted from the specific binding value. 
That value was then expressed as a percentage of the input fraction with the input fraction 
intensity being taken as 100%. All experiments were repeated three times and the results 
are expressed as the mean ± SD. All data analyses were conducted on GraphPad Prism 
version 6 (GraphPad Software, San Diego, California), where a one way ANOVA with 
Dunett’s post-test was performed to compare the individual stimulations against the 
unstimulated control; p˂0.05 was considered statistically significant. Although 
statistically analysis of the co-immunoprecipitations were performed the data is not 
presented in this thesis. Due to the limitations of the immunoprecipitation techniques any 
analysis can only be semi-quantitative and therefore the presentation of statistical data 
relating to these could be misleading.
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5.4 Expression of Accessory Proteins in Myometrial Cell Cultures. 
Prior to determining if the KCNMA1 and CACNA1C exist within a macromolecular 
complex and what form this complex takes it was first necessary to determine if the 
myometrial cells expressed the putative accessory proteins, Gαs, Cav-1 and β2AR and if 
either TNF or TSA had an effect of the level of expression of these proteins. To this end 
Western blots were carried out for each of the accessory proteins. 
 
5.4.1 Expression of Gαs in Myometrial Cell Cultures 
After whole cell lysis protein extraction, Gαs was detected in all the samples (Figure 5.3A 
left panel). On the western blots two isoforms of the Gαs protein were detected, a ~54kDa 
and a ~46kDa variant (Figure 5.3A left panel), these are designated the long and short 
isoforms of Gαs respectively (Northup, Sternweis et al. 1980, Mumby, Kahn et al. 1986, 
Olney, Tsuchiya et al. 1996, Pollard, Krainer et al. 2002). These two isoforms of Gαs, 
have been shown to be generated by alternative splicing with the short form being 
generated by the exclusion of exon 3 (Kozasa, Itoh et al. 1988). These two different 
isoforms have been shown to have different regulatory functions, with the longer form 
more able to support hormone-stimulated AC activity (Sternweis, Northup et al. 1981), 
and preferentially coupling to β-adrenergic receptors (Yagami 1995) in comparison to the 
short form. Expression of these two isoforms has been found to be tissue specific 
(Novotny and Svoboda 1998). Within the myometrium it has been reported that both the 
long and short Gαs isoforms are expressed at a considerably higher level in pregnant 
myometrium versus non-pregnant and in labouring myometrium the levels are reduced to 
that seen in non-pregnant (Europe-Finner, Phaneuf et al. 1994, Europe-Finner, Phaneuf 
et al. 1996).  
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Figure 5.3 Expression of Gαs, Cav-1 and β2AR in Myometrial Cell Cultures  
Myometrial cell cultures were stimulated with 10ng/ml TNF for 1 hour, 100ng/ml TSA for twenty-four 
hours, or left un-stimulated. Protein was extracted, separated by SDS PAGE and western blotted. Manual 
quantification of the relative band intensities were used to quantify the level of expression and this was 
expressed as a percentage of the un-stimulated expression (n = 3) (A) Left Panel Representative Gαs blot, 
both the long (54kDa) and short (46kDa) Gαs isoforms were detected, Right panel – Quantification. There 
was no change in total Gαs expression with either treatment. (B) Left Panel Representative Cav-1 blot, Right 
panel – Quantification. TSA caused a significant down regulation of Cav-1 (*p<0.05). (C) Left Panel 
Representative β2AR blot, Right panel – Quantification. Both TNF and TSA caused a significant down 
regulation of β2AR (*p<0.05) 
 
There was no significant change in the total level of Gαs protein detected after either TNF 
or TSA stimulation compared to the un-stimulated controls (Figure 5.3A right panel).  
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5.4.2 Expression of Caveolin 1 (Cav-1) in Myometrial Cell Cultures 
As mentioned previously caveolae are small flask-shaped invaginations of the cell 
membrane, the formation of these structures requires the expression of caveolin proteins 
(Fra, Williamson et al. 1995, Drab, Verkade et al. 2001, Razani, Engelman et al. 2001). 
Caveolins are a family of three integral membrane proteins, Cav-1, Cav-2 and Cav-3, 
which all form hairpin loops which are inserted into the membrane with the N and C 
termini both facing the cytoplasmic side of the membrane (Monier, Parton et al. 1995). 
These caveolin proteins form oligomers and when these associate with cholesterol and 
sphingolipids they result in the formation of caveolae. In smooth muscle Cav-1 has been 
shown to be crucial for the formation of caveolae. 
 
After whole cell lysis protein extraction, Cav-1 was detected in all the samples (Figure 
5.3B left panel). There was no significant change in the level of Cav-1 protein detected 
after TNF stimulation compared to the un-stimulated controls (Figure 5.3B right panel). 
After TSA stimulation, however, the amount of Cav-1 protein detected was significantly 
reduced (p<0.05; Figure 5.3B right panel). 
 
A large number of bands were observed on the Cav-1 western blots, these are labelled 
non-specific (n/s; Figure 5.3B left panel). However, there is evidence to suggest that Cav-
1 can form stable hetero-oligomeric complexes with Cav-2 (Scherer, Lewis et al. 1997) 
and this may explain the banding pattern seen on the western blot. The proteins 
represented by these other bands have not been conclusively identified for this thesis. 
 
5.4.3 Expression of β2-Adrenergic Receptor in Myometrial Cell Cultures 
The β2AR is a G-protein coupled receptor located within the cell membrane which binds 
Norepinephrine and Epinephrine. When stimulated, the β2AR results in the 
hyperpolarization of smooth muscle, an effect mediated by the augmentation of potassium 
ion conductance (Kotlikoff and Kamm 1996). Briefly, stimulation of the β2AR activates 
AC via Gαs which in turn converts ATP to cAMP. cAMP then catalyses the activation of 
PKA which in turn phosphorylates key proteins, including the KCNMA1 channel. 
Phosphorylation of the KCNMA1 channel leads to its activation and hence relaxation of 
the muscle (Kume, Takai et al. 1989, Tanaka, Yamashita et al. 2003). β2AR agonists such 
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as ritrodine were used to inhibit labour by causing relaxation in the smooth muscle of the 
uterus (Haram, Mortensen et al. 2003).   
 
Using whole cell protein extracts, β2AR was detected in all the samples (Figure 5.3C left 
panel). There was a significant decrease in the level of β2AR protein detected after both 
TNF and TSA stimulation compared to the un-stimulated controls (p<0.05; Figure 5.3C 
right panel). This reduction in expression was greatest in the TSA stimulated samples. 
 
5.5 Optimisation of Immunoprecipitation  
5.5.1 Optimisation of Antibody Binding 
Each step of the antibody binding and crosslinking process was tested using two amounts 
of both the KCNMA1 and CACNA1C N-terminal antibodies (2.5μg and 5.0μg). The 
effects of adding either reducing or non-reducing sample buffer to the sample prior to 
analysis by SDS PAGE were also compared.  The first step in this process was to verify 
that the antibody was successfully bound to the beads. After crosslinking the antibody to 
the beads, the supernatant, termed the flow through, was collected. This would contain 
any antibody that has not bound to the beads.  Next, non-cross-linked antibody was eluted 
from the beads using elution buffer (0.1% (v/v) HCl pH2.0), this step was repeated and 
the two elutions collected. Finally a sample of the beads was collected, this should contain 
cross-linked antibody.    
 
Following co-immunoprecipitaion the presence of the immunoprecipitating antibody in 
the protein eluate can mask specific signals from the subsequent western blot. This is due 
to the fact that the HRP-conjugated secondary antibody can bind to the 
immunoprecipitation antibody as well as the primary antibody utilised in the western blot. 
Depending on the size of the protein that is being detected the immunopreciptating 
antibody IgG heavy and light chains can mask the specific protein signal. The apparent 
size of these IgG bands depends on if the antibody is intact or reduced. If the antibody is 
intact, both the heavy and light chains will migrate together through the gel and will be 
detected higher on the membrane (~75kDa) than reduced antibody where the heavy and 
light chains migrate separately (50-75kDa and ~25-kDa respectively). To determine the 
level of interference from both reduced and intact contaminating immunoprecipitating 
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antibody, each sample was divided into two aliquots. One aliquot was diluted in non-
reducing laoding buffer and the second in reducing loading buffer. The SDS and DTT in 
the reducing buffer combined with boiling the sample breaks the secondary and tertiary 
structure of the proteins resulting in the separate migration of the heavy and light IgG 
chains, whilst non-reducing loading buffer will leave the antibody intact.  
 
Each of the samples was analysed by SDS PAGE on an 8% resolving gel, transferred to 
nitrocellulose membrane and then after blocking, incubated with the appropriate 
secondary antibody to detect the presence of any primary antibody in the sample.  
 
There was no antibody detected in the flow through samples, indicating that the antibody 
had successfully bound to the beads. The first elution contained a detectable amount of 
antibody indicating that the crosslinking was not 100% efficient. The second elution 
contained much less antibody demonstrating that the elutions have removed the majority 
of non-crosslinked antibody. Finally the beads did contain detectable antibody 
demonstrating that a portion of the antibody had been successfully cross-linked to the 
beads (Figure 5.4A).  
 
Two different amounts of antibody were examined 2.5μg or 5μg per immunoprecipitation 
to determine if this affected the efficiency of the crosslinking. There were no differences 
in the amount of antibody detected at each of the stages between these two groups (Figure 
5.4A).  
 
Intact antibody was detect high up on the membrane and therefore, will not interfere with 
the visualisation of the specific proteins of interest. Reduced antibody, however, was 
detected in the same region as the specific proteins are expected to be and so these will 
interfere with the interpretation of the co-immunoprecipitation blots (Figure 5.4A).  
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Figure 5.4 Optimisation of Co-Immunoprecipitation Protocol  
After crosslinking of the Gβ antibody to the beads the crosslinked beads and antibody were incubated both 
with and without protein (+p and –p respectively), un-bound protein was removed and bound protein was 
eluted from the beads. (A) Verification of Antibody Cross-linking. No antibody was detected in the wash 
(flow through) following antibody crosslinking. Antibody was detected following elution from the beads 
(Eluion1; Elution2). Antibody was detected in the bead sample indicating the crosslinking was partially 
effective. Detected antibody was high on the blot in samples diluted in non-reducing loading buffer and the 
heavy and light IgG chains were detected separately in samples diluted in reducing loading buffer. (B) 
Verification of Protein Immunoprecipitation. No antibody is detected in either of the flow though lanes 
indicating that the antibody is crosslinked to the beads. Gβ is detected in the +p flow through lane. In the -
p elution antibody is detected indicating that the elution removes some of the crosslinked antibody, this was 
also seen in the +p elution. In the +p elution Gβ was also detected indicating that the immunoprecipitation 
was successful. (C) Protein-A HRP Trial. Flow Through and Elution (+p; –p) samples were diluted in 
reducing loading buffer, one elution sample (+p/nr) was diluted in non-reducing sample buffer. No antibody 
was detected in either of the flow though lanes indicating that the antibody is crosslinked to the beads. Gβ 
is detected in the +p flow through lane. No antibody was detected in the –p and +p elutions, Gβ was detected 
in the +p elution. In the +p/nr elution antibody is detected indicating that antibody is present but just not 
detected by protein-A HRP. +p – +0.3mg protein; -p – no protein 
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5.5.2 Optimisation of Immunoprecipitation Western Blots 
To ensure the antibodies did not obscure data interpretation on the blot, they were 
chemically cross-linked to the beads. To determine if this cross-linking had been 
effective, a test immunoprecipitation was carried out using Gβ antibody.  
 
The immunoprecipitation was carried out both with 500μl IP Lysis / Wash buffer (without 
protein: -p) and with 0.3mg total cellular protein in 500μl IP Lysis / Wash buffer (with 
protein: +p). Under both these conditions samples were collected at each step of the 
immunoprecipitation protocol namely, the flow through from the beads following the first 
incubation and the elution of the immunoprecipitated protein from the beads. Reducing 
loading buffer was added to all the samples which were subsequently analysed by SDS 
PAGE followed by western blotting for Gβ.  
 
In the “without protein” (-p) sample there were no immunoprecipitating antibody IgG 
bands detected on the blot in the flow through lanes, however, in the elution sample lanes 
immunoprecipitating antibody heavy and light chain IgG bands were detected on the blot 
(Figure 5.4B). The lack of bands in the flow through sample indicates that the antibody 
cross-linking experiment was effective in removing contaminating immunoprecipitating 
antibody. The IgG bands in the elution samples, however, indicate that the elution 
procedure removes some of the cross-linked antibody from the beads. 
 
In the “with protein” (+p) sample there was no immunoprecipitating antibody IgG bands 
detected on the blot in the flow through lanes, however, in this sample a band for Gβ was 
detected. This may indicate that too much protein has been added to the 
immunoprecipitation. In the elution lane both immunoprecipitating antibody IgG bands 
and a Gβ band were detected on the blot (Figure 5.4B). This indicates that the 
immunoprecipitation is working and recovering the expected protein. 
 
As a final optimisation step, a different secondary antibody was trialled. The traditional 
secondary antibodies used for western blotting recognise both intact and reduced antibody 
which can lead to high background especially on western blots from immunoprecipitated 
protein. As has been explained previously this high background can mask the signals of 
interest on the western blot. Lal et al. demonstrated that this issue can be resolved by 
using Protein-A HRP as an alternative secondary. Protein-A HRP recognises almost 
199 
 
exclusively intact antibody. As the SDS and DTT in the reducing buffer combined with 
boiling the sample breaks the secondary and tertiary structure of the proteins this renders 
the immunoprecipitating antibody undetectable by the Protein-A HRP secondary (Lal, 
Haynes et al. 2005).  
 
To determine if a Protein-A HRP conjugated secondary antibody could overcome the 
issues associated with immunoprecipitating antibody contamination of the 
immunoprecipitated protein the follow experiment was carried out.  
Immunoprecipitations were performed with both with 500μl IP Lysis / Wash buffer 
(without protein: -p) and with 0.3mg total cellular protein in 500μl IP Lysis / Wash buffer 
(with protein: +p). Under both these conditions samples were collected at each step of the 
immunoprecipitation protocol namely, the flow through from the beads following the first 
incubation and the elution of the immunoprecipitated protein from the beads. The ‘with 
protein’ (+p) elution sample was then divided equally into two aliquots. One aliquot was 
diluted in reducing sample buffer (+p/r) which should render the immunoprecipitating 
antibody undetectable by Protein-A HRP. The second aliquot was diluted in non-reducing 
sample buffer (+p/nr) meaning that the immunoprecipitating antibody is detectable by 
Protein-A HRP. The remaining samples were diluted in reducing sample buffer (-p/r; 
+p/r). All the resulting samples were then analysed by SDS PAGE followed by western 
blotting using the Protein-A HRP secondary antibody. 
 
In all the “with protein” (+p) samples, Gβ protein was detected both in the flow through 
and in the elution (Figure 5.4C), this indicates that the protein-A HRP secondary is of a 
comparable sensitivity to the traditional  HRP-conjugated secondary’s routinely used for 
western blotting. 
 
In the sample diluted in non-reducing loading buffer contaminating antibody was detected 
high up on the membrane (Figure 5.4C). However, in all the samples diluted in reducing 
loading buffer there was no contaminating IgG detected (Figure 5.4C). This demonstrates 
that if reducing loading buffer is used in combination with the Protein-A HRP secondary 
the high background due to the immunoprecipitating antibody is eliminated. 
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5.6 Association of KCNMA1 and CACNA1C with Other Proteins in 
Myometrial Cell Cultures. 
KCNMA1 and CACNA1C present within myometrial cells, were extracted from cell 
cultures which were either left unstimulated, or stimulated with 10ng/ml TNF or, 2µg/ml 
TSA. The protein was extracted using a non-denaturing IP Lysis buffer (pH7.4, 25mM 
Tris, 150mM NaCl, 1mM EDTA, 1% (v/v) NP40, 5% (v/v) glycerol; Pierce IP/Co-IP 
Kit). The protein was quantified using a nanophotometer, by UV absorption at A280nm. 
Once the protein was extracted the Pierce IP/Co-IP kit was used to immunoprecipitate 
protein complexes containing KCNMA1 or CACNA1C protein by utilising KCNMA1 
and CACNA1C specific antibodies. Non-specific IgG was also used to 
immunoprecipitate the protein as a measure of the non-specific background signal from 
the immunoprecipitations. Finally proteins which had not been immunoprecipitated was 
used as an input control to demonstrate that the protein of interest was present in the 
sample. Pre-cast 4-20% SDS PAGE gels were loaded with input protein, IgG, KCNMA1 
and CACNA1C immunoprecipitated protein and then probed with each of the putative 
accessory proteins. The exceptions to this were the KCNMA1 N-terminal IP subsequently 
western blotted with the KCNMA1 N-terminal antibody and the IP subsequently blotted 
with Gαs, these were incorrectly loaded as follows; input, KCNMA1, IgG, CACNA1C 
due to limited samples it was not possible to re-run these blots. 
 
5.7 Immunoprecipitation Control Blots 
As controls, western blots were also probed with the same antibody that was used to 
immunoprecipitate the protein. 
 
When proteins immunoprecipitated with the KCNMA1 N-terminal antibody was western 
blotted using the same KCNMA1 N-terminal antibody there were bands detected at 
138kDa, 65kDa and 50kDa as well as some non-specific (n/s) bands (Figure 5.5A). The 
138kDa, 65kDa and 50kDa bands correlate with bands detected by the KCNMA1 N-
terminal antibody in Chapter 4 Figure 4.4. The controls and tests of the 
immunoprecipitation, described previously, suggest that the interactions are specific for 
the KCNMA1 protein. Therefore, these bands are representative of full length KCNMA1 
channel (138kDa; Figure 5.5A), and two C-terminally truncated KCNMA1 channel 
(50kDa and 65kDa; Figure 5.5A). Also there is some KCNMA1 banding in the IgG lanes 
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(Figure 5.5A) which would indicate that there has been some non-specific binding by the 
IgG antibody during the immunoprecipitation step, which has not be removed by the 
subsequent washing steps. 
 
There was banding for the KCNMA1 protein in all three of the immunoprecipitations 
carried out using the KCNMA1 N terminal antibody (un-stimulated, +TNF and +TSA) 
indicating that all the immunoprecipitations have been successful (Figure 5.5A).  
 
When the protein immunoprecipitated with the CACNA1C N-terminal antibody was 
western blotted using the same CACNA1C N-terminal antibody there were bands 
detected at 240kDa and 190kDa as well as some non-specific (n/s) bands in the 
immunoprecipitation lanes (Figure 5.5B). The 240kDa and 190kDa bands correlate with 
bands detected by the CACNA1C N-terminal antibody detailed in Chapter 4 Figure 4.6. 
The controls and tests of the immunoprecipitation run previously would again suggest 
that the interactions are specific for the CACNA1C protein. Therefore, these bands are 
representative of full length CACNA1C channel (240kDa; Figure 5.5B), and a C-
terminally truncated CACNA1C channel (190kDa; Figure 5.5B). There are also some 
intense non-specific bands detected, these are below the CACNA1C bands and are not of 
the correct size to be the IgG heavy or light chains. It is possible that these bands represent 
IgG heavy chain dimers, however, it has been demonstrated that the protein-A HRP 
secondary used does not detect the reduced IgG heavy and light chains. Therefore, at 
present the identity of these bands is unclear. Some CACNA1C banding was also noted 
in the IgG lanes (Figure 5.5A) indicating that there has been some non-specific binding 
during the immunoprecipitation step, which was not removed during the washing steps. 
 
There was banding for the CACNA1C in each of the immunoprecipitations carried out 
using the CACNA1C N-terminal antibody (un-stimulated, +TNF and +TSA) indicating 
that the immunoprecipitations have been successful (Figure 5.5B). 
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Figure 5.5 Immunoprecipitation Controls  
Myometrial cell cultures were stimulated with 10ng/ml TNF, 100ng/ml TSA, or left un-stimulated. Protein 
was extracted, immunoprecipitated with KCNMA1 N-terminal, CACNA1C N-terminal and IgG antibodies 
then separated by SDS PAGE and western blotted. (A) Representative blots of KCNMA1 N-terminal and 
IgG immunoprecipitations western blotted with KCNMA1 N-terminal antibody. KCNMA1 protein was 
detected in all KCNMA1 N-terminal immunoprecipitations indicating that the immunoprecipitation was 
successful. (B) Representative blots of CACNA1C N-terminal and IgG immunoprecipitations western 
blotted with CACNA1C N-terminal antibody. CACNA1C protein was detected in all CACNA1C N-
terminal immunoprecipitations indicating that the immunoprecipitation was successful. IP – 
immunoprecipitation, WB – western blot, n/s – non-specific. 
 
5.7.1 The KCNMA1 Channel is Found Associated with Gαs in Myometrial Cell 
Cultures 
When the protein immunoprecipitated with the KCNMA1 N-terminal antibody was 
western blotted using the Gαs antibody there was a band detected at 54kDa as well as 
some non-specific (n/s) bands (Figure 5.6A). This 54kDa band correlates with the band 
detected by the Gαs
 antibody in Figure 5.3A. The presence of this Gαs specific band 
indicates that Gαs is associated with the KCNMA1 channel in un-stimulated samples. 
Following exposure to TNF and TSA the KCNMA1 channel was again found associated 
with Gαs. Within the TNF-stimulated samples there was also a second Gαs band detected 
at 46kDa, this correlates with the band detected by the Gαs
 antibody in Figure 5.3A. 
Although the association was evident in each of the repeats the intensity of the band 
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observed varied between repeats. There was no corresponding bands detected in the IgG 
IP lanes indicating a low level of background signal (Figure 5.6A).  
 
5.7.2 The CACNA1C Channel is not Found Associated with Gαs in Myometrial Cell 
Cultures 
When the protein immunoprecipitated with the CACNA1C N-terminal antibody was 
western blotted using the Gαs antibody there was no banding observed at either 54 or 
46kDa, there was some non-specific banding detected (Figure 5.6A). Indicating that Gαs 
is not found associated with CACNA1C in un-stimulated samples. Following exposure 
to TNF there was no association between the CACNA1C and Gαs evident. Exposure to 
TSA, however, resulted in the association of Gαs and the CACNA1C as evidenced by the 
observation of a 54kDa band (Figure 5.6A). Unlike the KCNMA1 channel there was no 
association found between the CACNA1C and the short Gαs isoform.  The results from 
these co-immunoprecipitations were inconsistent, and the association between Gαs and 
the CACNA1C was only evident in one repeat from the TSA stimulated samples. The 
input band was clear on these blots indicating that the lack of Gαs band in the CACNA1C 
IP lanes was not a consequence of an unsuccessful western blot but rather that Gαs is not 
routinely associated with the CACNA1C in these primary myocytes. There was no 
corresponding bands detected in the IgG IP lanes indicating a low level of background 
signal (Figure 5.6A). 
 
5.7.3 Cav-1 Immunoprecipitations 
It is pertinent to note that in the input lanes on these blots the Cav-1 band is high on the 
blots this, may be due to a failure to dissociate the stable hetero-oligomeric complexes 
which Cav-1 has been show to form (Scherer, Lewis et al. 1997). However, this high 
molecular weight band has not been positively identified for this thesis. In the input lanes 
there was no band detected corresponding to the 22kDa Cav-1 protein, however following 
IP with either the KCNMA1 channel or CACNA1C antibodies and subsequent western 
blotting with the Cav-1 antibody, bands were detected at 22kDa, which corresponds to 
the accepted size of the Cav-1 protein. The following discussions of the association of the 
KCNMA1 and CACNA1C with Cav-1 are based on the presence of the 22kDa bands. 
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Figure 5.6 KCNMA1 N-terminal and CACNA1C N-terminal Associations with Gαs, Cav-1 and β2AR  
Myometrial cell cultures were stimulated with 10ng/ml TNF, 100ng/ml TSA, or left un-stimulated. Protein 
was extracted, immunoprecipitated with KCNMA1 N-terminal, CACNA1C N-terminal and IgG antibodies 
then separated by SDS PAGE and western blotted (n = 3). (A) Representative blots of KCNMA1 N-
terminal, CACNA1C N-terminal and IgG immunoprecipitations western blotted with Gαs antibody (B) 
Representative blots of KCNMA1 N-terminal, CACNA1C N-terminal and IgG immunoprecipitations 
western blotted with Cav-1 antibody. Cav-1 protein was detected in all KCNMA1 N-terminal and 
CACNA1C N-terminal immunoprecipitations. (C) Representative blots of KCNMA1 N-terminal, 
CACNA1C N-terminal and IgG immunoprecipitations western blotted with β2AR antibody. Β2AR protein 
was detected in all KCNMA1 N-terminal and CACNA1C N-terminal immunoprecipitations. IP – 
immunoprecipitation, WB – western blot, n/s – non-specific. 
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5.7.4 The KCNMA1 Channel is Found Associated with Cav-1 in Myometrial Cell 
Cultures 
When the protein immunoprecipitated with the KCNMA1 N-terminal antibody was 
western blotted using the Cav-1 antibody there was a band detected at 22kDa as well as 
some non-specific (n/s) bands (Figure 5.6B). This 22kDa band correlates with the band 
detected by the Cav-1 antibody in Figure 5.3B. The presence of this Cav-1 specific band 
indicates that Cav-1 is associated with the KCNMA1 channel in un-stimulated samples. 
Following exposure to TNF and TSA, the KCNMA1 channel was again found associated 
with Cav-1. There was no corresponding bands detected in the IgG IP lanes indicating a 
low level of background signal (Figure 5.6A). 
 
5.7.5 The CACNA1C Channel is Found Associated with Cav-1 in Myometrial Cell 
Cultures 
When the protein immunoprecipitated with the CACNA1C N-terminal antibody was 
western blotted using the Cav-1 antibody there was a band detected at 22kDa as well as 
some non- specific (n/s) bands (Figure 5.6B). This 22kDa band correlates with the band 
detected by the Cav-1 antibody in Figure 5.3B. The presence of this Cav-1 specific band 
indicates that Cav-1 is associated with the CACNA1C channel in un-stimulated samples. 
Following exposure to TNF and TSA, the CACNA1C channel was again found associated 
with Cav-1. 
 
There was no corresponding bands detected in the IgG IP lanes indicating a low level of 
background signal (Figure 5.6A). 
 
5.7.6 The KCNMA1 Channel is Found Associated with β2-Adrenergic Receptor in 
Myometrial Cell Cultures 
When the protein immunoprecipitated with the KCNMA1 N-terminal antibody was 
western blotted using the β2AR antibody there was a band detected at 85kDa (Figure 
5.6C). This 85kDa band correlates with the band detected by the β2AR antibody in Figure 
5.3C. The presence of this β2AR specific band indicates that β2AR is associated with the 
KCNMA1 channel in un-stimulated samples. Following exposure to TNF and TSA, the 
KCNMA1 channel was again found associated with β2AR. There was no corresponding 
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bands detected in the IgG IP lanes indicating a low level of background signal (Figure 
5.6A). 
 
5.7.7 The CACNA1C Channel is Found Associated with β2-Adrenergic Receptor in 
Myometrial Cell Cultures 
When the protein immunoprecipitated with the CACNA1C N-terminal antibody was 
western blotted using the β2AR antibody there was a band detected at 85kDa (Figure 
5.6C). This 85kDa band correlates with the band detected by the β2AR antibody in Figure 
5.3C. The presence of this β2AR specific band indicates that β2AR is associated with the 
CACNA1C channel in un-stimulated samples. A second band at ~42kDa was also 
observed within the CACNA1C IP lanes. It is possible that the 85kDa band represents a 
β2AR dimer whilst this smaller band represents a β2AR monomer (Angers, Salahpour et 
al. 2000).  Salahpour et al. demonstrated that homodimerisation of the β2AR was a 
prerequisite for cell surface targeting. Therefore the 42kDa putative monomer band may 
indicate that this β2AR is internalised, the implications of this will be explored in the 
discussion. Following exposure to TNF and TSA, the CACNA1C channel was again 
found associated with β2AR and again both the 85kDa and 42kDa were present. There 
was no corresponding bands detected in the IgG IP lanes indicating a low level of 
background signal (Figure 5.6C).  
 
5.7.8 The KCNMA1 N- and C-termini are Associated in Myometrial Cell Cultures 
When the protein immunoprecipitated with the KCNMA1 N-terminal antibody was 
western blotted using the KCNMA1 C-terminal antibody the 138kDa band detected 
(Figure 5.7A) was very faint, and no band was detected at 65kDa. This 138kDa band 
correlates with the band detected by the KCNMA1 C-terminal antibody in Chapter 4 
Figure 4.5. Neither TNF nor TSA stimulation had any effect on this association. 
 
5.7.9 The CACNA1C N-terminus and the KCNMA1 C-terminus are Associated in 
Myometrial Cell Cultures 
When the protein immunoprecipitated with the CACNA1C N-terminal antibody was 
western blotted using the KCNMA1 C-terminal antibody there was a 138kDa band and a 
65kDa band detected in the un-stimulated samples (Figure 5.7A). Both the 138kDa and 
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65kDa bands correlate with the band detected by the KCNMA1 C-terminal antibody in 
Chapter 4 Figure 4.5. The presence of this KCNMA1 specific band indicates that the 
KCNMA1 C-terminal is associated with the CACNA1C N-terminal in un-stimulated 
samples. The presence of the 65kDa band indicates there is an association between the 
CACNA1C and KCNMA1 channels which lack the N-terminal region including the pore. 
The significance of this association between the CACNA1C and non ion conducting 
KCNMA1 channel forms is still to be elucidated.  Neither TNF nor TSA stimulation had 
any effect on this association. 
 
 
Figure 5.7 KCNMA1 N-termial and CACNA1C N-terminal Associations with the KCNMA1 C-
terminal and CACNA1C C-terminal  
Myometrial cell cultures were stimulated with 10ng/ml TNF, 100ng/ml TSA, or left un-stimulated. Protein 
was extracted, immunoprecipitated with KCNMA1 N-terminal, CACNA1C N-terminal and IgG antibodies 
then separated by SDS PAGE and western blotted. (A) Representative blots of KCNMA1 N-terminal, 
CACNA1C N-terminal and IgG immunoprecipitations western blotted with KCNMA1 C-terminal 
antibody. (B) Representative blots of KCNMA1 N-terminal, CACNA1C N-terminal and IgG 
immunoprecipitations western blotted with CACNA1C C-terminal antibody. IP – immunoprecipitation, 
WB – western blot, n/s – non-specific. 
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5.7.10 The CACNA1C N-terminus and the CACNA1C C-terminus are Associated 
in Myometrial Cell Cultures 
When the protein immunoprecipitated with the CACNA1C N-terminal antibody was 
western blotted using the CACNA1C C-terminal antibody there was a band detected in 
the un-stimulated samples (Figure 5.7B). This band appears to lie between the 240kDa 
and 190kDa bands detected in the input lane. As explained above this may either be an 
artefact of the gel or it may represent a CACNA1C which has lost a smaller portion of 
the C-terminal region during the extraction of immunoprecipitation protocols. The 
presence of this CACNA1C specific band indicates that the CACNA1C N-terminal is 
associated with the CACNA1C C-terminal in un-stimulated samples. Neither TNF nor 
TSA stimulation had any effect on this association. Also there is some CACNA1C 
banding in the IgG lanes (Figure 5.5A) which would indicate that there has been some 
non-specific binding during the immunoprecipitation step, which has not be removed by 
the subsequent washing steps. 
 
5.8 Discussion 
5.8.1 Gαs Expression in Myometrial Cell Cultures. 
The results reported herein appear to conflict with previous research which has reported 
repression of Gαs expression both with TNF stimulation and in labouring myometrial 
biopsies, however this previous research either examined the effect of TNF on Gαs 
promoter activity (Chapman, Smyrnias et al. 2005, Webster, Waite et al. 2013) or 
compared the expression of Gαs in non-pregnant, pregnant non-labouring and pregnant 
labouring biopsy samples. As such neither can be directly correlated to the data presented 
here.  
 
There is a paucity of information reported regarding the effect of TSA on the expression 
of Gαs although Europe-Finner et al. reported an up-regulation of Gαs in pregnant 
myometrium and Webster et al.reported that Gαs-luciferase reporter plasmid promoter 
activity is induced by TSA which would suggest that acetylation of the promoter and/ or 
other factors regulating this region are needed for expression (Europe-Finner, Phaneuf et 
al. 1993, Webster, Waite et al. 2013). The data reported above, again appears to conflict 
with these previous studies. However, Webster et al. looked at the effect of TSA on the 
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Gαs promoter and induction of a promoter does not necessarily lead straight to an increase 
in protein. Increasing levels of protein are dependent on increased translation and possibly 
increased retention or decreased removal of the protein as well as an increase in the 
transcription of the mRNA. These other factors may explain the differences seen between 
the effect of TSA on Gαs protein levels and its effect on the promoter. 
 
5.8.2 Cav-1 Expression in Myometrial Cell Cultures. 
TNF has been reported to both repress the expression of Cav-1 in HUVEC cells (Sun, 
Muller et al. 2003) and to have no effect on Cav-1 expression in Bovine aortic endothelial 
cells (Wang, Wang et al. 2008) therefore the effect of TNF on Cav-1 appears to be tissue 
specific. Cav-1 has been reported to gradually increase during pregnancy up to the start 
of labour and then decrease to levels seen in non-pregnant myometrium (Turi, Kiss et al. 
2001).  The data reported herein demonstrate that TNF has no significant effect on the 
expression of Cav-1. In contrast to this observation TSA appears to cause a small but 
statistically significant reduction in expression. This would suggest that within 
myometrial smooth muscle cells TNF is not the driving force for the reduction in Cav-1 
seen at parturition.  
 
Boopathi et al. demonstrated that the transcritption factor GATA-6 is responsible for the 
transcriptional repression of Cav-1 (Boopathi, Gomes et al. 2011) and Caslini et al. 
demonstrated that expression of GATA-6 was restored after TSA treatment (Caslini, 
Capo-chichi et al. 2006). This was shown to be via the increased acetylation of H3 (lys9 
and lys4), H4 (lys5, 8, 12 and 16) and H3 Lysine K4 methylation which led to a more 
open gene structure and hence increased the transcription of GATA-6. The effect of TSA 
could therefore be via its promotion of the up-regulation of GATA-6 and then the 
subsequent repression of Cav-1 expression by GATA-6. The data reported herein is in 
broad agreement with these previous findings. 
 
5.8.3 β2-Adrenergic Receptor Expression in Myometrial Cell Cultures. 
As β2AR agonists have been utilised as tocolytics it would be expected that TNF would 
cause a down regulation in the expression of the β2AR and that is indeed the case in data 
described above.  
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As the β2AR is well documented to support relaxation (Kotlikoff and Kamm 1996, Liu, 
Nwosu et al. 1998, Chanrachakul, Matharoo-Ball et al. 2003, Tanaka, Yamashita et al. 
2003) and TSA has also been shown to cause relaxation (Moynihan, Hehir et al. 2008, 
Webster, Waite et al. 2013) it appears contradictory, therefore, that TSA would down-
regulate the β2AR. In fact there has been a study which indicates that pan-acetylation of 
key histones, namely Histone 3 and Histone 4, mediates an increase in β2AR transcription 
although this research was conducted in murine TH1 and TH2 cells and therefore this may 
be a tissue-specific effect. The findings reported above, however, indicate that in the case 
of cultured myometrial smooth muscle cells TSA causes a significant down regulation of 
the β2AR. Although outside the scope of this thesis, the mechanism by which TSA 
supresses’ β2AR expression is certainly worthy of further investigation. 
 
5.9 Protein-Protein Interactions 
5.9.1 Gαs Interactions 
Gαs is a heterotrimeric G protein subunit that activates AC and hence the cAMP-
dependant pathway, it is activated by G protein-coupled receptors. Upon activation, 
proteins such as Gαs, which are involved in signal transduction, can undergo regulated 
and reversible translocation within the cell, moving between the membrane, cytoplasm or 
nucleus. Upon activation, Gαs has been shown to reversibly detach from the membrane 
and become a soluble protein (Ransnäs, Svoboda et al. 1989, Levis and Bourne 1992, 
Wedegaertner, Bourne et al. 1996). Some G proteins and G protein coupled receptors are 
concentrated within caveolae (Chang, Ying et al. 1994, Chun, Liyanage et al. 1994, 
Lisanti, Scherer et al. 1994, Chakrabarti, Chang et al. 2010). The nature of Gαs protein 
interactions is therefore transient and non-covalent in nature which explains the difficulty 
in getting consistent co-immunoprecipitation repeats for this protein. 
 
Gαs has been shown to stimulate dihydropyridine-sensitive calcium channels, such as the 
CACNA1C (Yatani, Imoto et al. 1988). In these skeletal muscle T tubules, however, the 
CACNA1C displayed notably different kinetics and ion conductance. By using patch 
clamp experiments that study demonstrated addition of exogenous purified Gαs protein 
increased the open probability of these channels. They concluded that this activation of 
the CACNA1C by Gαs was via a second pathway which is distinct from the activation of 
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the CACNA1C by PKA as there was no ATP in the system. However, this study was 
performed on T-tubule calcium channels which had been reconstituted into lipid bilayers 
and so have been removed from their cellular context. This may explain the difference in 
the kinetics and ion conductance observed and may affect the effect of Gαs on the channel. 
 
G proteins have also been shown to have a role in both the stimulatory and inhibitory 
regulation of calcium activated potassium channels such as the KCNMA1 channel 
(Kume, Graziano et al. 1992). This regulation of calcium-activated potassium channels 
was again two-fold as described for the CACNA1C. In one pathway after activation of 
the G-protein coupled receptor, Gαs diffuses along the membrane and activates the ion 
channel. In the second pathway Gαs activates AC which catalyses the conversion of ATP 
to cAMP. In turn cAMP binds to the inhibitor subunit of PKA, inducing a conformational 
change which allows PKA to break away in an active form. PKA then phosphorylates and 
activates the ion channel. 
 
The co-immunoprecipitation blots revealed that in the unstimulated cells there is no 
apparent interaction between Gαs and the CACNA1C, this could be an indication that the 
channel has not been activated at this point. There is evidence of an interaction between 
Gαs and the KCNMA1 channel. After TNF stimulation both channels show interaction 
with Gαs and, although the interaction with the CACNA1C was only seen in one of the 
repeats, this is an indication that Gαs is interacting with these channels. After TSA 
stimulation both the KCNMA1 and the CACNA1C show an interaction with Gαs. As has 
been explained previously, Gαs can both inhibit and stimulate the KCNMA1 channel and 
the switch between these two roles is thought to be regulated by changes in the properties 
of the KCNMA1 channel itself (Kume, Graziano et al. 1992). It is therefore possible that 
the effect of Gαs on the KCNMA1 channel could change depending on which splice 
variant of the KCNMA1 channel it is interacting with. This thesis has already 
demonstrated that TNF and TSA affect the expression of the KCNMA1 channel and its 
splice variants. This could then lead to the hypothesis that under TNF stimulation Gαs 
inhibits the KCNMA1 channel while under TSA stimulation Gαs stimulates the KCNMA1 
channel.  
 
Confirmation of these results and more investigation as to the mechanism by which TSA 
seems to promote Gαs stimulation of the CACNA1C is necessary. TSA is a broad spectrum 
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lysine de-acetylase inhibitor and as such it prevents the removal of lysine acetyl groups 
from a range of cellular proteins. Gαs has been shown to stimulate the CACNA1C via the 
cAMP/PKA pathway, and therefore TSA may promote this interaction via the 
maintenance of acetylation of key proteins in this pathway.  
 
5.9.2 Cav-1 Interactions 
Cav-1 is a scaffolding protein within the caveola complex and as such forms strong stable 
interactions with a variety of proteins (Thomas and Smart 2008). Caveolae, and hence 
cavolin, are thought to have a role in calcium signalling, through their ability to house 
key calcium signalling molecules within caveolae microdomains (Darby, Kwan et al. 
2000, Chanrachakul 2006). This arrangement allows efficient signalling between the ion 
channels and their downstream targets.   
 
The KCNMA1 channel has been shown to interact with Cav-1 via a key caveolin binding 
motif located between amino acids 1007-1015 within the C-terminal region (Alioua, Lu 
et al. 2008). This  association of the KCNMA1 channel with Cav-1 is thought to have a 
negative effect on the gating properties of the KCNMA1 channel, as disruption of 
caveolae  has been shown to increase KCNMA1 current (Lu, Alioua et al. 2006) this has 
been shown to be due a reduction in the surface expression of KCNMA1 when it is 
associated with Cav-1 (Alioua, Lu et al. 2008). However, this reduction in surface 
expression of the KCNMA1 channel may not equate to a removal of the KCNMA1 
channel from either the plasma membrane or caveolae. Studies into the function of 
caveolae have demonstrated that they can open and close this means they can further 
regulate the surface expression of the KCNMA1 channel while it is still housed within 
the caveolae (Oh, McIntosh et al. 1998). Briefly, association of the KCNMA1 channel 
with Cav-1 promotes the localisation of the KCNMA1 channel to caveolae (Brainard, 
Miller et al. 2005). Once housed within the caveolae, surface expression of the KCNMA1 
channel can then be regulated by the opening and closing of the caveolae. Taking this into 
account the observations by Lu et al. that the disruption of caveolae increases KCNMA1 
current, could be explained by the disruption causing the caveolae to open hence 
increasing the surface expression of the KCNMA1 channel and subsequently increasing 
the KCNMA1 current. The observation by Alioua et al. could be interpreted as the 
KCNMA1 channels being housed in closed caveolae. Being able to regulate KCNMA1 
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surface expression in this way would allow rapid changes in KCNMA1 current depending 
on the needs of the cell. 
 
Studies demonstrating the association between the CACNA1C and caveolae has mostly 
been undertaken in cardiac myocytes. In this cell system there appears to be a separation 
between CACNA1C which are involved in excitation-contraction coupling and those 
which are localised to caveolae and have a role in calcium signalling. For example it has 
been shown that caveolae-localised CACNA1C can selectively signal to the nucleus via 
the NFAT transcription factor, when this signalling is blocked there is no effect on the 
contractility of the cell (Makarewich, Correll et al. 2012). Moreover, in airway smooth 
muscle, CACNA1C have also been seen to localise within caveolae however the effect 
of this co-localisation on the contractility of the cell or on the kinetics of the CACNA1C 
gating were not examined (Darby, Kwan et al. 2000). A further study, within intestinal 
smooth muscle, again found CACNA1C to be localised within caveolae, however, unlike 
in cardiac muscle, this localisation is thought to have a role in contraction, relaxation, the 
production of calcium ’sparks’ and possibly calcium waves  (Daniel, El-Yazbi et al. 
2006). This research would indicate that the localisation of CACNA1C within caveolae 
serves different functions within different tissues. However, these three studies were 
undertaken in different tissues and utilised different methodologies so it is difficult to 
determine if the observations are from distinct processes or whether each study has 
highlighted an aspect of a larger more complicated process. Ideally the techniques in each 
individual study should be utilised together in order to get a more complete picture of the 
role of the interaction between Cav-1 and CACNA1C. 
 
Cav-1 forms covalent interactions with other proteins and the presence of these more 
stable protein interactions has meant that the co-immunoprecipitation data is much more 
consistent than was seen with the Gαs co-immunoprecipitation data. As discussed above 
association with Cav-1 was seen to reduce KCNMA1 cell surface expression (Lu, Alioua 
et al. 2006), although this may be via its association with closed caveolae, as Cav-1 has 
also been shown to target the KCNMA1 channel to caveolae (Brainard, Miller et al. 
2005). A second site in the C-terminal region of the KCNMA1 channel has been shown 
to be important for plasma membrane localisation of the channel, this is located between 
amino acids 1117-1123 so it is possible that the KCNMA1 channel could still be 
transported to the membrane but that it is subsequently housed outside of the caveolae. If 
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this is the case then a lack of association with Cav-1 would increase surface expression 
of the KCNMA1 channel, whilst an association with Cav-1 would increase the 
localisation of the KCNMA1 channel to caveolae. As explained previously housing 
KCNMA1 channels within caveolae results in the decreased surface expression on the 
KCNMA1 channels (Alioua, Lu et al. 2008). 
 
It is difficult to interpret the effect of these changes in association between the KCNMA1 
and Cav-1 without further research into the associated changes in contractility, KCNMA1 
protein localisation and KCNMA1 splice variant expression.  
 
There is an association between CACNA1C and Cav-1 after TNF stimulation. This 
association could improve the efficiency of calcium signalling and excitation-contraction 
coupling and hence promote contraction.  
 
5.9.3 β2AR Interactions 
The β2AR is one of a family of adrenergic receptors and this family is among the best 
characterised of the G-protein coupled receptors. The adrenergic receptor family can act 
as scaffolding proteins and in this way they can bring together a variety of proteins and 
the proteins housed in this complex will then determine what cellular effect is seen upon 
activation of the adrenergic receptor (Cotecchia, Stanasila et al. 2012).  
 
The KCNMA1 channel has been shown to be linked to the β2AR and to mediate β2AR 
activated relaxation.  The mediation of relaxation has been shown to both cAMP 
dependent via PKA phosphorylation and cAMP independent possibly through direct 
action by Gαs independent of PKA-mediated phosphorylation (Kume, Graziano et al. 
1992, Scornik, Codina et al. 1993, Kume, Hall et al. 1994, Tanaka, Yamashita et al. 2003, 
Tanaka, Horinouchi et al. 2005).  
 
β2AR agonists have been used to treat preterm labour. The caveat of these drugs, however, 
is that the longer they are administered the less effective they are at stopping contractions. 
This is due to the phenomenon of receptor internalisation which results in desensitization 
(van Geijn, Lenglet et al. 2005) 
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The CACNA1C has also been shown to be regulated by the β2AR, in cardiac myocytes 
(Jurevicius and Fischmeister 1996, Schröder and Herzig 1999). However, unlike the 
KCNMA1 channel this regulation is completely cAMP-dependant via PKA 
phosphorylation (Jurevicius and Fischmeister 1996, Kuschel, Zhou et al. 1999, Schröder 
and Herzig 1999). Direct interaction between the CACNA1C and the β2AR has also been 
reported in the brain, this complex was shown to be housed in the plasma membrane but 
did not associate with Cav-1 or Cav-3 indicating that this complex exists separately from 
caveolae (Davare, Avdonin et al. 2001). The regulation of the CACNA1C by the β2AR 
within rat ventricular myocytes has been shown to be highly localised to the cell 
membrane and the signal did not diffuse through the cytosol (Chen-Izu, Xiao et al. 2000). 
This demonstrates that the β2AR needs to be co-localised with the CACNA1C in order to 
be able to regulate it.   
 
The data shown herein demonstrates that both the KCNMA1 and CACNA1C channels 
associate with the β2AR in un-stimulated cells and following both TNF and TSA 
stimulation. This is a good indication that both channels are regulated by the β2AR under 
these conditions. However neither TNF nor TSA had any detectable effect on the level of 
these associations. 
 
The CACNA1C was also shown to associate with a 42kDa β2AR protein, although the 
level of association was unchanged by the different stimulations. Salahpour et al. 
demonstrated that homodimerisation of the β2AR was a prerequisite for cell surface 
trafficking (Salahpour, Angers et al. 2004). This would then suggest that the 42kDa β2AR 
has either been internalised or retained in the ER. Receptors that fail to reach the plasma 
membrane have been shown to be capable of exerting a dominant negative effect on the 
trafficking of other receptors to the membrane (Lan, Kuravi et al. 2011). It would 
interesting to elucidate if the association between the 42kDa β2AR and the CACNA1C is 
a mechanism by which the CACNA1C can be retained intracellularly or whether this 
localisation is co-incidental due to both proteins being independently retained in the ER. 
The later could putatively occur if the β2AR failed to dimerise and the CACNA1C channel 
expressed the Mk44 +132bp variant which has been shown to result in the C-terminus 
being localised to the ER. 
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5.9.4 Channel Interactions 
The KCNMA1 channel has been shown to undergo proteolytic cleavage and as a result 
the N-terminal localises to the plasma membrane while the C-terminal localises to the 
endoplasmic reticulum (Korovkina, Brainard et al. 2006). The C-terminal can then non-
covalently re-associate with the N-terminal domain following calcium release from the 
sarcoplasmic reticulum. Association of the N- and C-termini results in a decrease in 
calcium and voltage sensitivity of the KCNMA1 channel. This may be a result of 
increased interaction with Cav-1 which is dependent on the C-terminal region (Alioua, 
Lu et al. 2008). The data described herein reveals an association between the KCNMA1 
N- and C-termini which could result in the decreased calcium and voltage sensitivity of 
the KCNMA1 channel which would result in a more contractile phenotype. 
 
As with the KCNMA1 channel the CACNA1C channel has also been shown to undergo 
proteolytic cleavage. Following this cleavage the cleaved CACNA1C C-terminal can 
non-covalently associate with the rest of the channel negatively affecting channel gating. 
The IP data from the CACNA1C N-terminal IP followed by western blotting with the 
CACNA1C C-terminal antibody reveal a 240kDa in the un-stimulated and both a 240 and 
a 190kDa band in the un-stimulated and TNF stimulated groups (Figure 5.7B).  This 
would lead to idea that the 190kDa protein could be formed in an alternative way through 
use of alternative splice variants possibly at splice site L10. These splice variants alter the 
length of the linking loop between IV S2 and IV S4 in the channel. A shorter linking loop, 
which would need to be utilised to form the shorter channel, results in a CACNA1C with 
decreased excitation-contraction coupling and ultimately a less contractile phenotype. 
This would result in a shorter channel containing both the N- and C-terminii as detected 
on the blots.  It would be necessary to sequence this shorter form of the protein to 
determine if the truncation is as a result of differences in the length of the linking loop 
between IV S2 and IV S4 or as a result of the cleavage of the C-terminal domain. 
Folllowing TSA stimulation a single band was seen, this band was between 240 and 
190kDa (Figure 5.7B) and therefore may be representative of the 190kDa proteolytically 
cleaved CACNA1C channel with the C-terminal region non-covalently associated with 
it. 
 
The KCNMA1 C-terminal was also found associated with the CACNA1C N-terminal in 
un-stimulated samples and following exposure to either TNF or TSA (Figure 5.7A). This 
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association was seen both with full length KCNMA1 channel and with the 65kDa 
KCNMA1 channel which lacks the N-terminal domain (Figure 5.7A). As explained above 
the C-terminal domain can be cleaved from the body of the channel and can then non-
covalently re-associate with the N-terminal domain. Therefore the interaction between 
the 65kDa KCNMA1 protein and the CACNA1C may demonstrate that the N- and C-
termini of the KCNMA1 channel are non-covalently associated. This non-covalent 
association can be lost during the immunoprecipitation procedure and hence the results 
show the KCNMA1 C-terminal domain is associated with CACNA1C N-terminal. 
Alternatively, it is possible that the CACNA1C N-terminal is interacting only with this 
C-terminal domain without any link to the N-terminal domain of the KCNMA1 channel. 
 
The CACNA1C C-terminal region was found associated with the KCNMA1 N-terminal 
following exposure to either TNF or TSA (Figure 5.7B). Following TNF stimulation this 
association was between the KCNMA1 N-terminal domain and the 190kDa CACNA1C 
protein which is lacking its C-terminal domain. This isoform of the CACNA1C has four 
to six fold higher ion conductance than the longer 240kDa isoform (Gao, Cuadra et al. 
2001).  Association between the KCNMA1 channel and this 190kDa isoform may permit 
the KCNMA1 channel to respond more rapidly and hence limit the effect of the increased 
ion conductance of the 190kDa CACNA1C. Following TSA stimulation this association 
was between the KCNMA1 N-terminal and a CACNA1C channel between 240 and 
190kDa (Figure 5.7B) and therefore may be representative of the 190kDa proteolytically 
cleaved CACNA1C channel with the C-terminal region non-covalently associated with 
it. 
 
5.10 Conclusion 
Although the KCNMA1 and CACNA1C were seen to associate with each other, Gαs, Cav-
1 and β2AR, it is difficult to determine from the blotting data if this association is 
representative of close proximity to each other on the membrane or if they are housed 
together either in a complex with the β2AR or within caveolae or both. This is a limitation 
of the co-immunoprecipitation technique as it cannot identify simultaneously all the 
proteins within a complex. It also does not provide evidence of direct protein:protein 
interactions. Positive results therefore, may indicate that two proteins interact directly or 
may indicate that they interact via one or more bridging molecules. This could include 
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bridging proteins, nucleic acids (DNA or RNA), or other molecules. To determine the full 
complement of proteins with the putative complexes discussed above it would be 
necessary to carry out triple staining and confocal microscopy analysis, and this is 
something which should be done in the near future. To identify direct interaction between 
the proteins methods like protein affinity chromatography, or affinity blotting could be 
utilised, ion exchange column could then be used to determine the strength of this binding.  
 
In the preceding chapters of this thesis it has been demonstrated that the myometrial cell 
cultures express a range of KCNMA1 channel, CACNA1C and CACNA1G splice 
variants. Alongside, and perhaps as a result of, these different splice variants they also 
have been shown to express a range of different protein isoforms and protein fragments, 
which may be generated as a result of proteolytic cleavage. It has been demonstrated that 
these different protein isoforms and fragments are localised to both the cytoplasm and 
plasma membrane. In addition, it has been demonstrated that the KCNMA1 and 
CACNA1C channels associate with each other as well as Gαs, Cav-1 and β2AR.  
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Chapter 6: Regulation of Transcription 
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6.1 Introduction 
In Chapter three the expression of the KCNMA1, CACNA1C and CACNA1G channels 
was examined to determine if the contractile effect of TNF or the relaxatory effect of TSA 
was mediated via changes in the amount of channels expressed or in the splice variant 
profile of the expressed channels. The results of these studies indicated that in the model 
i.e. in the un-stimulated samples, there were a number of different splice variants being 
expressed by the channels. These included the KCNMA1 Mk44+132bp, Mk44-132bp, 
M2 (exon 11+12), M3 (exon 19), M4 (STREX2) and M5 (exon 29) variants, the 
CACNA1C L4 (exon 8* or Exon 8), L10 (exons 30, 31, 33 and 34 or exons 30, 31, 32 
and 34) and L11 (40, 41, 42 and 43) variants and the CACNA1G T2 (exon 14 deleted),  
T4 (exon 25a), T6 (exon 26) and T7/8 (exon 31A or exon 30B and 31A) variants. Upon 
TNF stimulation, expression of both the KCNMA1 and CACNA1C channel mRNA was 
significantly up-regulated. Moreover, upon TSA stimulation, both channels were 
significantly down-regulated and the splice variant profile of the CACNA1C and 
CACNA1G was significantly altered. Consequently, the next step was to examine how 
these changes in channel expression were regulated at the transcriptional level.  
 
In vivo, DNA is found in complex with histones and other ancillary proteins: this complex 
is termed chromatin. The purpose of chromatin is to package the DNA into a small enough 
volume to fit in the nucleus while protecting the DNA structure and sequence. This 
packaging of the DNA also has a role in controlling gene expression. Heterochromatin is 
a tightly packed form of chromatin which can silence gene transcription. Euchromatin is 
less condensed and contains the majority of actively transcribed genes. 
 
The basic unit of chromatin is the nucleosome, this consists of 147bp of DNA wrapped 
1.65 times round an octamer of histones which contains two copies of each histone 
protein: H2A, H2B, H3 and H4. Within this complex the DNA has 14 contact points with 
the histone octamer (Luger, Mäder et al. 1997), this forms a stable protein:DNA complex. 
Although this is a stable complex it is also dynamic.  
 
These nucleosomes have been shown to impede transcription (Knezetic and Luse 1986, 
Lorch, LaPointe et al. 1987), and so to enable transcription to take place a number of 
modification of this nucleosome complex occur. 
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The histones themselves can undergo modifications including acetylation (Bannister and 
Kouzarides 1996, Greer and Shi 2012), methylation (Rea, Eisenhaber et al. 2000, Fuks, 
Hurd et al. 2003, Fuks, Hurd et al. 2003, Levy, Kuo et al. 2011, Greer and Shi 2012, 
Yang, Guo et al. 2012) and phosphorylation (Hurd, Bannister et al. 2009) all of which 
are laid down in a dynamic fashion and can potentially be inherited during meiosis (Greer 
and Shi 2012).  Histone acetylation is the covalent modification of the epsilon-amino 
group of conserved lysines by histone acetyltransferases. Histone acetylation was first 
observationally linked to transcription by Allfrey et al. (Allfrey, Faulkner et al. 1964). 
Since this early observation a large amount of research has focused on this link between 
acetylation and transcription (Brownell, Zhou et al. 1996, Candau, Zhou et al. 1997, Kuo, 
Zhou et al. 1998) and has strengthened the hypothesis that histone acetylation is an 
important part of transcriptional activation.  Conversely, histone deacetylation, the 
process by which the acetylation is removed from the lysine by histone deacetylases 
(HDACs) has been linked to transcriptional repression (Taunton, Hassig et al. 1996, Yang 
and Seto 2003).  In the de-acetylated state the tail of the histone proteins have a positive 
charge and this promotes interaction with the negatively charged phosphate groups of the 
DNA, when the tail is acetylated the charge changes from positive to neutral and this 
disrupts the histone:DNA interaction. This weaker association has the result of making 
the DNA more accessible to transcription factors (Reinke and Hörz 2003, Zhao, Herrera-
Diaz et al. 2005).   
 
The first step in the initiation of transcription is formation of the preinitiation complex, 
containing Transcription Factor (TF) IIB, TFIID, TFIIE, TFIIF and TFIIH. These 
assemble on the promoter DNA with RNA polymerase II and support the accurate 
initiation of transcription (Nikolov and Burley 1997). Following the formation of this 
complex, further transcription factors are then recruited to the promoter these 
transcription factors bind to DNA in a sequence-specific manner. Once bound to the DNA 
they can either promote or block the action of RNA polymerase II, which controls the 
transcription of the gene, and in this way can enhance or reduce the expression of specific 
genes. These transcription factors can be either constitutive or inducible. Constitutive 
transcription factors are continually expressed, and their expression is not dependent on 
extracellular signals; on the other had inducible transcription factors are synthesised 
within the cell in response to certain stimuli. One such stimuli which can induce nuclear 
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localisation of transcription factors is TNF. This may be the mechanism by which TNF 
regulates the expression of the channels. 
 
Another factor which can affect the transcription of a gene is DNA methylation. This is a 
biochemical process which adds a methyl group to either the fifth carbon atom of cytosine 
nucleotides or the sixth nitrogen atom of adenine nucleotides. In mammals approximately 
60-90% of all CpGs are methylated, the un-methylated CpGs are often clustered in CpG 
islands which are located in the regulatory regions of gene (Deaton and Bird 2011). 
Abnormal methylation of these CpG islands can result in the gene being transcriptionally 
silenced. There are two methods by which methylation can affect transcription, the first 
is by the methyl group physically hampering transcription factor binding. Secondly, 
methylated DNA can be bound by proteins termed, methyl-CpG-binding domain proteins, 
these proteins then recruit other proteins such as histone deacetylases, which then modify 
the histones resulting in the formation of tightly packed heterochromatin which is 
inaccessible to transcription factors. Increased expression of pro-inflammatory cytokines, 
including TNF, have been shown to mediate inflammation-induced DNA methylation 
changes (Hahn, Hahn et al. 2008, Niwa, Tsukamoto et al. 2010, Hur, Niwa et al. 2011, 
Kominsky, Keely et al. 2011, Katsurano, Niwa et al. 2012) and therefore this may be an 
alternative method by which TNF can regulate the transcription of the channels. 
 
Although there has been some research indicating that hormones such as estrogen, 
progesterone (Holdiman, Fergus et al. 2002, Zhu, Eghbali et al. 2005), and insulin 
(Davies, Zhao et al. 2007) can regulate the expression of the KCNMA1, CACNA1C and 
CACNA1G channels or their splice variants, there is very little research into how this 
regulation occurs at the level of chromatin:protein interactions. This is a significant void 
in the understanding of how these channels are regulated and in turn how they regulate 
the contractility of the myometrium. If the aim is to be able to manipulate the expression 
of the channels and their splice variants in order to directly modulate the contractility of 
the myometrium it is vitally important to fill in this void in our understanding of how the 
channels are regulated. 
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6.2 Identification of Transcription Factor Binding Sites 
For each of the channels the region encompassing the promoter regions of the genes, was 
identified and the sequence entered into the TransFac® database (Matys, Kel-Margoulis 
et al. 2006). Transfac® provides data on eukaryotic transcription factors, their 
experimentally proven binding sites and consensus sequences (http://www.gene-
regulation.com/pub/databases.html). Using the TFsearch tool the genomic sequences 
were interrogated to identify putative transcription factor binding sites. From the list of 
transcription factor binding sites identified, a number of transcription factors were 
selected for further analysis (Figure 6.1).  
 
 
Figure 6.1 Schematic Representation of the KCNMA1, CACNA1C and CACNA1G Promoters  
(A) KCNMA1 promoter; (B) CACNA1C promoter and (C) CACNA1G promoter. The transcription start 
site (TSS) is indicated by a black arrow. CpG islands identified within the promoters are represented by the 
grey bar. Transcription factor binding motifs are indicated by vertical bars, green represents SP1 motifs, 
Red indicates MZF1 motifs, Blue indicates CBP motifs, Orange indicates p50 motifs and Yellow indicates 
RelA motifs. 
 
NFκB has been implicated in the regulation of all three channels (Furukawa and Mattson 
1998, Green and Peers 2002, Scragg, Fearon et al. 2005, Cookson, Waite et al. 2015). 
Although, binding sites for RelA, cRel and p50 were identified within the CACNA1G 
promoter, NFκB binding sites were not identified from the genomic sequence of either 
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the KCNMA1 or CACNA1C promoters. However, it was decided to perform ChIPs on 
all three promoters with both RelA and p50 antisera as  the lack of NFκB consensus 
binding site may indicate that within these promoters NFκB is binding to a less well 
described non-canonical motif (Wong, Teixeira et al. 2011).  
 
6.3 Identification of CpG Islands Within the Promoter Regions of 
the Channel Genes 
The region encompassing the promoter regions of the genes, was found to be GC rich. 
The sequence of these regions was entered into the MethPrimer database (Li and Dahiya 
2002) for CpG island prediction. The following parameters were used for CpG island 
prediction: window size was set to 100, so the program will calculate parameters within 
this window, the step was set to 1, the observed-to-expected GC ratio was set to 0.6 and 
the percentage of G plus C was set to 50%. Briefly the program will examine 100bp at 
once, this is termed the window, then it will move along one bp, termed the step, and 
examine 100bp from this location. Within each window the program will calculate the 
observed number of CpGs within the window in comparison to the expected number of 
CpGs. Finally within each window the program will calculate the total number of C and 
G and express this as a percentage of the total number of bp in the window. The formal 
definition of a CpG island is a region with an observed to expected ratio of >60%, 
meaning 60% of the G and C in the sequence are in the form of CpG, and a GC percentage 
>50%, meaning more than 50 of the nucleotides in the window are either C or G. 
 
Within the KCNMA1 promoter a single CpG island encompassing 898bp (653bp 
upstream to 244bp downstream of the TSS) was identified (Figure 6.1A). There were two 
CpG island identified within the CACNA1C promoter sequence: the first encompassing 
480bp (654bp to 175bp upstream of the TSS) and the second encompassing 383bp (141bp 
upstream to 241bp downstream of the TSS; Figure 6.1B). Finally two CpG islands were 
also identified within the CACNA1G promoter sequence: the first encompassing 386bp 
(548bp to 163bp upstream of the TSS) and the second encompassing 342bp (96bp 
upstream to 245bp downstream of the TSS; Figure 6.1C). 
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6.4 ChIP / MeDIP Primer Design and PCR Optimisation. 
Primers were designed to flank each of the CpG Islands predicted in the CACNA1C and 
CACNA1G promoters for use in the ChIP and MeDIP assays. Due to the predicted size 
of the CpG Island in the KCNMA1 promoter, it was decided to design primers sets to 
cover the 5’ region and 3’ region individually. The primer sequences, location and product 
size are listed in Chapter Two Materials and Methods; Table 2.4. 
 
It was not possible to get PCR amplification utilising Taq polymerase for any of the 
promoter region primer pairs (data not shown) and the reason for this could not be 
defined. Therefore this lack of amplification could be due to a combination of factors 
including the GC-rich nature of both the promoter regions and primers and possibly the 
particular batch of Taq used had lower specific activity. However, the same Taq 
polymerase was utilised successfully for the PCR reactions detailed in chapter 3. Due to 
these difficulties, the Herculase II fusion polymerase was trialled. Herculase II fusion 
polymerase is specifically engineered to amplify difficult targets such as GC-rich regions. 
Consequently after optimisation, PCR amplification of the GC-rich regions was possible 
with all the primer sets. 
 
For optimisation an initial annealing temperature of 5°C below the average Tm of the 
primer pair was selected. Then the optimisation parameters suggested by the Herculase II 
fusion polymerase manufacturer were used. Briefly, 0.25μl Herculase II Fusion 
polymerase (note that the manufacturer, Agilent, did not provide a value for the number 
of enzyme units/μl), 0.25μM each primer, 250μM each dNTP. Manufacturers’ guidelines 
suggested DMSO should be trialled at between 0-8% (v/v) of the final concentration. 
Therefore optimisation PCRs were performed with 1%, 4% and 8% (v/v) DMSO. Initially 
the manufacturers’ guidelines regarding PCR cycling conditions were also followed. 
Briefly, these were: 95°C for 2 minutes then 30 cycles of 95°C for 20 seconds, Primer Tm 
less 5°C for 30 seconds, 72°C for 20 seconds then a final extension at 72°C for 3 minutes. 
 
Following the initial steps detailed above, further optimisation reactions were undertaken 
as needed for each of the individual primer sets. These steps included: increasing the 
number of cycles to improve the signal intensity, decreasing the annealing time or altering 
the annealing temperature to improve the specificity of primer binding, increasing the 
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elongation time to decrease the number of low molecular weight non-specific amplicons, 
decreasing the elongation time to decrease the number of high molecular weight non-
specific amplicons and decreasing the amount of input DNA to reducing smearing. The 
specific optimisations undertaken for each primer set is summarised below 
 
For the KCNMA1 3’ primers, PCR amplification was successful with both 1% and 4% 
(v/v) DMSO (Figure 6.2A I). The reaction utilising 4% (v/v) DMSO had fewer non-
specific PCR products and so it was decided to further optimise this reaction. The 
following parameters were altered, the number of cycles was increased to 34, the 
annealing time was decreased to 20 seconds and the elongation increased to 30 seconds. 
These adjustments proved successful and the non-specific PCR products were almost 
eliminated (Figure 6.2A II). 
 
For the KCNMA1 5’ primers, PCR amplification was most successful with 4% (v/v) 
DMSO. However, the specific band was very faint in comparison to non-specific 
amplicons (Figure 6.2B I). Therefore the annealing temperature was reduced by 1°C and 
the other parameters were unchanged. After this modification the specific band had 
brighter intensity but there was a smear on the gel (Figure 6.2B II). This may have been 
a reflection on too great an amount of input DNA, therefore, the input DNA was reduced 
to 1μl to try and eliminate the smearing, while all the other parameters remained the same. 
Reducing the input DNA reduced the smear but significant non-specific amplicons 
remained (Figure 6.2B III). To overcome this two further optimisation protocols were 
tried: firstly the number of cycles was increased to 38; secondly the elongation step was 
increased to 30 seconds. Again all other parameters were unchanged. Increasing the cycle 
number was not effective (Figure 6.2B IV). However, increasing the elongation time 
significantly reduced the non-specific PCR products (Figure 6.2B IV). 
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Figure 6.2 Optimisation of KCNMA1 Promoter ChIP PCRs  
(A) Optimisation of KCNMA1 3’ Primers. PCRs were performed with different concentrations of DMSO 
((v/v) 1%, 4% and 8%) PCRs worked best with 4% (v/v) DMSO (I).  PCRs were repeated with 4% (v/v) 
DMSO, 34 cycles, a 20 second annealing step and a 30 second elongation step; this PCR was successful 
(II). (B) Optimisation of KCNMA1 5’ Primers. PCRs were performed with different concentrations of 
DMSO ((v/v) 1%, 4% and 8%) PCRs worked best with 4% (v/v) DMSO (I). PCRs were repeated with 4% 
(v/v) DMSO and an annealing temperature of 54.6°C (II). These PCRs were obscured by smearing on the 
gel. The previous PCR was repeated but with 1μl DNA (III). This improved the results but there was still 
non-specific bands. The previous PCR was repeated with either 38 cycles or a 30 second elongation step 
(IV). The PCR with a 30 second elongation step was successful. 
 
For the CACNA1C CpG Island 1 primers, PCR amplification was successful with 4% 
DMSO, however there was smearing and non-specific banding also present (Figure 6.3A 
I). As with the KCNMA1 5’ primers, a number of different optimisation steps were 
employed.  
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Figure 6.3 Optimisation of CACNA1C Promoter ChIP PCRs  
(A) Optimisation of CACNA1C CpG 1 Primers. PCRs were performed with different concentrations of 
DMSO ((v/v) 1%, 4% and 8%) PCRs worked best with 4% (v/v) DMSO (I).  PCRs were repeated with 4% 
(v/v) DMSO and with either a 10 second or a 30 second elongation step (II). The PCRs were improved by 
the 30 second elongation step. This PCR was repeated a three different annealing temperatures; 54.9°C, 
55.9°C and 56.9°C (III). The PCR was successful at 54.9°C. (B) Optimisation of CACNA1C CpG 2 
Primers. PCRs were performed with different concentrations of DMSO ((v/v) 1%, 4% and 8%) PCRs 
worked best with 4% (v/v) DMSO (I). PCRs were repeated with 4% (v/v) DMSO and 38 cycles (II), this 
PCR was successful.  
 
Briefly, these included: reducing the DNA input to 1μl alongside either increasing the 
elongation to 30 seconds or decreasing the elongation to 20 seconds (Figure 6.3A II) and 
optimisation of the annealing temperature (Figure 6.3A III). The lowest annealing 
temperature (54.9°C) produced a band of the correct size although this was faint it was 
un-obscured by non-specific banding (Figure 6.3A III). 
 
For the CACNA1C CpG Island 2 primers, PCR amplification was successful with 4% 
DMSO (Figure 6.3B I), however this band was faint. The cycle number was increased to 
38 to improve the intensity of this band. This produced a clear band of the correct size 
without either smearing or non-specific bands (Figure 6.3B II). 
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For the CACNA1G CpG Island 1 primers, PCR amplification was successful with 1% 
DMSO, therefore no further optimisation was required (Figure 6.4A). 
 
For the CACNA1G CpG Island 2 primers, PCR amplification was successful with 1% 
DMSO, therefore no further optimisation was required (Figure 6.4B). 
 
 
Figure 6.4 Optimisation of CACNA1G Promoter ChIP PCRs  
(A) Optimisation of CACNA1G CpG 1 Primers. PCRs were performed with different concentrations of 
DMSO ((v/v) 1%, 4% and 8%) PCRs worked with 1% (v/v) DMSO. (B) Optimisation of CACNA1G CpG 
2 Primers. PCRs were performed with different concentrations of DMSO ((v/v) 1%, 4% and 8%) PCRs 
worked best with 1% (v/v) DMSO. 
 
6.5 Experimental Results 
6.5.1 The ChIP Assay 
In order to study the transcription of the KCNMA1, CACNA1C and CACNA1G channels 
the ChIP assay was used. From the TransFac analysis of the promoter regions a number 
of transcription factors were selected for study utilising the ChIP assay. These were: CBP, 
MZF, SP1, H3, p50 and RelA. Briefly, six T-75 flasks of primary myocytes were grown 
to 100% confluence. Two of these flasks were then stimulated with 10 ng/ml TNF for 1 
h, two were stimulated with 100 ng/ml TSA for 24hrs and two were left unstimulated. 
The ChIP assay was then carried out as detailed in Chapter 2 Materials and Methods.  
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6.5.2 The MeDIP Assay 
The MeDIP assay is a modified version of the ChIP assay, instead of isolating chromatin 
which is bound by specific transcription factors, the MeDIP assay selectively isolates 
methylated genomic DNA sequences. It does this by utilising an antibody specific for 5-
methylcytosine. Six T75 flasks of primary myocytes were grown to 100% confluence. 
Two of these flasks were then stimulated with 10ng/ml TNF for one hour, two were 
stimulated with 100ng/ml TSA for 24 hours and two were left unstimulated. The MeDIP 
assay was then carried out using the EpiQuik™ Methylated DNA Immunoprecipitation 
Kit as detailed in Chapter 2 Materials and Methods section 2.8  
 
6.6 Analysis of Data 
After manual band quantification of the PCR images, analysis was performed as follows: 
the value ascribed to nonspecific binding of IgG was subtracted from the specific binding 
value. That value was then expressed as a percentage of the input fraction with the input 
fraction intensity being taken as 100%. All experiments were repeated three times and the 
results are expressed as the mean ± SD. Each repeat represented a single myometrial 
biopsy. All data analyses were conducted on GraphPad Prism version 6, where a one way 
ANOVA with Dunett’s post-test was performed to compare the individual stimulations 
against the unstimulated control; p˂0.05 was considered statistically significant.  
 
6.6.2 DNA Shearing 
The importance of correctly shearing the DNA for use in the ChIP and MeDIP assays 
cannot be overstated. Over shearing the DNA will result in very small promoter fragments 
which can be detrimental to the downstream PCR analysis. This phenomenon occurs 
because very small fragments (<100bp) can reduce primer recognition and hence reduce 
PCR efficiency. Moreover, over-shearing the DNA can damage the transcription factor 
proteins and hence reduce the antibody binding efficiency thus compromising the 
immunoprecipitation. Under-shearing the DNA is also problematic. This produces large 
fragments which can result in the immunoprecipitation of chromatin distant from the 
transcription factor binding site and hence increase the risk of false positive results. After 
sonication, a portion of the chromatin from each sample was analysed by AGE to 
determine all the samples had fragments within the correct range (200 – 1000bp; Figure 
6.5). 
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6.6.3 ChIP Controls 
A Histone H3 antibody was used as a control for the ChIP assay as the amount of H3 
associated with a promoter should be relatively consistent across all stimulations. 
Significant variations in the normalised H3 enrichment would indicate significantly 
different cell numbers in the different ChIP samples. Significant differences in cell 
numbers may skew the results of the ChIP assay. Following the ChIP assay, when the 
promoter primer PCRs were subsequently performed on the H3 immunoprecipitated 
chromatin, the results were inconsistent (Figure 6.5B). Therefore, no further analysis of 
these was undertaken 
 
 
Figure 6.5 ChIP Assay Controls 
(A) Ultrasonic Cavitation of Myometrial Cell DNA. Formaldehyde fixed nuclei isolated during the ChIP 
and MeDIP assays were sonicated on ice for 3 x 10 second intervals. The sheared DNA was visualised on 
a 1.5% (w/v) agarose gel and calibrated against a LowRanger ladder (M). The DNA shears were most 
intense between 500 and 200bp. (B) Histone H3 Conrol ChIP Immunoprecipitation – Repesentative gels. 
ChIP chromatin was immunoprecipitated using Histone H3 antisera or non-specific rabbit IgG, the resulting 
chromatin was then amplified using the channel promoter specific primers. 
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6.6.4 Validation of ChIP Protocol 
The difficulties in generating consistent results which were experienced during the ChIP 
and MeDIP assays could be due to a number of factors. Firstly the ChIP and MeDIP assay 
themselves may have been poorly executed and hence the inconsistency between the 
repeats. Secondly, the high GC content of the promoter regions under study may be 
affecting the efficiency and hence the consistency of the PCR reactions. ChIP has been 
routinely carried out within the research group utilising RelA antiserum and a robust 
positive control for this ChIP is available. Therefore, this positive control PCR was 
performed utilising the same ChIP chromatin immunoprecipitated with RelA as was used 
for the PCRs above. This will reveal if the ChIP assay has worked as expected. The 
positive control IκBα PCR worked well with minimal IgG signal and consistent strong 
input and specific signal intensity (Figure 6.10). This indicates that the problems 
experienced are likely due to the GC rich nature of the promoter regions. 
 
 
Figure 6.6 IκBα Positive Control ChIP PCR  
ChIP chromatin was immunoprecipitated using RelA or non-specific rabbit IgG, the resulting chromatin 
was then amplified using primers specific to the IκBα promoter. The IgG signal intensity is low, indicating 
that there is little non-specific banding. There is a low level of Rel A binding in the un-stimulated sample, 
TNF results in an increase in the signal intensity for RelA binding and TSA results in the loss of RelA 
binding. These results indicate that the ChIP assay is working correctly. 
 
6.7 Transcription Factor Binding  
Despite the optimisation of the promoter primer PCRs described above the ChIP PCRs 
were repeatedly inconsistent, displaying a high degree of variability in the input, IgG and 
specific signal intensities. This made analysis difficult and any meaningful interpretation 
of the analysis impossible. A high level of IgG binding was observed in number of the 
ChIP reactions (Figure 6.6A I, B I and 6.8 A 1). The intensity of the IgG band is a measure 
of the level of non-specific binding within the specific IP reaction. Therefore, the intensity 
of the IgG bands observed in the figures listed above, would suggest that there is a high 
level of non-specific binding in these ChIP reactions. The IgG samples underwent the 
same PCR amplification as the specific IP samples and, as stated above, also suffered 
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from the same inconsistencies. It is therefore, possible that these IgG bands do not 
accurately reflect the level of background signal. Therefore, figures are only shown for 
gels were the intensity of the specific band is greater than that for the IgG and only simple 
observations from the ChIP PCRs are discussed below.  
 
6.7.1 The KCNMA1 Promoter 
6.7.1.1 The KCNMA1 Promoter 3’ Region 
In the un-stimulated sample SP1, CBP. MZF (Figure 6.7 A I) and RelA (Figure 6.7 A 
II) were observed to occupy this region of the promoter. Following exposure to TNF, 
the binding observed in this region of the promoter was unchanged (Figure 6.7 A I and 
II). However, following exposure to TSA no binding was observed for MZF (Figure 6.7 
A I) or RelA (Figure 6.7 A II) on the 3’ end of the promoter. 
 
 
Figure 6.7 KCNMA1 Promoter ChIP PCRs - Representative Gels 
ChIP chromatin was immunoprecipitated using CBP, MZF, SP1 (I), p50, RelA (II) or non-specific rabbit 
IgG, the resulting chromatin was then amplified using either the KCNMA1 channel 3’ promoter specific 
primers (A) or the KCNMA1 channel 5’ promoter specific primers (B). The IgG signal intensities varied 
greatly between repeats and between the different PCRs. Specific signal within the IP lane also varied 
greatly. No further analysis was undertaken. 
 
6.7.1.1 The KCNMA1 Promoter 5’ Region 
In the un-stimulated sample SP1 CBP, MZF (Figure 6.7 B I) and p50 (Figure 6.7 B II) 
were observed to occupy this region of the promoter. Following exposure to either TNF 
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or TSA, the binding observed in this region of the promoter was visually decreased 
(Figure 6.7 B I and II).  
 
6.7.2 The CACNA1C Calcium Channel Promoter 
6.7.2.1 The CACNA1C Promoter CpG1 Region 
In the un-stimulated sample SP1 CBP, and MZF were observed to occupy this region of 
the promoter (Figure 6.8 A). Binding was not observed for either p50 or RelA, these PCRs 
also had high levels of IgG signal. Exposure to either TNF or TSA did not appear to affect 
the binding of SP1, CBP or MZF (Figure 6.8 A). Exposure to TSA did result in the 
observation of RelA and p50 binding to this region of the promoter, however these PCRs 
also had high levels of IgG signal and so little confidence can be placed in the specificity 
of the RelA or p50 bands. 
 
 
Figure 6.8 CACNA1C Promoter ChIP PCRs - Representative Gels 
ChIP chromatin was immunoprecipitated using CBP, MZF, SP1, p50, RelA or non-specific rabbit IgG, the 
resulting chromatin was then amplified using either the CACNA1C CpG1  promoter specific primers (A) 
or the CACNA1C CpG2 promoter specific primers (B). The IgG signal intensities varied greatly between 
repeats and between the different PCRs. Specific signal within the IP lane also varied greatly. No further 
analysis was undertaken. 
 
6.7.2.2 The CACNA1C Promoter CpG2 Region 
In the un-stimulated sample SP1 CBP, and MZF were observed to occupy this region of 
the promoter, intense IgG was also observed in these ChIPs. Unlike the CACNA1C CpG1 
region binding was also observed for RelA (Figure 6.7 B). Exposure to either TNF or 
TSA did not appear to affect the binding of SP1, CBP or MZF, however, these ChIPs 
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again showed a high level of IgG signal. Exposure to TSA did result in the observation 
of p50 binding to this region of the promoter (Figure 6.7 B). 
 
6.7.3 The CACNA1G Calcium Channel Promoter 
6.7.3.1 The CACNA1G Promoter CpG1 Region 
In the un-stimulated sample SP1 CBP, MZF and RelA were observed to occupy this 
region of the promoter (Figure 6.9 A I and II). Following exposure to TNF, only CBP and 
RelA binding were observed bound to this region of the promoter (Figure 6.9 A I and II). 
Following exposure to TSA the promoter was seen to be bound by SP1, CBP, MZF and 
RelA as seen in the un-stimulated samples but in addition p50 was also observed binding 
to this region of the promoter. However all TSA stimulated ChIPs for SP1, CBP and MZF 
also displayed high intensity IgG signals. 
 
 
Figure 6.9 CACNA1G Promoter ChIP PCRs – Representative Gels.   
ChIP chromatin was immunoprecipitated using CBP, MZF, SP1 (I), p50, RelA (II) or non-specific rabbit 
IgG, the resulting chromatin was then amplified using either the CACNA1C CpG1  promoter specific 
primers (A) or the CACNA1C CpG2 promoter specific primers (B). The IgG signal intensities varied 
greatly between repeats and between the different PCRs. Specific signal within the IP lane also varied 
greatly. No further analysis was undertaken. 
 
6.7.3.2 The CACNA1G Promoter CpG2 Region 
In the un-stimulated sample SP1 CBP, MZF were observed to occupy this region of the 
promoter, however, these ChIPs also displayed high intensity IgG signals. RelA was also 
seen to occupy this region of the promoter (Figure 6.8 B). Unlike the CACNA1G CpG1 
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region, exposure to either TNF or TSA had no visual effect on the observed transcription 
factor binding in this region (Figure 6.8 B). 
 
6.8 Methylation of the Channel Promoters 
As with the ChIP assay, the MeDIP assay PCRs were again repeatedly inconsistent, 
displaying a high degree of variability in the input, IgG and specific signal intensities. 
This made analysis difficult and any meaningful interpretation of the analysis impossible. 
Therefore, only simple observations from the MeDIP PCRs are discussed below.  
 
There was some methylation observed on the 3’ KCNMA1 promoter region in the un-
stimulated and TNF stimulated samples (Figure 6.9). However, continual high 
background precluded any meaningful analysis. No methylation was observed following 
exposure to TSA (Figure 6.9).  
 
Some methylation of the CACNA1C CpG 2 promoter region was evident in the un-
stimulated samples. This methylation was also evident following both TNF and TSA 
stimulation (Figure 6.9)  
 
Some methylation of the CACNA1G CpG 2 promoter region was evident in the un-
stimulated samples. This methylation was also evident following both TNF and TSA 
stimulation (Figure 6.9) 
 
 
 
Figure 6.10 KCNMA1, CACNA1C and CACNA1G Promoter MeDIP PCRs  
MeDIP chromatin was immunoprecipitated using 5-Methyl Cytosine antisera or non-specific rabbit IgG, 
the resulting chromatin was then amplified using the channel promoter specific primers. The IgG signal 
intensities varied greatly between repeats and between the different PCRs. Specific signal within the IP 
lane also varied greatly. No further analysis was undertaken. 
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6.10 Discussion 
There were confounding factors when it came to interpreting the results of the ChIP and 
MeDIP assays. Firstly, the promoter regions of the three channels were GC-rich making 
PCR optimisation difficult. Regions of DNA with high GC content are more stable than 
regions with low GC content. These regions have a tendency to form complex secondary 
structures meaning that they are more resistant to melting. In addition to this, the primers 
designed for GC-rich regions are more likely to form self- or cross-dimers and can also 
form stem-loop structures which then impedes the progress of the DNA polymerase. This 
means that there can be a high proportion of incomplete DNA templates formed during 
the PCR reaction. To overcome these problems, DMSO was used in the PCR reactions as 
it disrupts the base pairing, reducing secondary structure and making the DNA more labile 
for heat denaturation, DMSO also facilitates primer annealing and hence improves 
amplification. 
 
Secondly, even after optimisation of the PCR, the results were repeatedly inconsistent, 
with the same reaction mix and times producing clear results in one experiment and poor 
results in a second experiment. GC-rich regions are not only more stable they are also 
less specific, meaning they are more prone to mis-priming with other GC-rich regions; 
this leads to inconsistent results. The only option to overcome this was to re-design the 
primers so they were less GC-rich. This, however, was not an option due to the constraints 
of the ChIP assay. ChIP primers have to be designed within the promoter region in order 
to be able to interpret the results effectively, and the promoter regions in question are GC-
rich. 
 
Finally, the myometrial cell cultures were not cell cycle synchronised prior to the ChIP 
assay. The principle behind cell synchronisation is to ensure all the cells in culture are at 
the same phase in the cell cycle; the assumption is then made that synchronised cells will 
all respond identically to stimuli. The decision was taken not to synchronise the cells for 
the following reason. Progression through the cell cycle has been shown to be regulated 
by both potassium and calcium channels. Potassium channels are responsible for 
hyperpolarising the plasma membrane, which is necessary for the cells to move from G1 
to S (Wonderlin and Strobl 1996, Ouadid-Ahidouch and Ahidouch 2013). Calcium 
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channels are thought to provide transient signals at checkpoints within the cell cycle 
which are necessary for the cell to continue cycling (Whitaker 2006).  
 
Serum starvation which is routinely used to synchronise cells has been shown to have an 
effect on the expression of the KCNMA1, CACNA1C and CACNA1G channels. It causes 
an up regulation of both the KCNMA1 and CACNA1C and a down regulation of the 
CACNA1G (Woodfork, Wonderlin et al. 1995, Panner, Cribbs et al. 2005, Patel, Clunn 
et al. 2005). These changes in regulation of transcription of the channels may obscure 
changes in regulation due to TNF and TSA.  Instead of synchronising the cells the 
decision was taken to grow the cell cultures to complete confluence as within vascular 
tissue, smooth muscle cells have been shown to switch from a proliferative to a contractile 
phenotype (Charron, Nili et al. 2006) upon reaching confluence. This has primarily been 
studied in vascular smooth muscle cells and in these cells this switch in phenotype is 
accompanied by changes in the expression of both potassium and calcium channels. By 
growing the cells until they were confluent in the culture flasks the majority of cells 
should have moved out of the proliferative phenotype into the contractile phenotype and 
hence any changes in transcriptional regulation would be more reflective of this 
contractile phenotype and not due to the cells being in different phases of the cell cycle. 
 
6.11 Conclusion 
Unfortunately due to the difficulties encountered while carrying out the ChIP experiments 
on the channel promoters, it has not been possible to reach any conclusion regarding the 
regulation of the transcription of any of the channels. Further work is needed to 
circumvent these issues in order to be able to generate consistent results which can then 
be analysed and interpreted. It was decided that the focus should now switch to the 
examining putative role of the KCNMA1 channel within the nucleus. The transcription 
factor CCAT has been shown to be generated from the C-terminal tail of the CACNA1C 
channel protein (Gomez-Ospina, Tsuruta et al. 2006), therefore, the nuclear localisation 
of KCNMA1 observed in Chapter 3 Figure 3.1 D I and Chapter 4 Figure 4.10 may indicate 
that the C-terminal of KCNMA1 channel may also function as a transcription factor. 
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Chapter 7: ChIP Sequencing 
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7.1 Introduction 
Immunocytochemistry staining of the primary myocyte cultures and western blotting of 
both the soluble nuclear and chromatin bound protein fractions revealed nuclear 
localisation of the KCNMA1 channel. In order to determine if this nuclear-localised 
KCNMA1 protein bound to DNA and hence had a role in the regulation of transcription 
it was decided to undertake a proof of concept study by utilising the ChIP assay followed 
by DNA sequencing (ChIP-seq). This approach was decided upon as there was no 
information regarding what genes the KCNMA1 protein may be associated with and 
therefore there were no known targets for standard PCR analysis of the ChIP DNA. The 
advantage of using ChIP-seq as opposed to the conventional PCR or ChIP-on-chip 
approaches is that ChIP-seq sequences all the DNA found to be associated with the 
KCNMA1 protein, these sequences can then be aligned with the genome and 
subsequently with individual genes. In this way it is possible to reveal the full complement 
of KCNMA1 protein:DNA associations within the nucleus. ChIP-seq also gives improved 
signal-to-noise ratio, is able to detect more peaks and the detected peaks are narrower in 
comparison ChIP-on-chip (Ho, Bishop et al. 2011). 
 
This putative dual role of the KCNMA1 protein as an ion channel and a transcription 
factor, although novel for the KCNMA1 protein, has been reported previously for the 
CACNA1C protein. In this channel the C-terminus has been shown to enter the nucleus 
and regulate gene transcription (Gomez-Ospina, Tsuruta et al. 2006). 
 
The CACNA1C transcription factor, termed CCAT, is generated from the C-terminal tail 
of the CACNA1C calcium channel protein and its entry into the nucleus is negatively 
regulated by the electrical activity of the cell. CCAT can also bind to the remainder of the 
channel protein reducing calcium influx through the channel. In this way it is similar to 
the potassium channel binding protein Kchip/DREAM. These proteins interact with Kv 
K+ channels increasing potassium efflux (Bähring, Dannenberg et al. 2001) and also act 
as transcriptional repressors (Venn, Haynes et al. 2008). The production of the CCAT 
fragment was not found to be a regulated process. However its nuclear localisation and 
subsequent transcriptional activity was found to be regulated by intracellular calcium 
levels; with a reduction in intracellular calcium promoting nuclear localisation and an 
increase repressing nuclear localisation. Once within the nucleus, CCAT was found to 
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up-regulate a number of genes including gap junction membrane channel protein beta 5 
and EGR-1, it also down-regulated a number of genes such as the transcription factor 
GATA6 and the potassium intermediate/small conductance calcium activated channel 
Kcnn3 (Gomez-Ospina, Tsuruta et al. 2006). Further research has demonstrated that the 
CCAT transcription factor is generated from a promoter within the coding region of the 
CACNA1C gene (Gomez-Ospina, Panagiotakos et al. 2013). This internal promoter 
drives the expression of exons 46 and 47 independently, however, they also demonstrated 
that CCAT and the CACNA1C protein are expressed in a complementary fashion in the 
developing brain this would suggest that there is still a link between the expression of 
these two proteins. The CCAT fragment is approximately 75kDa in size, the size of the 
KCNMA1 protein localised to the nucleus is between approximately 65kDa and 138kDa, 
the smaller of these is comparable with CCAT. 
 
As explained above ChIP-seq is a powerful tool used to map global DNA binding sites 
for any protein of interest. The workflow for ChIP-seq firstly involves characterising the 
antibody to be used, then using the ChIP assay to selectively enrich for DNA sequences 
bound to a particular protein. Oligonucleotide adaptors are then added to the fragments 
of DNA isolated in the ChIP assay to enable these fragments to be sequenced using 
parallel sequencing. Finally, the ChIP fragments are sequenced, this involves size 
selection for fragments that are approximately 300bp long. These fragments are then 
sequenced simultaneously using a genome sequencer. In this study, cluster amplification 
was utilised, this involves creating clusters of approximately 1000 clonal copies of each 
of the adapter ligated ChIP DNA fragments on a solid flow cell substrate. This then 
produces a high density array of clusters on the flow cell surface which is then sequenced 
by a genome analysing program. Each cluster is sequenced in parallel base by base during 
each read using novel fluorescently labelled reversible terminator nucleotides. This data 
is then collect as .fastq files which can then be aligned to the genome and individual genes 
identified. 
 
Characterisation of the antibody to be used is important as the quality of a ChIP 
experiment and hence the downstream ChIP-seq is governed by the specificity of the 
antibody and the degree of enrichment achieved in the immunoprecipitation. The 
ENCODE and modENCODE consortia recommend using a primary and secondary test 
to characterise each monoclonal antibody (Landt, Marinov et al. 2012). The primary tests 
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recommended are either a western blot or immunofluorescence staining. These will 
provide information on nuclear localisation, cross-reactivity and any isoforms detected 
by the antibody. The secondary tests are then, factor “knockdown”, ChIP using antibodies 
against a different epitope or a different member of a complex, immunoprecipitation using 
epitope tagged constructs or binding site motif analysis. These tests ensure the antibody 
is suitable for use in the ChIP assay and add confidence to the data obtained from ChIP-
seq. 
 
The sensitivity of the ChIP-seq is dependent on a number of factors including, the depth 
of the sequencing run, the library complexity and the distribution of the target protein. 
The depth of the sequencing run is the number of mapped sequence tags, for example a 
‘lane’ can generate 200 million reads and so if 20 libraries are loaded it can generate 
10million reads per library. The ENCODE and modENCODE consortia recommend a 
minimum of 20million mapped reads per sample in order to have confidence in the data 
(Landt, Marinov et al. 2012). Library complexity, the amount of unique DNA molecules 
in the sample also affects the sensitivity of ChIP-seq, this can be affected by both the 
genome being studied and the amount of DNA recovered from the ChIP assay. Finally 
the distribution of the target protein; this will depend on what the protein of interest is. 
Transcription factors tend to be “point source” factors which produce localised sharp 
peaks, these are easier detected and as a result the ChIP-seq is more sensitive (Bailey, 
Krajewski et al. 2013).  
 
Once the .fastq files are generated it is then necessary to utilise NGS analysis software to 
align the reads to the genome, perform peak calling to identify regions of ChIP 
enrichment, and if possible to identify DNA binding site motifs. In this study Galaxy 
(https://usegalaxy.org) an open access web based platform was used for NGS analysis 
(Giardine, Riemer et al. 2005, Blankenberg D, Von Kuster G et al. 2010, Goecks, 
Nekrutenko et al. 2010). Within this platform Bowtie for Illumina was used to align the 
reads to the genome, this uses a Burrows-Wheeler transformation to create a permanent, 
reusable index of the genome. Greater than 80% of the reads should be mapped otherwise 
this indicates that there is an issue with the sequencing data. Peak calling uses algorithms 
to identify regions which have more reads than the background in this study the SCIER 
algorithm was used (Zang, Schones et al. 2009). Finally, motif identification was 
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undertaken, this was done using only the highest confidence peaks and the Panoptic Motif 
Search Tool (Dinh and Rajasekaran 2013). 
 
7.2 Antibody Characterisation 
As this was a proof-of-concept study it was decided that it would be best use one of the 
two antibodies which had been used previously during immunocytochemistry and 
Western Blotting. The ENCODE and modENCODE consortia recommend utilising a two 
stage antibody characterisation were the primary test can be a western blot, as these two 
antibodies have been used in western blots already this was utilised as the primary test. 
The C-terminal antibody gave much cleaner western blots which revealed nuclear 
localisation (Chapter 4 Figures 4.5 and 4.9A), no apparent cross reactivity and only two 
isoforms of the KCNMA1 protein (138kDa and 65kDa) and therefore this antibody was 
selected. It is not possible at this stage to determine conclusively if either the 138kDa or 
the 65kDa KCNMA1C proteins are used to generate this putative transcription factor. 
However, the protein detected within the chromatin bound nuclear fraction in chapter 4 
Figure 1.10B was larger than 65kDa so it is more probable that it is generated from the 
138kDa KCNMA1 protein. A second possibility is that, like CCAT, the putative 
transcription factor is transcribed from an internal promoter. No secondary test was 
undertaken at this stage but this will need to be done prior to any further experimentation 
should the KCNMA1 protein be shown to act as a transcription factor.  
 
7.3 The ChIP Assay 
In order to study the putative transcription factor activity of the KCNMA1 channel the 
ChIP assay was used. Briefly, six T-75 flasks of primary myocytes were grown to 100% 
confluence these were left unstimulated. The ChIP assay was carried out as detailed in 
chapter 2 Material and Methods Section 2.7. The samples included three repeats each of 
input and KCNMA1 immuoprecipitated chromatin. It was not possible to carry out a 
control PCR to determine if the ChIP had been successful - as stated previously this is a 
novel putative transcription factor and therefore there is no known target to serve as a 
positive control. After quantification of the ChIP chromatin it was apparent that there was 
insufficient chromatin for use in the sequencing reaction (Table 7.1). To circumvent this 
issue whole genome amplification was carried out, as detailed in chapter 2: Materials and 
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Methods Section 2.10.1.1, on the ChIP chromatin this gave sufficient DNA for ChIP 
sequencing (Table 7.2).  
 
Table 7.1 Quantification of ChIP Chromatin 
Sample Input (total) KCNMA1 IP (total) 
Rpt 1 4.0ng/ul (180ng) 4.5ng/ul (202ng) 
Rpt 2 4.5ng/ul (202ng) 2.0 ng/ul (90ng) 
Rpt 3 1.0ng/ul (45ng) 2.0 ng/ul (90ng) 
 
A portion of the chromatin was analysed by 2% AGE in order to determine if the 
fragments were in the correct size range (100-500bp; Figure 7.1). Figure 7.1 shows the 
majority chromatin fragments are between 100 – 200bp with the smear extending up to a 
maximum of 500bp. 
Table 7.2 Quantification of ChIP Chromatin Following Whole Genome Amplification 
Sample A260/A280 A260/A230 ng/μl Total ng  
in 25μl 
Input R1 1.793 2.364 130 3,250 
KCNMA1 IP R1 1.607 1.216 113 2,825 
Input R2 1.833 2.276 165 4,125 
KCNMA1 R2 1.683 2.156 173 4,325 
Input R3 1.724 2.174 125 3,125 
KCNMA1 R3 1.811 2.030 168 4,200 
 
 
Figure 7.1 Ultrasonic Cavitation of ChIP DNA - Representative Gels  
Formaldehyde fixed nuclei isolated during the ChIP assay were sonicated on ice for 3 x 10 second intervals. 
The sheared DNA was visualised on a 1.5% (w/v) agarose gel and calibrated against a LowRanger ladder 
(M). The DNA shears were most intense between 200 and 100bp with a smear extending up to 500bp. 
 
7.4 ChIP Sequencing 
ChIP sequencing was conducted by Dr Paul Heath, SITraN. The first step in the process 
was library preparation, this was initially undertaken using the Kapa Biosystems Library 
preparation Kit (Kapa Biosystems KR0426), however, after starting it was discovered 
that the required adapters were not included in the kit. It was therefore necessary to switch 
to the NEB Next Ultra DNA library preparation kit Multiplex Oligos for Illumina (Index 
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Primers Set 1; New England Biolabs E7370) and the library preparation was completed 
with this kit. Although the ChIP samples have a range of fragment sizes, this library 
preparation preferentially selects fragments of ~300bp and in this way, the library loaded 
onto the flow cells consists of approximately equal fragment sizes.  All the prepared 
libraries where then loaded onto lane five of the flow cells at a concentration of 10pM 
and onto lane six of the flow cell at a concentration of 8pM. The library samples were 
prepared and then sequenced as paired-end reads. This means that the sequence is read 
from each end of the molecule. Paired-end reads, in addition to knowing the length of the 
library fragments, gives one sufficient information to then map the reads to a reference 
genome. Table 7.3 details the labels for the samples on the Illumina HiScan SQ system 
and how these relate to the ChIP samples (Table 7.3). 
 
Table 7. 3 Sample Labels for ChIP-seq 
Sample ChIPseq Label Information 
Input Chromatin 
Repeat 1 
Rpt1-input CGATGT L005 R1 001 Paired end reads 
loaded on lane 5 Rpt1-input CGATGT L005 R2 001 
Rpt1-input CGATGT L006 R1 001 Paired end reads 
loaded on lane 6 Rpt1-input CGATGT L006 R2 001 
KCNMA1 IP 
Chromatin Repeat 1 
Rpt1-KCNMA1 TGACCA L005 R1 001 Paired end reads 
loaded on lane 5 Rpt1-KCNMA1 TGACCA L005 R2 001 
Rpt1-KCNMA1 TGACCA L006 R1 001 Paired end reads 
loaded on lane 6 Rpt1-KCNMA1 TGACCA L006 R2 001 
Input Chromatin 
Repeat 2 
Rpt2-input ACAGTG L005 R1 001 Paired end reads 
loaded on lane 5 Rpt2-input ACAGTG L005 R2 001 
Rpt2-input ACAGTG L006 R1 001 Paired end reads 
loaded on lane 6 Rpt2-input ACAGTG L006 R2 001 
KCNMA1 IP 
Chromatin Repeat 2 
Rpt2-KCNMA1 GCCAAT L005 R1 001 Paired end reads 
loaded on lane 5 Rpt2-KCNMA1 GCCAAT L005 R2 001 
Rpt2-KCNMA1 GCCAAT L006 R1 001 Paired end reads 
loaded on lane 6 Rpt2-KCNMA1 GCCAAT L006 R2 001 
Input Chromatin 
Repeat 3 
Rpt3-input CAGATC L005 R1 001 Paired end reads 
loaded on lane 5 Rpt3-input CAGATC L005 R2 001 
Rpt3-input CAGATC L006 R1 001 Paired end reads 
loaded on lane 6 Rpt3-input CAGATC L006 R2 001 
KCNMA1 IP 
Chromatin Repeat 3 
Rpt3-KCNMA1 CTTGTA L005 R1 001 Paired end reads 
loaded on lane 5 Rpt3-KCNMA1 CTTGTA L005 R2 001 
Rpt3-KCNMA1 CTTGTA L006 R1 001 Paired end reads 
loaded on lane 6 Rpt3-input CTTGTA L006 R2 001 
 
7.5 Sequencing Run Quality Control 
A number of quality controls are undertaken during the sequencing run, the first of these 
is analysis of the raw cluster counts. The raw cluster counts should have a maximum of 
950,000, on the graph in Figure 7.2 blue is the raw count data and green is the percentage 
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that have passed the quality scoring. The Q30 value for the green bars should be greater 
than 80%, for this sequencing run the Q30 values were 75.1 and 76.4% these are a little 
lower than the recommended value (Figure 7.2 A, B).  
 
 
Figure 7.2 Raw Cluster Counts  
ChIP fragments were sequenced simultaneously on a genome sequencer by cluster amplification. Clusters 
of approximately 1000 clonal copies of each of the adapter ligated ChIP DNA fragments are created on a 
solid flow cell substrate. Producing a high density array of clusters on the flow cell surface which is then 
sequenced by a genome analysing program. At cycle four of the sequencing reaction a count of the raw 
clusters is performed. The bars represent the raw count data and the blue bars are those that have passed 
quality scoring. (A) Raw cluster counts for flow cell lane 5. 75.1% of clusters passed the quality control 
check. (B) Raw cluster counts for flow cell lane 6. 76.4% of clusters passed the quality control check 
 
Next, at cycle four, the cluster density for each lane is plotted as a box plot. The samples 
for this study were loaded in lanes five and six, in figure 7.3 it is evident that that the 
cluster density in these lanes is much lower than in the other lanes (Figure 7.3). Later in 
the run, however, the cluster density improved and these lanes were equivalent to the 
other lanes. At cycle 12, the phasing and pre-phasing data is checked. Phasing occurs 
when sequencing of some molecules in the in the cluster falls behind by one or more 
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cycles. Pre-phasing occurs when sequencing of some molecules in the in the cluster skips 
ahead by one or more cycles. Therefore, the percentage phasing/pre-phasing is a measure 
of the number of molecules in a cluster which have either fallen behind or skipped ahead. 
Libraries with low diversity or unbalanced libraries can have high levels of phasing/pre-
phasing. The percentage phasing/pre-phasing should be less than 0.5%, this was the case 
in lanes five and six (Table 7.4). At the 25th cycle the chastity filter results are displayed. 
Each base gives off a signal and the base with the higest intensity signal is the base called. 
The chastity filter measures the purity of the signal from each cluster and removes clusters 
that have too much intensity corresponding to bases other than the called base. It is 
calculated by dividing the higest intensity signal from the called base and dividing this 
by the higest intensity from the called base plus the next higest intensity signal.  The 
purpose of the chastity filter is to remove data which does not meet the overall quality 
criteria of the filter. The results are displayed as Clusters PF % (passing filter) in the 
analysis report within lanes five and six less than 50% of the clusters passed the filter 
(Table 7.4). This is low and indicates that either the ChIP assay or the library preparation 
or both need optimising. 
  
 
Figure 7.3 Cluster Density  
ChIP fragments were sequenced simultaneously on a genome sequencer by cluster amplification. Clusters 
of approximately 1000 clonal copies of each of the adapter ligated ChIP DNA fragments are created on a 
solid flow cell substrate. Producing a high density array of clusters on the flow cell surface which is then 
sequenced by a genome analysing program. At cycle four of the sequencing reaction a measure of the 
cluster density is performed. The box plots represent the cluster density, flow cell lane 5 and 6 box plots 
are highlighted with a black box. The cluster density for both flow cell lanes 5 and 6 are low. 
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Table 7.4 ChIP-seq run Quality Control Checks 
 
 
Lane 
Cluster
s PF 
(%) 
Phas/Pr
ephas 
(%) 
Cluster
s PF 
(%) 
Phas/ 
Prephas 
(%) 
Clusters 
PF (%) 
Phas/Pr
ephas 
(%) 
Cluster
s PF 
(%) 
Phas/Pr
ephas 
(%) 
5 38.98 
+/- 
36.72 
0.155 / 
0.294 
38.98 
+/- 
36.72 
0.000 / 
0.000 
38.98 +/- 
36.72 
0.000 / 
0.000 
38.98 
+/- 
36.72 
0.011 / 
0.018 
6 49.45 
+/- 
35.41 
0.212 / 
0.403 
49.45 
+/- 
35.41 
0.000 / 
0.000 
49.45 +/- 
35.41 
0.000 / 
0.000 
49.45 
+/- 
35.41 
0.005 / 
0.007 
 
7.6 Quality Control of Data on Galaxy 
For quality control purposes summary statistics was computed for each of the .fastq files 
generated by the sequencing. The FastQC quality control gives information regarding the 
quality of the .fastq data. For the following quality controls data is only shown for the 
paired end reads from both input and KCNMA1 immunoprecipitated chromatin repeat 
one loaded in flow cell lane five. 
 
7.6.1 Basic Statistics 
This gives simple composition statistics for the data set, including total number of 
sequences, sequence length and percentage GC. Table 7.5 shows that these basic statistics 
are consistent across all the data sets. 
 
7.6.2 Per Base Sequence Quality 
This plot represents the range of quality values over all the bases at each position, 
interestingly the reverse read of the paired end reads (R2) for each sample in each lane 
failed this quality assessment but the forward read of the paired end reads (R1) all passed 
(Figure 7.4 A, B). 
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Table 7.5 ChIP-seq Basic Statistics 
 No of 
Sequences 
Poor Quality 
Seq 
Sequence 
Length 
%GC 
Rpt1 Input L005 R1 873205 0 93 43 
Rpt1 Input L005 R2 873205 0 93 43 
Rpt1 Input L006 R1 1016194 0 93 43 
Rpt1 Input L006 R2 873205 0 93 43 
Rpt1 KCNMA1 L005 R1 1012337 0 93 44 
Rpt1 KCNMA1 L005 R2 1012337 0 93 43 
Rpt1 KCNMA1 L006 R1 1159413 0 93 44 
Rpt1 KCNMA1 L006 R2 1159413 0 93 43 
Rpt2 Input L005 R1 752076 0 93 43 
Rpt2 Input L005 R2 752076 0 93 43 
Rpt2 Input L006 R1 873673 0 93 43 
Rpt2 Input L006 R2 873673 0 93 43 
Rpt2 KCNMA1 L005 R1 1164338 0 93 43 
Rpt2 KCNMA1 L005 R2 1164338 0 93 43 
Rpt2 KCNMA1 L006 R1 1353323 0 93 43 
Rpt2 KCNMA1 L006 R2 1353353 0 93 43 
Rpt3 Input L005 R1 833431 0 93 43 
Rpt3 Input L005 R2 833431 0 93 43 
Rpt3 Input L006 R1 989943 0 93 43 
Rpt3 Input L006 R2 989943 0 93 43 
Rpt3 KCNMA1 L005 R1 950257 0 93 44 
Rpt3 KCNMA1 L005 R2 950257 0 93 43 
Rpt3 KCNMA1 L006 R1 1115135 0 93 44 
Rpt3 KCNMA1 L006 R2 1115135 0 93 43 
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Figure 7.4 Per Base Sequence Quality  
A measure of the probability that a base is called incorrectly, the Phred Score, was calculated for each base 
in the sequence. For each position a BoxWhisker plot was drawn. The central red line is the median value, 
the yellow box represents the inter-quartile range (25-75%), the upper and lower whiskers represent the 
10% and 90% points and the blue line represents the mean quality. The y-axis shows the quality scores. 
The background of the graph is divided into very good quality reads (green), reasonable quality reads 
(orange) and poor quality reads (red). (A) Per base sequence quality for Input repeat 1. The forward read 
passed this quality control check (left panel), the reverse read failed this check as the lower quartile for a 
number of bases was less than 5 and the median for a number of bases was less than 20 (right panel). (B) 
Per base sequence quality for KCNMA1 IP repeat 1. The forward read passed this quality control check 
(left panel), the reverse read failed this check as the lower quartile for a number of bases was less than 5 
and the median for a number of bases was less than 20 (right panel). 
 
7.6.3 Per Sequence Quality Scores 
This quality control identifies if there is a subset of the sequences which have low scores. 
A good quality dataset should have a mean quality score of 37, whilst a poor quality data 
set will have a mean quality score of around 17. These values are determined using the 
Phred algorithm, which is a measure of the probability that a base is called incorrectly. 
For example a Phred score of 30 means that there is a 1:1000 probability of an incorrect 
base call giving a base call accuracy of 99.9%. All of the sample reads passed this test 
with a peak at around 37, a number of the samples also had a peak of around 29 (Figure 
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7.5 A, B). This should not be a problem as it routine to count bases with a quality score 
of greater than 20.  
 
 
Figure 7.5 Per Sequence Quality Score  
A measure of the probability that a base is called incorrectly – The Phred Score, was calculated for each 
sequence. This quality control identifies if there is a subset of the sequences which have low scores. A 
good dataset should have a mean quality score of 37, whilst a bad data set will have a mean quality score 
of around 17.  The x-axis shows the quality scores. (A) Per sequence quality score for Input repeat 1. The 
forward read passed this quality control check (left panel), the reverse read also passed this check (right 
panel). (B) Per sequence quality score for KCNMA1 IP repeat 1. The forward read passed this quality 
control check (left panel), the reverse read also passed this check (right panel). 
 
7.6.4 Per Base Sequence Content 
This shows the proportion of each base at each position in the read. In a random library 
the base frequency should be approximately equal at all positions over all the reads. If 
there are strong biases which change for different bases this represents an overrepresented 
sequence which is contaminating the library. All datasets failed this quality control, this 
appears to be an issue with the first 30bp of each sequence as beyond this point they have 
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passed the quality control check (Figure7.6 A, B). This may be associated with either the 
adapters or the whole genome amplification step that was undertaken. 
 
 
Figure 7.6 Per Base Sequence Content  
Plot of the proportion of each base position in a file for which each of the four normal DNA bases has been 
called. The x-axis shows the position in the read and the y-axis shows the percentage. In a random library 
all four lines should run roughly parallel to each other. (A) Per Base Sequence Content for Input repeat 1. 
Both the forward (left panel) and reverse (right panel) failed this quality control check as the difference 
between A and T, and G and C were greater than 20% in a number of positions. (B) Per Base Sequence 
Content for KCNMA1 IP repeat 1. Both the forward (left panel) and reverse (right panel) failed this quality 
control check as the difference between A and T, and G and C were greater than 20% in a number of 
positions. 
 
7.6.5 Per Sequence GC Content 
This plot show the GC content across each sequence. A random library there should be 
little difference between positions and the overall GC content should be similar to that 
seen in the genome. Deviations from this can indicate that there is an over-represented 
sequence, or there has been a problem in the library preparation. All but one of the data 
sets passed this quality control (Figure 7.7 A, B); the one exception was Rpt3 KCNMA1 
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L006 R2 this didn’t fail the quality control but had a caution as the distribution was 
slightly offset from normal (Data not shown). 
 
 
Figure 7.7 Per Sequence GC Content  
This measures the GC content across the whole length of the sequence (Red line) and compares it to a 
modelled normal distribution of GC content (Blue line). The x-axis shows the mean GC content. (A) Per 
sequence GC content for Input repeat 1. The forward read passed this quality control check (left panel), the 
reverse read also passed this check (right panel). (B) Per sequence GC content for KCNMA1 IP repeat 1. 
The forward read passed this quality control check (left panel), the reverse read also passed this check (right 
panel). 
 
7.6.6 Duplicate Sequences 
This counts the number of times any sequence occurs in the data set and then plots the 
relative number of sequences with different degrees of duplication. Diverse libraries 
should not have a high degree of duplication, low level of duplication may indicate a high 
level of coverage of the target sequence. High levels of duplication are indicative of some 
kind of enrichment bias. All the samples passed this quality control as the percentage of 
duplicated sequences was below 0.72% (Table 7.6, Duplicate Sequences). 
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7.6.7 Over-represented Sequences 
This creates a list of all the sequences in the library that constitute over 0.1% of the total 
library. Finding an over-represented sequence can mean either it is highly biologically 
significant or the library is contaminated. Interestingly the R2 reads for each sample in 
each lane had a caution for this quality assessment due to the high number of N bases but 
the R1 reads all passed (Table 7.6, Overrepresented Sequences). N bases are called during 
sequencing when the sequencer detects either missing peaks or where there are multiple 
peaks for different nucleotides at a single position. Therefore the presence of a large 
number of N calls in the reverse reads may indicate a problem with the chromatin or the 
reverse sequencing is of a poor quality. The R2 reads did not fail this quality check, as no 
sequences were found to represent more than 1% of the total. 
 
Table 7.6 ChIP-seq Quality Control Checks 
 Duplications Overrepresented Sequence 
Rpt1 Input L005 R1 0.16 Pass 
Rpt1 Input L005 R2 0.27 Caution 
Rpt1 Input L006 R1 0.35 Pass 
Rpt1 Input L006 R2 0.27 Caution 
Rpt1 KCNMA1 L005 R1 0.13 Pass 
Rpt1 KCNMA1 L005 R2 0.25 Caution 
Rpt1 KCNMA1 L006 R1 0.3 Pass 
Rpt1 KCNMA1 L006 R2 0.6 Caution 
Rpt2 Input L005 R1 0.14 Pass 
Rpt2 Input L005 R2 0.28 Caution 
Rpt2 Input L006 R1 0.31 Pass 
Rpt2 Input L006 R2 0.65 Caution 
Rpt2 KCNMA1 L005 R1 0.2 Pass 
Rpt2 KCNMA1 L005 R2 0.31 Caution 
Rpt2 KCNMA1 L006 R1 0.3 Pass 
Rpt2 KCNMA1 L006 R2 0.64 Caution 
Rpt3 Input L005 R1 0.09 Pass 
Rpt3 Input L005 R2 0.26 Caution 
Rpt3 Input L006 R1 0.21 Pass 
Rpt3 Input L006 R2 0.66 Caution 
Rpt3 KCNMA1 L005 R1 0.2 Pass 
Rpt3 KCNMA1 L005 R2 0.37 Caution 
Rpt3 KCNMA1 L006 R1 0.33 Pass 
Rpt3 KCNMA1 L006 R2 0.72 Caution 
 
7.8 Data Analysis on Galaxy 
The first step in the data analysis was to map the reads to a reference genome, the human 
hg19 reference genome was used for this. Unfortunately it was only possible to map one 
repeat of each of the input and KCNMA1 immunoprecipitation .fastq files this was the 
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input and KCNMA1 immunoprecipitated chromatin repeat one loaded in flow cell lane 
five. After mapping the data, peak calling was performed using SICER comparing input 
to immunoprecipitation. Peak calling is used to identify regions of the genome that are 
enriched in the immunoprecipitated samples in comparison to the input controls, these 
represent areas where the protein of interest, KCNMA1 C-terminal domain, binds to the 
DNA. SICER is a statistical clustering based approach utilised to perform peak calling. 
This resulted in 48 regions which were significantly enriched in KCNMA1 C-terminal 
domain binding compared to the input control. (Table 7.7). 
 
Table 7.7 Peak Calling using SICER 
Chromos
ome 
Peak Start 
Position 
Peak End 
Position 
Read 
Counts 
KCNM
A1 
Read 
Counts 
Input 
P-
value 
Fold 
Change 
SICER 
Score 
chr1 1772600 1772800 2 0 <0.05 238626.41 2.69E-16 
chr1 50625000 50625200 2 0 <0.05 238626.41 2.69E-16 
chr1 146897000 146897200 2 0 <0.05 238626.41 2.69E-16 
chr1 187521400 187521600 2 0 <0.05 238626.41 2.69E-16 
chr1 216311400 216311600 2 0 <0.05 238626.41 2.69E-16 
chr2 191288200 191288400 2 0 <0.05 238626.41 2.69E-16 
chr2 222789400 222789600 2 0 <0.05 238626.41 2.69E-16 
chr2 239959600 239959800 2 0 <0.05 238626.41 2.69E-16 
chr4 8748200 8748600 2 0 <0.05 119313.21 9.08E-16 
chr4 48269400 48269600 2 0 <0.05 238626.41 2.69E-16 
chr4 74360800 74361200 2 0 <0.05 119313.21 9.08E-16 
chr4 97284600 97284800 2 0 <0.05 238626.41 2.69E-16 
chr4 105034600 105035000 2 0 <0.05 119313.21 9.08E-16 
chr4 117748800 117749200 2 0 <0.05 119313.21 9.08E-16 
chr5 35748200 35748400 2 0 <0.05 238626.41 2.69E-16 
chr5 115940000 115940200 2 0 <0.05 238626.41 2.69E-16 
chr5 132020800 132021000 2 0 <0.05 238626.41 2.69E-16 
chr5 148650400 148650600 2 0 <0.05 238626.41 2.69E-16 
chr6 90557600 90557800 2 0 <0.05 238626.41 2.69E-16 
chr7 121872800 121873000 2 0 <0.05 238626.41 2.69E-16 
chr7 138381200 138381400 2 0 <0.05 238626.41 2.69E-16 
chr8 84320000 84320200 2 0 <0.05 238626.41 2.69E-16 
chr8 86322400 86322600 2 0 <0.05 238626.41 2.69E-16 
chr8 106949400 106949800 2 0 <0.05 119313.21 9.08E-16 
chr8 118205600 118206000 2 0 <0.05 119313.21 9.08E-16 
chr8 140334000 140334200 2 0 <0.05 238626.41 2.69E-16 
chr9 106480400 106480800 2 0 <0.05 119313.21 9.08E-16 
chr10 32926000 32926400 2 0 <0.05 119313.21 9.08E-16 
chr10 68222000 68222200 2 0 <0.05 238626.41 2.69E-16 
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Chromos
ome 
Peak Start 
Position 
Peak End 
Position 
Read 
Counts 
KCNM
A1 
Read 
Counts 
Input 
P-
value 
Fold 
Change 
SICER 
Score 
chr10 73954000 73954200 2 0 <0.05 238626.41 2.69E-16 
chr10 81768600 81768800 2 0 <0.05 238626.41 2.69E-16 
chr11 34038200 34038400 2 0 <0.05 238626.41 2.69E-16 
chr11 71963400 71963600 2 0 <0.05 238626.41 2.69E-16 
chr11 102480000 102480200 2 0 <0.05 238626.41 2.69E-16 
chr11 103341600 103341800 2 0 <0.05 238626.41 2.69E-16 
chr11 121300400 121300600 2 0 <0.05 238626.41 2.69E-16 
chr13 48327400 48327800 2 0 <0.05 119313.21 9.08E-16 
chr13 62802800 62803200 2 0 <0.05 119313.21 9.08E-16 
chr14 27521600 27522000 2 0 <0.05 119313.21 9.08E-16 
chr15 48778200 48778400 2 0 <0.05 238626.41 2.69E-16 
chr18 76152400 76152600 2 0 <0.05 238626.41 2.69E-16 
chr19 49387000 49387200 2 0 <0.05 238626.41 2.69E-16 
chr20 38233400 38233800 2 0 <0.05 119313.21 9.08E-16 
chr20 44123000 44123400 2 0 <0.05 119313.21 9.08E-16 
chr21 31527000 31527200 2 0 <0.05 238626.41 2.69E-16 
chrX 31004400 31004600 2 0 <0.05 238626.41 2.69E-16 
chrX 67033200 67033600 2 0 <0.05 119313.21 9.08E-16 
chrX 121928200 121928400 2 0 <0.05 238626.41 2.69E-16 
 
7.9 Identification of Genes Associated with the Peaks 
The NCBI genome browser was used to align the peak regions generated above with 
known genes (Pruitt, Brown et al. 2014). This done by entering the chromosomal 
locations identified above into the NCBI genome browser and then identifying genes 
within the region. Of the 48 peaks identified above 27 were able to be aligned with known 
genes (Table 7.8) 
 
7.10 Identification of the Region of the Gene Corresponding to the 
Location of the Peak. 
The next step was to identify which region of the aligned genes the peaks were associated 
with. If the KCNMA1 protein has transcription factor function it would be expected that 
the binding should be in the regulatory region of the gene. Although some transcription 
factors have been found bound in non-coding intronic regions of genes, the significance 
of this binding is not fully understood as yet. The Ensemble database (Cunningham, 
Amode et al. 2015) was used for this purpose, this database provides information 
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regarding the location of introns, exons and the regulatory regions of the genes. Briefly 
the gene was located in the Ensemble database and then the gene examined to identify 
which of these regions corresponded to the region covered by the peak. 
 
Of the 27 peaks that were aligned with known genes, all 27 peaks occurred with the 
regulatory regions of the genes they were aligned with. Five occurred in regions annotated 
as the promoter region, five occurred in the promoter flanking region, four occurred in 
regions of known CTCF binding, six occurred in enhancer regions, two occurred in sites 
associated with transcription factor binding and two occurred in open chromatin. The 
remaining three crossed over annotated regions, one crossed between a promoter flanking 
region and an enhancer region, a second crossed between a promoter region and an 
enhancer region and the third crossed between a region of CTCF binding and an enhancer 
region (Table 7.8). 
 
7.11 Gene Ontology Analysis of Peak Associated Genes 
The Gene Ontology Consortium database was used to identify which biological process 
the genes identified above could be involved in (Ashburner, Ball et al. 2000, Carbon, 
Ireland et al. 2009). This revealed an interesting array of possible processes that the 
KCNMA1 protein could have a role in regulating. Including the G1/S transition in the 
cell cycle, apoptosis, Histone H3-K4 methylation, fertilisation, NFκB signalling and 
calcium ion homeostasis among others. 
 
Table 7.8 Alignment of Peaks and Localisation of KCNMA1 C-terminal Domain to Genomic 
Regions 
Chromosome Peak Start 
Position 
Peak End 
Position 
Gene Location 
chr1 1772600 1772800 Nicotinamide 
adenine 
dinucleotide 
Kinase 
Promoter 
chr1 50625000 50625200 FAS-associated 
Factor 1 
Promoter Flanking 
/ Enhancer 
chr1 146897000 146897200 Neuroblastoma 
breakpoint family 
member 12 
CTCF Binding 
chr1 216311400 216311600 Usher Syndrome 
2A 
CTCF Binding 
chr2 191288200 191288400 Myosin 1B Enhancer 
chr2 222789400 222789600 Novel miRNA Promoter Flanking   
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Chromosome Peak Start 
Position 
Peak End 
Position 
Gene Location 
chr2 239959600 239959800 NADH 
dehydrogenase 
(ubiquinone) 1 
alpha subcomplex 
10 
CTCF Binding 
chr4 48269400 48269600 TEC Tyrosin 
protein kinase 
Promoter 
chr4 97284600 97284800 Sperm Tail PG-rich 
repeat containing 2 
Open Chromatin 
chr4 105034600 105035000 Tet methycytosine 
dioxygenase 2 
Promoter 
chr5 35748200 35748400 Sperm flagellar 2 Enhancer 
chr5 148650400 148650600 5-
Hydroxytryptamine 
(serotonin) 
receptor 4, G-
protein coupled 
Transcription 
Factor Binding 
chr6 90557600 90557800 Mitogen activated 
protein kinase 
kinase kinase 7 
CTCF Binding 
chr7 121872800 121873000 Protein tyrosin 
phosphatase 
receptor type 2 
polypeptide 1 
Promoter 
chr8 84320000 84320200 Heterogeneous 
nuclear 
ribonucleoprotein 
C-like 2 
Transcription 
Factor Binding 
chr8 118205600 118206000 Sterile alpha motif 
domain containing 
12 
Promoter Flanking 
chr8 140334000 140334200 Trafficking protein 
particle complex 9 
CTCF Binding / 
Enhancer 
chr10 32926000 32926400 Integrin beta 1 Promoter Flanking 
chr11 34038200 34038400 Cell Cycle 
Associated Protein 
1 
Promoter 
chr11 71963400 71963600 Ring Finger 
Protein 121 
Promoter Flanking 
chr11 103341600 103341800 Dynein, 
Cytoplasmic 2, 
Heavy Chain 1 
Enhancer 
chr11 121300400 121300600 Sterol-C5-
Desaturase 
Enhancer 
chr13 48327400 48327800 Retinoblastoma 
Protein 1 
Promoter / 
Enhancer 
chr15 48778200 48778400 Centrosomal 
Protein 152kDa 
Enhancer 
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Chromosome Peak Start 
Position 
Peak End 
Position 
Gene Location 
chr20 38233400 38233800 KIAA1755 
Uncharacterised 
Protein 
Promoter Flanking 
chr20 44123000 44123400 Juncophillin 2 Open Chromatin 
chr21 31527000 31527200 T-cell Lymphoma 
Invasion and 
Metastasis 1 
Enhancer 
 
7.12 DNA Binding Motif Discovery 
In order for the KCNMA1 protein to bind to the DNA it must harbour a DNA binding 
motif in the protein sequence. There are various on-line analysis tools which can be 
utilised to identify these motifs within a protein sequence. GYM is the most recent of the 
tools, which identifies Helix-Turn-Helix motifs within a protein sequence (Gao, Mathee 
et al. 1999, Narasimhan, Bu et al. 2002). The Helix-Turn-Helix motif is one of the most 
comprehensively studied protein motifs, it has been shown that these HTH motifs are 
responsible for binding to DNA and the majority of proteins harbouring these motifs are 
transcription factors. 
 
The KCNMA1 protein sequence was entered into the GYM on-line program and a search 
for HTH motifs carried out. GYM successfully identified a HTH motif within the 
KCNMA1 protein sequence, this motif commenced at amino acid 938 of the protein 
sequence and had a Maximum Blosum score of 31. The sequence was LRQPSI 
TTTGVNIPIITELVN (Figure 7.8).  
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Figure 7.8 Location of Helix-turn-Helix Motif Within the KCNMA1 Protein Sequence  
The KCNMA1 protein sequence was entered into the GYM on-line program and a search for HTH motifs 
carried out. GYM successfully identified a HTH motif within the KCNMA1 protein sequence, this motif 
commenced at amino acid 938 of the protein sequence and had a Maximum Blosum score of 31. The 
sequence was LRQPSI TTTGVNIPIITELVN (red). 
 
This Blosum score indicates that this sequence has a 31% homology with the accepted 
HTH motif. This would appear to be quite a low degree of similarity however, LysR a 
well defined transcriptional regulator, containing a well characterised HTH motif 
(Maddocks and Oyston 2008) has a Blosum score of 55. It is therefore plausible that this 
HTH motif in the KCNMA1 C-terminal domain could be responsible for DNA binding. 
Zinc Fingers and Leucine zippers are alternative structural motifs that facilitate the 
interaction between protein and DNA however, the KCNMA1 protein was not found to 
contain either of these motifs (Data not shown).  
 
7.13 KCNMA1 DNA Binding Motif Discovery 
As well as a motif in the protein enabling it to bind to the DNA there should also be a 
motif in the DNA to which the protein binds. To discover any motifs within the peak 
regions initially the Galaxy Motif Tools > Sequence Logo algorithm was tried, this failed 
as the sequences were not exactly the same length and there is no functionality within 
Galaxy to adapt the sequence lengths.  
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Table 7.9 Motif Discovery in Aligned Enriched Peaks 
MOTIF DETAILS Probability Matching Matrix 
AAACAATAA Length: 9 
Quorum percent: 74% 
Occurs in 20 input 
sequences 
Average #mismatches: 
1.6 
 
 A A A C A A T A A 
A .9 .9 1 .1 .8 .8 .2 .9 .9 
C 0 0 0 .7 .1 .1 .1 0 0 
G .1 .1 0 .1 0 0 .1 0 0 
T .1 .1 0 .2 .1 .2 .7 .1 .1 
 
AAAATAATT Length: 9 
Quorum percent: 81% 
Occurs in 22 input 
sequences 
Average #mismatches: 
1.68 
 
 A A A A T A A T T 
A .8 .9 .8 .9 .1 .7 .9 .1 .1 
C .1 0 .1 0 .1 .1 0 0 0 
G .1 .1 .1 0 0 .1 0 .1 .1 
T 0 0 0 0 .7 .1 .1 .8 .8 
 
AAAAAAATT Length: 9 
Quorum percent: 77% 
Occurs in 21 input 
sequences 
Average #mismatches: 
1.67 
 A A A A A A A T T 
A .8 .8 1 .8 .8 .7 .9 0 0 
C .1 0 0 .1 .1 .1 0 0 0 
G 0 .1 0 0 0 .1 0 .2 .1 
T 0 .1 0 .1 .1 .1 0 .8 .8 
 
AAAAATAAG Length: 9 
Quorum percent: 74% 
Occurs in 20 input 
sequences 
Average #mismatches: 
1.65 
 
 A A A A A T A A G 
A .7 .9 .6 1 1 0 .8 1 .2 
C .1 0 .2 0 0 .2 0 0 .1 
G .2 0 .1 0 0 .1 .1 0 .7 
T 0 .1 .2 .1 0 .8 .2 .1 .1 
 
GAAAATAAG Length: 9 
Quorum percent: 74% 
Occurs in 20 input 
sequences 
Average #mismatches: 
1.7 
 
 G A A A A T A A G 
A .2 .8 .8 1 1 .1 .9 .9 .1 
C .2 .1 .1 0 0 .1 0 0 .1 
G .7 0 .1 0 0 .1 .1 .2 .8 
T 0 .1 .1 .1 .1 .8 .1 0 .1 
 
TTTTTATAA Length: 9 
Quorum percent: 74% 
Occurs in 20 input 
sequences 
Average #mismatches: 
1.7 
 
 
 
 
 
 
 
 
 T T T T T A T A A 
A .1 .1 .1 .1 .1 .8 0 .8 .9 
C .1 .1 .1 0 0 .1 0 .1 0 
G .1 .1 0 .2 .1 .1 .1 .1 .1 
T .8 .8 .8 .8 .9 .2 .9 .1 0 
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Next the peaks were downloaded and the regions not aligned to known genes were 
removed then the online Panoptic Motif Search Tool was utilised. Briefly, the sequences 
were entered into the tool and the parameters adjusted to identify a motif of any length 
represented in quorum of 75% of the sequences and the program was ran. The program 
discovered 10 motifs these are detailed in Table 7.9. For the first of these motifs the 
location of the Motif in the sequence is detailed in Table 7.10.
MOTIF DETAILS Probability Matching Matrix 
AAAAAGATT Length: 9 
Quorum percent: 74% 
Occurs in 20 input 
sequences 
Average #mismatches: 
1.7 
 
 A A A A A G A T T 
A .9 .7 .9 .8 .9 .2 .9 .1 .1 
C .1 .1 .1 .1 .1 .1 0 0 .1 
G 0 .1 0 0 .1 .7 0 .1 0 
T 0 .2 .1 .2 .1 .1 .2 .9 .9 
 
AGAAAATAA Length: 9 
Quorum percent: 77% 
Occurs in 21 input 
sequences 
Average #mismatches: 
1.76 
 
 A G A A A A T A A 
A .6 .2 .9 .8 .9 .9 .1 .8 .9 
C 0 .2 0 0 0 0 0 0 .1 
G .2 .6 0 .1 .1 0 0 .1 0 
T .2 0 0 0 0 .1 .8 .1 0 
 
AATTTATTA Length: 9 
Quorum percent: 74% 
Occurs in 20 input 
sequences 
Average #mismatches: 
1.75 
 
 A A T T T A T T A 
A .8 .9 .1 .1 .1 .6 .1 .1 .7 
C .1 .1 0 0 0 .1 0 0 .1 
G .1 0 .1 .1 .1 .1 0 .2 .1 
T 0 .1 .9 .9 .9 .2 1 .8 .2 
 
AAAATAAGT Length: 9 
Quorum percent: 74% 
Occurs in 20 input 
sequences 
Average #mismatches: 
1.75 
 
 A A A A T A A G T 
A .9 .9 1 1 .2 .7 .9 .2 .2 
C 0 .1 0 .1 0 0 0 .1 .2 
G 0 .1 0 0 .1 .2 .1 .6 .1 
T .1 0 .1 0 .8 .2 .1 .2 .7 
 
265 
 
Table 7.10 Location of Motif 1 in Peak Regions 
Sequence Information Motif Highlighted in Sequence 
Seq 1 has 6 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr7_121872800_121
873000_+ 24.0721701501 
ATTGATTCCACNA1GTACCCATGAGCATGGAATGTTCCA
CNA1GATTTGTTTGTGTCCTCTTTTATCACNA1GTTGAGC
AGTGGTTTGTAGTTCTCCTTGAAGAGGTCCTTCACATCC
CTTGTAAGTTGGACACNA1GTAGGTATTTTATTCTCTTTG
AAGCAATTGTGAATGGGAGTTCACCCATGATTTGGCTCT
CTGTTTGTCTGTTGT 
 
Seq 2 has 7 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr6_90557600_9055
7800_+ 24.0721701501 
TTGAACTCCTGACCTCAGGTGATCTACCCACCTTGGCCT
CCCAAAGTGCTGGAACTACAGGTGTGAGCCACCGTGCC
CAGCCCAAAATAGAAATATTTTAAAtAATAtGCAGAAGG
TAAACCACNA1GAAACACTGACATAACATTATTATCTCT
TTCTTTTAATGATAATCATGCTGTGACCTCATTGAATTTG
TTGAGATA 
 
Seq 3 has 8 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr5_35748200_3574
8400_+ 24.0721701501 
CGAAATCAAGATGGAAATTAAAAAATTATTCGAACTGA
ATGACAGTGACACAACCTACCAAAACCTCGGATACAGC
AAAGGCAGTGCTAAGAGGAAAGTTCATAGCCCTAAATG
CCTACATCAAAAAGATCAAAAGAGCACAAACTGACATT
CTAAGGTCACACCTCAAGGAACTAGAAAAACAAgAACA
AACCAAACCC 
 
Seq 5 has 7 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr4_48269400_4826
9600_+ 24.0721701501 
tgACAATAAGGCAAGCCCAAGCACAGGCGTGTTTGGAG
GTGGAGGCAACTACTAGGCCCCCACNA1GTTCTGGGTTG
TTTCTTATTTCACNA1GACAAACCTTTTATAATAGCATA
ACCACATCGTACAGGATAATTTTACAATTGCCAGTGACC
ATGAGCCAATTTCACTTTTCACNA1GAACAGACTTGAAT
GCCCAATTTATGATC 
 
Seq 6 has 8 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr4_97284600_9728
4800_+ 24.0721701501 
TTAATTTTTTAAATGGCCAAAAAACTTAAATAGATTCAC
NA1GTCCAAAGAAGGTATACAAATGGCCAATAAGCATA
TGAAAATGTGCACNA1GTTTGTGAAATGCAAATCAAAA
CAAcAATGAGCTATTGTTCATACCTAGTAGGATGGATAT
ACTAGAAAAGACAGAGAATAACAAATGTTGATGAGGTT
GTGGATAAATTGAA 
 
Seq 7 has 7 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr4_105034600_105
035000_+ 23.3790313508 
AGATGGTGCCCACCCAGATTGAAGGTGGGTCTGCCTCTC
CCAAACCACTGACTCAAATGTTAATCTTCTTTGGCAACA
CCTTCACAGACACACCCAGAAACATATTTTGCATTGTTC
AATGCAATCAAATTGACACATGAATTAGTCCATTCTCAT
GCTGCTAATAAAGACAGGCCCAAGACTCGGTAATTTAT
AAGGAAAAGAGGTTTAATGGGCTCACTGCACNA1GATA
TGGCTGGGAGACCTCACAATCATGGCAGAAGGCAAAgA
AgAAGCAAAGGCACATTTTACATGGCAGCAGGCAAGAG
AGCTTTTGCAGGGGAACTCCCATTTATAAAACCATCATA
TCTTGTGAGAGTTATTCAGTATCATGAGAACAGTATGGG
AGAAAATGCCCCCATGA 
 
Seq 8 has 7 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr20_38233400_382
33800_+ 23.3790313508 
TTGACGTATTGTCACNA1GTGCAACTATATCATCTCCTT
GCTTTCACTGTAAACctTAAGTGAATGCTTGCTACCGCAA
ATGAGCATCGTGTTACTAACATTATCAGGATTTCATGAA
GGAAGGGGTTGGTGTTTGGCTTAGGTGAGCCACNA1GC
CCAGAAGGAGATGCTGTAACATGCGTTTCAGTGAAGTA
GATCATCTGGGATTTGGGGAGCACCTATAAGGGAGCAT
AGAAGTGAGATAAAGGGAAGAAAACGATTCAATATGA
GTTCATGAACAGGTTACCTCTGTGAACAACTAGGGCTCA
GTCTCCCTGGAACTCTCTGCAAGGCTGTGTAGAACAAG
ACTCAGAATTATCCCTGGGGCAGGAAACGGAGGGCGAT
AACTACTTAAAGTCTAGGTCTC 
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Sequence Information Motif Highlighted in Sequence 
Seq 9 has 6 matches against 
Motif 1 AAACAATAA 
Comment: 
hg19_chr20_44123000_441
23400_+ 23.3790313508 
CTTTGATTGTGGATATAGGGAGGGTGATGAATTGGAGC
CAGTAACTCAATCTACCACAGTTATTATGTTTAATAACA
AGATATGCTTTGGTTGCTCTGATCCATTTATTCTGGCTGT
GGGAAAAAAAGCACCATATGCTGGTTGCTGATTGAGAG
CATGTACAGTATCCTGCGAGATAGAACCTTACCCACTCG
AAGTTTTATCACNA1GAAGTTGTTAATGTCACACCTGCA
GGACATCCCACCACACNA1GACAAGTCTGGCTGCTTCTG
GGTGATGGAGAACAGGATAAAACTGGTGAATCCCATGA
ATAACAGGCCCTTTCTTTCTTTATTTTACTGTAGCACTCT
CCCTAGATGTCTGTATGGTTAATCTTCACTCACCTCATTC
AAGACTTTGCTTAAGT 
 
Seq 10 has 5 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr1_1772600_17728
00_+ 24.0721701501 
TTACAGGCGTGAGCCACTGCACATGGCCACATTTATTAA
TTTTTTGAGACAGATTCTCACTCTGTCACCCTGGCTGGA
GTGCAGTGGCATGATCTTGGCTCACTGCAACCTCTGCAT
CCCAGGCACNA1GAGCGATTCACNA1GTGCCTCAGCCTC
CTGAGTAGCTGGGATTACAGGCACACGCCATGCCTTTTA
TTATTTATTAG 
Seq 12 has 8 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr1_146897000_146
897200_+ 24.0721701501 
AGACACAGACTGGCAAATTGGATAAAGAGTCAAGACCT
ATCAGTGTGCTGTATTCAGGAAACCCATCTCACGTGCAG
AGACACACATAGGCTCAAAATAAAAGGATGGAGGAAG
ATCTACCAAGCAAATCGAAAACAAaAAAAGGCAGGGGT
TGCAATCCTAGTCTCTGATAAAACAGACTTTAAACCAAC
AAAGATCAA 
Seq 13 has 7 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr1_216311400_216
311600_+ 24.0721701501 
AACAATTTCTTATGAGATATGGAGAATGATATGATTGTA
TTGGAATTAGATTGTTATATATAAACcATAtGTAAAAATT
AATCTCATGTTGCTACAGATTATAAGAGTTTTGAAAGCA
GATAGACACATCACTAATCTTTGTACACTGGTATTTAGG
ATAATGGCCGGTACACAGCAGGCCTCTTAACAAATTGC
TGTTC 
Seq 14 has 8 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr8_84320000_8432
0200_+ 24.0721701501 
AGTATGCATCACTGCACTCCAGCCTGGAAGACAGAGTG
AGACCCTGTCTCAACAAAATAAATTAAAATAAAaAATA
ATATATTTTTCTAACTATCATCCCTTCACNA1GAAATCA
GGAACACNA1GCCTTAAGTTCACNA1GTCAATCACNA1G
ATGGCAATATCTTTGCATAGATTCATTAAGAATTTGTCC
TTTTTAAATAAAAAATATA 
Seq 15 has 8 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr8_118205600_118
206000_+ 23.3790313508 
GAGAGATTTTTATCACCACGAGGCCTGCCCTAAAAGAG
CTCCTGAAGGAAGCACTAAACATGGAAAGGAAAAACCG
GTACCAGCCACTGCAAAATCATGCCAAATTGTAAAGAC
CACCGAGGCTAGGAAGAAACTGCATCAACTAATGAGCA
AAATAACCAGCTAACATCATAATGACAGGATCAAATTC
ACACATAACAATACTAACCTTAAATGTAAATGGGCTAA
ATGCTCAAATTAAAAGGCACAGACTGGCAAATTGGATA
AAGAGTCAAGACCCATCAGTGTGCTCTATTCAGGAAAC
CCATCTTATGTGCAGAGACACACATAGGCTCAAAATAA
AGGGATGGAGGAAGATCTACCAAGCAAATGGAAAACA
AaAAAAGGCAGGGGTTGCAAT 
 
Seq 16 has 8 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr8_140334000_140
334200_+ 24.0721701501 
AGAGAATAAGAATACCCTTCTTTTCTCACNA1GCATTCT
CCCTGTGGAATTTATGGGGTTTGAAACACTGTCCTAGCA
GGGATACAGGAGAAGCCGTGAGAAATCTGATGCCACTA
ACCTAATTATGACATGATTGATTTGACAGCTATGTCCCA
ACTCAGCTGGGGTCCCTGCACNA1GTCTTCTTTAGAAgA
CAATAAACACNA1GT 
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Sequence Information Motif Highlighted in Sequence 
Seq 17 has 8 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr21_31527000_315
27200_+ 24.0721701501 
AACACCTACAAGACCTACTCCGTTTGCTTACAGATAATT
ACAAAGTGAGGGAGAAAACAGGCGTATCCATCCCATTG
CCTTTGGCAAGTCCACNA1GTCAAACtATAAGGTATGCG
TAAGATTACTCTAGAGCGTGTGTAGGTTACAGGATGCTG
GGCCCCTCCCCAGATGATCTAATTGAATAAATCCAGGAT
GGGGCACAG 
Seq 18 has 8 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr13_48327400_483
27800_+ 23.3790313508 
GAACATATCTCAAAAtAATAAGAGCTATTTACGACACAC
CCACAGCCAATATCATACTGAATGGGCAAAAGCTGGAA
GCACACNA1GCTTTGAAAACTGGCACAAGACAAGGATG
CTGTCTCTCACCACTCCTATTCAACATAATATTGGAAGT
TCTGGCCAGGGCAATCAGGCAGGAGAAAGAAATAAAG
GTATTCAAATAGGAAGAGAGGAACTCAAATTGTACAAT
TTGCAGATGACATGATTGTATATTTAGAAAACCCCATCA
CCTCAGCCCAGAAAATCCTTAAGCTGATAAGCAACTTC
AGCAAAGTCTCAGGATACAAAATCAATGTGCAAAAATC
ACAAGCACACNA1GTATACACCAATAACAGAGAGCCAA
ATCATGAGTGAACCACNA1GATTCATA 
 
Seq 20 has 7 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr11_71963400_719
63600_+ 24.0721701501 
GCTGTGATTACAGGCGTGAGCCACCGTGCTGGCGGGAT
GCTTTCTTTAAGGATCACNA1GCAGTCTGGTGGGCACAT
GGAAACTTACCTGGGGAGAGGGGGGATTTCTCTTTAGA
ATGTCTTAGTTGTTTTTGTAAGACAATGGTACAGAGAAG
TCTTGTTGCCACNA1GTTTAAAAAGGGGAAAgAAaAAAC
AAAGTTTGACCCT 
Seq 21 has 6 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr11_103341600_10
3341800_+ 24.0721701501 
CATACGTGTGCATGTGTCTTTATAGCAGCATGATTTATA
ATCCTTTGGGTATATACCCAGTAATGGGATGGCTGGGTC
AAATGGTATTTCTAGTTCTAGATCCCTGAGGAATCGCCA
CACTGACCACNA1GACAATGGTTGAACTAGTTTACAGTC
CCACCAACAGTGTAAAAGCACACNA1GTATTTCTCCACA
TCCTCTCCAGC 
Seq 22 has 7 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr11_121300400_12
1300600_+ 24.0721701501 
AGAGCTCAAATTTCACTTCAGTTCTGGCAATTTGCAGGG
CCCAGGATTTTTTATTACACCAGTAAATAAGCACNA1GT
CTTTTGTCTTTGCTTAAAGCAGTCCTGGGGATGAGGGTA
GAGGGAAGGAATGGCTACACAGAGACAGAAGACATCC
CTGCCCAAGAACACACTCACATCCCAAGACTCAGGAAA
CttTAAATCCA 
Seq 23 has 6 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr10_32926000_329
26400_+ 23.3790313508 
GTTGTTTGTTTTTTTCTTGTGAATTTGTTTGAGTTCATTG
TAGATTCTGGATATTAGCCCTTTGTCAGATGAGTAGATT
GCAAAAGTTTTCTCCCATTCTGTAGGCTGCCTGTTCACT
CTGATGGTAGTTTCTTTTGCTGTGCAGAAGCTCTTTAGTT
TAATTAGATCCTATTTGTCAATTTTGGCTTTTGTTGCCAT
TGCTTTTGGTGTTTTAGACATGAAGTCCTTGCCCATGCC
TATGTCCTGAATGGTATTGCCTAGGTTTTCTTCTAGGGTT
TTTATGGTTTTAGGTCTAATGTTTAAGTATTTAATCCATC
TTGAATTAATTTTTGTATAAGGTGTAAAGAAGGGATCCA
GTTTCAGCTTTCTCCATATGGCTAGCCAGTTCACNA1GC
AGCACCAT 
 
Seq 24 has 7 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr15_48778200_487
78400_+ 24.0721701501 
ATGCTAGAGATGAGACTCTAATAGTGAATGGGACAGAC
ACAATCTTTGACTTCAAAATGATTACACTGTGGCCAGGA
GACAGATgAACAATtAATTGCACCATGCATGATGTGCCA
TTTGCAATGCAGGAGAAGTATTGGGTGCTAGGAGAACA
CATCTCAGTTATGATAATAGGCACGTGGATGAAATTCTC
TTGGCCA 
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Sequence Information Motif Highlighted in Sequence 
Seq 25 has 7 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr2_191288200_191
288400_+ 24.0721701501 
TATTGCTGCATAATATCCCATAGTAAAGCTGTAGTACAA
TTTGTTTAATTAGTCCCACNA1GATCCTTTGAAGGGCTTT
TGGGTTGTCTCCACTTTTTGGCTATTATGAAGAAAGCTG
CTATAAACAtTtATGCATGGGTTTCTGTGTGAAAATAAGT
TTTCATTTATCTGGAATAAACACNA1GCAGAAGTGTAAT
TACTGGGTT 
Seq 26 has 7 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr2_222789400_222
789600_+ 24.0721701501 
TCTGTCTAGTATGTTTCTCATTGCAGCTGGCTCCTTCTAA
ACCACTGCACAAGACACTTTTGGTGGTTATTATAGCTGT
TTGTTTCTTgAAaAATAATGGAAACCATGTGATCCAAAA
ACCTCTTTGCTAGTAAACAAAGGCATTCATTGTATCTAT
GAAGCAGGCTGTTTTTTAACTTAAAAAAAAGTTTTGGCT
GTAG 
 
Seq 27 has 6 matches 
against Motif 1 
AAACAATAA 
Comment: 
hg19_chr2_239959600_239
959800_+ 24.0721701501 
AGTTCTTTTAATTTTTTTAGTATTTATTGATCATTCTTGG
GTGTTTCTTG 
GAGAGGGGGATTTGGCAGGGTCATAGGACAATAGTGGA
GGGAAGGTCAGCAGATAAACATGTGAACAAGGGTCTCT
GGATCACNA1GTAGGCAGAGGTCCCTGCCGCCCACNA1
GGCAGTGTTTGTGTCCCTGGGTACTTGAGATTAGGGAGT
GGC 
 
 
7.14 Validation of ChIP-seq 
To validate the ChIP-seq findings three genes which were identified as enriched with 
KCNMA1 binding where selected these were; Mitogen Activated Protein Kinase Kinase 
Kinase 7 (MAP3K7), Retinoblastoma Protein (RB1) and Juncophillin 2 (JHP2). Primers 
for these genes were designed within the relevant sequences identified during peak 
calling. PCR was then performed for each of these, utilising the same chromatin as was 
used in the ChIP-seq analysis but which had not undergone whole genome amplification. 
Specific enrichment for each of these promoters was seen in the KCNMA1 IP in all three 
ChIP repeats (Figure 7.9 A, B). This strengthens the case for role of the KCNMA1 C-
terminal domain as a protein that also has the ability to bind to DNA. 
269 
 
 
 
Figure 7.9 Validation of ChIP-seq Results  
ChIP chromatin was immunoprecipitated using KCNMA1 c-terminal antisera or non-specific rabbit IgG, 
the resulting chromatin was then amplified using promoter specific primers. (A) MAP3K7 ChIP PCR. A 
band was observed in the KCNMA1 IP lane, and no band was observed in the IgG lane indicating that 
KCNMA1 binds to the MAP3K7 promoter. (B) Rb1 ChIP PCR. A band was observed in the KCNMA1 IP 
lane, and no band was observed in the IgG lane indicating that KCNMA1 binds to the Rb1 promoter. (C) 
JPH2 ChIP PCR. A band was observed in the KCNMA1 IP lane, and no band was observed in the IgG lane 
indicating that KCNMA1 binds to the JPH2 promoter. 
 
7.15 Discussion 
7.15.1 The ChIP Assay 
There are a number of places where the ChIP assay could be optimised to improve the 
outcome of the ChIP-seq. Firstly, antibody selection, further characterisation of the 
primary antibody is needed to confirm its validity for use in the ChIP assay, alternative 
antibodies could also be trialled and the most suitable selected. Once an appropriate 
antibody is selected it would then be necessary to optimise the antibody concentration 
used in the ChIP assay, this first repeat of ChIP-seq has provided information which can 
be utilised to develop a robust positive control for the KCNMA1 ChIP assay. 
Development of a robust positive control is necessary prior to further ChIP-seq to build 
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confidence in the ChIP-seq data and to ensure good quality ChIP chromatin is being used 
for ChIP-seq and hence improve the quality and reproducibility of the ChIP-seq results. 
 
Secondly, the fragmentation step in the ChIP assay needs improved, although ultrasonic 
cavitation is effective and adequate for routine ChIP assay protocols it does not produce 
consistent enough chromatin fragments for ChIP-seq. An alternative approach to 
ultrasonic cavitation are enzymatic fragmentation using micrococcal nuclease, once 
optimised this mode of chromatin fragmentation should produce more consistent results. 
A second alternative is the use of a Bioruptor system. While this also employs ultrasonic 
cavitation, it is used in a waterbath. This, therefore, ensures more consistent inter-sample 
temperatures are obtained. Moreover, it allows batch processing of samples, again 
reducing inter-experimental variation. 
 
The final optimisation of the ChIP concerns the amount of chromatin generated. In this 
study it was necessary to increase the yield using whole genome amplification. It is 
possible that this extra step was the reason that the first ~30 bases of each fragment failed 
the per base sequence content quality control step. A second issue with using whole 
genome amplification to increase the yield is that it results in the reduction of the 
complexity of the library, meaning there are fewer unique sequences in the library. This 
can result in the same fragment being sequenced repeatedly.  Optimisation of the two 
steps above, antibody and fragmentation, should result in the maximum yield possible, if 
this is still too low then increasing the input DNA may be a preferable step rather than 
amplifying the resulting chromatin. 
 
7.15.2 ChIP-sequencing 
Optimisation of the ChIP protocol will have the effect of improving the ChIP-seq results 
even before optimisation of the ChIP-seq protocols themselves. There are still a number 
of areas which could be optimised in the ChIP-seq. Firstly the library preparation, there 
were experimental problems with the initial kit used as it lacked the adapters required for 
the library preparation and so it was necessary to switch to a second kit. This switch may 
have resulted in a less efficient library preparation. The successful addition of the adaptors 
is necessary as these then bind to the flow cell and allow the fragment to be sequenced. 
If the library preparation is inefficient this will reduce the number of fragments available 
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for sequencing. Second, is the optimisation of the amount of DNA loaded into the flow 
cell, two concentrations were tried in this study 10pM in lane 5 and 8pM in lane 6. Lane 
5 was more effective and so further optimisation of this could be carried out.  
 
During library preparation different adapters were added to each end of the fragments 
then during the sequencing run paired end reads were carried out. This effectively means 
the fragments were firstly sequenced using a primer for one of the adaptors, then secondly 
using a primer for the second adaptor. This means the fragment gets sequenced from both 
ends hence paired-end reads. The principle behind this is that using the two sequence 
fragments generated and the size of the space between them (calculated from the length 
of the total fragment) will enable more accurate alignment with the genome. In this study, 
however, there was a clear difference in the quality of the two paired end reads, the 
forward reads passed the quality control checks whilst the reverse reads failed a large 
number of the checks. There are a number of reasons why this could happen, firstly over-
clustering of the adapter ligated DNA on the flow cell surface, this is unlikely in this study 
as the number of clusters was quite low. Secondly, degraded read-2 sequencing primer 
this is a possibility, however, the other flow cell lanes did not suffer with the same degree 
of difference between the two paired end reads. Thirdly, low diversity in 3' end of library 
fragments introduced by library preparation method. This is the most likely source of the 
problem as there were issues with the library preparation. Again this will need to be 
optimised prior to any further experimentation. 
 
7.16 Conclusion 
As discussed above there are a number of areas which need optimisation in order to build 
confidence in the data, however, there is strong evidence to support the theory that the 
KCNMA1 protein appears to have a role in regulating transcription of specific 
myometrial genes. 
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Chapter 8: Discussion
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8.1 Discussion 
Throughout this thesis, a model system, consisting of isolated human myometrial cells 
grown in culture, has been utilised. The benefit of this system is that smooth muscle-
specific changes can be elucidated without other cell types reducing the measureable 
impact of these changes. However, as a consequence of isolating these myometrial cells 
the complexity of the signalling pathways seen in vivo will have been reduced. 
Specifically, signalling from both the fetus and surrounding myometrial tissues will have 
been lost. It is difficult to quantify what affect this loss of input will have on the changes 
seen within the myometrial cell cultures. In addition to this it is also pertinent to note that 
only one cytokine, TNF, was utilised within this study. As has been explained previously 
at the onset of parturition there is an increase in SP-A, MMPs, prostaglandins, TNF, IL1β 
and IL6, all of which may affect the contractility of the myometrium and hence may have 
an effect on the KCNMA1 potassium channels, CACNA1Cs and CACNA1Gs. However, 
this limitation can be addressed in future studies where different combinations of these 
factors can be utilised and their effect on the KCNMA1 potassium channels, CACNA1Cs 
and CACNA1Gs examined. These limitations need to be taken into consideration when 
extrapolating from this data to explain the regulation of parturition. 
 
8.2 The Biological Significance of the Observed Changes in the 
KCNMA1, CACNA1C and CACNA1G Channels. 
A number of the changes un-covered in this study, although statistically significant, were 
numerically small and this may lead one to question their biological relevance. This is a 
complex question and must be addressed in the context not only of the protein involved 
but also the downstream pathways which are subsequently activated and the effects on 
other associated proteins.  
 
Firstly, it is necessary to understand the difference between statistical significance and 
biological relevance. Every scientific experiment starts with a null hypothesis, which 
states: There is no difference between the groups. The purpose of any statistical test is to 
measure the probability (p) of observing an effect given that the null hypothesis is true. 
The probability is termed the p-value. If the p-value is small it means the results are 
statistically significant and the null hypothesis can be rejected i.e. there is a difference 
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between the groups. Biological relevance on the other hand is a measure of the importance 
of the difference. It can be defined as a meaningful change in the state of the cell, tissue 
or organ under study. 
 
In the context of this thesis, which seeks to understand the regulation of myometrial 
contractility, an increase in contraction would be considered a meaningful change in the 
state of the cells under study and therefore biologically relevant. Therefore, as the small 
statistical changes in the KCNMA1 channel, CACNA1C and CACNA1G following 
exposure to TNF, correlated with an increase in the contractility of the cells they meet the 
criteria to be considered biologically relevant.  
 
8.3 The Role of the KCNMA1, CACNA1C and CACNA1G Channels 
in Myometrial Cells. 
The majority of previous research has focused on a single aspect (either DNA or RNA or 
protein or electrophysiology) of a single channel, whereas, this thesis has sought to 
examine multiple aspects (DNA, RNA, protein, localisation and interactions) of multiple 
channels (KCNMA1, CACNA1C and CACNA1G). In doing so, this research, has 
revealed novel potential links between the different aspects of the KCNMA1 channel, 
CACNA1C and CACNA1G, and these are discussed below. 
 
8.3.1 The Relationship Between KCNMA1 Channel Splice Variant Expression and 
Protein Expression 
Previous research by Knaus et al. determined that the various protein fragments detected 
when western blotting for the KCNMA1 channel were by-products of proteolytic 
cleavage which occurred as a result of the purification process (Knaus, Eberhart et al. 
1995). However, examination of the western blotting and splice variant data together 
suggests that the presence of these KCNMA1 fragments could be related to the expression 
of specific splice variants. 
  
Examination of the KCNMA1 protein sequence suggests that the 50kDa protein fragment 
detected will still contain a pore and, as the C-terminal region is missing, it could have 
decreased calcium and voltage sensitivity (Figure 8.1 A and B). This fragment was 
localised to the membrane, as shown in the western blots, if it is generated in vivo rather 
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than as a result of the extraction process it would alter the gating kinetics of the KCNMA1 
channels and hence the contractility of the cell.  At splice site M2 the data revealed that 
the cultured myometrial cells express exons 11 and 12.  The use of exon 11 introduces a 
premature stop codon (Miranda-Rottmann, Kozlov et al. 2010), this stop codon results in 
the truncation of the protein. Given the sequence data it is possible to predict that this 
truncated protein would be approximately 50kDa in size (Figure 8.1 A). Therefore the 
presence of this variant could be correlated with the expression of the 50kDa KCNMA1 
protein fragment.  
 
Examination of the putative protein sequence for the 65kDa KCNMA1 protein fragment 
detected suggests that it would also contain the pore region, but would contain a larger 
portion of the C-terminal region than the 50kDa fragment above. This protein fragment 
will contain the regulator of potassium conductance domain 1 (RCK1; Figure 8.1 A and 
C). The full length KCNMA1 channel contains two RCK domains, these RCK domains 
are thought to have a role in the calcium dependant activation of the KCNMA1 channel. 
The RCK2 has been shown to have a higher affinity for calcium than RCK1 (Yusifov, 
Javaherian et al. 2010). Therefore as this 65kDa fragment does not contain the RCK2 
domain it could have decreased calcium sensitivity. At splice site 3, the entire of exon 19 
was shown to be utilised, this variant was only expressed at a low level similar to the 
expression of the 65kDa protein fragment. The utilisation of exon 19 also results in a 
decrease in the calcium sensitivity of the channel. The similarities in the putative 
electrophysiological effects and the expression patterns of the 65kDa protein fragment 
and the splice site 3 variant would suggest that these two are linked. In addition to this, 
given the location of splice site 3, it is possible to speculate that if exon 19 contained 
either a stop codon or a proteolytic cleavage site the protein generated would be 
approximately 65kDa (Figure 8.1 A). This putative link between splice site 3 and the 
65kDa fragment is worthy of more in-depth research. 
 
Finally, examination of the putative protein sequence for the 90kDa KCNMA1 fragment 
detected, suggests that it will contain the pore and also both the RCK1 and RCK2 domains 
(Figure 8.1 A and D). This should result in an increase in the calcium responsiveness of 
the resulting channel compared to the 65kDa fragment. At the same time the M6 variant 
containing exon 29 was expressed, variants containing exon 29 have been shown to have 
increased activation rates and open more rapidly upon increases in intracellular calcium. 
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The expression of this variant appears to correspond to the 90kDa protein found within 
the nuclear fractions. Therefore, the increased activation rate of the M6 variant containing 
exon 29 may be as a result of the loss of the inhibitory C-terminal tail region. 
 
One way to more clearly define these putative links between splice variant and protein 
fragment expression would be to clone the KCNMA1 protein into an expression vector 
and selectively express the splice variants of interest. The KCNMA1 protein subsequently 
produced could then be characterised. 
 
 
Figure 8.1 Schematic Representation of the Various Putative KCNMA1 Isoforms  
Diagram of the KCNMA1 channel a-subunit, showing the seven membrane spanning domains, with a pore 
region (Pore). The long cytoplasmic tail contains four hydrophobic domains. The regulator of potassium 
conductance (RCK) 1 and RCK2 are highlighted by yellow shading. The Ca2+ bowl (Red circle) is a high-
affinity Ca2+ binding site that lies within RCK2. (A) Full length KCNMA1 channel.  Splice sites putatively 
associated with the shorter isoforms are highlighted (red triangles) and the putative end of the various 
KCNMA1 protein fragments are highlighted (green stars). (B) 50kDa KCNMA1 fragment, (C) 65kDa 
KCNMA1 fragment and (D) 90kDa KCNMA1 fragment. 
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8.3.2 The Relationship Between CACNA1C Splice Site 4 Variant Expression and 
Acetylation 
This research has demonstrated that CACNA1C exon 8 is only expressed following 
exposure to TSA. Suggesting that acetylation has a role in the expression of this particular 
splice variant.  
 
Previous research has demonstrated that nucleosomes, DNA methylation and histone 
modifications are enriched on exons (Zhou, Luo et al. 2014) and this enrichment has been 
linked to splicing regulation (Hnilicová and Staněk 2011). It was noted that 
hyperacetylation localised to the region surrounding an alternative exon resulted in the 
skipping of this exon (Zhou, Hinman et al. 2011). Furthermore, HDAC inhibition has 
been shown to affect the splicing of ~700 genes (Hnilicová, Hozeifi et al. 2011), one way 
in which this is thought to occur is through an increase in histone H4 acetylation and 
subsequently an increase in RNA polymerase II processivity. It is thought, due to the 
rapid nature of histone acetylation and deacetylation, that acetylation preferentially 
modulates the alternative splicing of genes that respond rapidly to changing cellular 
conditions (Hnilicová and Staněk 2011). Recently, TSA has been shown to affect 
alternative splicing, this is thought to be through it induction of a more relaxed chromatin 
state which results in the redistribution of multiple splicing factors (Kadener, Cramer et 
al. 2001, Karolczak-Bayatti, Sweeney et al. 2011, Schor, Llères et al. 2012). 
 
Utilising the ChIP assay it would be possible to determine if increased acetylation of the 
region surrounding CACNA1C exons 8 and 8* was involved in the inclusion or exclusion 
of a particular exon. 
 
 
8.3.3 The Relationship Between CACNA1G Splice Variant Expression, Protein 
Expression and Localisation. 
As with both the KCNMA1 and CACNA1C, different sized CACNA1G proteins were 
detected on the western blots. Two forms of the CACNA1G have been defined by Monteil 
et al., a short version termed CACNA1G α1G-b and a longer version termed CACNA1G 
α1G-a. These two forms were shown to contain distinct III-IV loops, α1G-b is formed 
utilising an alternative 5’ splice donor site in exon 25 combined with the acceptor site on 
exon 27 (Monteil, Chemin et al. 2000). The splice variant analysis revealed that the 
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primary myocytes express exons 25 and 26 this would account for the longer form of the 
CACNA1G. However, there was no alternative variant detected in the RNA, which lacked 
exon 26 that could account for the shorter CACNA1G channel protein detected. 
Therefore, it would appear that the shorter 249kDa channel detected in this study must 
have arisen via a different mechanism. Combining the protein data and RNA splicing data 
revealed that the short CACNA1G isoform terminates in a splicing region. The splice site 
in question involves a splice donor site on exon 30 (30B) and a splice acceptor site on 
exon 31 (31A; Figure 8.2 A and B).  
 
 
Figure 8.2 Schematic Representation of the Putative CACNA1G Isoforms  
Diagram of the CACNA1G channel a-subunit, showing the membrane spanning domains, and linking loops 
(A) Full length CACNA1G channel.  Splice sites putatively associated with the shorter isoforms are 
highlighted (red triangles) and the putative end of the various CACNA1G protein fragments are highlighted 
(green stars). (B) 249kDa CACNA1G fragment, (C) 69kDa CACNA1G fragment. 
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Exon 30B has been shown to affect the voltage dependant activation of the channel while 
exon 31A was shown to result in the premature truncation of the channel (Emerick, Stein 
et al. 2006). This, however, does not seem to fit with the data presented here. Within this 
study exon 31A was constitutively expressed whereas exon 30B was expressed at 
different levels dependant on the stimulation. However both long and truncated 
CACNA1G were present in un-stimulated samples and following both TNF and TSA 
stimulation. This may suggest that exon 31A is not linked to the 249kDa isoform or it 
may suggest that the truncation of the channel is due to proteolytic cleavage rather than 
the introduction of a stop codon. This proteolytic cleavage may therefore not be a 
constitutive event but rather a controlled event driven by the needs of the cell. 
 
A final point to note is the observation that membrane localisation of the CACNA1G 
seems to be promoted by both TNF and TSA. Previous research has identified splice site 
1 variants as having a role in trafficking of the protein (Shcheglovitov, Vitko et al. 2008). 
This site involves the insertion or deletion of exon 8 and unfortunately was not examined 
in this study. However, there was a 69kDa CACNA1G protein fragment detected, and 
this fragment terminates within splice site 1 (Figure 8.2 A). It is possible, therefore, that 
either insertion or deletion of exon 8 results in the truncation of the CACNA1G (Figure 
8.2 C) and hence affects the membrane trafficking of the CACNA1G protein. Future work 
should involve examining the expression of this variant within these primary myocytes 
in order to determine if changes in splice variant expression at this location are 
responsible for the changes in either membrane localisation or premature truncation of 
this channel. 
 
8.4 The Role of the KCNMA1, CACNA1C and CACNA1G Channels 
in the Generation of Relaxation in Cultured Myometrial Cells  
During pregnancy the myometrium is quiescent allowing it to expand to accommodate 
the growing fetus. TSA, a broad spectrum deacetylase inhibitor, has been shown to cause 
relaxation in myometrial smooth muscle strips (Carvajal, Germain et al. 2000, Moynihan, 
Hehir et al. 2008, Webster, Waite et al. 2013) and in this study it was seen to cause 
relaxation of the primary myometrial cells grown in culture. Therefore, it was decided to 
use TSA to simulate the relaxed state of the myometrium during pregnancy. 
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8.4.1 The KCNMA1 Channel  
TSA stimulation resulted in a significant decrease in KCNMA1 channel mRNA, 
however, this coincided with an increase in the amount of KCNMA1 protein. This 
discrepancy between the mRNA levels and protein levels could be as a result of an 
increase in translation from a cytoplasmic store of KCNMA1 channel mRNA which 
would result in the observed decrease in RNA and concurrent increase in protein levels. 
Alternatively, the increase in protein could be due to either an increase in retention of the 
KCNMA1 channel or a decrease in the degradation of the KCNMA1 channel. Research 
has demonstrated that the KCNMA1 channel undergoes ubiquitination (Kyle and Braun 
2014) and separate research has demonstrated that acetylation can protect proteins from 
ubiquitination (Caron, Boyault et al. 2005). Therefore the up-regulation in KCNMA1 
protein could be as a result of TSA inhibition of lysine de-acetylation and subsequently 
the decreased ubiquitination of the KCNMA1 channel. This theory could be tested by 
measuring the turnover of the KCNMA1 protein. Interestingly, the observed increase in 
KCNMA1 channel protein was confined to the cytoplasmic fraction indicating that two 
separate mechanism exist, one to trigger the translation of the protein and a second to 
trigger its translocation to the membrane. This delay in trafficking of the KCNMA1 
protein to the plasma membrane has been demonstrated by Kim et al. in chick cochlear 
development (Kim, Beyer et al. 2010). Further studied to identify the trigger responsible 
for trafficking the KCNMA1 channel to the plasma membrane would be an important 
next step in this research. 
 
Following TSA stimulation there was an association between the membrane localised 
KCNMA1 channel and Cav-1 indicating that a portion of the KCNMA1 channels are 
putatively housed within caveolae. There was an association between the KCNMA1 
channel and both Gαs and the β2-AR. The inconsistency of the detected association with 
Gαs may be as a result of the transient nature of its interactions. In future work it would 
be pertinent to stabilise these transient interactions prior to co-localisation studies as this 
will give a more accurate measure of its interaction with the KCNMA1 and CACNA1C. 
The association with the β2-AR may indicate that the KCNMA1 channel is being 
regulated by the β2-AR under these conditions. 
 
 
282 
 
8.4.2 The CACNA1C Channel  
Following TSA stimulation, CACNA1C channel mRNA was unchanged and this 
corresponded to a small decrease in the expression of both the full length and C-terminally 
truncated CACNA1C protein isoforms. The membrane-localised CACNA1C channel 
was found associated with both Gαs and the β2AR indicating indicating that they may be 
regulating the CACNA1C channel under these conditions. The observed association 
between Gαs and the CACNA1C would indicate that activation of the CACNA1C is 
occurring via the cAMP independent pathway through the direct interaction of Gαs with 
the CACNA1C (Yatani, Imoto et al. 1988).  The CACNA1C was also found associated 
with Cav-1 under these conditions. Localisation of the CACNA1C with caveolae has been 
linked to both calcium signalling to the nucleus via the NFAT transcription factor 
(Makarewich, Correll et al. 2012), the production of calcium sparks and possibly calcium 
waves (Daniel, El-Yazbi et al. 2006).  
 
CACNA1C splice variant analysis also revealed the novel expression of exon 8, the 
inclusion of this exon results in channels with higher DHP sensitivity, slower activation 
and more rapid deactivation kinetics meaning that they are less supportive of contraction 
(Soldatov 1992). There was also an overall reduction in the level of splice variants 
expressed in the C-terminal region of the channel. This observation may indicate that the 
majority of the channels are truncated which would increase their ion conductance, or this 
may be an artifactual result due to the significant reduction in the overall channel. 
 
8.4.3 The CACNA1G Channel  
In the TSA-stimulated myocytes there was no significant change in CACNA1G channel 
mRNA and no significant change in the expression of the CACNA1G protein. 
CACNA1G was, however, detected within the membrane fraction suggesting it was 
inserted therein. This observation suggests that TSA supports the membrane localisation 
of the CACNA1G rather than inducing an increase in expression of the CACNA1G 
protein. Membrane-localisation of the CACNA1G has been shown to be enhanced by 
activation of the Ras-ERK pathway (Mor, Beharier et al. 2012), therefore, the observed 
increase in membrane localised CACNA1G may be as a result of the action of TSA on 
this pathway. A second possibility is that acetylation of the CACNA1G may promote its 
membrane localisation. Further study of the activation of the Ras-ERK pathway in the 
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context of CACNA1G membrane localisation and the myometrium would be a logical 
next step in this research.  
 
8.4.4 The Combined Role of the KCNMA1, CACNA1C and CACNA1G Channels in 
the Generation of Relaxation in Cultured Myometrial Myocytes 
Within the relaxed myometrial cells, the KCNMA1, CACNA1C and CACNA1G 
channels are transcribed at a low level and a proportion of both the KCNMA1 and 
CACNA1C channels were detected associated with Cav-1 and hence with caveolae. The 
splice variants expressed by the KCNMA1 channel; Mk44 +132bp, M2 (+exons 11 and 
12), M3 (STREX-2) and M5 (+exon 29), are less responsive to both calcium and voltage. 
However, these are expressed alongside CACNA1C isoforms harbouring slower 
activation and more rapid inactivation kinetics, as well as proteolytically cleaved 
CACNA1Gs which lack the C-terminal tail region. This region of the CACNA1G has 
been shown to be responsible for the rate of inactivation of the channel (Staes, Talavera 
et al. 2001), therefore, inclusion of exon 31A which can result in premature truncation of 
the protein may alter the inactivation of the channel.  Overall this would result in cells 
which are less responsive to calcium and voltage and hence are less contractile. 
 
 
8.5 The Role of the KCNMA1, CACNA1C and CACNA1G Channels in 
Un-stimulated Cultured Myometrial Myocytes 
8.5.1 The KCNMA1 Channel  
The myometrial cell cultures were derived from term pregnant, non-labouring biopsies 
and therefore un-stimulated samples in this study represent this stage of pregnancy, just 
prior to the onset of contractions. In the un-stimulated samples, there is evidence for both 
full length and C-terminally truncated KCNMA1 channel protein within the membrane 
fraction suggesting they were inserted therein, at the same time there is membrane 
localisation of the 50kDa N-terminal fragment. The KCNMA1 channel mRNA is also 
increased compared to that seen in the TSA-stimulated myometrial cell cultures. These 
membrane-localised channels were shown to associate with Cav-1 and therefore may 
exist within caveolae. This association would enable the KCNMA1 channel to respond 
rapidly to changes in membrane potential and calcium signalling. In addition, these 
KCNMA1 channels also were shown to associate with the β2AR and Gαs. Co-localisation 
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of the KCNMA1 channel and Gαs would suggest that Gαs is directly activating the 
KCNMA1 channel. As the direct activation of the KCNMA1 channel by Gαs is a highly 
localised membrane-delimited process (Forscher, Oxford et al. 1986, Dolphin 2003). 
Although it is pertinent to remember that co-localisation can indicate that either two 
proteins interact directly or interact via one or more bridging molecules. As explained for 
the CACNA1C previously, this putative direct interaction between Gαs and the KCNMA1 
channel would indicate that activation of the channel is occurring in a cAMP-independent 
manner (Kume, Graziano et al. 1992). This putative direct interaction between the 
KCNMA1 channel and Gαs may also indicate that activation of the KCNMA1 channel by 
the β2AR is also occurring via a cAMP independent pathway (Scornik, Codina et al. 1993, 
Kume, Hall et al. 1994, Tanaka, Yamashita et al. 2003, Tanaka, Horinouchi et al. 2005), 
as the β2AR activates the KCNMA1 channel via Gαs (Tanaka, Yamashita et al. 2003, 
Tanaka, Horinouchi et al. 2005).  When Gαs activates the KCNMA1 via the cAMP 
pathway, Gαs directly interacts with AC not the KCNMA1 channel.   
 
The STREX-2 variant was found to be utilised in the channel at this juncture, the effect 
of this variant is dependent on the level of PKA in the tissue and the subsequent 
phosphorylation of STREX-2 by PKA. Therefore, as the levels of PKA rise towards the 
onset of parturition, there may be an increase in STREX-2 phosphorylation. This 
increased STREX-2 phosphorylation will then support the contractile phenotype of the 
cells (Europe-Finner, Phaneuf et al. 1994, Europe-Finner, Phaneuf et al. 1997, Zhou, 
Wang et al. 2000, Zhu, Eghbali et al. 2005). However, as explained above the co-
immunoprecipitation data suggest that at this juncture the activation of the KCNMA1 
channel is at least partially cAMP-independent. Although the precise mechanism by 
which Gαs directly activates the KCNMA1 channel has not been elucidated it does not 
appear to involve phosphorylation of the channel (Brown and Birnbaumer 1988).  
Therefore, PKA phosphorylation may have a reduced role in activating the KCNMA1 
channel which may in turn lead to a reduction in the phosphorylation of the STREX-2 
variant. This could mean that the contractile effect of the phosphorylated STREX-2 
variant may also be reduced. Finally, the KCNMA1 channel RNA also contained exon 
29, this variant once again affects the channels calcium sensitivity. This appears to be due 
to the introduction of a cleavage site which, results in the cleavage of the C-terminal 
region decreasing the calcium sensitivity of the channel and possibly creating the 90kDa 
fragment observed in the western blots. 
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8.5.2 The CACNA1C Channel  
The CACNA1C protein is also present, however in the un-stimulated samples it is 
predominantly contained within the cytoplasm. The portion of the channel housed within 
the membrane is again associated with both caveolae via Cav-1 and the β2AR, although 
unlike the KCNMA1 channel it is possible that these represent two distinct complexes 
rather than one multiprotein complex. At this juncture the CACNA1C does not appear to 
co-localise with Gαs. This lack of association may be due to the transient nature of Gαs 
interactions or it may represent a switch in the pathway of CACNA1C activation to a 
cAMP-dependent pathway. 
 
 As with the KCNMA1 channel, both full length and C-terminally truncated channel 
forms were detected within the membrane fraction, suggesting they were inserted therein, 
and also within the cytoplasm. Splice variant analysis reveals the presence of exon 8* 
which promotes calcium influx, and hence would support contraction. There were two 
variants detected at splice site 10, a longer version containing exons 30, 31, 32 and 34 
and a shorter form containing exons 30, 31, 33 and 34. The longer form has increased 
excitation-contraction coupling (Huang, Xu et al. 2006) in comparison to the shorter 
form. The presence of both these variants within the myometrial cell cultures could 
provide a balance to each other, one supporting contraction and one supporting relaxation. 
Finally, at splice site 11/12 only one variant was present containing exons 40, 41, 42 and 
43 without any insertions are deletions, cleavage of the C-terminal region of the channel 
occurs in the region of this variant. The lack of alternative variants in this region would 
indicate that the presence particular splice variants does not drive the cleavage of the 
channel, instead there must be an alternative mechanism causing the cleavage of the C-
terminal tail region. 
 
8.5.3 The CACNA1G Channel  
The CACNA1G was not detected within the membrane fraction at this stage, suggesting 
it is not inserted therein and so will not be contributing to the excitability of the cells, 
however, two forms were detected within the cytoplasm. 
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Splice variant analysis of the CACNA1G reveals, exon 14 is not present, exon 25 is 
present without any insertions, as is exon 26, these variants will have the effect of 
producing functional channels with midpoint activation rates (Bertolesi, Walia Da Silva 
et al. 2006). Finally, in splice site 7/8 there are two variants expressed one containing 
exons 30B and 31A and one containing just exon 31A. Exon 31A has been shown to 
result in prematurely truncated protein (Emerick, Stein et al. 2006) and may account for 
the shorter protein detected within the cytoplasm. 
 
Following ChIP analysis, binding of the CACNA1G promoter by CBP, SP1 and RelA 
was observed. There was no evidence of enrichment of the promoter with p50 and so a 
different NFκB subunit, possibly RelA homodimers, appear to be responsible for this 
regulation. The presence of CBP may again indicate that an enhanceosome like complex 
is involved in the basal transcription of this channel. 
 
8.5.4 The Combined Role of the KCNMA1, CACNA1C and CACNA1G Channels in 
Un-stimulated Cultured Myometrial Cells. 
Taken together, the data above reveals a picture of cells primed to contract. There are 
KCNMA1 channels with decreased calcium sensitivity housed in complexes to minimise 
the effect of this decreased sensitivity. There are CACNA1C with increased ion 
conductance capabilities which are housed in complexes to maximise the efficiency of 
calcium ion signal transduction. Finally, there are CACNA1G prepared in the cytoplasm 
ready to be inserted into the membrane to regulate the timing and force of the contractions 
(Figure 8.3).  
 
 
Figure 8.3 Schematic Representation of the KCNMA1 channel, CACNA1C and CACNA1G 
location and associations prior to parturition  
CACNA1C – CACNA1C calcium channel; GPCR – G protein coupled receptor, α – G protein alpha 
subunit, β – G protein beta subunit,  - G protein gamma subunit, CACNA1G – CACNA1G calcium 
channel 
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8.6 The Role of the KCNMA1, CACNA1C and CACNA1G Channels 
in the Generation of Contraction in Cultured Myometrial Cells  
The onset of parturition is characterised by an influx of cytokines including TNF, IL-1β 
and IL6 (Romero, Mazor et al. 1992, Opsjln, Wathen et al. 1993, Keelan, Marvin et al. 
1999, Osman, Young et al. 2003). Within this study, TNF stimulation was shown to cause 
significant contraction of the myometrial cells grown in culture. Therefore, it was decided 
to use TNF to simulate the contractile state of the myometrium during parturition. 
  
8.6.1 The KCNMA1 Channel  
Following TNF stimulation, there was a significant increase in the transcription of the 
KCNMA1 channel. However, there was no corresponding increase in membrane-
localised full length KCNMA1 channel. Kim et al. demonstrated this lag between 
KCNMA1 RNA and protein up-regulation in chick cochlear development and determined 
that it was due to delays in protein synthesis and trafficking / scaffolding of the channel 
subunits (Kim, Beyer et al. 2010) a similar delay may be occurring in the myometrium. 
There was, however, an increase in the membrane localisation of the 50kDa KCNMA1 
fragment.  
 
This increase in the 50kDa fragment was not associated with an increase in the expression 
of the splice site 2 variant containing exons 11 and 12. This would indicate that although 
the presence of this variant may permit the proteolytic processing of the channel, a 
different mechanism is in place to regulate this processing. This membrane-localised 
KCNMA1 channel is found associated with Gαs and the β2AR demonstrating that the 
KCNMA1 channel is likely to be active. There is an association between the KCNMA1 
channel and Cav-1 indicating that the KCNMA1 channel is likely to be housed within 
caveolae meaning that its surface expression will be reduced. 
 
Splice variant analysis demonstrates that TNF does not cause a significant change in the 
splice variants of the KCNMA1 channel being expressed with the exception of the exon 
19 variant. The exon 19 variant is significantly reduced and this coincides with the 
reduction in the 65kDa N-terminal fragment supporting the theory that this variant and 
protein fragment are linked. This may have the result of increasing the calcium sensitivity 
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of the KCNMA1 channel. Although there is no change in the expression of the STREX-
2 variant, the role of this variant will alter as parturition progresses. Early in parturition, 
as the Gαs levels are high, the levels of PKA will be correspondingly high and hence this 
variant will support contraction (Europe-Finner, Phaneuf et al. 1994, Europe-Finner, 
Phaneuf et al. 1997). As parturition progresses, levels of Gαs and PKA will decrease and 
hence the support of contraction by the STREX-2 splice variant will also decrease, this 
switch may have a role in the termination of parturition. 
 
8.6.2 The CACNA1C Channel  
Following TNF stimulation there was a significant increase in the transcription of the 
CACNA1C and this coincided with a significant increase in the membrane localisation 
of C-terminally truncated channel. This membrane localised channel was found 
associated with Gαs and the β2AR indicating that, like the KCNMA1 channel, it is also 
likely to be active. There is also an increase in association with Cav-1 indicating that more 
CACNA1C is housed within caveolae after TNF stimulation. Localisation of the 
CACNA1C within caveolae will improve the efficiency of calcium signal transduction 
and increase excitation-contraction coupling. 
 
Splice variant analysis again shows that TNF does not cause any significant changes in 
the splice variant profile of the CACNA1C. 
 
8.6.3 The CACNA1G Channel  
TNF stimulation had no effect on the transcription of the CACNA1G. There was, 
however, a significant increase in the membrane localisation of this channel, 
demonstrating that TNF may promote the insertion of this channel into the membrane 
where it can then regulate the timing and force of contractions. TNF did, however, 
significantly increase the expression of the splice site 2 variant without exon 14. The 
omission of this exon will result in the loss of a PKC phosphorylation site.  PKC 
phosphorylation has been shown to activate the CACNA1G (Park, Kang et al. 2006).  
Therefore, the loss of a PKC phosphorylation site may act to limit the activation of the 
CACNA1G at this juncture.  
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TNF also caused an increase in the expression of the splice site 4 variant containing exon 
25. This variant results in channels which open more easily at more negative membrane 
potentials and as such these variants may be key to the ability of the myometrium to 
generate spontaneous phasic contractions. The generation of these spontaneous phasic 
contractions is due to the ability of the cell to fire regenerative action potentials (Lee, Ahn 
et al. 2009). Regenerative action potentials are created when a channel opening at a low 
threshold is able to initiate the opening of enough channels to initiate an action potential. 
CACNA1Gs with the ability to open at more negative membrane potentials due to the 
presence of these variants will allow calcium to enter the cell and so will push the 
membrane potential to more positive potentials which will then allow the CACNA1Cs to 
open and generate an action potential. 
 
8.6.4 The Combined Role of the KCNMA1, CACNA1C and CACNA1G Channels in 
the Generation of Contraction in Cultured Myometrial Cells. 
It is evident that the splice variant profiles of the KCNMA1 channels and CACNA1C are 
set prior to the influx of cytokines characteristic of parturition. The effect of TNF is two-
fold, firstly it increases the transcription of all the channels and secondly it affects the 
localisation of the channels. The 50kDa KCNMA1 channel fragment, with decreased 
calcium sensitivity, is mobilised to the membrane and at the same time membrane-bound 
KCNMA1 channel is associated with caveolae microdomains. The short form of the 
CACNA1C channel, with increased ion conductance, is also mobilised to the membrane 
and there is CACNA1C associated with Cav-1. Finally the full length CACNA1G is also 
mobilised to the membrane. One would speculate that these changes could result in cells 
that can counteract changes in calcium signalling less efficiently because the KCNMA1 
channels present are less sensitive to calcium. Therefore they respond less efficiently to 
increasing intracellular calcium. At the same time these cells have a greater ability to 
contract as they possess CACNA1C with greater ion conductance. These particular 
CACNA1C isoforms are housed within microdomains which can initiate calcium sparks 
and more efficient excitation-contraction coupling (Darby, Kwan et al. 2000, Daniel, El-
Yazbi et al. 2006). Finally, these cells are equipped with CACNA1G which can modulate 
the frequency, force and amplitude of the contractions stimulated by the activation of the 
CACNA1C. 
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In summary, this thesis has demonstrated that in myometrial cells generated from term 
pregnant biopsies the expression and splice variant profile of the KCNMA1, CACNA1C 
and CACNA1G has already been adapted to support contraction. The influx of cytokines 
into the myometrial tissue, specifically TNF, then alters the localisation of these channels 
to optimise the efficiency of calcium signalling and excitation-contraction coupling via 
the calcium channels and minimise the counteraction of contraction by the KCNMA1 
channel. In this way the myometrium is moved from quiescence to contractility. 
 
A further finding from this thesis is the dual role of the KCNMA1 protein as an ion 
channel and a transcription factor. This transcription factor activity is a further way in 
which the KCNMA1 protein can regulate the timing of parturition. 
 
8.7 The KCNMA1 Protein as a Transcriptional Regulator 
Throughout this thesis it has been demonstrated that the KCNMA1 channel can regulate 
its response to the changing cellular environment through the use of splice variants, its 
sub-cellular localisation and its association with other proteins. In this way it can regulate 
the contractility of the tissue and hence, in terms of this project, it may regulate the timing 
of parturition. This study has uncovered a further level at which the KCNMA1 protein 
can regulate the cells responses, through its action as a transcription factor. Although this 
research needs further optimisation and validation it has provided a fascinating insight 
into the processes which the KCNMA1 protein can regulate. 
 
8.7.1 Transition Through G1/S Cell Cycle  
The ChIP-seq and subsequent ChIP validation PCR experiments revealed that the 
KCNMA1 protein bound to the promoter/enhancer region of the Retinoblastoma protein 
(RB1) gene. RB1 is a tumour suppressor protein which has been shown to be 
dysfunctional in several cancers (Murphree and Benedict 1984). The role of the RB1 
protein is to prevent excessive cell growth, this is accomplished by blocking cell cycle 
progression at the G1/S transition until the cell is ready to divide (Goodrich, Wang et al. 
1991, Templeton, Park et al. 1991, Connell-Crowley, Harper et al. 1997). This block in 
cycle progression is achieved via RB1 binding and inhibiting transcription factor E2F 
which is needed for S phase gene transcription (Connell-Crowley, Harper et al. 1997, 
Funk and Galloway 1998). Once the cell is ready to divide, RB1 is inactivated by 
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phosphorylation, the block is released and the cell cycle proceeds. The phosphorylation 
of RB1 is thought be carried out by G1 cyclin depenant kinases (Cdk) and in particular 
cyclin D-type (Cdk4) and E-type (Cdk2), phosphorylation of RB1 means RB1 can no 
longer bind E2F and therefore the inhibition of E2F is removed (Dynlacht, Flores et al. 
1994, Connell-Crowley, Harper et al. 1997). 
The uterus, and specifically the myometrium, increases in size by around 20-fold during 
pregnancy, smooth muscle cell proliferation (hyperplasia) is the key process in achieving 
this expansion during early pregnancy (Ramsey 1994). RB1 has been shown to be 
involved in cell cycle progression and proliferation in vascular smooth muscle cells (Li, 
Duman-Scheel et al. 2010) and myometrial smooth muscle cells (Taniguchi, Morita et al. 
2001). 
Later in pregnancy there is a switch and the increase in the capacity of the uterus is then 
achieved predominantly by an increase in cell size (hypertrophy) this hypertrophy is 
driven by stretch. At the end of pregnancy and the onset of parturition it has been shown 
that this stretch induces the expression of both contraction associated proteins and pro-
inflammatory cytokines (Ou, Orsino et al. 1997, Parry, Bathgate et al. 1997, Ou, Chen et 
al. 1998, Wu, Ma et al. 1999, Loudon, Sooranna et al. 2004) this then tips the balance 
from the quiescent phenotype seen during pregnancy to the contractile phenotype typical 
of parturition.  
Excess hyperplasia will reduce both hypertrophy and stretch whilst a lack of hyperplasia 
will result in increased hypertrophy and stretch. A balance, therefore, between 
hyperplasia and hypertrophy late in pregnancy is necessary for parturition to occur at the 
right juncture. Regulation of the RB1 protein by the KCNMA1 protein is one way in 
which this balance could be regulated.  
 
8.7.2 Calcium Homeostasis 
The overriding trigger for the onset of spontaneous myometrial contractions is the 
increase in intracellular calcium. This increase is achieved through a balance between 
calcium influx, calcium release from intracellular stores and calcium removal (Tribe, 
Moriarty et al. 2000, Tribe 2001). The influx of calcium generates an action potential 
which then initiates cross-bridge cycling and muscle contraction. The link by which this 
292 
 
change in membrane potential then leads to physical contraction is termed excitation-
contraction coupling.  
 
Calcium Sparks are important in this excitation-contraction coupling  (Cheng, Lederer et 
al. 1993). Calcium sparks are generated through the activation of a cluster of ryanodine 
receptors which then cause calcium to be released from the sarcoplasmic reticulum, it is 
possible that caveolae have a role in the generation of these sparks. Caveolae create 
microdomains which can house spatially contained increases in calcium, these transient 
increases can then cause a calcium spark from the closely associated sarcoplasmic 
reticulum (Cheng, Lederer et al. 1993, Löhn, Fürstenau et al. 2000). 
 
Juncophillin 2 (JPH2) is a member of a family of junctional membrane complex proteins, 
these proteins provide a physical link between the plasma membrane and the membranes 
of the endoplasmic and sarcoplasmic reticulum (Garbino, van Oort et al. 2009). This 
physical association will facilitate the transduction of the calcium signal and hence 
promote the generation of calcium sparks (Golini, Chouabe et al. 2011, Landstrom, 
Kellen et al. 2011).  
 
The KCNMA1 protein was found bound to the regulatory region of the JPH2 gene, 
regulation of the JPH2 protein will affect excitation-contraction coupling and this in turn 
will affect the contractility of the tissue. In terms of parturition, regulation of this protein 
is another level at which the KCNMA1 protein can affect the timing of parturition by fine 
tuning the cells excitation-contraction coupling. 
 
8.7.3 NFκB Signalling 
The process of parturition has been shown involve a controlled inflammatory response. 
NFκB is a key regulator of the inflammation cascade and therefore NFκB signalling is an 
important part of the regulation of the parturition process. Mitogen Activated Protein 
Kinase Kinase Kinase 7 (MAP3K7) is a key protein in the signalling cascade following 
both TNF and LPS activation of NFκB.  
 
Following TNF stimulation MAP3K7 is rapidly polyubiquitinated leading to its activation 
(Hamidi, von Bulow et al. 2012). Once activated it can have either a stimulatory (Craig, 
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Larkin et al. 2000) or inhibitory (Ajibade, Wang et al. 2012) effect on the NFκB pathway. 
Activated MAP3K7 then acts via IκB Kinase (IKK), which subsequently acts via IκBα 
which then either retains NFκB in the cytoplasm or releases NFκB which then moves to 
the nucleus, a similar process occurs after LPS stimulation but is less rapid. MAP3K7 
signalling also occurs in the non-canonical NFκB pathway via NIK signalling (Ninomiya-
Tsuji, Kishimoto et al. 1999). In these ways MAP3K7 can affect nuclear localisation of 
not only p50/RelA dimers but also RelB/p52 dimers. 
 
It has been demonstrated in a mouse model that nuclear localisation of the p50/RelA 
NFκB dimers increases towards parturition and that blocking this nuclear localisation 
delays the onset of parturition (Lindstrom and Bennett 2005). Gene deletion of MAP3K7 
has been shown to impair IKK and NFκB activity, therefore it is plausible that down 
regulation of MAP3K7 transcription, regulated by KCNMA1, could lead to a reduction 
in NFκB nuclear localisation and a delay in the onset of parturition.  
 
MAP3K7 has also been shown to have a regulatory role in human tracheal smooth muscle 
proliferation, in these cells MAP3K7 promotes cell proliferation and suppresses 
contraction (Pera, Sami et al. 2011). As stated above a balance between hyperplasia and 
hypertrophy is critical for parturition to occur at the right juncture, an up-regulation of 
MAP3K7 transcription would lead to increased hyperplasia and subsequently decreased 
hypertrophy. Too little hypertrophy then means the cells do not receive the signals to 
produce the pro-contractile proteins and cytokines and therefore ultimately results in 
decreased contractility, 
 
The ChIP-seq data and ChIP validation PCRs revealed KCNMA1 protein binding in the 
regulatory region of the MAP3K7 gene and so again this has revealed a further 
mechanism by which the KCNMA1 protein may have a role governing the timing of 
parturition.  
 
8.7.4 The KCNMA1 Channel and KCNMA1 Protein Transcriptional Regulation 
Interestingly the KCNMA1 channel has been shown to have a role in all the processes 
discussed above. Firstly, studies have revealed that potassium channels are responsible 
for hyperpolarising the plasma membrane, which is necessary for the cells to move from 
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G1 to S (Wonderlin and Strobl 1996, Ouadid-Ahidouch and Ahidouch 2013). Secondly, 
KCNMA1 channels are sensitive to both voltage and calcium, transient increases in 
calcium can activate the KCNMA1 channel and in this way it can regulate calcium 
homeostasis. Finally, it has been shown that the KCNMA1 channel is activated by LPS 
and if this activation is blocked then the nuclear localisation of NFκB following LPS 
stimulation is abolished due to the non-degradation of IκBα (Dhulipala and Kotlikoff 
1999, Papavlassopoulos, Stamme et al. 2006). 
 
This ChIP-seq data adds to the picture of KCNMA1 regulation by demonstrating that the 
KCNMA1 channel does not regulate these processes purely in its role as a potassium 
channel, but that it may also have a role in regulating the expression of other proteins 
involved in these various processes.   
 
8.8 Future Work 
Further work needs to be undertaken to define the trigger which causes the switch in ion 
channel expression and splice variant profile; understanding this may enable this switch 
to be manipulated and in this way the timing of parturition could be delayed. 
 
Further work examining the effect of different combinations of the various factors seen 
to be up-regulated at parturition (SP-A, MMPs, prostaglandins, TNF, IL-1β and IL6) on 
the expression and localisation of the KCNMA1, CACNA1C and CACNA1Gs is an 
important next step in order to better mimic the complexity of signalling that occurs at 
the onset of parturition. 
 
Other areas which are also worthy of further investigation include clearly defining the 
link between the splice variants expressed and their corresponding protein isoforms, an 
examination of the phosphorylation of the KCNMA1 channel in order to better define the 
extent of the contribution of STREX-2 variant in the support of membrane depolarisation, 
determining the level of phosphorylation of the CACNA1C and CACNA1G to better 
understand how they are activated, defining the role of acetylation in the retention of the 
KCNMA1 channel and the membrane trafficking of the CACNA1Gs and optimisation of 
the ChIP protocols in order to define how expression of the KCNMA1, CACNA1C and 
CACNA1G is regulated. 
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Finally, the KCNMA1 protein transcription factor needs to be fully characterised 
including, defining what portion of the protein is required for its transcriptional activity, 
what stimulates its nuclear localisation, what genes it regulates and the nature of this 
regulation whether it is stimulatory or inhibitory. 
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Appendix 1 : The Single-Letter Amino Acid Code 
 
G Glycine Gly  P Proline Pro 
A Alanine Ala  V Valine Val 
L Leucine Leu  I Isoleucine Ile 
M Methionine Met  C Cysteine Cys 
F Phenylalanine Phe  Y Tyrosine Tyr 
W Tryptophan Trp  H Histidine His 
K Lysine Lys  R Arginine Arg 
Q Glutamine Gln  N Asparagine Asn 
E Glutamic Acid Glu  D Aspartic Acid Asp 
S Serine Ser  T Threonine Thr 
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Appendix 3 : Dot Blots 
Dot Blots 
Dot blots were utilised to optimise the protein and antibody concentrations for use in 
western blotting. A dot blot is a simplified version of a western blot where the proteins 
are not first separated by electrophoresis. It is a quick and effective method of determining 
the optimum combination of protein amount and primary antibody dilution. In this study, 
dot blots were used to determine the following values:  amount of protein to load on the 
gel, what concentration of primary antibody to use, what temperature the primary 
antibody should be incubated at and which detection reagent to use to develop the blots 
was determined from these dot blots. 
 
Different quantities of protein (5, 10 and 50μg) were applied directly to nitrocellulose 
membrane (Geneflow, Staffs) as dots, then incubated with different dilutions of primary 
antibody. The only exceptions to these optimisations are the amount of protein loaded 
from the soluble nuclear and chromatin bound nuclear fractions. These fractions do not 
contain enough protein to load 5μg per gel and so instead an equal volume of these 
fractions from each sample was loaded on the gel. This meant these fractions were only 
used once to determine the presence or absence of a particular protein and not the relative 
quantities of the protein present as a result of the different stimulations. Secondary 
antibody was then added and the blots developed using Westar Supernova detection 
reagents.  
 
Clear dots were produced for each of the antibodies (Figure 4.3.1). The CACNA1G 
(Alomone, Jerusalem), KCNMA1 C-Terminal (Alomone, Jerusalem) and CACNA1C C-
Terminal (Abcam, Cambridge USA) quickly became over exposed and so these dot blots 
were repeated using the lowest antibody dilution, with incubations at either room temp or 
4ºC and developed using the less sensitive EZ-ECL detection kit (Geneflow, Staffs), with 
these combinations all three produced clear dots (Figure 4.3.1)  
 
The KCNMA1 C-terminal (Alomone, Jerusalem) had a high level of background and so 
the primary antibody was diluted in blocking buffer and incubated at 4ºC overnight, this 
significantly reduced the level of background. 
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Figure 4.3.1 Optimisation of Protein and Antibody concentrations using Dot Blot The amount and 
location of the protein blotted on to each membrane is illustrated (A) The lack of dot in the negative 
control of each blot and the lack of background on the majority of blots show the block is effective and 
the antibody is specific. The dark spots indicate the antibody is detecting protein. Blots were developed 
with either WestStar Supernova (B) or EZ-ECL (C) detection reagents. Dilutions of primary antibodies 
used are detailed below the individual blot
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